Pharmacokinetics and allometric scaling of antimalarial drugs by Senarathna, Senarathna Mudiyanselage Dona Kalyani Ganga
    
 
School of Pharmacy 
 
 
 
 
 
Pharmacokinetics and Allometric Scaling of Antimalarial Drugs  
 
 
 
Senarathna Mudiyanselage Dona Kalyani Ganga Senarathna  
 
 
 
 
This thesis is presented for the Degree of  
Doctor of Philosophy  
of  
Curtin University 
 
 
March 2015
   i 
 
 
Declaration 
 
To the best of my knowledge and belief this thesis contains no material previously 
published by any other person except where due acknowledgement has been 
made. This thesis contains no material which has been accepted for an award of 
any other degree or diploma in any university. 
 
 
 
 
S M D K Ganga Senarathna  
March 2015   
   ii 
Abstract  
In order to delay development of drug resistance and to obtain maximum drug efficacy, 
it is important to prescribe optimum drug combinations and doses, which requires clear 
knowledge of the pharmacokinetics of antimalarials. This study covered two main 
areas of pharmacokinetics of antimalarials. The first aim of this study was to carry out 
allometric scaling of antimalarial drugs to interpolate pharmacokinetic parameters and 
drug doses for children. The second principal aim was to establish drug permeability, 
P-glycoprotein mediated drug transport and regulation of P-glycoprotein expression 
by antimalarials in single and combination therapy using in-vitro Caco-2 cell lines.  
Strong allometric relationships were found for clearance and volume of distribution 
with r2 values ≥ 0.9 except for volume of distribution of artesunate. Clearance 
exponents ranged from 0.4 for quinine to 0.96 of piperaquine. The exponents and 95 
% confidences interval did not encompass fixed exponent values of 0.67 or 0.75, and 
exponent 1 for all drugs studied. Therefore fixed exponent allometry and linear (mg/kg 
adult dose) dosing are not supported by the current study. The exponents for volume 
of distribution ranged from 0.78 for mefloquine to 1.16 for piperaquine (artesunate was 
excluded). Half-life had poor allometric relationships with low r2 for the majority of 
the drugs. The clearance predicted using simple allometry was within the threshold 
limits of the observed drug clearance in clinical studies. The correction factors 
maximum life span potential, Rule of Exponents and liver blood flow correction did 
not improve the simple allometric predictions. The liver weight correction performed 
well and had the predictive success for all drugs compared. However a clear 
improvement in clearance prediction compared to simple allometry was not observed. 
Comparison of drug clearance in healthy human adults and malarial infected patients 
showed quinine clearance to be significantly lower in the former compared to the latter. 
The paediatric doses predicted based on exponents derived from simple allometry of 
healthy species for arbitrary body weights of 15 and 25 kg were 10 to 70% higher than 
the currently recommended mg/kg adult dosing except for artemether. The artemether 
doses used are higher than the mg/kg adults dosing and similar or higher than the 
allometrically predicted doses.  
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The conventional allometry where preclinical clearance data are used to extrapolate 
pharmacokinetics for humans did not work for all antimalarials. Addition of human 
pharmacokinetic data improved clearance prediction and was within threshold values 
at all times.  
The second part of the study which consisted of bidirectional transport studies required 
development of a robust Caco-2 cell monolayer with sufficient P-gp expression. Three 
interventions [exposure of cells to a potent P-gp inducer rifampicin (Caco-2 RIF), 
exposure of cells to a potent P-gp substrate vinblastine at nanomolar concentration 
(Caco-2 VIN) and regular passaging to attain late passage Caco-2 cells] were adopted 
to improve P-gp expression in early passage Caco-2 cells (passage 44). Caco-2 VIN 
model had the highest P-gp expression with an efflux ratio of 13, however development 
of this model was a time consuming process. Late passage Caco-2 cells had sufficient 
improvement on P-gp expression with an efflux ratio of 4.7 compared to 1.4 of the 
early passage Caco-2 cells.  
Mefloquine showed P-gp inhibitory properties, where 50% inhibition of P-gp mediated 
efflux transport of rhodamine123 was observed at 100 µM in late passage Caco-2 cells. 
Amodiaquine, artesunate, methylene blue and artemisone did not show inhibitory 
properties in early and late passage Caco-2 cells.  
Out of the antimalarials studied, mefloquine, amodiaquine, artesunate and artemisone 
permeated through passive diffusion. The apical to basolateral directional apparent 
permeability (Papp) values for mefloquine and artesunate were 6 to 10 × 10
-6 and 7 to 
10 × 10-6 cm/sec respectively, therefore showing medium permeability and incomplete 
drug absorption in-vivo. Whereas amodiaquine and artemisone showed near complete 
drug absorption with apical to basolateral directional Papp of 16 to 23 × 10
-6 and 37 to 
60 × 10-6 cm/sec, respectively. Mefloquine permeability was not altered when co-
incubated with artesunate, artemisone and methylene blue and artesunate. 
Amodiaquine and artesunate showed some efflux with efflux ratios in the range of 1.2 
to 1.5; however such small increases in efflux are unlikely to change the in-vivo drug 
absorption and systemic availability of drug.  
Methylene blue showed higher basolateral to apical transport compared to apical to 
basolateral transport which suggested possible P-gp mediated efflux transport of 
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methylene blue. Efflux transport was consistently observed in all Caco-2 models. 
However the efflux transport of methylene blue was not completely inhibited by 
PSC833 with 50% inhibition observed. Therefore it is probable that methylene blue 
efflux transport is mediated.  
A clear up-regulation of P-gp was observed for artemisone and dihydroartemisinin in 
combination with amodiaquine or mefloquine in both Caco-2 and LS174 T cells. This 
was not observed for artesunate combinations. An up-regulation of P-gp was not 
observed for antimalarials in single therapy for 48 hours. However up-regulation was 
observed for methylene blue, amodiaquine, artesunate and dihydroartemisinin when 
exposed for 96 hours.  
Overall, simple allometric scaling is a plausible technique for dose determination in 
children. The correction factors were unable to show clear improvement in clearance 
prediction compared to simple allometry. Mefloquine exhibited P-gp inhibitory 
properties. Mefloquine, amodiaquine, artesunate and artemisone did not exhibit P-gp 
substrate activity. Methylene blue was found to have P-gp mediated efflux transport as 
one of the multiple mechanisms available to transport methylene blue. It also showed 
low permeability, while mefloquine and artesunate showed medium and amodiaquine 
and artemisone high permeability across Caco-2 monolayers. A clear up-regulation of 
P-gp expression was observed for dihydroartemisinin and artemisone in combination 
with amodiaquine and mefloquine in Caco-2 and LS174 T cells.  
 
 
 
 
 
 
 
 
   v 
Acknowledgment 
I would like to extend my sincerer gratitude to my supervisors Dr Andrew Crowe and 
Prof Kevin Batty who spend their valuable time to guide me achieve my objectives.  
First of all I would to like thank to Dr Andrew Crowe for agreeing to take the full 
responsibility of supervising my work after Prof. Kevin Batty left the University. Your 
through knowledge in the areas of drug transport and protein studies helped me 
immensely to overcome many hurdles I came across.  
I am grateful to Prof Kevin Batty for introducing me to the pharmacokinetic research 
and your patience, critical comments and empathetic guidance was instrumental for 
completion of my work.  
I am extremely grateful to Dr Madhu Page Sharp for teaching me all the analytical 
skills needed and being the pillar of strength. Without your constant support, guidance, 
close supervision, invaluable advices and friendship, I wouldn’t have been able to 
complete my work.    
I wish to acknowledge with gratitude my friend, Gaewyn Ellison for proof reading and 
Joyce Thomas for providing the thesis template.  
I wish to thanks my roommates Julia Koehn, Gaewyn Ellison, Malini Visweswaran, 
Chee Wai Wong, Naz Huda, Aparna Warrier, Hilai Ahmadzai, Vishal Chaturvedi and 
Aziz Niazi for their friendship and moral support throughout my study.  
I acknowledge the staff of the School of Pharmacy, Curtin University for supporting 
me in various ways and welcoming and making me part of the big family.  
I thank Curtin University for supporting me with Curtin Strategic International 
Research scholarship to support my financial needs.  
I admire and thank most fondly my son Manuka Wickramasuriya and daughter 
Gihanga Wickramasuriya for bearing with me for all the long hours spend away from 
them for during last 3.5 years. I thank my husband Asoka Wickramasuriya for taking 
all the family responsibilities and being patient with me during my PhD Journey. I 
most gratefully acknowledge my mother and mother in-law for looking after my 
   vi 
children during my study, without for them I won’t be able to complete my work. I am 
thankful to my father, brother, sister and sister-in laws for accommodating their needs 
and sending our mothers away to support my work.  
I also would like to thank my family friend Sisira Jayarathna and his family for housing 
us when we first came to Australia and my landlord James Britain for helping us in 
various ways.  
I would like to extend my gratitude to all the Pharmacy Lecturers at the University of 
Sri Jayewardenepura for shouldering my teaching responsibilities while I was away. I 
wish to thank Professor Sherain Fernando, Professor Mohan De Silva and University 
of Sri Jayewardenepura, Sri Lanka for granting me study leave.  
 
 
 
 
 
 
 
 
 
 
 
 
 
   vii 
Abbreviations  
DHA   Dihydroartemisinin  
ART   Artesunate 
MQ   Mefloquine  
MB   Methylene blue  
AM   Artemisone  
Rh123   Rhodamine123 
IM   Intramuscular  
IR   Intra rectal  
IV   Intravenous  
IP   Intraperitoneal  
SC   Subcutaneous  
CL   Clearance  
AUC   Area under the curve  
CL/F   Apparent clearance  
Vz   Volume of distribution  
Vz/F   Apparent volume of distribution  
t1/2   Half-life 
Cmax   Maximum concentration   
tmax   Time taken to reach maximum concentration  
Vss   Volume at steady state  
   viii 
WHO   World Health Organization  
FDC   Fixed dose combination  
CSF   Cerebrospinal fluid  
ACT   Artemisinin combination therapy  
P-gp   Permeability glycoprotein, P-glycoprotein 
F   Bioavailability  
r   Rat  
m   Mice  
d   Dog 
p   Pig 
h   Human  
CI   Confidence interval  
MLP   Maximum life span potential  
Poct    Octanol water portioning coefficient  
Papp   Apparent permeability  
DMEM  Dulbecco’s modified eagle medium 
FCS   Foetal calf serum 
HBSS   Hank balance salt solution  
Ap-Bas  Apical to basolateral  
Bas-Ap  Basolateral to apical  
TEER   Transepithelial electrical resistance  
   ix 
TBS   Tris Buffered saline 
TBST   Tris Buffered saline with 0.05% Tween 20  
DMSO   Dimethyl Sulfoxide 
KH2PO4  Potassium dihydrogen ortho phosphate 
H3PO4   Phosphoric acid 
Caco-2   Colorectal adenocarcinoma-2 cells 
HPLC   High performance liquid chromatography  
LC-MS-MS  liquid chromatography and mass spectrometry 
SEM   Standard error of mean 
BCS   Biopharmaceutical classification system 
IVIV   In-vivo and In-vitro correlation   
PXR   Pregnane X receptor  
MDCK  Madin Darby canine kidney 
ATCC   American Type Culture Collection 
FDA   Food and drug administration  
MDR   Multi drug resistance  
LS174 T  Dukes' type B,colorectal adenocarcinoma cells 
PBS   Phosphate buffered saline  
P    Passage 
 
 
   x 
Publications and Presentations  
Full research papers  
Senarathna SG, Batty KT. Interspecies allometric scaling of antimalarial drugs and 
potential application to pediatric dosing. Antimicrobial Agents Chemotherapy. 2014; 
58(10):6068-78 
S M D K Ganga, Senarathna, Andrew, Crowe. The influence of passage number for 
Caco-2 cell models when evaluating P-gp mediated drug transport. PHARMAZIE. 
2015;70:1-6 
 
Abstracts and presentations  
Senarathna S.M.D.K.G, Batty Kevin T. Allometric scaling of antimalarial drugs. In 
Joint Australasian Society of Clinical and Experimental Pharmacologist and 
Toxicologist and Australasian Pharmaceutical Sciences Association 2012 conference. 
Sydney, Australia, 2-5 December 2012 
Senarathna S.M.D.K.G, Batty Kevin T. Allometric scaling of antimalarial drugs. Mark 
Liveris Research Seminar, Faculty of Health Sciences, Curtin University, Australia, 
11 November 2013 
Senarathna S.M.D.KG. Page-Sharp Madhu, Crowe A. In-vitro drug transport of anti-
malarials; amodiaquine, mefloquine and methylene blue. In 63rd Annual meeting of 
American Society of Tropical Medicine and Hygiene, New Orleans, USA, American 
Society of Tropical Medicine and Hygiene,2-6 November 2014. 
Senarathna S.M.D.KG, Crowe A. Development of a robust Caco-2 cell model for drug 
transport studies. In Science on the Swan Inaugural Conference 2015, Perth, Australia, 
21-23 April 2015. 
Crowe A, Senarathna S.M.D.KG. Page-Sharp Madhu. The interactions of P-
glycoprotein with antimalarial drugs, including substrate affinity and inhibition. In 
Science on the Swan Inaugural Conference 2015, Perth, Australia, 21-23 April 2015 
   xi 
Senarathna S.M.D.KG. Page-Sharp Madhu. Crowe A. The influence of artemisone 
exposure in Caco-2 cell monolayers on P-gp mediated transport and expression; 
Comparison with Artesunate. In 128th International conference of Sri Lanka Medical 
Association, Colombo, Sri Lanka, 5-8 July 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   xii 
Table of Contents 
Declaration .............................................................................................................. i 
Abstract .................................................................................................................. ii 
Table of Contents ................................................................................................. xii 
List of Tables ..................................................................................................... xviii 
List of Figures .......................................................................................................xx 
1 Introduction .................................................................................. 1 
1.1 Malaria ......................................................................................................... 1 
1.2 Epidemiology of malaria .............................................................................. 3 
1.3 Drug development in malaria ........................................................................ 4 
1.4 Drugs in malaria ........................................................................................... 5 
1.4.1 Artemisinin ..................................................................................... 8 
1.4.2 Artesunate....................................................................................... 9 
1.4.3 Artemether .....................................................................................10 
1.4.4 Dihydroartemisinin ........................................................................11 
1.4.5 Artemisone ....................................................................................13 
1.4.6 Amodiaquine .................................................................................14 
1.4.7 Piperaquine ....................................................................................15 
1.4.8 Mefloquine ....................................................................................16 
1.4.9 Quinine ..........................................................................................18 
1.4.10 Clindamycin ..................................................................................20 
1.4.11 Methylene blue ..............................................................................20 
1.5 Artemisinin combination therapy (ACTs) and pharmacokinetics .................22 
1.6 Antimalarial drugs resistance .......................................................................23 
1.7 Introduction overview..................................................................................24 
1.8 Objectives ...................................................................................................25 
2 Allometric scaling of antimalarial drugs ................................... 27 
2.1 Introduction .................................................................................................27 
2.1.1 Interspecies scaling ........................................................................27 
2.1.2 Past and the present of allometry ....................................................30 
xiii 
2.1.3 Simple allometric power equations for pharmacokinetics ...............31 
2.1.4 Allometric scaling approaches in pharmacokinetics .......................32 
2.1.4.1 Fixed exponent allometry ...............................................32 
2.1.4.2 Variable exponent allometry ..........................................33 
2.1.5 Methods used in improving allometric drug clearance prediction ...34 
2.1.5.1 Maximum life span potential (MLP) ..............................35 
2.1.5.2 Two term power equations .............................................37 
2.1.5.3 Brain weight correction ..................................................38 
2.1.5.4 Rule of Exponents ..........................................................39 
2.1.5.5 Correction using in-vitro metabolic data .........................39 
2.1.5.6 Allometry using unbound clearance ...............................40 
2.1.5.7 Glomerular filtration ratio (GFR) correction factor .........41 
2.1.5.8 Correction for biliary excreted drugs ..............................42 
2.1.5.9 Unbound clearance corrected intercept method ..............43 
2.1.5.10 Monkey liver blood flow method ...................................44 
2.1.6 Criticism of correction factors ........................................................44 
2.1.7 Physiologically based models.........................................................46 
2.1.8 Dedrick plots .................................................................................47 
2.1.9 Applications of interspecies scaling ...............................................48 
2.1.9.1 Veterinary medicine .......................................................48 
2.1.9.2 Pre-clinical to clinical dosing .........................................48 
2.1.9.3 Population pharmacokinetic modelling...........................48 
2.1.10 Drug dosing in children ..................................................................49 
2.1.10.1 Scaling by body size/weight ...........................................49 
2.1.10.2 Age based rule ...............................................................50 
2.1.10.3 Weight ranges ................................................................50 
2.1.10.4 Body surface area...........................................................51 
2.1.10.5 Fixed exponent allometry ...............................................51 
2.1.10.6 Variable exponent allometry ..........................................52 
2.1.11 Current evidence for the need of antimalarials dose optimisation in 
children ..........................................................................................53 
2.2 Rationale for allometric scaling ...................................................................54 
2.3 Specific objectives .......................................................................................56 
2.4 Methods ......................................................................................................57 
   xiv 
2.4.1 Data collection ...............................................................................57 
2.4.2 Pharmacokinetic parameters...........................................................58 
2.4.3 Interpolation of pharmacokinetics parameters for children .............59 
2.4.4 Application of correction factors ....................................................59 
2.4.5 Maximum life-span potential (MLP) correction .............................60 
2.4.6 Liver weight and liver blood flow correction ..................................61 
2.4.7 Interpolation of drug clearance .......................................................63 
2.4.8 Predictive success ..........................................................................64 
2.4.9 Interpolation of paediatric doses.....................................................64 
2.4.10 Extrapolation of human pharmacokinetic parameters .....................64 
2.4.11 Statistical analyses .........................................................................65 
2.5 Results.........................................................................................................66 
2.5.1 Published pharmacokinetic parameters for antimalarials ................66 
2.5.2 Interspecies allometric scaling for clearance, volume of distribution 
and half-life of anti-malarials .........................................................67 
2.5.2.1 Simple allometry for clearance of drugs .........................71 
2.5.2.2 Simple allometry for volume of distribution of drugs .....78 
2.5.2.3 Simple allometry for half-life of drugs ...........................84 
2.5.3 Comparison of pharmacokinetics in healthy and malaria infected 
adults .............................................................................................90 
2.5.4 Application of correction factor, maximum life span potential .......92 
2.5.5 Application of liver weight  and liver blood flow correction factors.
 ......................................................................................................92 
2.5.6 Interpolation of drug clearance for children ....................................96 
2.5.7 Paediatric dose determination.........................................................98 
2.5.8 Extrapolation of clearance for human adults using preclinical species
 .................................................................................................... 100 
2.6 Discussion ................................................................................................. 103 
2.7 Limitations ................................................................................................ 111 
2.8 Conclusion ................................................................................................ 113 
3 In-vitro drug permeability and P-gp mediated efflux transport 
studies ........................................................................................ 114 
3.1 Introduction ............................................................................................... 114 
   xv 
3.1.1 Drug permeability ........................................................................ 114 
3.1.2 Physicochemical properties of drugs ............................................ 115 
3.1.3 Drug transporting ABC efflux transporters ................................... 116 
3.1.4 P-glycoprotein (MDR) ................................................................. 116 
3.1.4.1 Mechanism of action .................................................... 118 
3.1.4.2 P-gp mediated drug transport studies ............................ 118 
3.1.4.3 Role of P-gp efflux transport in the body ...................... 119 
3.1.4.4 P-gp substrates ............................................................. 120 
3.1.4.5 P-gp inhibitors ............................................................. 122 
3.1.4.6 P-gp mediated drug interactions ................................... 123 
3.1.4.7 P-gp inhibitor interactions ............................................ 123 
3.1.4.8 P-gp regulation and induction ...................................... 124 
3.1.5 In-vitro cell models for drug transport studies .............................. 125 
3.1.6 Caco-2 monolayers in drug transport studies ................................ 126 
3.1.7 Correlation of in-vitro drug permeability and in-vivo drug absorption
 .................................................................................................... 128 
3.1.8 Bio-pharmaceutical classification system ..................................... 129 
3.1.9 Current evidence on drug permeability, P-gp mediated efflux 
transport and P-gp expression regulation on antimalarials ............ 131 
3.2 Specific Objectives .................................................................................... 132 
3.3 Methods .................................................................................................... 133 
3.3.1 Materials ...................................................................................... 133 
3.3.1.1 Drugs ........................................................................... 133 
3.3.1.2 Chemicals .................................................................... 133 
3.3.1.3 Cells and cell culture reagents ...................................... 133 
3.3.2 Buffers, reagents and solvents ...................................................... 134 
3.3.2.1 Buffers for HPLC......................................................... 134 
3.3.2.2 Solvents for LC-MS-MS sample preparation ................ 135 
3.3.3 Preparation of stock and working solutions .................................. 135 
3.3.4 Assay of rhodamine123 ............................................................... 136 
3.3.5 Development of cell model for transport studies........................... 138 
3.3.5.1 Caco-2 monolayers and maintenance ........................... 138 
3.3.5.2 Development of Caco-2 cell monolayer for transport 
experiments.................................................................. 138 
   xvi 
3.3.5.3 Development of Caco-2 cell model using P-gp inducer 
rifampicin (Caco-2 RIF) ............................................... 139 
3.3.5.4 Development of Caco-2 cell model using increasing 
concentration of vinblastine (Caco-2 VIN) ................... 139 
3.3.5.5 Development of late passage Caco-2 cell monolayers... 140 
3.3.6 Determinations of relative abundance of P-gp transporter protein in 
different Caco-2 models ............................................................... 140 
3.3.6.1 Study of bidirectional transport of a P-gp substrate ...... 140 
3.3.6.2 Visual confirmation of P-gp by Western blotting.......... 144 
3.3.7 Data analysis ................................................................................ 146 
3.4 Results....................................................................................................... 147 
3.4.1 Development of a robust Caco-2 model for bidirectional transport 
studies.......................................................................................... 147 
3.5 Discussion ................................................................................................. 154 
3.6 Limitations ................................................................................................ 158 
3.7 Conclusion ................................................................................................ 157 
4 Antimalarial transport studies ................................................. 159 
4.1 Rationale ................................................................................................... 159 
4.2 Specific Objectives .................................................................................... 161 
4.3 Methods .................................................................................................... 162 
4.3.1 P-gp inhibitory properties of antimalarials.................................... 162 
4.3.1.1 Assay of rhodamine123 in the presence of methylene blue
 .................................................................................... 162 
4.3.2 Drug permeability and P-gp substrate of antimalarial drugs.......... 163 
4.3.3 Drug transport studies .................................................................. 164 
4.3.4 Assays of mefloquine, amodiaquine and methylene blue .............. 164 
4.3.4.1 HPLC instrumentation and chromatographic conditions
 .................................................................................... 164 
4.3.4.2 Development of calibration curves for mefloquine, 
amodiaquine and methylene blue ................................. 165 
4.3.4.3 Assay of artesunate, dihydroartemisinin and artemisone 
using liquid chromatography and mass spectrometry (LC-
MS-MS) drug Assay .................................................... 171 
   xvii 
4.3.5 Determination of P-gp regulation in the presence of antimalarials 176 
4.4 Results....................................................................................................... 177 
4.4.1 Inhibitory properties of anti-malarial drugs against P-gp mediated 
drug efflux ................................................................................... 177 
4.4.2 Determination of drug permeability and P-gp substrate activity of 
antimalarial drugs ........................................................................ 180 
4.4.2.1 Bidirectional transport of mefloquine ........................... 181 
4.4.2.2 Bidirectional transport of amodiaquine ......................... 183 
4.4.2.3 Bidirectional transport of methylene blue ..................... 185 
4.4.2.4 Bidirectional transport of artesunate and 
dihydroartemisinin ....................................................... 188 
4.4.2.5 Bidirectional transport of artemisone ............................ 189 
4.4.3 Antimalarial regulation of P-gp expression .................................. 190 
4.5 Discussion ................................................................................................. 194 
4.5.1 Transport studies using the Caco-2 cell model.............................. 194 
4.5.2 P-gp inhibitory action of antimalarial drugs ................................. 194 
4.5.3 Permeability and  P-gp mediated drug transport of  antimalarials . 198 
4.5.3.1 Mefloquine drug transport ............................................ 198 
4.5.3.2 Amodiaquine drug transport ......................................... 199 
4.5.3.3 Methylene blue drug transport ...................................... 200 
4.5.3.4 Artesunate drug transport ............................................. 202 
4.5.3.5 Artemisone drug transport ............................................ 203 
4.5.4 Biopharmaceutical classification (BCS) of antimalalarials ........... 204 
4.5.5 Antimalarial regulation of P-gp expression .................................. 207 
4.6 Limitations ................................................................................................ 208 
4.7 Future studies ............................................................................................ 209 
4.8 Conclusion ................................................................................................ 210 
5 Summary ................................................................................... 211 
6 References ................................................................................. 220 
7 Appendix ................................................................................... 266 
7.1 Buffers ...................................................................................................... 266 
  
   xviii 
 List of Tables  
Table 2-1: MLP in years for animal species and human  ......................................... 36 
Table 2-2: Glomerular filtration factors for preclinical and human species.............. 42 
Table 2-3: Liver weight and liver blood flow as a percentage of total body weight  62 
Table 2-4:  Simple allometric scaling data for clearance of antimalarial drugs ........ 77 
Table 2-5:  Simple allometric scaling data for volume of distribution (Vz) of 
antimalarial drugs ................................................................................. 83 
Table 2-6: Simple allometric scaling data for half-life of antimalarial drugs ........... 89 
Table 2-7: Mean clearance of antimalarial drugs in healthy adults compared to 
malaria infected patients ....................................................................... 91 
Table 2-8: The exponent, coefficient and coefficient of determination (r2) values for 
simple allometry and MLP, liver body weight and liver blood flow 
corrections ............................................................................................ 95 
Table 2-9: Observed drug clearance of children in clinical studies compared to 
interpolated drug clearance using simple allometry and MLP, liver 
weight and liver blood flow corrections. ............................................... 97 
Table 2-10: Allometric interpolation of antimalarial doses in comparison to current 
dosage recommendations ...................................................................... 99 
Table 2-11: Allometric prediction of drug clearance for 70 kg adult using preclinical 
species compared to observed clearance in human studies and clearance 
predicted using preclinical and humans data........................................ 102 
Table 3-1: Apparent permeability for Rhodamine123 (5 µM) alone and when 
combined with PSC 833 (4 µM) for different Caco-2 cell monolayer 
models ................................................................................................ 148 
Table 4-1: Apparent permeability for rhodamine123 (5 µM) alone and when 
combined with of antimalarial drugs (100 µM) across P-44 Caco-2 cell 
monolayers ......................................................................................... 177 
   xix 
Table 4-2: Apparent permeability for rhodamine123 (5 µM) alone and when 
combined with of antimalarial drugs (100 µM) across P-80 Caco-2 cell 
monolayers ......................................................................................... 178 
Table 4-3: Apparent permeability for rhodamine123 (5 µM) alone and when 
combined with 300 µM of antimalarials across P-82 Caco-2 cell 
monolayers ......................................................................................... 180 
Table 4-4: Apparent permeability and efflux ratio for mefloquine through Caco-2 
cell monolayer. ................................................................................... 183 
Table 4-5: Apparent permeability and efflux ratio for amodiaquine through Caco-2 
cell monolayer .................................................................................... 184 
Table 4-6: Apparent permeability and efflux ratios for methylene blue transport 
through different Caco-2 cell models .................................................. 185 
Table 4-7: Apparent permeability and efflux ratios for of artesunate through Caco-2 
cell lines ............................................................................................. 188 
Table 4-8: Apparent permeability and efflux ratios for artemisone through Caco-2 
cell lines ............................................................................................. 190 
Table 4-9: Estimated gastrointestinal concentration for highest strenght dose of the 
drug, drug solubility and Ap-Bas directional Papp values for antimalarials 
found in the present study are listed. ................................................... 204 
Table 4-10: Biopharmaceuctical classitifiaction for antimalarials ......................... 205 
  
   xx 
List of Figures 
Figure 1-1: Exo-erythrocytic and erythrocytic phases of plasmodium parasite in 
human host ............................................................................................. 2 
Figure 1-2: The reported malaria deaths over 2000 to 2013 in the world based on 
World Malaria report 2014...................................................................... 4 
Figure 1-3: Chemical structures of selected antimalarial drugs ................................. 7 
Figure 2-1: Dihydroartemisinin:  allometric scaling relationship for clearance in 
healthy species (from IV artesunate data) .............................................. 68 
Figure 2-2: Dihydroartemisinin:  allometric scaling relationship for clearance in 
healthy species. Drug clearance in malaria infected adult and children are 
plotted for comparison (from IV artesunate data) .................................. 68 
Figure 2-3: Dihydroartemisinin: allometric scaling relationship for volume of 
distribution in healthy species (from IV artesunate data) ....................... 69 
Figure 2-4: Dihydroartemisinin: allometric scaling relationship for volume of 
distribution in healthy species. Drug volume of distribution in malaria 
infected adult and children are plotted for comparison (from IV 
artesunate data) ..................................................................................... 69 
Figure 2-5: Dihydroartemisinin: allometric scaling relationship for half-life in 
healthy species (from IV artesunate data) .............................................. 70 
Figure 2-6: Dihydroartemisinin: allometric scaling relationship for half-life in 
healthy species. Drug half-life in malaria infected adult and children are 
plotted for comparison (from IV artesunate data) .................................. 70 
Figure 2-7: Artesunate: allometric scaling relationship for clearance in healthy 
species. Drug clearance in malaria infected adult and children are plotted 
for comparison (IV data) ....................................................................... 71 
Figure 2-8: Artemisinin: Allometric scaling relationship for clearance of in healthy 
species. Drug clearance in malaria infected adult and children are plotted 
for comparison ...................................................................................... 72 
   xxi 
Figure 2-9: Artemether: allometric scaling relationship for clearance in healthy 
species. Drug clearance in malaria infected adult and children are plotted 
for comparison (IM data) ...................................................................... 73 
Figure 2-10: Clindamycin: allometric scaling relationship for clearance in healthy 
species. Drug clearance in malaria infected adult and children are plotted 
for comparison (IV data) ....................................................................... 74 
Figure 2-11: Piperaquine: allometric scaling relationship for clearance in healthy 
species. Drug clearance in malaria infected adult and children are plotted 
for comparison (oral data) ..................................................................... 74 
Figure 2-12: Mefloquine: allometric scaling relationship for clearance of in healthy 
species. Drug clearance in malaria infected adult and children are plotted 
for comparison (oral data) ..................................................................... 75 
Figure 2-13: Quinine: allometric scaling relationship for clearance of in healthy 
species. Drug clearance in malaria infected adult and children are plotted 
for comparison (IV data) ....................................................................... 76 
Figure 2-14: Artesunate: allometric scaling relationship for volume of distribution in 
healthy species. Drug volume of distribution in malaria infected adult and 
children are plotted for comparison (IV data) ........................................ 78 
Figure 2-15: Artemether: Allometric scaling relationship for volume of distribution 
in healthy species. Drug volume of distribution in malaria infected adult 
and children are plotted for comparison (IM data) ................................. 79 
Figure 2-16: Clindamycin: allometric scaling relationship for volume of distribution 
in healthy species. Drug volume of distribution in malaria infected adult 
and children are plotted for comparison (IV data) ................................. 80 
Figure 2-17: Piperaquine: allometric scaling relationship for volume of distribution 
in healthy species. Drug volume of distribution in malaria infected adult 
and children are plotted for comparison (oral data) ............................... 80 
Figure 2-18: Mefloquine: allometric scaling relationship for volume of distribution 
in healthy species. Drug volume of distribution in malaria infected adult  
and children are plotted for comparison (oral data) ............................... 81 
   xxii 
Figure 2-19: Quinine: allometric scaling relationship for volume of distribution in 
healthy species. Drug volume of distribution in malaria infected adult and 
children are plotted for comparison (IV data) ........................................ 82 
Figure 2-20: Artesunate: allometric scaling relationship for half-life of in healthy 
species. Drug half-life in malaria infected adult and children are plotted 
for comparison (IV data) ....................................................................... 84 
Figure 2-21: Artemether: allometric scaling relationship for half-life of in healthy 
species. Drug half-life in malaria infected adult and children are plotted 
for comparison (IM data) ...................................................................... 85 
Figure 2-22: Clindamycin: allometric scaling relationship for half-life of in healthy 
species. Drug half-life in malaria infected adult and children are plotted 
for comparison (IV data) ....................................................................... 86 
Figure 2-23: Piperaquine: allometric scaling relationship for half-life in healthy 
species. Drug half-life in malaria infected adult and children are plotted 
for comparison (oral data) ..................................................................... 86 
Figure 2-24: Mefloquine: allometric scaling relationship for half-life of in healthy 
species. Drug half-life in malaria infected adult and children are plotted 
for comparison (oral data) ..................................................................... 87 
Figure 2-25: Quinine: allometric scaling relationship for half-life of in healthy 
species. Drug half-life in malaria infected adult and children are plotted 
for comparison (IV data) ....................................................................... 88 
Figure 2-26: The regression line and 95% CI for allometric scaling relationship for 
dihydroartemisinin using simple allometry ............................................ 93 
Figure 2-27: The regression line and 95% CI for allometric scaling relationship for 
dihydroartemisinin using MLP correction ............................................. 93 
Figure 2-28: The regression line and 95% CI for allometric scaling relationship for 
dihydroartemisinin using liver weight correction................................... 94 
Figure 2-29: The regression line and 95% CI for allometric scaling relationship for 
dihydroartemisinin using liver blood flow correction ............................ 94 
   xxiii 
Figure 2-30: Regression line and 95% CI for interspecies scaling relationship for 
dihydroartemisinin (following IV artesunate) clearance using preclinical 
species ................................................................................................ 101 
Figure 2-31: Regression line and 95% CI for Interspecies scaling relationship for 
artemether (IM and IV data) clearance using preclinical species ......... 101 
Figure 3-1: Molecular structure of MDR1 (P-glycoprotein) .................................. 117 
Figure 3-2: Correlation of gene expression of drug efflux proteins of the ATP 
binding cassette transporter Family in human jejunum and human 
epithelial Caco-2 cell monolayers ....................................................... 127 
Figure 3-3: Calibration curve for rhodamine 123 .................................................. 137 
Figure 3-4: The diagram above shows the filter inserts placed in a 24 well plate and 
the arrows show the a) apical to basolateral and  b) basolateral to apical 
directional transport of the drugs ......................................................... 141 
Figure 3-5: Ap-Bas and Bas-Ap directional permeability of rhodamine123 across P-
44 Caco-2 cell monolayer  .................................................................. 147 
Figure 3-6: Ap-Bas and Bas-Ap  transport rhodamine123 alone and combined with 
P-gp inhibitor PSC 833 across Caco-2 RIF ......................................... 150 
Figure 3-7: Ap-Bas and Bas-Ap transport rhodamine123 alone and combined with P-
gp inhibitor PSC 833 across Caco-2 VIN  ........................................... 151 
Figure 3-8: Ap-Bas and Bas-Ap transport rhodamine123 alone and combined with P-
gp inhibitor PSC 833 across P-80 Caco-2 cell monolayer .................... 151 
Figure 3-9: Western blot analysis for MDR1 P-glycoprotein and beta-actin for 3 
Caco-2 cell models ............................................................................. 152 
Figure 3-10: Expression of P-gp over day 21 to 28 for P-44 cells and 3 cell models; 
P-44, Caco-2 RIF, P-83 caco-2 and Caco-2 VIN ................................. 153 
Figure 4-1: Calibration curve for rhodamine 123 in the presence of methylene blue 
for concentration range ....................................................................... 163 
Figure 4-2: Calibration curve for mefloquine ....................................................... 166 
Figure 4-3: Calibration curve for amodaiquine ..................................................... 167 
   xxiv 
Figure 4-4: Calibration curve for methylene blue  ................................................ 168 
Figure 4-5: Calibration curve for mefloquine for simultaneous assay of mefloquine 
and methylene blue ............................................................................. 169 
Figure 4-6: Calibration curve for methylene blue for simultaneous assay of 
mefloquine and methylene blue .......................................................... 170 
Figure 4-7: Calibration curve for artesunate ......................................................... 173 
Figure 4-8: Calibration curve for artemisone ........................................................ 175 
Figure 4-9: Ap-Bas and Bas-Ap transport of rhodamine123 alone and Ap-Bas and 
Bas-Ap ransport of rhodamine123 when combined with mefloquine ... 179 
Figure 4-10: Ap-Bas and Bas-Ap transport of rhodamine123 when combined with 
mefloquine and Ap-Bas and Bas-Ap transport of rhodamine123 when 
combined with mefloquine and artesunate ........................................... 179 
Figure 4-11: Ap-Bas and Bas-Ap transport of mefloquine across late passage Caco-2 
cells .................................................................................................... 181 
Figure 4-12: Ap-Bas and Bas-Ap transport of methylene alone and Ap-Bas and Bas-
Ap of methylene blue when combined with PSC 833 across late passage 
Caco-2 cell monolayer ........................................................................ 186 
Figure 4-13: Ap-Bas and Bas-Ap transport of methylene alone and Ap-Bas and Bas-
Ap of methylene blue when combined with PSC 833 across Caco-2 VIN 
cell monolayer  ................................................................................... 187 
Figure 4-14: Ap-Bas nd Bas-Ap transport of methylene blue alone and Ap-Bas and 
Bas-Ap of methylene blue when combined with PSC 833 across Caco-2 
RIF cell monolayer ............................................................................. 187 
Figure 4-15: Western blot for 96 hours exposure of antimalarials on Caco-2 cell 
monolayer. .......................................................................................... 191 
Figure 4-16: Regulation of P-gp transporter protein compared to control following 
96 hours of antimalarials exposure  on confluent Caco-2 cell monolayer.
 ........................................................................................................... 191 
Figure 4-17: Western blot for 48 hours exposure of 10 µM antimalarials as single 
drug or combination on LS174T cells ................................................. 192 
   xxv 
Figure 4-18: Regulation of P-gp transporter protein compared to control following 
20 µM  antimalarials exposure  for 48 hours on LS174T cells. ............ 193 
 
   Page 1 of 294 
1 Introduction 
1.1 Malaria  
The history of malaria goes back over 4000 years, and a disease with symptoms similar 
to malaria was described in ancient Chinese medical writing. Later this seasonal, 
intermittent fever was named as mal’aria and widely recognized along with its clinical 
symptoms in the 4th century BC (1). 
Even today, malaria is a devastating fatal parasitic infection and a significant cause of 
morbidity and mortality in the developing world in spite of the advancement of biology 
and discovery of new drugs (2-4). The disease killed about 0.5 million children in 2013 
(5). 
Malaria is a protozoan parasitic infection of red blood cells caused by the Apicomplexan 
pathogen of genus Plasmodium. There are five Plasmodium species that can cause 
malaria in human; Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, 
Plasmodium malariae and Plasmodium knowlesi even though there are over 200 species 
of Plasmodium. Of these, the most deadly is Plasmodium falciparum which causes more 
than 95% of all malaria deaths (6). Inoculation of the Plasmodium parasite into a human 
host is commonly through the female Anopheles mosquito, though transmission may 
also occur through blood transfusions and transplacentally. The parasitic life cycle in 
the human has two phases (7).  
Exo-erythrocytic phase 
Sporozoites, the infective form of Plasmodium, are introduced through the skin by the 
Anopheles mosquito, commencing the human cycle. Sporozoites not destroyed by the 
human host immune system, travel into the liver and undergo multiplication. A number 
of days later, merozoites are liberated causing clinical symptoms of the primary attack 
(7, 8).  
Erythrocytic phase  
The erythrocytic phase begins when red blood cells become infected with merozoites. 
In the red blood cells, merozoites pass through several stages of development from early 
trophozoites (rings) to late schizonts. The erythrocytic cycle terminates with the rupture 
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of red blood cells and the release of merozoites to commence the next cycle of red blood 
cell invasion. Release of merozoites causes clinical symptoms of malaria and this 
happens 48 hourly for Plasmodium falciparum, every 48-72 hours for Plasmodium vivax 
and Plasmodium ovale, every 72 hours for Plasmodium malariae and every 24 hour for 
Plasmodium knowlesi (7). The figure below shows the exo-erythrocytic and erythrocytic 
stages of the life cycle.  
 
   
Figure 1-1: Exo-erythrocytic and erythrocytic phases of plasmodium parasite in 
human host (obtained from Baird (8)) 
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The clinical symptoms of uncomplicated malaria consist of a cold (sensation of cold, 
shivering), hot (fever, headaches, vomiting; seizures in young children) and sweating 
(sweats, return to normal temperature, tiredness) stages (1). Whereas cerebral malaria, 
metabolic acidosis and severe anaemia are the three overlapping clinical symptoms of 
severe malaria (1, 9).  Cerebral malaria and metabolic acidosis still account for 15-20% 
of malaria mortality (9).    
The diagnosis of malaria is mostly based on clinical symptoms and microscopic 
detection of parasite on a blood film (10). The laboratory finding of mild anaemia, 
elevation of bilirubin and aminotransferases and mild decrease in blood platelets 
(thrombocytopaenia) are additional laboratory investigations that could help in the 
diagnosis of malaria (1).   
Drugs used in the management of malaria target asexual blood parasitic stages and 
reduce the disease symptoms, parasite load and progression to severe malaria (11). 
Drugs used in malaria are discussed in section 1.4 of the thesis.  
 
1.2 Epidemiology of malaria 
Malaria is a major global health problem with an estimated 225 million cases of malaria 
in 2009 and 584,000 deaths reported in world in 2013 (3, 5, 12). Worldwide malaria 
mortality over 2000-2013 is shown in Figure 1.2 (5).  There are 106 malaria endemic 
countries. Of these, 43 are in Africa, 23 in South America and 20 in the South East Asian 
and Western Pacific regions (3, 12). The highest mortality (91%) and morbidity (81%) 
of malaria is in Africa, with children under five years old and pregnant women most 
severely affected (5). Asia is recognised as a region with a high risk of malaria and 6% 
of total malaria deaths were reported from South-East Asia (12, 13). 
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1.3 Drug development in malaria  
Antimalarials along with antipyretics are the most commonly used and misused 
medications in tropical parts of the world (14).  The extensive use of inexpensive, long 
elimination half-life medication such as chloroquine and sulphadoxine-pyrimethamine 
were subjected to drug resistance minimising the potential use of these medications in 
the treatment of malaria (14). The control of malaria is not an easy task, one of the main 
reasons being the gap in demand and supply of new and affordable drugs. The 
antimalarial drug market is one of the largest in the world requiring over half a billion 
treatments per year. However, the majority of patients are unable to afford their 
medication (15). The antimalarial drug market is not attractive to the pharmaceutical 
industry due to lack of financial return. Thus investment for new drug development is 
minimal. However with an increase in funding for new drugs and malaria control 
programs from philanthropic organizations (15), some control in malaria morbidity and 
mortality has been observed over recent years as shown in Figure 1.2 (5). 
The need for development of new antimalarial drugs will continue as there is a high 
probability that malaria parasites will eventually develop resistance to all existing 
remedies. Pharmacokinetic research for optimum dosing and dosage regimens for 
existing and new medication is also of crucial importance as drug resistance is mostly 
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Figure 1-2: The reported malaria deaths over 2000 to 2013 in the world based on 
World Malaria report 2014 (5).  
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linked to suboptimal drug concentrations of medication with a long elimination half-life 
(16). Altered pharmacokinetics in malaria infection is observed for drugs such as 
quinine and therefore pharmacokinetics established in healthy volunteers might not be 
valid in malaria infection (17, 18). The presently recommended artemisinin-based 
combination therapy for uncomplicated Plasmodium falciparum malaria need to be 
replaced with non-artemisinin based combinations if resistance emerged for most potent 
artemisinin and its derivatives. Severe Plasmodium falciparum malaria requires 
intravenous medication. Hence, new drugs that can be administered intravenously and 
their pharmacokinetic profile need to be established to replace quinine and artesunate. 
Another important goal would be to develop medications that can reverse severe malaria 
complications and risk of long-term disability (9).  
 
1.4 Drugs in malaria  
There are about 10 different chemical classes of antimalarial drugs available for the 
management of malaria; sesquiterpene lactones, arylaminoalcohols, 4-aminoquinolines, 
8-aminoquinolines, cinchona alkaloids, dihydrofolate reductase inhibitors, 
naphthoquinones and antibiotics. These drugs are used in single and combination 
therapy in the chemoprophylaxis (to prevent persistence of the parasite and 
chemotherapy (to suppress and clear parasitaemia) of malaria (6, 19). 
Antimalarials act on various stages of the parasite life cycle to exert their 
pharmacological action and drugs can be classified based on the specific stage of 
parasite activity they target; blood schizonticide (chloroquine, quinine, mefloquine, 
amodiaquine, artemisinin derivatives, tetracycline and sulfadoxine-pyrimethamine), 
tissue schizonticides (primaquine, pyrimethamine and proguanil), gametocytocides 
(primaquine and artemisinin derivatives) and sporonticides (primaquine, 
chloroguanidine and proguanil) (6, 20). 
Pharmacokinetic literature on the drugs of interest for my thesis are summarized in the 
below section.  
The chart below classifies the antimalarials based on their chemical class. 
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Chemical classification of anti-malarial drugs (19, 21) 
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Artemisinin derivatives  
(Sesquiterpene lactone)
Artemisinin, artesunate, 
artemether, dihydroartemisinin, 
artemisone  
Quinolines
4-aminoquinolines: chlroquine, 
amodiaquine, piperaquine
Quinoline methanol: mefloquine
8-aminoquinoline: piperaquine
Cinchona alkaloids 
Quinoline methanol: quinine
Antibiotics
Tetracycline, doxycycline, 
clindamycin
Antifolates
Biguanides: proguanil, 
chloroproguanil 
Sulfonamides: sulfadoxine, dapsone 
Diaminopyrimidines: pyrimethamine  
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Chemical structures of selected drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3: Chemical structures of selected antimalarial drugs 
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Artemisinin derivatives 
1.4.1 Artemisinin  
Molecular formula: C15H22O5, Molecular weight: 282.3 g, Log P: 3.14 ± 0.84 (3, 22, 
23) 
Artemisinin (Qinghaosu) is a natural antimalarial agent isolated from the Chinese herb 
sweet wormwood Artemisia annua L, which was used in China for the treatment of 
malaria (24). The clinically active isolate has a sesquiterpene lactone with an internal 
endoperoxide linkage, an essential component for the parasiticidal effect (25). 
Artemisinin has a low solubility and can only be given orally and rectally, hence 
artemisinin derivatives with increased solubility and efficacies were developed. The 
semi-synthetic artemisinin derivatives: dihydroartemisinin (DHA), artesunate (ART), 
artemether and arteether were later introduced into clinical practice. It is strongly 
discouraged for artemisinin and its derivatives to be given as single therapy due to the 
short duration of action, instead combinations with long acting quinolines are 
recommended.  
Pharmacokinetics: The artemisinin rectal bioavailability relative to the oral route, and 
oral bioavailability relative to intramuscular (IM) route was found to be 30% and 32% 
respectively (26-28). Artemisinin has shown good in-vitro drug permeability with 
bidirectional transport values of 30 × 10-6 in Caco-2 cell models (29). It is suggested that 
artemisinin could have a high liver extraction due to its high permeability, lower 
bioavailability and lack of correlation between oral clearance (CL) and half-life of the 
drug (30).  
Artemisinin is metabolised in the liver mainly via CYP2B6 to its inactive metabolites 
(27, 31). Auto induction of enzymes/time dependent pharmacokinetic (increase in half-
life with increase in doses) and inter-individual variability in pharmacokinetic were 
observed for artemisinin (31, 32). The fraction of unbound artemisinin in plasma was 
15% and correlated weakly with alpha 1-acid glycoprotein (27).  
A pharmacokinetic study of artemisinin in combination with mefloquine found a lower 
area under the curve (AUC) and lower apparent clearance (CL/F) in combination 
therapy compared to artemisinin therapy alone. This could be due to the metabolic 
interactions in the gut or in the liver (33).  
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The World Health Organisation (WHO) Guide for malaria (3) has not published 
artemisinin dosing recommendations for uncomplicated malaria. However the standard 
dosage regimen used is 250 mg two times a day for 5 days (34). There are tablets (250 
mg) and suppositories (100 mg, 200 mg, 300 mg, 400 mg and 500 mg) available to 
deliver the current regimen.   
 
1.4.2 Artesunate  
Molecular formula: C19H28O8, Molecular weight: 384.4 g, pKa: 4.28±0.17, Log P: 
3.291±0.883 (3, 23) 
Artesunate is a salt of the hemisuccinate ester, prepared by reducing the artemisinin and 
adding a hemisuccinate ester component. This is the only artemisinin derivate soluble 
in water at physiological pH, but has a poor stability when solubilized (21, 35, 36). The 
drug can be administered parenterally, orally and through the rectum. There are 
pharmacokinetic advantages of parenteral artesunate compared to IM artemether, 
therefore it is preferred in severe malaria (37). There are reports of increasing rates of 
treatment failure and an increase in parasite clearance time for artesunate-mefloquine 
combination in uncomplicated Plasmodium falciparum malaria, hence signs of decrease 
in efficacy of artesunate combination therapy (38).  
Pharmacokinetics: Artesunate is rapidly converted to the active metabolite 
dihydroartemisinin. The ratio of AUCDHA/AUCAS is 5.26 and 4.3-9.7 for malarial 
infected rats and humans respectively and therefore is considered as a pro-drug of 
dihydroartemisinin (39-41).  
It is claimed that a pH dependent chemical hydrolysis conversion of artesunate to 
dihydroartemisinin occurs in the stomach. Artesunate has better stability in plasma than 
in the stomach (42). The dihydroartemisinin peak concentration was achieved in 10 
minutes after intravenous (IV) artesunate indicating rapid conversion of artesunate to 
dihydroartemisinin in the systemic circulation. The oral bioavailability for artesunate 
was found to be 23% for five patients on oral artesunate (40, 41). 
A gradual decline in drug concentration was seen when artesunate was administered 
over three days to malaria infected rats. This was attributed to possible auto induction 
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of hepatic drug metabolising enzymes (39). In comparison, a decline in plasma 
concentration of dihydroartemisinin was observed in malarial infected patients 
following five days of oral treatment with artesunate (43). A pharmacokinetic study of 
artesunate and piperaquine combination in children with uncomplicated malaria 
suggested an auto induction of artesunate metabolism (44). However no auto induction 
of CYP2B6 was observed following five days of treatment with oral artesunate in 
healthy volunteers (45). Similar to this finding, in a pharmacokinetic study of artesunate 
in healthy volunteers found no decline in drug concentration over three days of treatment 
(46). Therefore decline in concentration in malaria infected patients could be explained 
by the increase in hepatic enzymes and blood flow due to disease recovery rather than 
auto induction of enzymes. It is possible that not all endoperoxide antimalarials are 
inducers of their own metabolism and the metabolic pathway of dihydroartemisinin may 
be different to that of artemisinin (46).  
No change in pharmacokinetics of artesunate or its active metabolite dihydroartemisinin 
was found when combined with mefloquine for three days (47).  
Artesunate is recommended in uncomplicated malaria in combination with amodiaquine 
or mefloquine at an oral dose of 4 mg/kg/day and the therapeutic dose range is 2-10 
mg/kg/day (3). It is strongly recommended to use intravenous (IV) artesunate in the 
treatment of severe malaria in preference to IV quinine therapy. The dose recommended 
for both adults and children is 2.4 mg/kg IM or IV artesunate at 0, 12 and 24 hours, 
followed by once daily treatment (3). Artesunate is available in tablets (50 or 200 mg 
sodium artesunate), parenteral dosage forms (60 mg anhydrous artesunic acid ampoules) 
and fixed dose combinations (Artesunate and amodiaquine at 25/67.5, 50/135 and 
100/270 mg and artesunate and mefloquine at 50/250 mg). 
 
1.4.3 Artemether  
Molecular formula: C16H26O5, Molecular weight: 298.4 g, Log P: 2.82±0.86 (3, 23). 
Artemether is the O-methyl ether derivative of dihydroartemisinin. This is more lipid 
soluble than the other artemisinin derivatives and is administered intra muscularly and 
orally. Artemether is recommended to be combined with long acting lumefantrine in 
malaria treatment (3).  
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Pharmacokinetics: Absorption of artemether following IM administration is variable 
and erratic (37, 48). Artemether undergoes extensive first pass metabolism in the liver 
following oral administration and is metabolised by CYP3A4, 2B6 and 3A5 to its active 
metabolite dihydroartemisinin (37). The metabolite, dihydroartemisinin predominates 
following oral administration and artemether predominates following IM administration 
(49). Artemether is 95% plasma protein bound, mainly to alpha 1-acid glycoprotein and 
to a lesser extent to albumin (50). Pharmacokinetic studies of artemether for five days 
in rats and two days in patients with Plasmodium falciparum malaria have shown time 
dependent pharmacokinetics or auto induction of enzymes (51, 52)  
The relative bioavailability of oral artemether compared to oral artesunate was 58% 
(53). The bioavailability of IM DHA and Intrarectal (IR) DHA relative to oral 
artemether was 25% and 35% respectively. The relative bioavailability of oral compared 
to IM artemether was 43.2% (54). In rats, bioavailability of IM artemether was 54% 
(55). 
Bioavailability and maximum concentration (Cmax) of artemether increased significantly 
when administered with grapefruit juice and inhibitors of CYP3A4 (56). 
Artemether doses are recommended for uncomplicated malaria considering body weight 
ranges of the patient. The WHO guide recommends 1, 2, 3 and 4 of 20 mg tablets twice 
a day for three days for 5-14, 15-24, 25-34 and > 34 kg body weights respectively (the 
therapeutic dose range 1.4 to 4 mg/kg) (3). Artemether is recommended as an alternative 
therapy at the dose of 2 mg/kg on admission followed by 1.6 mg/kg per day for severe 
malaria in situations where first line therapy IV artesunate is not available (3). 
Artemether is available in both oral and parenteral dosage forms; tablets (50 mg), 
capsules (40 mg), injectable (40 and 80 mg in 1 mL) and fixed dose combinations (FDC) 
(20 mg artemether and 120 mg lumefantrine).  
 
1.4.4 Dihydroartemisinin  
Molecular formula: C15H24O5, Molecular weight: 284.4 g, pKa: 12.61 ± 0.70, Log P: 
2.19 ± 0.86 (3, 23) 
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Dihydroartemisinin is the main active metabolite of artemisinin derivatives; artesunate 
and artemether. Dihydroartemisinin is also administered orally as a drug in its own right. 
It has similar efficacy to that of artesunate and is therapeutically 3-5 fold more active 
than the parent compound artemisinin. The increased activity also makes it more toxic 
with increased adverse effects (57). Dihydroartemisinin needs to be prepared in suitable 
excipients due to its poor water solubility and stability.  
Pharmacokinetics: Dihydroartemisinin is 93% protein bound in malaria patients and 
the ratio of α-DHA: β-DHA was found to be 6 and 5 for malaria patients and volunteers 
respectively (58). Drug metabolism is through intestinal and hepatic glucuronidation 
and has a high hepatic extraction ratio (59). Dihydroartemisinin has shown a higher 
hepatic extraction ratio in an isolated perfused rat liver model where the hepatic 
extraction ratio was reduced by 20-30% in rodents infected with Plasmodium berghei 
malaria (60). A mass balance study of dihydroartemisinin in rats has shown 
enterohepatic cycling (61). 
Bioavailability of dihydroartemisinin is reported for both healthy volunteers and malaria 
infected patients following administration of the pro-drug artesunate and oral 
dihydroartemisinin. In healthy volunteers, the absolute oral bioavailability of 
dihydroartemisinin was 80% and 45% following artesunate and dihydroartemisinin 
administration. Dihydroartemisinin parenteral dosage forms are not available, therefore 
calculation was based on the assumption that IV artesunate was completely converted 
to dihydroartemisinin (62). Oral bioavailability of dihydroartemisinin (35-48%) relative 
to oral artesunate was twofold higher when compared to oral dihydroartemisinin (15-
21%) in healthy Caucasian volunteers. It is suggested that the higher bioavailability of 
dihydroartemisinin following oral artesunate could be due to protection of the 
metabolite from pre-systemic glucuronide conjugation. Thus it is recommended that oral 
artesunate should be used over oral dihydroartemisinin. (59).  
In malaria infected patients, absolute IM bioavailability of dihydroartemisinin was 86-
88% after administration of the pro-drug (36, 63) whereas the oral bioavailability of 
dihydroartemisinin relative to oral artesunate was 82-88% in patients with malaria (40, 
41, 62). Newton, van Vugt (64) found a higher total area under the curve, smaller Cmax, 
prolonged time to reach maximum concentration (tmax) and lag time for 
dihydroartemisinin following oral administration of dihydroartemisinin compared to 
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oral artesunate in malaria infected patients. The authors recommended that oral 
dihydroartemisinin could be a satisfactory alternative to oral artesunate given the ease 
of manufacture and lower cost. The bioavailability of dihydroartemisinin for IR 
artesunate ranged from 16-85% in patients with malaria (36, 65).  
The WHO (3) recommends dihydroartemisinin oral dosage regimen for the management 
of uncomplicated malaria at 4 mg/kg once daily for 3 days in combination with 
piperaquine (therapeutic range 2-10 mg/kg). Dihydroartemisinin tablets are available in 
20, 60 and 80 mg tablet strengths.  
  
1.4.5 Artemisone  
Molecular formula: C19H31NO6S, Molecular weight: 401.52 g, log P = 2.49 (66). 
The newly developed artemisone is a promising semi synthetic artemisinin derivative 
that can be synthesized from dihydroartemisinin in a one step process (67). In-vitro and 
animal studies have shown that artemisinin and its derivatives are neurotoxic (in 
particular dihydroartemisinin), although the mechanisms are not fully understood (68, 
69). Artemisone development was based on evidence that an artemisinin derivative with 
better aqueous solubility and decreased lipid solubility would give increased systemic 
activity and decreased neurotoxicity.  
Efficacy of artemisone was determined in in-vitro and in-vivo (using Plasmodium 
berghei infected rodents) studies where both studies found artemisone to be 4 to 10 time 
more potent than artesunate (70). The in-vitro study showed that artesunate and 
artemisone to have similar trends of interactions, a synergistic interaction with 
mefloquine and somewhat antagonistic interaction with amodiaquine are observed. An 
in-vivo rodent model showed synergistic interaction between artemisone and 
mefloquine. 
Pharmacokinetics: Pharmacokinetic studies of artemisone in malaria infected monkeys 
have shown increased in-vivo activity of artemisone compared to artesunate Ex-vivo 
bioassay study was conducted by testing blood samples against Plasmodium falciparum 
K1 (67). A comparative bioavailability study of 30 mg/kg artesunate and artemisone in 
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healthy Saimiri monkeys found a higher bioavailability of artemisone compared to 
artesunate (67).  
Artemisone underwent a Phase I clinical trial in 32 healthy Caucasian volunteers (66). 
The trial used single and multiple doses in the range of 10 to 80 mg (oral solution and 
20 mg immediate release tablets were administered) and the pharmacokinetic 
parameters obtained were similar to other artemisinin derivatives. The drug was rapidly 
absorbed and peak concentration was attained at 1.5 hours. The half-life and volume of 
distribution were 3.1 hours and 13.7 litres (66).  
The metabolism of artemisone was through CYP3A4 and produced minimum of six 
metabolites with three of the metabolites still having anti-malarial properties (66, 67). 
Unlike the other artemisinin derivatives and artemisinin, (artemether more evident and 
artesunate and dihydroartemisinin less evident) artemisone does not undergo auto 
induction of enzymes (67).  
 
Quinolone derivatives  
1.4.6 Amodiaquine 
Molecular formula:  C20H22ClN3O, Molecular weight: 355.9 g, Most acidic pKa: 
9.43±0.50, Most basic pKa = 5.62±0.50, log P = 2.6 (3, 23, 71) 
Amodiaquine (AQ) is a 4-aminoquinoline and has similar action and efficacy to that of 
chloroquine. Amodiaquine (amodiaquine dihydrochloride dihydrate) is soluble in 22 
parts of water and 70 parts of alcohol (21). A solution with 2% W/V amodiaquine in 
water has a pH of 3.6 to 4.6. Solubility of amodiaquine decreases with increasing pH 
(72, 73). 
Pharmacokinetics:  This drug is rapidly absorbed from the gastrointestinal tract (tmax 
within 30 minutes) and rapidly converted to its active metabolite desethylamodiaquine 
in the liver (74). Amodiaquine is considered to be a pro-drug. Both amodiaquine and its 
active metabolite are more than 90% protein bound (75). The metabolite contributes to 
most of the antimalarial effects and is accumulated in the blood cells with 3:1 blood to 
plasma ratio. The active metabolite has a longer half-life than the parent drug and is 
detected after 96 hours of the oral dosing (74). 
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Pharmacokinetic interactions for concurrent administration of artesunate and 
amodiaquine were studied in healthy volunteers. The study found that the area under the 
curves for the active metabolites of the drugs, desethylamodiaquine and 
dihydroartemisinin were significantly lower compared to the single therapy. The 
clearance and the tmax values for dihydroartemisinin were similar to the single therapy. 
The day 7 desethylamodiaquine plasma levels were lower in the combination therapy 
and no change in Vz/F and Cmax was observed (76). 
Concurrent administration of artesunate and amodiaquine combination therapy with 
antiviral efavirenz increased the AUC for amodiaquine and decreased the 
desethylamodiaquine exposure in two of the five healthy human volunteers. This was 
linked to CYP2C8 inhibition by the antiretroviral medication (77, 78). 
The WHO guide for malaria recommends amodiaquine to be administered in the dose 
range of 7.5 to 10 mg/kg for the treatment of uncomplicated Plasmodium falciparum 
malaria. Amodiaquine is available only for oral administration and the amodiaquine 
base is available in dosing strengths of 153 and 200 mg in the salts of hydrochloride and 
chlorohydrate. 
 
1.4.7 Piperaquine  
Molecular formula: C29H32CL2N6, Molecular weight: 535.51g, Most basic pKa: 8.92 ± 
0.50, Log P: 6.8 ± 1.4 (3, 23) 
Piperaquine is a highly lipophilic bisquinoline molecule (20). This is commercially 
available either as the base or as the water soluble salt, piperaquine phosphate. 
Piperaquine, first synthesized in 1960s, was widely used as a single therapy for 
chloroquine resistant malaria from the 1970s to 1980s in China, until piperaquine 
resistance became widespread in the 1990s (79, 80). However, use of piperaquine 
resurfaced as a partner drug for artemisinin combination therapy. Currently 
dihydroartemisinin and piperaquine combination therapy is recommended in the 
treatment of uncomplicated Plasmodium falciparum malaria (81). This combination is 
found to be advantageous over the other artemisinin combinations in high transmission 
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areas due to the longer period of post treatment prophylaxis of piperaquine with a half-
life of about 28 days (20).   
Pharmacokinetics: Piperaquine has shown multiphasic distribution with large Vz/F, 
low apparent clearance (CL/F) and long terminal half-life. The concentration time 
profile for piperaquine has shown multiple peaks, which is linked to entrohepatic 
recycling or multisector intestinal absorption (82). However studies in rats have shown 
that there is negligible biliary and renal clearance of piperaquine and it is assumed to be 
eliminated mainly through hepatic metabolism (83). In rats and humans, a carboxylic 
acid metabolite is found to be the major metabolite in piperaquine metabolism (83). 
Piperaquine is more than 99% plasma protein bound in rat, mouse, dog and human (84) 
and the red blood cells to plasma ratio is 1.5 (85). 
It is recommended to increase weight adjusted piperaquine doses in children compared 
to that of adults (86). A marked increase in drug clearance in children compared to adults 
with Plasmodium vivax and Plasmodium falciparum malaria was observed in a 
pharmacokinetic study (87). Day 7 piperaquine concentration is suggested to determine 
the therapeutic success of such slowly cleared drugs (88). Piperaquine multiple dose 
pharmacokinetics were significantly different to single dose pharmacokinetics and it is 
suggested that this might be due to accumulation of piperaquine from the previous doses 
(89, 90). 
The oral bioavailability of piperaquine in rats was found to be 50% (83), yet high fatty 
meals are reported to increase its bioavailability (90, 91). 
Piperaquine is recommended to be given at the dose of 18 mg/kg/day (therapeutic dose 
range between 16–26 mg/kg/dose) in combination with dihydroartemisinin for the 
treatment of uncomplicated Plasmodium falciparum malaria.  Fixed dose combinations 
(FDCs) for dihydroartemisinin and piperaquine are available at the dose of 40 and 320 
mg respectively.  
 
1.4.8 Mefloquine  
Molecular formula: C17H16F6N2O, Molecular weight: 378.3g, Most acidic pKa: 
12.81±0.20, Most basic pKa: 9.24±0.10, Log P: 2.20±1.15 (3, 23)  
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Mefloquine (MQ) is a 4-methanolquinoline and available as mefloquine hydrochloride. 
This is recommended as a chemoprophylactic for chloroquine resistant strains, even 
though toxicity of the drug is a concern (92). The mechanism of action of mefloquine is 
unclear and claimed to have a strong blood schizonticidal activity against Plasmodium 
falciparum and Plasmodium vivax malaria (20). Mefloquine is only slightly soluble in 
water at physiological pH (0.3mg/mL at pH 7.4) and soluble in ethanol and is sensitive 
to light (93, 94). The molecule has two asymmetric carbon atoms and the commercially 
available mefloquine is the racemic mixture of two enantiomers. 
Pharmacokinetics: Mefloquine shows enantioselectivity after administration of 
racemic mixture (95). This drug can only be given orally and parenteral use is avoided 
due to severe local irritation (20, 96-98). Following oral administration, it undergoes 
little first pass metabolism and has low intrinsic clearance (96, 99). 
Mefloquine is well absorbed from the gastrointestinal tract and 98.3% bound to plasma 
protein (3, 20, 100, 101).  Blood to plasma ratio is 1.1 (102). The drug is metabolised in 
the liver into inactive metabolites, 2,8-bis(trifluoromethyl)-4-quinolinecarboxylic acid; 
a quinoline carboxylic acid derivative. Little drug is excreted in the urine. Animal 
studies suggest the drug is excreted in the bile and faeces and undergoes enterohepatic 
recycling; this could be the reason for long half-life of the drug (3, 20, 101, 103). In-
vitro studies on mefloquine suggest that it is a substrate and an inhibitor of CYP3A4 
and P-glycoprotein (104, 105). CYP3A4 mediated pharmacokinetic interactions for 
mefloquine are reported for cimetidine, rifampicin and ketoconazole and enterohepatic 
recycling related interactions for ampicillin and tetracycline (99, 106-109). The increase 
in the area under the curve and Cmax of mefloquine when co-administered with 
ketoconazole could also be due to inhibition of P-gp by ketoconazole (109). Drug 
absorption of mefloquine is increased when ingested with a high fatty meal (110).  
It was found that oral bioavailability and Cmax of mefloquine was significantly lower 
when mefloquine was given 24 hours after a single dose of artemether, which could be 
attributed to a decrease in mefloquine absorption or an increase in CL/F in the presence 
of artemether (111). In the combination therapy of artesunate and mefloquine, some 
pharmacokinetic parameters of mefloquine changed significantly, decrease in Cmax, an 
increase in CL/F and expansion of Vz/F were observed. This antagonistic 
pharmacokinetic interaction has overridden the synergistic effect of the combination 
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therapy with a lower cure rate for combination therapy (66%) compared to the 75% cure 
rate for the group receiving mefloquine alone (112). The change in pharmacokinetics 
could be attributed to high plasma protein binding of mefloquine; which will create 
competition for artesunate at plasma proteins. This could increase free mefloquine 
resulting in increase in CL/F and Vz/F. The decrease in Cmax could be attributed to a 
decrease in oral absorption and/or reduction in oral bioavailability. It is also worth 
noting that the change in pharmacokinetics of mefloquine could be attributed to 
artesunate itself or its active metabolite dihydroartemisinin (112).  
Mefloquine is recommended in combination with artesunate at either 25mg/kg split over 
two days (15 mg/kg on day one and 10 mg/kg on day two) or 10 mg/kg over 3 days in 
the treatment of uncomplicated malaria. The therapeutic dose range is 7-11 mg/kg/dose. 
Mefloquine hydrochloride tablets are available in 250 mg base, FDC of 25mg artesunate 
and 250 mg mefloquine (3) 
 
Cinchona alkaloids  
1.4.9 Quinine  
Molecular formula: C20H24N2O2, Molecular weight: 324.4 g, Most acidic pKa: 
12.80±0.20, Most basic pKa: 9.28±0.70, Log P: 2.83±0.43 (59) 
Quinine, a 4-methanol quinoline antimalarial, is an alkaloid obtained from the bark of 
the cinchona tree and has been used for treatment and prevention of malaria since 1820. 
Quinine has been used for treatment of severe malaria before clinical trials method was 
used to decide comparative efficacies (3).  
Pharmacokinetics: Following oral administration, quinine is rapidly and completely 
absorbed and is widely distributed in the body, including into cerebrospinal fluid (CSF), 
breast milk and the placenta. 
Quinine is extensively metabolised in the liver via CYP3A4 and polar metabolites are 
excreted in the urine (113, 114). The major metabolite 3-hydroxyquinine contributes to 
10% of the antimalarial activity. Renal clearance accounts for 20% of the excretion 
(115). Quinine is a drug with a low intrinsic clearance and sensitive to malaria infection, 
therefore, drug clearance could change with reduced liver enzyme activity (18, 116). 
   Page 19 of 294 
The pharmacokinetics of quinine varies depending on malaria infection status and age. 
Quinine is a weak base and 70% and 90% bound to alpha 1-acid glycoprotein (30% 
bound to albumin) in healthy volunteers and during malaria infection, respectively (117, 
118). The blood to plasma ratio of quinine is 0.7 (119). The Vz/F of quinine (basic drug) 
was reduced in acute malaria infection due to an increase in α-acid glycoprotein (120-
122). Mean elimination half-life is 11, 16 and18 hours in healthy subjects, 
uncomplicated malaria and severe malaria respectively (20).   
Malaria infection induced dysfunction of the hepatic mixed function oxidase (mainly 
CYP3A), impairs metabolic conversion of quinine resulting in reduction in drug 
clearance in malaria infection compared to the healthy state (18). The liver blood flow 
is also reduced in patients with acute Plasmodium falciparum malaria. Theoretically, 
hepatic drug clearance is not affected by the change in liver blood flow for low 
extraction ratio drugs (123), however liver blood flow could still become an important 
determinant of quinine clearance in very severe malaria (18, 124). Quinine clearance in 
malaria infected children was significantly lower than in convalescent children (125) 
Pre-treatment with cimetidine resulted in decreased CL/F of quinine and concurrent 
administration of quinine with ritonavir resulted in a 4 fold increase in area under the 
curve and a 4.5 fold decrease in drug clearance in healthy volunteers (126, 127). Pre-
treatment with the CYP450 enzyme inducers rifampicin, cigarette smoking and 
nevirapine increased the drug clearance and decreased the area under the curve of 
quinine (128-130).  No pharmacokinetic drug interaction was found when quinine and 
grapefruit juice were co-administered though (131).  
The oral bioavailability of quinine was 76-88% in healthy volunteers (132, 133). The 
relative bioavailability of rectal quinine compared to oral quinine was 21% (134). 
Quinine is recommended in severe malaria; loading dose of 20 mg/kg and maintenance 
dose of 10 mg/kg every 8 hours is administered in a rate controlled IV infusion or IM 
injections (3). 
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Antibiotics  
1.4.10 Clindamycin  
Molecular formula:  C18H33ClN2O5 S, Molecular weight: 424.98 g, pKa: 7.45 (135, 136) 
Clindamycin is available as hydrochloride or phosphate salts in capsule form or as 
palmitate hydrochloride in oral solutions. In children, doxycycline may be substituted 
with clindamycin and this is recommended as a second line therapy in combination with 
artesunate or quinine in the treatment of uncomplicated Plasmodium falciparum malaria 
(3).  
Pharmacokinetics: Clindamycin hydrochloride is rapidly absorbed from the 
gastrointestinal tract (3, 137). Clindamycin is about 90% plasma protein bound in 
humans and binds mainly to alpha 1-acid glycoprotein (138). In rats, the plasma protein 
binding of clindamycin was found to be 67.5% and 61% of the dose was subjected to 
first pass elimination (139). The drug undergoes metabolism primarily through human 
CYP3A4 in the liver to its active metabolites N-desmethyl clindamycin and 
sulphadoxides as well as to inactive metabolites (140, 141). Clindamycin has a low 
intrinsic clearance (142). The absolute bioavailability of clindamycin was 53% and 72% 
in human volunteers and dogs following oral administration of clindamycin 
hydrochloride.  
Clindamycin 10 mg/kg twice a day for 7 days is the recommended to be combined with 
artesunate or quinine in the management of uncomplicated Plasmodium falciparum 
malaria. Clindamycin base 75, 150 and 300 mg capsules are available in its salt form.  
 
1.4.11 Methylene blue  
Molecular formula: C16H18N3SCl, Molecular weight: 319.85 g, pKa of the reduced form: 
5.8, pKa oxidized form: 0 (143, 144) 
Methylene blue (MB: Methylthioninium chloride) was the first synthetic drug used in 
the treatment of malaria more than 100 years ago and the use of this drug was abandoned 
with the emergence of new treatments (145). During World War II methylene blue was 
disliked by soldiers because of blue colouration of urine (146). Reinvestigation of the 
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use of methylene blue in the treatment of malaria began in 1995 with the main aim of 
developing an accessible, available and affordable antimalarial to treat malaria infected 
children in developing countries (146). Efficacy of methylene blue in malaria has been 
shown in several clinical studies in children (145, 147-149). In-vitro studies have shown 
methylene blue has potent antimalarial properties (150). Methylene blue and 
chloroquine have shown synergistic action in combination, however a small reduction 
in chloroquine exposure was observed in a pharmacokinetic study of combination 
therapy (149). A controlled Phase II trial of children (6-10 years), randomised to receive 
methylene blue combinations (methylene blue-artesunate, methylene blue-amodiaquine 
and artesunate-amodiaquine), found a statistically significant reduction in gametocyte 
carrier rate in methylene blue containing regimens, thus reducing transmission of 
Plasmodium falciparum malaria (145) .  
Methylyene blue has redox potential and can be present in three forms, the blue colour 
oxidized form (MB+), semi-reduced form (MB·) and the colourless reduced form or 
leuco-methylene blue (LMB--). The reduced form gets readily oxidized in the presence 
of oxygen (143). The blue coloured oxidized (cationic) methylene blue, undergoes 
catalytic redox reaction under physiological conditions. The conversion of oxidized 
methylene blue into its reduced form, colourless leuco-methylene blue is facilitated by 
nicotinamide adenine dinucleotide phosphate (NADPH) (146). The colourless leuco-
methylene blue has very low ionization (3%) at physiological pH.   
Pharmacokinetics: Methylene blue demonstrated multi-compartment 
pharmacokinetics following IV and oral administration (151, 152). The drug achieves 
53 to 97% peak concentrations after 30 to 60 minutes (153). Methylene blue and leuco-
methylene blue are predominantly excreted in urine, but also in bile and faeces.  
The oral bioavailability of methylene blue was found to be very low (about 1%) in fasted 
healthy volunteers. A higher drug concentration of methylene blue was found in brain 
following IV administration and higher intestinal and liver concentrations were found 
following oral administration in rats (151).   
In contrast to this, a subsequent study found a much higher absolute bioavailability for 
methylene blue for the oral route of administration, being 72.3 ± 33% ( plasma as matrix) 
and 84 ± 20% (whole blood as the matrix). A high inter-individual variation in 
   Page 22 of 294 
methylene blue area under the curve was observed. The study also observed higher 
plasma concentration of methylene blue when co-administered with chloroquine, but 
this was not observed for whole blood (152).  
The blood to plasma ratio of methylene blue was 0.98 and 1.1 for IV and oral route data 
respectively. Investigators explained this as possible intake of methylene blue into the 
cells but absence of intracelluar accumulation (152). However other studies  have found 
that cationic methylene blue is reduced on the exofacial cell surface of human 
erythrocytes, which allows lipophilic reduced leuco-methylene blue to enter cells by 
diffusion and be sequestered within the cells followed by re-oxidation to the oxidized 
(blue) form (144, 154, 155) . 
Methylene blue is administered orally at 12 mg/kg twice daily for 3 days in children 
(146).   
 
1.5 Artemisinin combination therapy (ACTs) and 
pharmacokinetics  
The World Health Organization recommends artemisinin combination therapies (ACTs) 
as the first line therapy in the management of uncomplicated malaria. ACTs were 
introduced in 2001; however the widespread adoption of ACTs has been slow due to 
their relative cost, lack of awareness of its advantages, lack of suitable formulation and 
the imbalance between supply and demand (6, 156, 157).  
In ACTs, a short acting and rapid onset artemisinin derivative is combined with a partner 
drug with a longer half-life, which provides increased efficacy, extended prophylaxis 
and prevents development of resistance of artemisinin derivatives (87, 158-160). The 
potent artemisinin derivatives cause rapid reduction of parasite biomass and resolve 
clinical symptoms while the remaining parasites are removed by less active, slowly 
eliminated long acting drugs (81). The potential advantages of ACTs include rapid 
reduction in parasite biomass, delay in development of drug resistance for artemisinin 
derivatives, effectiveness against multidrug resistant malaria parasite, reduction of 
gametocyte carriage, extended drug prophylaxis and lower side effects (156, 160).  
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Most countries have updated their treatment guides to recommend artemisinin 
combination therapies when existing treatments such as chloroquine and sulfadoxine-
pyrimethamine treatments are no longer effective. By the end of 2010, 84 out of the 87 
countries adopted ACTs into their national policy as the first line therapy for 
management of uncomplicated Plasmodium falciparum malaria (12). There are four 
artemisinin combination therapies currently recommended to be used in the 
management of uncomplicated malaria: artemether plus lumefantrine, artesunate plus 
mefloquine, artesunate plus amodiaquine and dihydroartemisinin plus piperaquine (3). 
The treatment recommendations or choice of ACTs for malaria vary from country to 
country depending on the level of drug resistance, acquired protective immunity of the 
population and cost of the drug (12).  
 
1.6 Antimalarial drugs resistance  
The WHO defines resistance as the ability of the parasite strain to survive and/or 
multiply despite administration and absorption of drugs given in either the usual or 
higher than recommended dosage (3). In early resistance development, symptoms 
disappear and the patient appears recovered, but symptoms resurface in a few weeks’ 
time due to the original infection (recrudescence) (3). 
Antimalarial drug resistance development could be due to initial genetic change (de 
novo drug resistance) resulting in resistant mutants and followed by selection processes, 
where parasites survive in the presence of a drug leading to transmission and the spread 
of drug resistance (14, 16). De novo drug resistance to malaria is rare and is most likely 
to occur at peak infection when parasite numbers are greatest and antimalarial drug 
concentration is highest. Parasites surviving at this high drug concentration are likely to 
be highly resistant to the drug. Low-level resistance can be seen when inadequate 
standard treatments are received (14, 16). 
Chloroquine resistance was first reported in the late 1950s in Thailand, Cambodia and 
Colombia and by the 1960s the resistance spread into South America and South east 
Asia (161, 162). In the 1980s, sulphadoxine-pyrimethamine, the first line affordable 
antimalarial medicines used in the management of uncomplicated malaria developed 
increased resistance, which lead to treatment failure (163). Today resistance 
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development is a major problem and resistance (or reduced sensitivity) has been 
observed for almost all currently available antimalarials including artemisinin 
derivatives (8, 164, 165).  
Drug resistance in malaria can be slowed or prevented by combining drugs with 
different mechanisms of activity and ensuring patient compliance by adherence to 
correct dosage regimens.  
Pharmacokinetics of drugs plays a major role in the development and spread of drug 
resistance. Sub optimum drug doses, pharmacokinetic interactions in drug combination 
therapy and presence of sub-therapeutic plasma levels in the body for long period, 
especially for drugs with a long half-life, increase the emergence of resistant forms of 
the parasite (166, 167).    
 
1.7 Introduction overview  
The general introduction on allometric scaling and it is application to determine 
paediatric drug doses are covered in the chapter 2 of the thesis whereas the general 
introduction on P-glycoprotein is covered in chapter 3.  
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1.8 Objectives  
In order to delay development of drug resistance and for maximum drug efficacy, it is 
important to prescribe optimum drug combinations and doses, which require clear 
knowledge of pharmacokinetic parameters of antimalarials. Optimum drug doses are 
especially lacking in children and are mostly determined on the basis of linear scaling 
or mg/kg adult dosing (81, 88, 168-173). In this respect, one aim was to carry out 
allometric scaling of antimalarials drugs in order to consider the potential value of 
allometry in paediatric drug dose decisions in children. Determination of drug 
permeability/absorption and identification of antagonistic pharmacokinetic interactions 
in combination therapy further facilitates decisions about the optimum drug dosing.  
Hence the second principal aim was to establish drug permeability, identification of 
Permeability glycoprotein (P-glycoprotein, P-gp) mediated drug transport and 
pharmacokinetic drug interactions during drug absorption using in-vitro Caco-2 cell 
lines.   
The overall aim was therefore: 
To investigate allometric scaling relationships, gastrointestinal permeability, P-
gp mediated drug transport and regulation of P-gp expression of antimalarial 
drugs in single and combination therapy.  
 
Specific Objectives  
Chapter 2 of the thesis covers the allometric scaling of antimalarials and dosage 
consideration for children, which includes two specific objectives  
 To investigate the allometric scaling relationship of anti-malarial drugs using 
published pharmacokinetic data of healthy and malaria infected mammalian 
species  
 To predict paediatric antimalarial drug doses for children >2 years using an 
interspecies allometric scaling technique  
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Chapter 3 covers the development of an in-vitro cell model for determination of drug 
permeability and P-gp mediated drug transport of anti-malarial drugs. 
Chapter 4 covers antimalarial permeability, P-gp mediated drug transport and regulation 
of P-gp transporter in the presence of antimalarials and includes the specific objectives 
below 
 To establish analytical techniques for quantification of anti-malarial drugs 
(artesunate, artemisone, mefloquine, amodiaquine and methylene blue) in the 
laboratory 
 To determine the inhibitory properties of anti-malarial drugs against P-gp 
mediated drug efflux in single and combination therapy.  
 To determine drug permeability and the potential involvement of P-gp mediated 
drug efflux of antimalarials in single and combination therapy. 
 To determine the role of antimalarial drugs in the regulation of P-gp transporter 
expression.  
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2 Allometric scaling of antimalarial drugs  
 
2.1 Introduction  
Allometric scaling is a pharmacokinetic tool, which can be used for extrapolation of 
human pharmacokinetic parameters using pre-clinical data (174-177). The technique is 
also used to guide drug dose decision making in children > 2 years (178-180).  
 
2.1.1 Interspecies scaling  
The study of the proportional body size of mammals and its consequences on biological 
characteristics is known as allometry. The anatomical, physiological and biochemical 
similarities among mammals can be generalised and expressed mathematically by an 
equation. Hence allometry is based on the theory that the simple power law expression 
given below can describe the relationship between the body size of mammals with such 
as organ size and blood flow (181).  
Y = a × Wb          (1) 
Y : Parameter under study 
a  : Allometric coefficient 
W : Body size/weight of the species 
b  : Allometric exponent 
 
Allometric scaling has a more empirical approach compared to the mechanistic 
approach of the physiological models. This technique tends to study the relationships 
between the relative size of the mammals with its consequences such as physiological, 
biochemical and anatomical parameters without necessarily understanding the 
reasons/rationale for the relationship(s). The present work was based on interest in the 
relative relationship between body size/weight of the animal and the physiological 
parameters, which determine the pharmacokinetics of drugs (176, 182). 
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The allometric scaling technique has been available and in use for many years. Galileo, 
in 1637, was one of the first to apply this technique, having observed that large animals 
have disproportionally thicker bones than smaller animals to maintain the necessary 
mechanical support (182, 183). It has been recognised that all mammals have quite 
similar basic physiology and physiological processes, even though their outward 
appearance is distinctively different. Therefore allometric relationships were established 
to account for this biological relativity among the mammalian species. This concept was 
further explained by introducing the concept of “physiological time”, which is defined 
by Boxenbaum as “a species dependent unit of chronological time required to complete 
a species independent physiological event” (184). The life expectancy of dogs and man 
is 14 and 98 years, respectively. Therefore a dog ages at the rate of 7.14% of its life per 
year whereas man takes 7 years to age the same amount. Therefore 1 dog year is 
equivalent to 7 man years, these being equal physiological times necessary to produce 
a species independent physiological event (184).  
Out of the many examples given in the literature to support this, the relative relationship 
between the breath time and the heartbeat time in mammals was considered (185-187). 
The ratio for breath time divided by the heart beat time for any mammal will be 4.  This 
ratio remains the same irrespective of the size of the mammal, with every breath cycle 
being equal to four heart beats for each mammal. This is scaled using the equation below 
where bodyweight is given in gram.  
Breath time (seconds) = 0.169× (bodyweight) 0.28     (2) 
Heartbeat time (seconds) = 0.0428× (bodyweight) 0.28   (3) 
The power function of the equation, 0.28, is used to scale the lifetime of a mammal. 
Small animals breath faster and their heart beat more rapidly compared to larger animals. 
Therefore, a given number of breaths and heart beats comes to an end for smaller 
mammals more quickly than for larger mammals, hence their life time is shorter 
compared to a larger animal.  
Allometric scaling of pharmacokinetic parameters is based on this premise that 
physiological parameters of mammals such as heart rate, hepatic blood flow, glomerular 
filtration rate, cardiac output and specific organ weights are a function of the body 
size/weight of the animal species. Out of the given physiological parameters, glomerular 
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filtration rate and hepatic blood flow are closely linked physiological parameters, and 
are related to pharmacokinetic parameters such as clearance and half-life.  If hepatic 
blood flow and the glomerular filtration rates of mammalian species are plotted against 
species body weight on a log-log scale, a linear plot is obtained (182). Therefore it is 
logical to expect that clearance and half-life can be related to the body size/weight of 
the mammal (188). If the concept of physiological time is applied to pharmacokinetics, 
mammals with a shorter life expectancy such as a rat will have a faster metabolic rate 
and shorter drug clearance time compared to a mammal with a longer life expectancy. 
Therefore drug clearance in different mammals can be scaled across mammals 
depending on their body sizes.   
Drugs excreted unchanged are eliminated mainly by the renal filtration process. 
Filtration of a drug depends on the renal function of a mammal, which is assessed using 
the creatinine clearance. Creatinine clearance is allometrically related to the body size 
(188).  
The elimination rate of a drug with a high hepatic extraction ratio depends on the blood 
flow to the liver (123, 189). The drug clearance of a high extraction ratio drug correlates 
with the body size of the animal, as blood flow depends on the liver and the body size 
of the animal. The larger, longer living animals have a slower total body clearance 
compared to the smaller, short life-span mammals (188). 
With drugs having a poor extraction ratio, elimination depends on the enzymatic activity 
of the relevant enzymatic system rather than the liver blood flow. The intrinsic clearance 
of the unbound drug should correlate with the liver weight provided that the in-vivo 
enzyme activity per unit liver mass is constant among the different species (188, 190).    
The volume of distribution of a drug depends on binding to plasma and tissue proteins 
and permeability across biological membranes. The volume of distribution will be 
directly related to the body tissue mass for drugs having higher tissue protein binding. 
This in turn results in a direct relationship between the volume of distribution of the 
drug and body size (188). Similarly, clearance as described above generally correlates 
well with the body size of the mammal. Elimination half-life is a secondary 
pharmacokinetic parameter, which is dependent on two primary pharmacokinetic 
parameters: clearance and volume of distribution.  
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When hepatic blood flow or renal clearance is plotted against the body weight of the 
mammals, a disproportionally increasing curve against body weight is obtained. 
However when both axes are transformed to their log value, a linear plot is obtained, 
enabling direct interpolation of parameters in the Y axis. Similarly when the 
pharmacokinetic parameter is plotted against the species bodyweight in a log-log scale, 
a linear plot is obtained and the relationship between the pharmacokinetic parameter of 
a drug and body weight can be explained by a simple power equation (182). 
 
2.1.2 Past and the present of allometry  
A brief chronology of development of allometry is provided below.  
1637: Galileo observed the relationship between the skeletal sizes to the body 
mass (184). 
1838: Sarrus and Ramaeux proposed that metabolic rate would be proportional 
to the body mass using the power function of 2/3 (191). 
1932-1937: Kleiber published that mammalian basic metabolic rate is 
proportional to the body mass using the power function of 3/4 (192).  
1949: The quantitative relationship between body weight of mammals and their 
basic biological parameters was identified by Adolph (181).  
1967: First example of pharmacokinetic parameter scaling of alcohol metabolic 
oxidation rate (193).  
1969: The first use of log-log plot parameter scaling by Mellett (194). 
1970: Dedrick plots were introduced where application of alternative time scale 
was used for superimposition of various species’ plasma concentration time 
profiles (195).  
1977: Weiss and co-workers were the first to introduce allometric equations in 
pharmacokinetic parameter scaling (196).  
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1980-1986: Allometric scaling was used for scaling of pharmacokinetic 
parameters of drugs; antipyrine, phenytoin, caffeine, antibiotics (190, 197, 198).  
1990-1995:  Allometric scaling was used for scaling of anti-HIV drugs (199, 
200).  
1997: Theoretical explanation (fractal geometry) for allometric 0.75 power 
models (201).  
Current:  Increasing interest in using the technique for dose determination in 
children (178-180). 
 
2.1.3 Simple allometric power equations for pharmacokinetics  
The general allometric power equation used in comparative biology given below can be 
used for describing size and its consequences, in this case, pharmacokinetics (185). The 
power function given below describes the relationship between the pharmacokinetic 
parameters of a drug and species body weight across mammalian species.  
Y = a × Wb          (1) 
Y : Pharmacokinetic parameter under study (dependent variable) 
a : Allometric coefficient (intercept) 
W : Species body weight (W) (independent variable) 
b : Allometric exponent (slope of the curve) 
The allometric exponent and coefficient are obtained upon logarithmic transformation 
of the above equation.  
log Y= b log(W) + log(a)        (4) 
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2.1.4 Allometric scaling approaches in pharmacokinetics  
Allometric scaling of key pharmacokinetic parameters clearance, volume of distribution 
and half-life facilitate calculation of drug doses for humans (202, 203). Out of the three 
pharmacokinetic parameters, clearance is the most important, as the exponent value of 
clearance is used to determine the maintenance or regular dosing of a drug. The 
exponent value obtained by scaling the volume of distribution of a drug is used for 
determination of the loading dose for the dosing regimen. Half-life is a secondary 
pharmacokinetic parameter. 
The allometric scaling approach adopts two main methods in extrapolation of 
pharmacokinetic parameters across mammalian species.  
 Fixed exponent allometric scaling method 
 Variable exponent allometry, based on interspecies scaling 
 
2.1.4.1 Fixed exponent allometry  
Allometry has been used in biological sciences over many years and a large number of 
allometric relationships have been established.  In 1838, one of the earliest allometric 
relationship was established by Sarrus and Ramaeux between body size and basic 
metabolic rate [cited by Brody (204) in 1945). Authors claimed that metabolic rate 
would be proportional to the body mass using a power function of 2/3. This was 
supported by Rubner in 1883, who claimed that metabolic rate of resting dogs was 
independent of mass when divided by the surface area (205). The use of  2/3 power 
value was challenged, when Kleiber (206) in 1932 published mammalian BMR scaling, 
where metabolic rate is proportional to the body mass using a power function of 3/4. In 
his article he investigated animals weighing from 0.15 to 679 kg (rats to steer) and 
obtained the allometric equation, metabolic rate (calories/kg) = 73.3 × Body mass0.734 
(192). In a subsequent publication in 1961, he proposed rounding off the exponent value, 
0.734 to 0.75 (3/4) for convenience.  One of the notable advantages of the use of the 
simple fraction, 3/4 was the use of the slide rule in the past for simple calculations. This 
exponent value, 3/4 has been used widely ever since as a fixed exponent and applied 
universally for interspecies scaling. The exponent value for volume of distribution and 
half-life has been set at 1 and 0.25 respectively (182). The exponent value of 1 for 
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volume of distribution indicates that this has the most direct relationship with the body 
weight, whereas half-life has the most distant relationship with the body weight.  
According to the general pharmacokinetic theories (182) 
Half-life = 
0.693× volume of distribution
clearance
      (5) 
Half-life = 
0.693×A×W1
A'×W0.75
  (Where Volume of distribution = AW1,   (6) 
Clearance = A'W0.75) 
  
A : Coefficient for volume of distribution (Vz) 
 W1 : Body weight with power function of 1 (Vz exponent)  
 A' : Coefficient for clearance  
 W0.75  : Body weight with power function of 0.75 (CL exponent) 
Half-life ∝  Body weight0.25 
 
Allometric scaling was first used by (196) to scale the pharmacokinetic parameters 
among different mammals. The fixed exponent value of 0.75 has been used in 
pharmacokinetics universally for prediction of drug clearance and doses for humans 
using drug clearance values of preclinical species (207, 208).  
The theoretical basis for the basic metabolic rate exponent value of 0.75 for clearance 
was justified by West and co-workers (201, 209) using the concept of fractal geometry 
where a general model describe the transport of material through space filling fractal 
networks of branching tubes. It was hypothesised that this model is similar to 
mammalian circulatory system and terminal tubes do not vary with body size.  
 
2.1.4.2 Variable exponent allometry  
In variable exponent allometry, drug specific allometric exponents and coefficients are 
derived based on physiological function of animals. The method utilizes species specific 
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pharmacokinetic parameters of drugs, which are determined by the physiological 
function of the animal. The method commonly utilizes all available pharmacokinetic 
parameters of preclinical species. The pharmacokinetic parameter is plotted against the 
bodyweight of the mammal in a log-log scale. The slope of the regression line gives the 
allometric exponent, b, and the antilog of the intercept gives the allometric coefficient, 
a.  
The closer the power function/exponent to one, the more direct the linear relationship 
between the pharmacokinetic parameter and body weight. The correlation coefficient of 
the line determines the effectiveness of the scaling, with a correlation of determination 
(r2) value close to 1 indicative of a strong allometric relationship (188).  
Allometric scaling of pharmacokinetic parameters requires a minimum of three species 
and typically this would include one rodent species (mouse or rat). Beagle dogs, rabbits 
and nonhuman primate species are commonly used (175). Inclusion of at least one large 
animal in the scaling procedure could improve the prediction of pharmacokinetic 
parameters for other species (175).  
This technique assumes that pharmacodynamic differences among different species are 
clinically negligible.  
 
2.1.5 Methods used in improving allometric drug clearance 
prediction  
There is literature to indicate that the simple allometric power model can be insufficient 
for accurate prediction of human pharmacokinetic parameters (203, 210-212). The term 
“vertical allometry” is used to refer to prediction errors of human drug clearance, mostly 
the over-prediction of drug clearance by the scaling method. This could be a serious 
concern when determining the first-time human dosing, which could lead to drug 
toxicity (164, 167). Therefore various methods have been proposed over the years to 
improve simple allometric prediction of pharmacokinetic parameters. Several 
investigators developed correction factors to improve pharmacokinetic parameter 
prediction and some of the adopted approaches are explained below. 
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2.1.5.1 Maximum life span potential (MLP)  
Interspecies scaling of drug clearance correlates well with species’ body weight, when 
the drug clearance is mainly through the hepatic metabolism and has a high hepatic 
extraction ratio (184). 
For drugs with a low extraction ratio, clearance depends on the plasma protein binding 
(fraction unbound) and intrinsic clearance of the unbound drug according to the well 
stirred model described by Pang and Rowland (189). Therefore it is most likely that 
intrinsic clearance of these drugs correlates with the species body weight (184). 
Boxenbaum (184) correlated the intrinsic clearance of antipyrine, phenytoin and 
clonazepam with body size. However, for these drugs, predicted intrinsic clearance was 
found to be lower than the observed clearance and human data were found to be outliers. 
Hence it was proposed that unbound intrinsic clearance for drugs may correlate with the 
longevity in addition to the body size of the mammals and therefore maximum lifespan 
(MLP) correction was introduced the to improve simple allometric predictions. 
The life span and aging rate of a species is genetically controlled by a biological clock 
(184) and the biological properties of the organism. If the animal dies due to a natural 
reason, then the number of years the animal lived would be the maximum life span 
potential of that animal. Longevity relates to the anatomical developments, sociological 
and metabolic processes including heart rate, basal metabolic rate, body weight, 
temperature, brain size, gestation length, nitrogen out-flow, biological intelligence, 
postnatal developmental rates, onset of specific physiological functions and age of 
sexual maturation (184). The authors identified the total “life capacity” of an organism 
as its maximum lifespan potential calorie consumption, which was defined as the 
product of MLP and the specific metabolic rate. Therefore the rate of energy expenditure 
will affect the life span of a species. The rat, having a higher metabolic rate, will have a 
shorter longevity compared to a larger species such as the human. Therefore in order to 
increase life span, the species would need to economize metabolic activity. Humans 
have a slower maturation, reduced mixed function oxidases and a higher brain weight 
per unit mass than the other mammals. These variations were considered for the 
development of MLP correction (188). Further Brody (204) showed that resting 
metabolic rate and mammalian body weight had a strong power law relationship with a 
correlation coefficient above 0.99 for regression analysis of log body weight and 
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metabolic rate.  Jerison (214) discussed extensively the evolution of the mammalian 
brain and observed a strong correlation between the log-log relationship between the 
brain and body weight of 98 mammalian species. 
Based on these Sacher (215) in 1959 defined MLP as the maximum documented 
longevity of the species. He developed an equation to determine the MLP of an animal 
species based on the multiple regression technique. 
MLP = 10.839×BW0.636×W(- 0.225)       (7) 
 MLP : Maximum life span (years) 
 BW : Brain weight (grams) 
 W : Body weight (grams)  
 
The coefficient 10.839 is replaced with 185.5 if the brain and body weights are in kg 
(211). Table 2.1 gives the MLP for different species calculated from the above equation. 
 
Table 2-1: MLP in years for animal species and human (184) 
Species  Adult brain 
weight (g)  
Adults body 
weight (g) 
Brain weight as a % 
of body weight  
Calculated 
MLP in years  
Human  1530 70,000 2.19 93.4 
Rhesus monkey  62 4700 1.32 22.3 
Cattle  252 310,000 0.081 21.2 
Goat  130 31,00 0.416 23.3 
Sheep 110 57,600 0.191 18.3 
Pig  58.2 77,200 0.075 11.4 
Dog 75.4 14,200 0.531 19.7 
Rabbit  9.97 2,550 0.391 8.01 
Guinea pig  3.42 270 1.27 6.72 
Rat 1.88 250 0.751 4.68 
Mouse  0.334 23 1.45 2.67 
Boxenbaum (184) analysed the MLP correction using pharmacokinetic data for 
antipyrine. He tried several plots empirically and obtained the best fit when CLUint × 
MLP was plotted against the body weight in a log-log scale. Similar plots were tried for 
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phenytoin and clonazepam and based on these data, the MLP correction was proposed. 
The clearance obtained from simple allometry needs to be multiplied by the MLP of the 
species and the value obtained is plotted against species body weight in a log-log scale 
to obtain corrected allometric exponents and coefficient. The resultant corrected 
exponent value could be used for predicting pharmacokinetic data from one species to 
another (184). 
CLUint ×MLP = a(W)
b        (8) 
CLUint : The intrinsic clearance of unbound drug (mL/min) 
 MLP : Maximum life span potential (years)  
 W : Body weight (kg) 
 a : Allometric coefficient  
 b : Allometric exponent   
 
2.1.5.2 Two term power equations  
This correction factor was developed considering that genetically determined 
characteristics of mammalians results in species specific differences.  
According to this model, species specific phenotypes operating within the context of an 
integrated control system determines the drug disposition process (216, 217). The brain 
size could be an indicator of the control capacity of the species, therefore an allometric 
relationship could exist between the rate of drug metabolism and mammalian brain 
weight (215, 217).  
The increase in body size/weight enables the inclusion of more functional units related 
to drug disposition such as drug metabolising enzymes and nephrons, hence body weight 
could also have an allometric relationship with the drug metabolism (217).   
Two term power equation was proposed by Boxenbaum and Fertig (217) to improve 
clearance prediction of compounds that are excreted mainly by Phase I oxidative 
metabolism. The method was established using unbound intrinsic clearance data for 
antipyrine in 15 species. Antipyrine was selected because it mainly undergoes Phase I 
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oxidative metabolism and has a low extraction ratio. The authors made a mathematical 
assumption that the dependent variable CLUint could be correlated with the independent 
variables body weight, brain weight and the body temperature. Body temperature did 
not significantly contribute to variance in CLUint. This resulted in an empirical correction 
method, two term power equation based on brain weight and body weight of species 
(217). 
CLUint = 0.387×W
1.32×BW (- 0.619)         (9) 
CLUint : The intrinsic clearance of unbound drug (mL/min) 
W : Body weight (kg) 
BW : Brain weight (kg) 
 
2.1.5.3 Brain weight correction 
This correction method was proposed by Mahmood and Balian (212). In this empirical 
method, brain weights (Table 2.1) of different species were used to modify the drug 
clearance. The product of brain weight and clearance is plotted against the body weight 
of the species in a log-log scale based on below given power equation. The allometric 
plot generates provides a corrected allometric exponent and an allometric coefficient to 
determine pharmacokinetic parameters in humans. Human brain weight of 1.53 kg was 
used to determine the human clearance (212).  
CL×BW = a(W)b      (10) 
CL : Clearance (L/hr) 
 BW : Brain weight (kg) 
W : Body weight (kg) 
 a : Allometric coefficient  
 b : Allometric exponent   
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2.1.5.4 Rule of Exponents  
This rule was proposed by Mahmood and Balian (211, 218) based on the analysis of 40 
drugs. The allometric scaling relationships were established for all drugs based on 
simple allometry, MLP correction and brain weight correction techniques. Based on the 
study finding, it was suggested that out of the three methods, only one method should 
be used for prediction of human pharmacokinetic parameters from animal data. The 
authors proposed ‘the Rule of Exponents’ based on the exponent values obtained by the 
simple allometry techniques. The rule suggests that one should adopt simple allometry 
if the resulting simple allometry exponent lies between 0.55 and 0.70. In situations 
where the simple allometry exponent lies between 0.71 and 0.99, the CL × MLP method 
should be adopted and when the exponent is > 1, CL × BW should be adopted (211, 
218) . 
 
2.1.5.5 Correction using in-vitro metabolic data 
Simple allometry predictions have been shown to be predictive for renally excreted 
(198, 219), and highly metabolized drugs (184, 220). Allometric predictions for low 
extraction ratio drugs have been less predictive (184, 203, 221). Therefore another 
correction factor using in-vitro metabolic data was proposed to improve the 
pharmacokinetic parameter prediction of drugs with low or intermediate hepatic 
extraction ratio. 
In this method, it was assumed that the drug is solely metabolised by the liver and that 
the blood to plasma ratio of the drug in different animals is equal to one. Liver samples 
of animals and humans were obtained and isolation of hepatocytes was done by liver 
tissue perfusion. Cells were seeded with culture medium and drugs were added at 
different concentrations (below KM values). The unchanged compound in the media was 
assayed after incubation for 72 hours. Intrinsic clearance was calculated from the ratio 
of the initial amount of the compound in the incubation medium to the corresponding 
AUC value determined using the concentration obtained at six different time points 
(221). 
   Page 40 of 294 
When in-vitro metabolic rates were used as a correction factor, the in-vivo clearance   
value of each animal was normalized by the ratio of in-vitro clearance values as 
indicated in the below equation.  
CLin-vivo(animal) × 
in-vitro CLhuman (hepatocytes)
in-vitro CLanimal(hepatocytes)
     (11) 
The normalized values were extrapolated using allometric scaling technique power 
equation as given below. 
 CLin−vivo(animal) ×
in−vitro CLhuman (hepatocytes)
in−vitro CLanimal(hepatocytes)
 = a × Wb    (12) 
W : Body weight (kg) 
 a : Allometric coefficient  
 b : Allometric exponent   
 
An interspecies scaling of mofarotene and bosentan (drugs metabolized by CYP450) 
was carried out incorporating an in-vitro liver model to extrapolate in-vivo drug 
clearance in humans. The study found that this method better predicted drug clearance 
compared to the brain weight correction method (222, 223). Similarly, human clearance 
prediction of tolcapone, a drug metabolized by a Phase II reactions, was found to be 
satisfactory using the same technique (224). Lave, Dupin (221) adopted in-vitro 
correction technique to extrapolate human clearance of 10 extensively metabolized 
drugs, in which a significant improvement in clearance prediction was found. 
It is not certain that this method can be used for predicting human drug clearance for 
other drugs due to the smaller number of drugs tested and limited validation in 
subsequent reports.  
 
2.1.5.6 Allometry using unbound clearance 
Obach, Baxter (225) used unbound clearance values and MLP values to improve 
clearance predictions using allometry.  
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The free clearance was defined as below.  
CLp(free)=
CLp(total)
fu
           (13) 
fu  : Fraction unbound 
 CLp(free) : Unbound clearance  
 CLp(total) : Total clearance  
 
The investigators used four scaling approaches; CLp(free) vs body weight, CLtotal vs body 
weight, CLp(free)/MLP vs body weight and CLtotal/MLP vs body weight. No 
improvement in clearance predictions were found by incorporation of MLP into 
clearance values.  Clearance prediction from scaling CLp(free) and CLtotal were within 2 
fold of the actual clearance values.  
The study concluded the unbound clearance method prediction was slightly more 
accurate than the total clearance (225). Mahmood (174) tested scaling of unbound 
clearance, however claimed that unbound scaling method is no better than the total 
clearance prediction. He further proposed that drugs exhibiting vertical allometry can 
be better predicted using the unbound clearance method. 
 
2.1.5.7 Glomerular filtration ratio (GFR) correction factor   
This method was proposed for improving clearance prediction of the drugs mainly 
excreted by renal clearance, given that there could be differences in renal excretion, 
filtration, reabsorption and secretion among species. The study adopted (GFR × Blood 
Flow) / (Body weight × Kidney Weight) as given in Table 2.2 to determine the GFR 
correction factor for each species. The predicted clearances for different species were 
then divided by the GFR correction factor (210). The corrected clearance is plotted in a 
log-log scale based on the below given allometric power equation.  
Clearance
GFR correction factor
= a.Wb          (14) 
GFR : Glomerular filtration rate  
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W : Body weight (kg) 
 a : Allometric coefficient  
 b : Allometric exponent   
 
Table 2-2: Glomerular filtration factors for preclinical and human species (210) 
Species Body weight 
(kg) 
Kidney weight 
(kg) 
Blood flow GFR a(GFR×BF)/ 
(W×KW) 
Factor 
Human  70 0.3 1240 125 7381 1 
Pig 30 0.13 600 65 10000 1.4 
Sheep 50 0.2 900 90 8100 1.1 
Dog 14 0.05 216 45 13886 1.9 
Monkey 5 0.025 138 10.4 11482 1.6 
Rabbit 2.5 0.013 80 7.8 19200 2.6 
Guinea pig 0.29 0.0024 12.6 2.2 39828 5.4 
Rat 0.25 0.002 9.2 1.31 24104 3.3 
Mouse  0.02 0.00032 1.3 0.28 56875 7.7 
aGFR; Glomerular filtration rate, BF: Blood flow, W: Body weight, KW:  Kidney weight 
 
The authors tested this method to predict pharmacokinetic parameters of 10 renally 
excreted drugs. The results showed that the predicted total clearance and the renal 
clearance of drugs were lower than the observed clearance values. This method was 
unable to predict both the total and non-renal clearance of renally excreted drugs which 
could be due to variations in the mechanism of renal excretion of drugs in different 
species (218). However it is difficult to make a recommendation from this study due to 
the small number of drugs studied and limited subsequent research.  
 
2.1.5.8 Correction for biliary excreted drugs  
This correction factor was proposed to improve clearance prediction of drugs, which 
exhibit enterohepatic recycling. The enterohepatic recycling or biliary excretion could 
vary from species to species. Bile is excreted from the liver; therefore the body weight, 
liver weight and bile flow rate of the species were used to develop the correction factor 
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(mouse = 5.9, rat =11.6, rabbit = 2.0, dog = 1.9, monkey = 4.3). The bile flow rate of 
the species was normalised using the liver and body weight of the species. The 
investigators carried out simple allometry first and Rule of Exponents was applied.   The 
clearance was corrected based on the Rule of Exponents and resultant values were 
divided by the biliary clearance correction factor (226).  
 
Clearance 
Biliary clearance correction factor
=aWb       (15) 
Clearance :  CL or CL × BW or CL × MLP  
W  : Body weight (kg) 
 a  : Allometric coefficient  
 b  : Allometric exponent   
 
The clearance of eight drugs were analysed using the method and the predicted clearance 
of drugs undergoing enterohepatic recycling was improved by this method (226).  
Another correction method was proposed to improve clearance of biliary excreted drugs 
using bile flow rate and microsomal UDP glucuronosyltransferase activity and found 
that this method is also suitable for predicting clearance of biliary excreted drugs (227).  
 
2.1.5.9 Unbound clearance corrected intercept method  
Tang and Mayersohn (228) proposed this method to improve clearance prediction of 
drugs especially anticipated to exhibit vertical allometry. The study analysed 60 drugs 
using this method. Simple allometric scaling was carried out and the coefficient (a) from 
the regression line was obtained. The fraction unbound (fu) drug for human and rat was 
obtained from the literature. A mathematical model was developed and the equation 
below was obtained to determine the human drug clearance. 
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Human CL = 33.35 (ml/min) × (
a
Rfu
)
0.77
      (16) 
Human CL : Human clearance  
a  : Simple allometric coefficient  
Rfu  : Ratio of unbound fraction in rats compared to human 
The Rfu in the equation was obtained from the ratio of the plasma unbound fraction (fu) 
in rats compared to humans. The study found this method to be more predictive than the 
Rule of Exponents correction (228).   
 
2.1.5.10 Monkey liver blood flow method  
This assumed that drug clearance is mainly hepatic and blood to plasma ratio is constant 
across species. The clearance of the animal was expressed as a percentage of the liver 
blood flow.  Liver blood flow values of 85, 30, 45 and 21 mL/min/kg for rat, dog, 
monkey and human was used respectively (180, 181). Human clearance was predicted 
from the product of the animal clearance with the ratio of human liver blood flow to the 
animal liver blood flow (229).   
Human clearance=Animal clearance ×
Human liver blood flow
Animal liver blood flow
    (17) 
The investigators found incorporation of monkey pharmacokinetic data to provide most 
qualitative and quantitative estimation of human clearance, having calculated human 
clearance using each animal species clearance and liver blood flow. This could be due 
to the phylogenetic proximity of monkeys to humans compared to the other commonly 
studied preclinical species (182). 
 
2.1.6 Criticism of correction factors  
The effectiveness of the correction factors in predicting drug clearance has been debated 
and it is claimed that there is no rational basis for most of the empirical correction factors 
(221, 225, 230-232).  
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The Rule of Exponents is based on arbitrary cut off levels of exponent values and this 
method was developed looking at the allometric scaling relationship of small number of 
drugs. The selected drugs were not randomly selected and investigator did not adopt a 
scientific basis to select the cut levels. This method has been discussed in the literature 
more frequently; however validity of the method was mostly questioned (229, 233). 
Tang and co-workers (232) indicated that this rule need further testing in a variety of 
drugs prior recommending as a correction method. MLP correction was developed to 
improve clearance prediction of the low extraction ratio drugs. The correction has been 
tested by many investigators. However the validity of this method is also yet to be fully 
resolved. Correction using in-vitro metabolic data for drugs cleared through 
metabolism, unbound clearance correction for low extraction ratio drug, correction 
using bile flow rate of species for drug under enterohepatic recycling and correction 
using GFR factor for drugs renally cleared have some physiological basis. Therefore, 
these techniques are worth exploring further, in order to make recommendation. 
In a study of 103 drugs using simple allometry with and without correction factors such 
as brain weight, MLP and GFR, Rule of Exponents were tested (229, 233). It was 
concluded that none of the correction factors substantially improved the clearance 
predicted beyond simple allometric technique. The brain weight correction was tested 
by Lave and colleagues (221) and found that predicted clearance values to be tenfold 
lower than the observed values. Two term power equation was tested by Mahmood and 
Balian (211) who reported that two term power equations do not accurately predict the 
drug clearance. However, the noted advantage of these correction methods is that these 
methods can be easily tested due to readily availability of required parameters. 
Mahmood (174) tested unbound clearance intercept method for clearance prediction of 
renally and biliary excreted drugs and found this method to be equally useful as the Rule 
of Exponents for clearance predictions in humans. Both monkey liver blood flow and 
unbound clearance corrected intercept method belong to fixed exponent allometry as 
two techniques involves one species with a fixed exponent in the allometric function 
(232). Therefore these methods have the disadvantages of fixed exponent allometry.  
There have been many studies which compared predictive performance of different 
methods, however the controversy of this issue has not yet settled. It is apparent that 
none of these correction methods have been tested in large number of drugs with 
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differing physicochemical characteristics and differing drug clearance or metabolic 
pathways in one study. Therefore it appears that some of the current studies are 
subjected to investigator bias.  
Thus, the question of validity of correction factors and superiority of correction factors 
over simple allometry is yet to be answered (232). 
 
2.1.7 Physiologically based models  
Interspecies scaling uses animal data for determination of pharmacokinetic parameters 
for humans. The two methods used for this are the empirical allometric scaling approach 
and the mechanistic physiological based models, where both methods assume that 
pharmacokinetic parameters can be scaled following basic physiological principles.  
Physiological based models enable extrapolation of pharmacokinetic parameters from 
one species to another using a mechanistic approach (scaling based on physiological 
function) and require considerable model development (182). 
Physiologically based models describe drug movement and disposition in the body 
based on organ blood flow and organ spaces penetrated by the drug. This mathematical 
model assumes that drug movement in the body is blood flow limited (234). The model 
requires actual organ blood flow rates, organ size, tissue to blood partitioning, 
permeability of drug and metabolic chemical reaction rates to develop first order 
differential equations to represent concentration of drug in blood and the various organs 
as a function of time (182, 188). Most frequently rats are used to determine these 
parameters. 
In order to develop concentration-time profiles in man, differential equations are 
numerically solved assuming tissue binding and metabolic equivalency between man 
and animal, along with appropriate blood flow and organ size parameters of man (182). 
Physiological models have been found to be in limited use due to complexity, cost and 
time, even though the model provides inherent understanding of drug disposition.  
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2.1.8 Dedrick plots  
Drug eliminating organs such as the liver and kidney are relatively larger in smaller 
animals compared to larger animals, as is blood perfusion. This results in higher drug 
disposal capacity in smaller compared to larger animals (181, 197). In order to account 
for the pharmacokinetic changes occurring in mammals in relation to their relative size, 
Dedrick and co-workers (195) developed the Dedrick plot, where he obtained plasma 
levels of methotrexate from mammalian species and carried out a normalisation process 
before scaling. In the conventional plot, log plasma level is plotted against the 
chronological time. In order to normalise the X and Y axis, the plasma levels were 
divided by the mg/kg dose to account for differences in plasma levels caused by 
differences in mg/kg dosing. Smaller animals have higher drug clearance (mL/min/kg) 
compared to that of the larger animals owing to faster metabolic rate. Thus the drug 
concentration tends to decline faster in smaller animals compared to the larger animals 
and therefore chronological times in these species need to be decelerated relative to 
larger species. This was achieved by dividing the time by the body weight to the 0.25 
power. By doing this the chronological time was converted to pharmacokinetic time. 
Pharmacokinetic time scale is derived from the concept of physiological time scale, 
which is the time required to complete an independent physiological event of the species 
(184, 188, 195).  
Dedrick and co-workers (195) utilized the empirical relationship established by Adolph 
(181) for power transformation of physiological basis of the body weight. Boxenbaum 
(166) in his review stated that it is logical for authors to use 0.25 as interspecies variation 
in methotrexate clearance (this is primarily cleared by kidney) as it correlates with 0.31 
used for interspecies creatinine clearance by Adolph (181) in 1949 (184, 235). 
The ratio, plasma concentration divided by normalized dose was plotted against the 
pharmacokinetic time (Time/Body weight (0.25)) in a log- linear scale and resulting plot 
was named as the “elementary Dedrick plot” (184, 188, 195, 235).  
Dedrick plots have been developed for some drugs such as new carbapenem derivative, 
penem antibiotic (FCE 22101) (236, 237)  
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2.1.9 Applications of interspecies scaling  
2.1.9.1 Veterinary medicine 
In veterinary medicine, the typical method used for extrapolating doses for non-
domestic animal species was to use the mg/kg dosing of the domestic animals. This 
resulted in linear increase in the amount of drug administered as body weight increases. 
However, this tends to overdose large animals and under dose small animals. Allometric 
scaling of pharmacokinetic parameters of animals has been used as the final method for 
extrapolation of doses for new animal species (202). 
 
2.1.9.2 Pre-clinical to clinical dosing  
Pharmacokinetic investigations play an important role during the lead optimization in 
drug discovery. The pharmaceutical industry inputs substantial resources in identifying 
a drug with favourable in-vivo pharmacokinetics in preclinical species. This information 
is used in future preclinical pharmacology data and safety studies which increase the 
clinical success and decrease possible toxic effects from inappropriately high doses.  
In the US, new drugs need to be studied in at least two types of animal species prior to 
clinical studies in humans (238). However, the pharmacokinetics of animals could vary 
from humans. Therefore, in order to better utilize animal pharmacokinetic data in 
determining human pharmacokinetic parameters, there is a need to scale 
pharmacokinetic parameters, such as clearance and volume of distribution from one 
species to another and finally to humans (176). 
Interspecies allometric scaling is used in the pharmaceutical industry to establish the 
first dosage in human drug investigations. The established pharmacokinetic parameters 
of a few animal species are used to predict both human pharmacokinetic parameters and 
then the first IV dose for human Phase I studies (239, 240). 
 
2.1.9.3 Population pharmacokinetic modelling  
Population pharmacokinetic models utilize allometric expression to incorporate body 
weight/size to model the pharmacokinetic behaviour of a drug. The general practice is 
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to use fixed exponents, 0.75 for clearance and 1 for volume of distribution for scaling 
between adults and children (180, 201). However, it remains undecided whether 
allometric exponent used in population pharmacokinetic modelling should be fixed or 
variable (241). There are population pharmacokinetic studies where variable exponent 
allometry has been adopted where drug specific allometric exponents were used for 
model development (242-244). 
 
2.1.10 Drug dosing in children  
The need for age-based pharmacotherapy was recognized over 100 years ago. Dr. 
Abraham Jacobi wrote: “ Pediatrics  does not deal with miniature men and women, with 
reduced doses and the same class of disease in small bodies, but has its own independent 
range and horizon”(245). 
Pharmacokinetic studies, however, are often restricted in paediatrics, given the 
vulnerability of the subgroup, and dose decisions are frequently made by extrapolation 
from the adult population. Over the years different approaches have been used for dose 
selection in children. The initial dosing is scaled from adult doses and later adjusted 
based on the clinical response. The current textbooks of dose recommendations such as 
British National Formulary and Martindale Pharmacopoeia use a mixture of 
recommendation guides such as mg per kg dosing, age dependent dosing and weight 
ranges (246). British National Formulary has also published drug doses for children 
based on clinical experience and off-label use rather than on randomised clinical trial 
findings (246). There is a growing interest in using allometric scaling techniques for 
dose determination in children < 2 years. Some of the common drug dosing methods are 
described below.  
 
2.1.10.1 Scaling by body size/weight  
Body weight dependent dosage regimen for drug therapy was first proposed by 
Professor A.J Clark of Edinburgh, where child dose was determined by multiplying the 
adult dose by the ratio of child weight/150 (247). 
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This was later modified and improved and the equation below was proposed to 
determine the child dosing. However it wasn’t widely quoted due to mathematical 
complexity (247, 248).  
Child dose =(1.5 ×weight of the child)+10% of adult dose     (18) 
The most common mg/kg dosing method normalises adult dose by body weight, 
assuming a linear relationship between body weight and the drug dose. This method 
gained its popularity due to its apparent simplicity (247). 
Child dose = Adult dose ×
Child body weight
Adult body weight
       (19) 
However, this method has the least accuracy in dose prediction compared to the other 
methods (249, 250) can leads to over dosing (toxicity) and under dosing (sub therapeutic 
dosing). For example, chloramphenicol is metabolised by UDP-glucuronyl-transferase 
enzymes, which is immature in newborns and mg/kg dosing in infants can lead to 
fivefold higher dosing causing grey baby syndrome. Whereas carbamazepine is 
metabolized by CYP3A4 and the activity of CYP3A4 is higher in children, leading to 
lower therapeutic levels after mg/kg dosing (246).  
 
2.1.10.2 Age based rule  
Age based rule determines appropriate doses on the basis of age subgroup. Children are 
sub-grouped into different age groups; pre-term new born, term new born, infants, 
toddlers, children and adolescents and specific doses are prescribed for different age 
groups (246). This method fails to consider physiological and biochemical changes 
within each age subgroup of children. This creates a situation of absence of dose 
response relationship for each age group. 
 
2.1.10.3 Weight ranges  
In the weight range method, a dose is recommended using predetermined body weight 
ranges for children thus not individualised. These weight ranges  and corresponding 
doses are determined based on clinical experience (251). 
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2.1.10.4 Body surface area  
Body surface area (BSA) rule has been recognized as more accurate compared to body 
weight method in determining doses for children. The metabolic rate of a person reflects 
heat loss, which is proportional to the surface area of the body (247, 249). The concept 
of using body surface area was first recognized by Moore (252) in 1909. Du Bois and 
Du Bois (253) proposed the first multidimensional formula for the surface area by 
investigating the surface area of nine individuals. Surface area was calculated in cm2 
using height in cm and weight in kg applied to the below equation. 
 Surface area(S)(cm2) =Weight0.425×Height0.725×71.84     (20) 
Gehan and George (254) later proposed an improved equation to derive the surface area 
of an individual.  
Surface area(S) = 0.0235×Height0.42246×Weight0.51456     (21) 
Body surface area scales allometrically with a power model using exponent value of 2/3 
(0.67) (231). This assumes that metabolic rate is geometrically scaled based on body 
size and children and adults are geometrically similar.  
Dose =  a (Body surface area)
2
3       (22) 
 a : Allometric coefficient  
Limitations of this method include difficulty in measuring BSA due to the complexity 
of the equation and uncertainty in accuracy. Mostly, the pharmacokinetic profile across 
all children does not change in relation to body surface area. BSA is not a descriptor of 
metabolic function (247). 
 
2.1.10.5 Fixed exponent allometry  
Evidence from allometric scaling has shown that this technique is more reliable in 
determining first time dosing in children compared to the dose normalisation method, 
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age specific dosing, body surface area method and to dose determination based on 
empirical clinical experience (250).  
Pharmacokinetics of children are also determined using fixed exponent allometry, where 
fixed exponent values of 0.75 (3/4) or 0.67 (2/3) are used for maintenance dose 
determination in children. However, use of fixed exponents such as 0.75 for clearance 
and 1 for volume of distribution are similar to a size scaling method such as dose 
normalization by body weight and by surface area (246).   
There is conflicting evidence on the use of fixed exponents for dose determination (179, 
207, 208, 232, 246, 255-258). Body size may not be a surrogate for physiological change 
or growth development, hence it is unable to assume a linear relationship between body 
size and drug response, which is contrary to the principle used in the size scaling 
methods described above (246).  
Hence allometric scaling based on physiological function (interspecies allometric 
scaling) is discussed further as an improved method in dose prediction for children.  
 
2.1.10.6 Variable exponent allometry 
Allometric scaling of a drug based on available pharmacokinetic data allows 
determination of drug specific allometric exponent. Pharmacokinetic parameters such 
as clearance and volume of distribution of mammals are plotted against the body weights 
of the species in a log-log scale to obtain the drug specific allometric exponent. In here, 
body weights of the mammalian species are considered as a surrogate of their 
physiological function. Hence pharmacokinetic parameters are scaled against the 
physiological function of the species. The rationale for this is similar to rationale of 
assessing pharmacokinetic in obese patients and hepatic impairment (246).  
Variable exponent allometry allows, utilization of all available pharmacokinetics of 
drugs in preclinical and human species to derive exponents and therefore drug doses are 
determined based on best available pharmacokinetic information (259). 
Pharmacokinetics of drugs could vary in mammals due to their different 
physicochemical properties and therefore it is likely that drug specific allometric 
exponents exist. 
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In the development of variable exponents, it is also important to consider apparent 
physiological changes, for example if there are clear changes in pharmacokinetics due 
to the disease state, scaling need to be done using diseased mammals. In extreme age 
groups such as in neonates and children less than 2 years where there are clear 
differences in body physiology, body weight might not be a surrogate for physiological 
function needing to exclude this group.  
 
2.1.11 Current evidence for the need of antimalarials dose 
optimisation in children    
The current pharmacokinetic literature proposes a need for revision of drug doses in 
children with malaria. The evidence recommends an increase in drug doses for most 
drugs. 
A pharmacokinetic study of sulfadoxine-pyrimethamine in 307 malaria infected 
children, found that dose adjusted area under the curve of sulfadoxine and 
pyrimethamine in children aged 2- 5 years was half than that of adult patients. The study 
concluded that current dosing of sulfadoxine and pyrimethamine needs to be revised to 
decrease treatment failure (168). Another study of chloroquine and sulfadoxine-
pyrimethamine with two dosage regimens (low and high), found a strong relationship 
between high blood level and the cure rate in children (169). A pharmacokinetic study 
of 102 malaria infected children used three times higher dose of chloroquine than the 
current recommendation. This regimen proved to be of improved efficacy (170). Price, 
Hasugian (81)  in a study of dihydroartemisinin-piperaquine (2.2 and 18mg/kg) for the 
treatment of children with uncomplicated malaria, found 38% of the children to have 
below 30 ng/mL day 7 piperaquine blood levels (Day 7 piperaquine level < 30 ng/mL 
is used as a surrogate marker for occurrence of recurrent malaria). The authors stated 
that the currently recommended dose of piperaquine is suboptimal. Two subsequent 
studies of piperaquine have endorsed the same observations indicating the need for dose 
revision (88, 173).  
A population pharmacokinetic study of 70 children (6 months -11 years) with severe 
malaria on IM artesunate (2.5mg/kg 0, 12 and 24 hours) found lower blood levels of 
artesunate and metabolite dihydroartemisinin suggesting the need for dose changes in 
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children (171). Addition of a loading dose of quinine was also recommended for 
children (172).  
 
2.2 Rationale for allometric scaling  
It has been clearly recognised that pharmacokinetic properties of a drug could vary 
across different age groups (neonates, children, adult and the elderly) due to the 
differences in body composition, liver function, maturation of enzymes, kidney 
function, age and gender (246, 258).  Recognising the need of paediatric exclusive 
dosing, the first British National Formulary (BNF) for children was introduced as a joint 
publication of  the British Medical Association, the Royal Pharmaceutical Society, the 
Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric 
Pharmacists Group in 2005 (260).   
However, there is paucity in dose finding studies conducted in children compared to 
adults. In the past such studies were not warranted and considered ethically unsound due 
to the need for frequent blood samples of substantial volume for accurate determination 
of pharmacokinetic parameters. Today with the advancement of sensitive analytical 
techniques and availability of non-invasive assay techniques, pharmacokinetics studies 
in children are more feasible. However, such studies are not given priority in the 
pharmaceutical industry due to little financial gain from funding dose optimization 
studies in children once the drug has obtained market approval for adult usage (261, 
262).  
Hence current dosage regimens for children are mostly based on the prior 
pharmacokinetic information available from the adult population (263). However, it is 
challenging to determine how best available pharmacokinetic information can be 
utilized to determine the dosage regimens for children. 
The most commonly adopted method of dosing is the weight based mg/kg adult dosing 
considering the linear relationship between body weight and dose for adults and 
children. Children’s formularies also recommend doses based on paediatric age groups, 
weight bands and body surface area (246, 249). Apart from these methods, empirically 
based paediatric dosing recommendations are also available based on clinical 
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experience and off label use (246, 251). Out of these techniques, WHO and other 
pharmacopoeial sources recommend mg/kg adult antimalarials drug doses/linear dosing 
for children. Artemether and lumefantrine are exceptions, where dosing is based on 
predefined weight bands (3). However linear dosing could lead to under dosing of 
children and sub therapeutic dosing in antimicrobial chemotherapy which could lead to 
treatment failure and drug resistance in the long run (246, 249, 250, 255).  There are 
clinical reports supporting this and recommending higher drug doses for sulphadoxine 
and pyrimethamine, chloroquine, dihydroartemisinin and piperaquine, artesunate and 
quinine for adequate malarial therapy (81, 88, 168-173).Therefore, it is necessary to 
revised drug dosage regimens to deliver the optimum drug therapy for children.  
Allometry was traditionally used for first time dose determination in humans using 
preclinical pharmacokinetics data and also for dose extrapolations for new animal 
species in veterinary science (174-177). However there is a growing interest in using 
allometric scaling for paediatric dose determination (178-180). The allometric scaling 
relationship for chloroquine has been established where increase in chloroquine doses 
are recommended (25 mg/kg adult doses to 30 and 35 mg/kg for 10 and 20 kg body 
weights) (264).  
Further evaluation of allometric scaling in other antimalarial drugs would help establish 
the validity of the technique for antimalarial dose determination in children and could 
be used to determine first time doses for newly discovered antimalarial drugs.  
Pharmacokinetic literature for antimalarial drugs in malaria infected children are 
available for some drugs. This enable compare the validity of allometrically predicted 
pharmacokinetic parameters to that of observed pharmacokinetic parameter values in 
clinical studies, given that there is no difference in pharmacokinetic parameters in the 
malaria infected state compared to the healthy state. 
 In this context, it is aimed to adopt interspecies allometric scaling technique to 
interpolate pharmacokinetic parameters for children. Drug specific allometric exponents 
derived will be used to scale adult doses to determine optimum drug doses for children. 
Therefore the specific objectives for this part of the study are  
 
   Page 56 of 294 
2.3 Specific objectives  
 To investigate an allometric scaling relationship of anti-malarial drugs using 
published/ available pharmacokinetic data of healthy and malaria infected 
mammalian species  
 To predict paediatric antimalarial drug doses for children above 2 years using 
interspecies allometric scaling technique  
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2.4 Methods 
2.4.1 Data collection 
Antimalarials used in the treatment of malaria were identified using WHO treatment 
guidelines (3). The initial list comprised of artemisinin, artesunate, artemether, 
dihydroartemisinin, mefloquine, amodiaquine, piperaquine, chloroquine, quinine, 
primaquine, lumefantrine, sulfadoxine-pyrimethamine, atovaquone, proguanil, 
tetracycline, doxycycline and clindamycin. Of these, tetracycline, and doxycycline were 
excluded as they were contraindicated in children. Allometric relationship for 
chloroquine was already established and therefore it was not included in the present 
study (264).  
A comprehensive literature search of pharmacokinetic parameters for other selected 
drugs was done using key words: pharmacokinetics, disposition, pharmacokinetic 
parameters, specific antimalarials and mammalian species. Data base searches were 
done on PubMed, OvidSP, Google Scholar and citation records. Cross referencing of 
the articles was done to identify missing references.   
Data on species, age, sex, weight, ethnicity, assay techniques, sampling duration, sample 
matrix, routes of drug administration, doses administered, dosage regimen, other drugs 
administered, pharmacokinetic modelling techniques, healthy and malaria infected 
status and pharmacokinetic parameters for each drug were recorded.   
After compilation, data were screened for validity of pharmacokinetic parameters and 
study robustness. Criteria were set for the suitability of the data when screening 
pharmacokinetic studies. The data were screened for uniformity of biological matrix and 
data from a specific matrix were used for each drug. For example, quinine data generated 
from plasma were selected for the study and whole blood studies were excluded. A 
blood/plasma sample collection period of more than 3 times the half-life was preferred. 
Drug administered following the IV route is preferred in allometric scaling. However 
some antimalarials are administered only following oral routes, therefore such routes 
were considered more appropriate for those drugs. In instances where bioavailability of 
a drug was published, true or apparent clearance of the drug was calculated as required.  
The drugs with pharmacokinetic data available for less than three mammalian species 
(amodiaquine, lumefantrine) and Fixed Dose Combinations (FDCs): (sulfadoxine-
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pyrimethamine, artemether-lumefantrine, atovaquone-proguanil) were also excluded, as 
data for individual drugs were not readily available.  
The final list of drugs (and routes of administration) was: artesunate (IV), and the active 
metabolite, dihydroartemisinin (IV), artemether (IV and IM), artemisinin (IV, 
intraperitoneal and oral), clindamycin (IV), piperaquine (oral), mefloquine (oral), 
quinine (IV).  
Studies that met the selection criteria were screened for extraction of pharmacokinetic 
parameters; CL, Vz and half-life. A summary of pharmacokinetic parameter details of 
artemisinin, artesunate, dihydroartemisinin, artemether, clindamycin, piperaquine, 
mefloquine and quinine were tabulated. 
 
2.4.2 Pharmacokinetic parameters 
Clearance (CL), volume of distribution (Vz) and half-life (t½) data were collected or 
calculated from the available data using the model-independent equations given below. 
CL  =  k × Vz        (23) 
Vz  =  CL ÷ k        (24) 
k : Elimination rate constant 
Pharmacokinetic parameters mean resident time and Vss were reported in a limited range 
of studies and therefore not used for scaling purposes. The scaling for volume of 
distribution was done using Vz, however in instances where Vz was not available Vss 
was used for the analysis.  
In human studies where body weight was not reported, 60 kg was used for Asian and 
African subjects, whereas 70 kg was used for Caucasian subjects. The body weight of 
animals was not provided in a few animal studies, hence published standard body 
weights of the respective species were used for the allometric scaling (175, 184, 265, 
266). 
In human studies where different doses were administered to the same subjects and there 
was no evidence of dose-dependent variability, the mean value of the pharmacokinetic 
parameter was used. However, if separate groups were given different doses within a 
study, the data were treated independently. 
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In animal studies where different doses were administered to different groups of animals 
within the same study, each group was considered independently.  
 
2.4.3 Interpolation of pharmacokinetics parameters for children 
Simple allometry was used as the principal method for interspecies scaling and the 
equation given below was used to establish the allometric relationship (182, 256, 267). 
Y = a × Wb     (1) 
Y : Pharmacokinetic parameter, CL, Vz and t1/2 
W : Body weight of the species,  
a : Allometric coefficient  
b : Allometric exponent 
 
The pharmacokinetic parameter data were plotted against body weight on a log-log scale 
(SigmaPlot version 12.5; Systat Software, Inc., Chicago, IL) to determine the allometric 
coefficient and exponent by regression analysis. 
Pharmacokinetic parameters generated from both pre-clinical and human species were 
utilized for scaling purposes. Ideally, it was aimed to scale pharmacokinetic parameters 
of malaria infected species. However, only a limited number of pharmacokinetic studies 
were available on malaria infected non-human species. Hence data from healthy control 
subjects were used for the allometric scaling and this was considered appropriate when 
malaria infection has not altered the pharmacokinetic behaviour of the drug.  In order to 
determine this, drug clearance parameters from human (adult) studies of malaria 
infection were compared to the healthy control data, as a guide to the application of 
allometric interpolation to decisions on paediatric doses. 
 
2.4.4 Application of correction factors  
There are many correction factors reported in the literature to improve simple allometric 
scaling prediction and the physiological relevance and application of some methods was 
not applicable in the present study (174, 176, 182, 184, 188, 211). It was also not 
practical to carry out all the correction methods as some of them were unable to be 
implemented due to lack of required data. For example, given that selected antimalarials 
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are cleared mainly following hepatic metabolism, in-vitro metabolic data would have 
been a good correction factor to trial. However this information was not available for 
most of the study drugs. Out of the feasible methods, MLP correction was considered 
appropriate and was selected to evaluate allometric prediction for low extraction ratio 
drugs (184).  
In addition, it was hypothesised that liver weight and liver blood corrections could 
improve clearance prediction of these drugs as selected antimalarials are cleared through 
the hepatic metabolism.  
MLP, liver weight and liver blood flow corrections were applied to clearance prediction 
of the antimalarials as clearance was the most relevant pharmacokinetic parameter for 
maintenance dose determination.   
 
2.4.5 Maximum life-span potential (MLP) correction 
The MLP correction was also an essential part of the ‘Rule of Exponents’ approach 
(174, 211). Based on the Rule of Exponents, simple allometry is the best predictor for 
exponents in the range 0.50-0.77, whereas clearance × MLP provides the best prediction 
method when the exponent from simple allometry is in the range of 0.71-0.99 and 
clearance × brain weight provides the best prediction, when simple allometry prediction 
is greater than 1 (211). As the clearance exponent from simple allometry was less than 
1 for all antimalarial drugs, MLP correction was adopted and the brain weight correction 
was not implemented. 
The maximum life-span potential (MLP) was calculated from the equation given 
below (184): 
MLP = 10.839 × (BW)0.636 × (W)-0.225                                                            (25)  
MLP : Maximum life-span potential (years) 
BW : Brain weight (grams)  
W : Body weight (grams) 
 
Brain and body weight data for mammalian species were obtained from the literature 
(184, 265, 268). The age-specific data for 15 kg and 25 kg children (approximately 4 
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and 8 years of age) were calculated based on the equation provided by Haddad and 
colleagues (268). The brain weights for children were determined using the average for 
male and female brain weights calculated based on child age (a') using the equation 
below (268).  The calculated brain weight and body weights were used to determine the 
MLP values for children.  
Male BW = 104[(a'+0.213)/(6.030+6.895a')]     (26) 
Female BW = 104[(a'+0.226)/(6.521+7.514a')]    (27) 
  
BW : Brain weight (grams) 
 a' : Age (years) 
 
The total clearance × MLP data were plotted against body weight on a log-log scale 
(SigmaPlot) to determine the MLP corrected coefficient (a*) and exponent (b*) by 
regression analysis. The predicted clearance values were determined as per the equation 
below.   
CL × MLP =  a*× Wb
*
       (28) 
 CL : Clearance (L/h) 
 MLP : Maximum life span potential (years) 
 a* : MLP corrected coefficient 
 W : Body weight (kg) 
 b* : MLP corrected exponent  
 
2.4.6 Liver weight and liver blood flow correction  
The antimalarials used in the allometric scaling are mainly excreted following liver 
metabolism. Ritschel and co-workers (269) found a strong relationship between 
clearance of coumarin (high extraction ratio) with liver blood flow, liver weight and 
body weight among 6 mammalian species. Clearance of a drug with a high liver 
extraction ratio could relate to species liver blood flow, whereas clearance of a drug 
with  a low hepatic extraction ratio could relate to the intrinsic clearance or in-vivo 
enzyme activity (relative abundance of microsomal enzymes), therefore to the liver size 
of the mammalian species (123, 188, 189). Hence liver weights and liver blood flow of 
different preclinical species and humans were used to correct the clearance values. The 
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liver weights for different species were determined as a percentage of the body weight 
(197). Liver weight (calculated as a percentage of the body weight) and liver blood flow 
of different mammals given in Table 2.3 were used for analysis.  
 
Table 2-3: Liver weight and liver blood flow as a percentage of total body weight (197)  
Animal species  Liver weight  
(% of body weight) 
Liver blood flow  
(L/min)  
Mouse 5.06 0.00262 
Rat 4.04 0.0172 
Rabbit  4.78 0.122 
Dog 2.91 0.676 
Pig 1.97 3.36 
Human 2.42 1.78 
 
The total clearance × liver weight and total clearance × liver blood flow values were 
plotted against the species body weight in a log-log scale (SigmaPlot). The corrected 
allometric coefficient and exponents were used for determination of the drug clearance 
in humans.  
CL×LW=a** Wb
**
         (29) 
CL : Clearance (L/h) 
 LW : Liver weight (grams) 
 W : Body weight (kg) 
 a** : Liver weight corrected coefficient  
 b** : Liver weight corrected exponent  
 
Liver weight for male and female children were calculated based on child age (a) 
according to the equations provided in Haddad (268).   
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Male LW(g) = 0.0072a'5-0.3975a'4+7.9052a3-65.627a'2+262.02a'+157.52  (29) 
Female LW(g) = 0.0057a'5-0.3396a'4+7.0134a'3-59.539a'2+251.9a'+139.65 (30)
  
 LW : Liver weight (grams) 
  a' : Age (years) 
 
The liver weights for children (as calculated above), a** and b** were used for prediction 
of drug clearance using liver weight correction. 
Liver blood flow of the children was considered as 1.78 L/min (197) and, similarly to 
the liver weight method clearance × liver blood flow, was plotted to obtain the 
coefficient (a***) and exponent (b***) values. These values and liver blood flow were 
then used to interpolate drug clearance for children.  
CL×LBF=a*** Wb
***
         (31) 
CL : Clearance (L/h) 
 LBF : Liver blood flow (L/min) 
 W : Body weight (kg) 
 a*** : Liver blood flow corrected coefficient  
 b*** : Liver blood flow corrected exponent  
 
2.4.7 Interpolation of drug clearance 
Drug clearance was interpolated using simple allometry and the three correction 
methods and compared with observed clearance in clinical studies of children. The 
average body weight provided in the clinical study was used as the body weight and 
allometric exponents and coefficient for the four techniques were applied to the 
allometric power equation described in sections 2.4.5 and 2.4.6 to obtain interpolated 
drug clearance.  
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2.4.8 Predictive success 
The observed drug clearance in clinical studies was divided by the interpolated drug 
clearance to determine the predictive success of clearance for the simple allometry and 
correction methods. The ratio of observed drug clearance to predicted drug clearance in 
the range of 0.5 to 2 (2 fold) has been suggested as an acceptable difference in predicted 
drug clearance (233, 270-272).  
 
2.4.9 Interpolation of paediatric doses 
A standard allometric model for interpolation of paediatric dosing is to use the 
equation below: 
DoseCHILD=DoseADULT× (
WeightCHILD
WeightADULT
)
b
      (32) 
DoseCHILD : Total dose for a child at the specified weight 
Weight
CHILD  
: Weight of the child 
DoseADULT : Standard total dose for an adult at the specified weight 
Weight
ADULT
 : Weight of the adult   
b   : Drug specific allometric exponent  
 
The derived exponent (b) by allometric scaling was applied to the equation above to 
predict doses for children. These calculated doses were then compared to 
pharmacopoeial or reference doses for arbitrary weights of 15 kg and 25 kg. Dose 
estimates for children less than 2 years were not considered, due to the known 
physiological and pharmacokinetic differences between very young infants and adults 
(207, 208, 246). 
 
2.4.10 Extrapolation of human pharmacokinetic parameters 
It is argued in the literature that conventional allometry works for some, but not all drugs 
(230). 
In order to explore that, the allometric relationship between drug clearance of preclinical 
species and their body weight was established. The exponents and coefficients were 
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used to extrapolate drug clearance for healthy adults.  The extrapolated clearance values 
of humans were compared to observed values in clinical studies to determine how well 
conventional allometry works for scaled antimalarial drugs.  
 
2.4.11 Statistical analyses 
Data analysis was done using SigmaPlot version 12.5 (Systat Software, Inc., Chicago, 
IL). Data were presented as mean ± standard deviation (SD) unless otherwise indicated. 
The 95% confidence interval (CI) was determined for the allometric exponent (95% CI 
= mean ± 1.96 × standard error). The Students t-test was used for two-sample 
comparison as appropriate, with a significance level of P < 0.05. 
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2.5 Results  
2.5.1 Published pharmacokinetic parameters for antimalarials  
Pharmacokinetic parameters from selected studies were used for the allometric scaling 
of pharmacokinetic parameters of each drug. It was not possible to scale 
pharmacokinetics for malaria infected species due to lack of availability of 
pharmacokinetic studies in malaria infected mammalian species (<3 species) and 
therefore allometric scaling for drug clearance, volume of distribution and half-life were 
determined for healthy species. 
Artesunate pharmacokinetics were available following IV, IM, Intra peritoneal (IP), 
intra gastric and oral routes of drug administration to animals and IV, IM and oral drug 
administration to the healthy and malaria infected humans. Pharmacokinetic parameters 
for allometric scaling of dihydroartemisinin were based on pharmacokinetic studies of 
IV artesunate (the pro-drug of dihydroartemisinin) (Figure 2.1-2.6). Similar to 
artesunate analysis, pharmacokinetic parameters established following extra-vascular 
administrations of dihydroartemisinin were not utilized for allometric scaling. 
Artemether is soluble in organic solvents and available in dosage forms suitable to be 
administered by IM, IV and oral routes of administration. Pharmacokinetic parameters 
following IM, IV and oral routes of administrations were available in the published 
literature. Artemether scaling was done using IM pharmacokinetic data alone and 
incorporating IV and IM data. 
It was not possible to carry out scaling for artemisinin following a single route of 
administration. The animal pharmacokinetic data for this drug were available following 
IP and IV routes and human data were available following the oral route. Artemisinin 
has a low solubility and lacks a suitable solvent for parenteral dose formulation; hence 
pharmacokinetic studies for IV administration of artemisinin were absent. The apparent 
oral clearance was corrected using the oral/IM relative bioavailability value of 0.32 (28) 
and used for allometric scaling purposes. Further analysis of artemisinin was not done 
due to mixed routes of administration. 
Pharmacokinetic parameters for clindamycin were available following IV, IM, 
subcutaneous (SC) and oral routes of administration in animals and oral and IV 
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administration in humans. Pharmacokinetic parameters following IV administration 
were used for allometric scaling purposes.  
Mefloquine and piperaquine are drugs administered only through the oral route, hence 
allometric scaling was done using CL/F and Vz/F data resulting from oral drug 
administration. The exponents derived using apparent data were considered appropriate 
for prediction of oral doses.  
Pharmacokinetic data for quinine was available following IV, IP, intraduodenal and oral 
routes of administration in animals and IV, IM, IP and oral routes of administration in 
humans. Allometric scaling of quinine was done using pharmacokinetic parameters 
following IV data.   
 
2.5.2 Interspecies allometric scaling for clearance, volume of 
distribution and half-life of antimalarials  
The pharmacokinetic parameters for healthy preclinical animal species and humans used 
for allometric scaling were obtained from studies that met the selection criteria. 
Allometric relationships for clearance, volume of distribution and half-life of 
dihydroartemisinin using healthy species are provided in Figures 2.1, 2.3 and 2.5. 
Pharmacokinetic parameters of dihydroartemisinin in malaria infected children and 
adults were overlaid on the regression analysis established using healthy species in 
Figures 2.2, 2.4 and 2.6 
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Figure 2-1: Dihydroartemisinin:  allometric scaling relationship (regression line and 95% 
CI) for clearance in healthy species (from IV artesunate data)  
Figure 2-2: Dihydroartemisinin:  allometric scaling relationship (regression line and 95% 
CI) for clearance in healthy species ( ). Drug clearance in malaria infected adult ( ) and 
children ( ) are plotted for comparison (from IV artesunate data)  
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Figure 2-3: Dihydroartemisinin: allometric scaling relationship (regression line and 95% 
CI) for volume of distribution in healthy species (from IV artesunate data)  
Figure 2-4: Dihydroartemisinin: allometric scaling relationship (regression line and 95% 
CI) for volume of distribution in healthy species ( ). Drug volume of distribution in malaria 
infected adult ( ) and children ( ) are plotted for comparison (from IV artesunate data)  
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Figure 2-5: Dihydroartemisinin: allometric scaling relationship (the regression line and   
95%CI) for half-life in healthy species (from IV artesunate data)  
Figure 2-6: Dihydroartemisinin: allometric scaling relationship (regression line and 95% 
CI) for half-life in healthy species ( ). Drug half-life in malaria infected adult ( ) and 
children ( ) are plotted for comparison (from IV artesunate data) 
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2.5.2.1 Simple allometry for clearance of drugs  
Pharmacokinetic studies in preclinical species were limited and only 2-3 pre-clinical 
species clearance data were available to be included in the scaling. Interestingly for all 
drugs, a pharmacokinetic study conducted in rats was available. Pharmacokinetic 
studies in large mammals were not available for any of the drugs.  
The regression analysis of allometric scaling of clearance showed strong r2 value for all 
the drugs analysed and was ≥ 0.9. The allometric exponent and coefficient values for 
drug clearance are given in below Table 2.4. The allometric relationships for clearance 
were established based on healthy species clearance data and clearance of malaria 
infected adults, and children were overlaid on the same graph in Figures 2-7 to 2-13 for 
artesunate, artemisinin, artemether, clindamycin, piperaquine, mefloquine and quinine. 
Artesunate and dihydroartemisinin  
The allometric exponent for artesunate was found to be 0.71 and was equal to the 
universal exponent 0.75 (3/4) (Figure 2.7). The observed clearance of artesunate in 
malaria infected children found to be on the line of best fit of allometric scaling 
relationship established using healthy species. Hence interpolated clearance using 
healthy species would be similar to the observed clearance in malaria infected children. 
Drug clearances in malaria infected adults were within the 95% confidence interval of 
the simple allometric exponent line except for one study.   
 
 
 
 
 
 
 
 
Figure 2-7: Artesunate: allometric scaling relationship (regression line and 95% CI) for 
clearance in healthy species ( ). Drug clearance in malaria infected adult ( ) and 
children ( ) are plotted for comparison (IV data)  
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Dihydroartemisinin exponent value was higher than artesunate and the 95% confidence 
interval (CI) did not encompass universal exponent of 0.67 (2/3). The observed 
dihydroartemisinin clearance values of malaria infected adult were found to be just 
below the predicted clearance and clearance reported in majority of the studies were 
outside the 95% CI of healthy species scaling. The dihydroartemisinin clearance 
observed in infected children was within the 95% CI (Figure 2.2).  
 
Artemisinin  
Artemisinin gave an exponent value of 0.83 when mixed clearance data following IV, 
IP and oral routes of administration were used (Figure 2.8). Further analysis of 
artemisinin was not conducted due to mixed route of administration. The observed 
apparent oral clearance in malaria infected children was higher than the interpolated 
clearance using healthy species.  
 
 
 
 
 
 
 
 
 
 
Figure 2-8: Artemisinin: Allometric scaling relationship (regression line and 95% CI) 
for clearance of in healthy species ( ). Drug clearance in malaria infected adult ( ) and 
children ( ) are plotted for comparison 
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Artemether  
The exponent value, 0.66, for artemether remained unchanged for scaling following IM 
data and IM and IV data together. Similar to artesunate and dihydroartemisinin, the 
interpolated drug clearance using healthy species data was similar to observed drug 
clearance of artemether in malaria infected children (Figure 2.9).  
 
 
 
 
 
 
 
 
 
Clindamycin  
Clindamycin scaling gave an exponent value of 0.63, the narrow confidence interval did 
not encompass, universal exponent 0.75. The observed drug clearance of clindamycin 
in children (mean age of 24 weeks) was much lower compared to interpolated drug 
clearance, therefore was not used for the comparison of predicted verse observed drug 
clearance in children in Table 2.9. Clindamycin clearance in malaria infected adults 
were not available following IV route of drug administration for comparison (Figure 
2.10).  
 
Figure 2-9:  Artemether: allometric scaling relationship (regression line and 95% CI) 
for clearance in healthy species ( ). Drug clearance in malaria infected adult ( ) and 
children ( ) are plotted for comparison (IM data) 
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Piperaquine  
The piperaquine exponent value was 0.96 with a 95% CI interval encompassing 1; hence 
linear dosing for piperaquine could be supported. The observed drug clearance in 
malaria infected children and adults were within the 95% CI of the allometric 
relationship established using healthy species.  
 
 
 
 
 
 
Figure 2-10: Clindamycin: allometric scaling relationship (regression line and 95% 
CI) for clearance in healthy species ( ). Drug clearance in malaria infected adult ( ) 
and children ( ) are plotted for comparison (IV data)  
Figure 2-11: Piperaquine: allometric scaling relationship (regression line and 95% CI) for 
clearance in healthy species ( ). Drug clearance in malaria infected adult ( ) and children 
( ) are plotted for comparison (oral data)  
   Page 75 of 294 
Mefloquine  
The exponent for mefloquine was low (0.52) and did not encompass the both universal 
exponent values of 0.67 and 0.75 for clearance. A small exponent value for mefloquine 
indicates the need of large increment in doses. The reported mefloquine clearance values 
in healthy human adults were wide spread. Mefloquine clearance in children were 
available in 5 studies, however 3 of those used whole blood as the assay matrix, hence 
was not included in the Figure 2.12 and Table 2.11. The observed clearance for children 
was below and outside the 95% CI the interpolated clearance for children, however in 
the 2 studies; mefloquine was administered along with sulphadoxine and 
pyrimethamine.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-12: Mefloquine: allometric scaling relationship (regression line and 95% CI) 
for clearance of in healthy species ( ). Drug clearance in malaria infected adult ( ) and 
children ( ) are plotted for comparison (oral data)  
 
Quinine  
Out of the antimalarials studies, quinine had the lowest exponent of 0.40, hence 
requiring large increase in doses for healthy children. Similar to mefloquine the fixed 
exponent allometry was not supported for quinine scaling. The 95% CI of quinine did 
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not encompass either of the fixed exponent values. The observed quinine clearance was 
clearly lower than the allometrically interpolated clearance using healthy species and 
this is also true for malaria infected adults (Figure 2.13).  
 
 
 
 
 
 
 
 
 
Artesunate, artemether, artemisinin, clindamycin, mefloquine and quinine exponents 
indicate the absence of linear relationship between bodyweight and drug dose, therefore 
mg/kg dosing is not applicable fixed or universal exponent values were not supported 
by all the drugs. 
 
Figure 2-13: Quinine: allometric scaling relationship (regression line and 95% CI) 
for clearance of in healthy species ( ). Drug clearance in malaria infected adult ( ) 
and children ( ) are plotted for comparison (IV data)  
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Table 2-4:  Simple allometric scaling data for clearance of antimalarial drugs 
Drug Route of 
administrationa 
Number of 
species b 
r2 Allometric exponent 
(95% CI) 
Allometric 
coefficient 
References 
Artesunate IV 4 (r,d,p,h) 0.92 0.71 (0.53-0.88) 7.0 (46, 55, 62, 167, 273, 274) 
Dihydroartemisinin   
(from IV artesunate) 
IV 4 (r,d,p,h) 0.94 0.85 (0.68-1.03) 3.3 (46, 55, 61, 62, 167, 273, 
274) 
Artemether  IM 3 (r,d,h) 0.98 0.66 (0.38-0.93) 3.3 (54, 55, 275, 276) 
Artemether IM or IV 4 (r,rb,d,h) 0.99 0.66 (0.56-0.75) 3.3 (54, 55, 275-277) 
Artemisinin  IV, IP, Oral×Fc 3 (m,r,h) 0.92 0.83 (0.69-0.96) 4.2 (28, 30, 32, 278-285) 
Clindamycin  IV 3 (d,r,h) 0.98 0.62 (0.55-0.69) 1.4 (142, 286-290) 
Piperaquine Oral 3 (m,r,h) 0.99 0.96 (0.86-1.05) 1.6 (82, 83, 86, 90, 91, 291) 
Mefloquine Oral 3 (m,r,h) 0.90 0.52 (0.43-0.61) 0.2 (95, 99, 106, 109, 110, 292-
304) 
Quinine  IV 3 (r,d,h) 0.89 0.40 (0.33-0.47) 1.9 (116, 132, 133, 305-314) 
a Route of administration: IV: intravenous, IM: Intramuscular, IP: Intraperitoneal, b Species: m : mouse, r: rat, d: dog, p: pig, rb: rabbit, h:  human  c F: Relative 
bioavailability (oral/IM )  for artemisinin is 0.32 (28)
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2.5.2.2 Simple allometry for volume of distribution of drugs  
Similar to clearance data, allometric scaling of volume of distribution had a strong r
2 
with the exception of artesunate (r2 = 0.69). The r2 and exponents for volume of 
distribution of antimalarials are given in the Table 2.5. The exponents for volume of 
distribution can be used for determination of loading doses of antimalarials. The 
allometric relationships for the volume of distribution were established based on healthy 
species volume of distribution data and volume of distribution of malaria infected adults, 
and children were overlaid on the same graph in Figures 2-14 to 2-19 for artesunate, 
artemether, clindamycin, piperaquine, mefloquine and quinine 
 
Artesunate and dihydroartemisinin  
Artesunate had comparatively lower exponent value of 0.54 volumes of distribution and 
wide CI (Figure 2.14). The low exponent value for artesunate could be due to the pro-
drug nature of the drug. The volume of distribution of artesunate reported for malaria 
infected adults in the majority of the studies was lower and outside the 95% CI of the 
interpolated clearance using healthy species, so was for malaria infected children.    
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Figure 2-14 : Artesunate: allometric scaling relationship (regression line and 95% CI) for 
volume of distribution in healthy species ( ). Drug volume of distribution in malaria 
infected adult ( ) and children ( ) are plotted for comparison (IV data) 
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Further analysis was limited to dihydroartemisinin; the active drug for artesunate. 
Dihydroartemisinin had an exponent value of 0.86 with a narrow confidence interval 
(Figure 2.4). Similar to artesunate, the observed volume of distribution values of 
dihydroartemisinin in malaria infected adults and children were much lower compared 
to the interpolated volume of distribution and not within the 95% CI of the allometric 
relationship established using healthy species. 
 
Artemether  
Artemether exponents are 0.93 (IM data) and 1.06 (IM and IV data). The narrow 95% 
CI includes 1, therefore linear dosing can be recommended for loading dose of 
artemether. The observed volume of distribution of adults were similar to the 
interpolated, however the infected children volume of distribution was outside the 95% 
CI and higher than interpolated volume of distribution (Figure 2.15). 
 
 
 
 
 
 
 
Clindamycin  
The exponent for volume of distribution is 0.81 with narrow 95% CI. Clindamycin 
volume of distribution in infected adults was not reported. The observed drug clearance 
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Figure 2-15 : Artemether: Allometric scaling relationship (regression line and 95% CI) for 
volume of distribution in healthy species ( ). Drug volume of distribution in malaria 
infected adult ( ) and children ( ) are plotted for comparison (IM data) 
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in malaria infected children (mean age 24 weeks) was slightly lower than the 
interpolated clearance and just outside the 95% CI (Figure 2.16). 
 
 
 
 
 
 
 
Piperaquine  
Piperaquine volume of distribution exponent was above 1 and has wide CIs.  The 
observed volume of distribution of malaria infected adults and children were within the 
95% CI of healthy species allometric relationship (Figure 2.17).  
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Figure 2-16 : Clindamycin: allometric scaling relationship (regression line and 95% CI) for 
volume of distribution in healthy species ( ). Drug volume of distribution in malaria infected 
adult ( ) and children ( ) are plotted for comparison (IV data) 
Figure 2-17: Piperaquine: allometric scaling relationship (regression line and 95% CI) for 
volume of distribution in healthy species ( ). Drug volume of distribution in malaria 
infected adult ( ) and children ( ) are plotted for comparison (oral data) 
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Mefloquine  
Mefloquine volume of distribution was reported in large number of heathy human adult 
studies narrowing the 95% CI at this end. The observed volume of distribution in 
infected adults and children are spread apart leaving some of the reported values outside 
the 95% CI of the allometric relationship established using healthy species (Figure 
2.18).  
 
 
 
 
 
 
 
 
Quinine  
Quinine exponent was 0.88 and the 95 % CI enclosed 1, therefore quinine loading doses 
can be mg/kg adult doses for healthy humans. However the observed volume of 
distribution of malaria infected children and adults were much lower than the 
interpolated values using healthy species scaling and was outside the 95% CI, which 
indicate clear difference in volume of distribution of quinine in healthy species 
compared to malaria infected status (Figure 2.19). 
 
 
Figure 2-18: Mefloquine: allometric scaling relationship (regression line and 95% CI) for 
volume of distribution in healthy species ( ). Drug volume of distribution in malaria infected 
adult ( ) and children ( ) are plotted for comparison (oral data) 
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No further analysis of volume of distribution was done as loading doses are not 
recommended for adults with malaria infection for the drugs scaled, except for quinine 
in severe malaria (pharmacokinetic modelling studies have suggested loading dose of 
20 mg/mg quinine, in a rate controlled slow infusion (twice the maintenance dose) .  
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Figure 2-19: Quinine: allometric scaling relationship (regression line and 95% CI) for 
volume of distribution in healthy species ( ). Drug volume of distribution in malaria 
infected adult ( ) and children ( ) are plotted for comparison (IV data) 
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Table 2-5 :  Simple allometric scaling data for volume of distribution (Vz) of antimalarial drugs 
Drug Route of 
administration a 
Number of 
species b 
r2 Allometric exponent 
(95% CI) 
Allometric  
coefficient 
References 
Artesunate IV 4 (r,d,p,h) 0.69 0.54 (0.22-0.85) 3.2 (46, 55, 62, 167, 273, 274) 
Dihydroartemisinin 
(from IV artesunate) 
IV 4 (r,d,p,h) 0.99 0.86 (0.78-0.94) 4.2 (46, 55, 61, 62, 167, 273, 274) 
Artemether  IM 3 (r,d,h) 0.99 0.93 (0.82-1.05) 12.4 (54, 55, 275, 315) 
Artemether IM or IV 4 (r,rb,d,h) 0.96 1.06 (0.75-1.38) 6.7 (54, 55, 275, 277, 315) 
Clindamycin  IV 3 (d,r,h) 0.98 0.81 (0.72-0.91) 2.5 (139, 142, 286-290) 
Piperaquine Oral 3 (m,r,h) 0.94 1.16 (0.87-1.45) 280 (82, 91, 291) 
Mefloquine Oral 3 (m,r,h) 0.91 0.78 (0.66-0.90) 39.8 (95, 99, 106, 109, 110, 292-
304) 
Quinine  IV 3 (r,d,h) 0.92 0.88 (0.74-1.01) 4.61 (116, 132, 133, 305-314, 316) 
a Route of administration: IV: intravenous, IM: Intramuscular, b Species: m : mouse, r: rat, d: dog, p: pig, rb: rabbit, h:  human  
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2.5.2.3 Simple allometry for half-life of drugs  
Table 2.6 gives the allometric scaling relationship for half-life of antimalarials. As 
shown in the Table 2.6, half-life scaling did not provide strong r2 for most of the drugs. 
The allometric relationships for half-life were established based on healthy species half-
life data and half-life of malaria infected adults, and children were overlaid on the same 
graph in Figures 2-20 to 2-25 for artesunate, artemether, clindamycin, piperaquine, 
mefloquine and quinine. 
 
Artesunate and dihydroartemisinin 
The universal exponent value for half-life is 0.25 and artesunate and its active drug 
dihydroartemisinin exponent values for half-life deviated very much from the universal 
exponent value. The 95% CIs were wide for both artesunate and dihydroartemisinin 
scaling. Similar to volume of distribution, the observed artesunate half-life is below the 
95% CI interval of healthy species scaling, except for one reported study (Figure 2.20). 
The observed half-life values of dihydroartemisinin in malaria infected adults spread 
widely however mostly within the 95% CI of the healthy species scaling due to the wide 
CI whereas observed half-life of infected children was not within the CI (Figure 2.6). 
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Figure 2-20: Artesunate: allometric scaling relationship (regression line and 95% CI) 
for half-life of in healthy species ( ). Drug half-life in malaria infected adult ( ) and 
children ( ) are plotted for comparison (IV data) 
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Artemether  
Artemether (IM dataa0 showed a good allometric relationship for half-life with an r2 of 
0.94. The exponent value for artemether changed slightly (0.28 to 0.35) when IV data 
was combined with IM data. The observed half-life for malaria infected children was 
outside the 95% CI of healthy species scaling (Figure 2.21).  
 
 
 
 
 
 
 
 
Clindamycin 
Clindamycin half-life had a poor allometric relationship and exponent value was 0.17 
with fairly wide 95% CIs. The observed half-life of the infected children (mean age 24 
weeks) was outside the 95% CI of the healthy species scaling (Figure 2.22).         
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Figure 2-21: Artemether: allometric scaling relationship (regression line and 95% CI) 
for half-life of in healthy species ( ). Drug half-life in malaria infected adult ( ) and 
children ( ) are plotted for comparison (IM data) 
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Piperaquine  
Piperaquine gave a very low r2 and wide 95% CI for allometric relationship of half-life. 
The exponent was 0.27 and close to the fixed exponent of half-life. The observed half-
life of malaria infected adults and children were within the 95% CI of the healthy species 
(Figure 2.23).  
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Figure 2-22: Clindamycin: allometric scaling relationship (regression line and 95% CI) 
for half-life of in healthy species ( ). Drug half-life in malaria infected adult ( ) and 
children ( ) are plotted for comparison (IV data) 
Figure 2-23: Piperaquine: allometric scaling relationship (regression line and 95% CI) for half-
life in healthy species ( ). Drug half-life in malaria infected adult ( ) and children ( ) are plotted 
for comparison (oral data) 
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Mefloquine  
Mefloquine half-life exponent was similar to the fixed exponent value for half-life. The 
observed half-life values of the malaria infected children were much lower and outside 
the 95% CI of healthy species scaling (Figure 2.24).  
 
 
 
 
 
 
 
 
Quinine 
The allometric relationship for half-life had a r2 of 0.81 and the exponent was 0.35 with 
comparatively narrow 95% CI. The clearance and volume of distribution of quinine in 
malaria infected children was lower compared to the interplolated values using healthy 
species. The observed half life of the malarial infected children dependent on clearance 
and volume of distribution were higher than the interploated half-life using healthy 
species. Whereas observed half-life in malaria infected adults were moslty within the 
95% CI of healthy species scaling (Figure 2.25).  
Body weight (Kg)
0.01 0.1 1 10 100
H
a
lf
-l
if
e
 (
h
rs
)
1
10
100
1000
10000
Mice
Rats
Human adults
Malaria infected children
Malaria infected adults
Figure 2-24: Mefloquine: allometric scaling relationship (regression line and 95% CI) 
for half-life of in healthy species ( ). Drug half-life in malaria infected adult ( ) and 
children ( ) are plotted for comparison (oral data) 
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Half-life is dependent on drug clearance and volume of distribution. Given the poor 
allometric relationship of half-life of most of the antimalarials studied, no further 
analysis of half-life was carried out.  
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Figure 2-25: Quinine: allometric scaling relationship (regression line and 95% CI) for half-
life of in healthy species ( ). Drug half-life in malaria infected adult ( ) and children ( ) 
are plotted for comparison (IV data) 
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Table 2-6: Simple allometric scaling data for half-life of antimalarial drugs  
Drug Route of 
administration a 
Number of species b r2 Allometric exponent 
(95% CI) 
Allometric 
coefficient 
References 
Artesunate IV 4 (r,d,p,h) 0.23 -0.16 (-0.50-0.18) 0.32 (46, 55, 62, 167, 273, 274) 
Dihydroartemisinin  
(from IV artesunate) 
IV 4 (r,d,p,h) 0.003 0.01 (-0.16-0.18) 0.89 (46, 55, 61, 62, 167, 273, 274) 
Artemether  IM 3 (r,d,h) 0.94 0.28 (0.06-0.50) 2.62 (54, 55, 275, 315) 
Artemether IM or IV 4 (r,rb,d,h) 0.64 0.35 (-0.13-0.84) 1.71 (54, 55, 275, 277, 315) 
Clindamycin  IV 3 (d,r,h) 0.46 0.17 (-0.04-0.39) 1.38 121, 124, 242-244, 246, 271) 
Piperaquine Oral 3 (m,r,h) 0.27 0.21 (-0.19-0.60) 123                                                                                                                                            (82, 91, 291) 
Mefloquine Oral 3 (m,r,h) 0.70 0.26 (0.18-0.35) 135  (95, 99, 106, 109, 110, 292-
304) 
Quinine  IV 3 (r,d,h) 0.81 0.35 (0.26-0.45)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             2.31 (116, 132, 133, 305-314, 316) 
a Route of administration: IV: Intravenous, IM: Intramuscular, b Species: m: mouse, r: rat, d: dog, p: pig, rb: rabbit, h:  human   
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2.5.3 Comparison of pharmacokinetics in healthy and malaria 
infected adults  
There is a paucity of pharmacokinetic studies in malaria infected mammals. Therefore 
it was not possible to establish an allometric scaling relationship for pharmacokinetic 
parameters using malaria infected species. In order to determine changes in 
pharmacokinetic profile during malaria infection, drug clearance in healthy adults and 
malaria infected patients were compared (Table 2.7). Quinine drug clearance in malaria 
infected adults was significantly lower compared to healthy adult clearance. Despite 
limited data, quinine showed a clear difference in drug clearance in malaria infection. 
Similar trends were observed for dihydroartemisinin, however the power of the test was 
low (0.56) and was below the desired value of 0.8, and therefore was unable to establish 
a definitive difference in clearance in malaria infection compared to the healthy status. 
Drug clearance for artesunate, artemether and mefloquine was not significantly different 
in malaria infection compared to healthy adults. However the power of the statistical 
tests was low and with high standard deviation, therefore similar to dihydroartemisinin 
it was difficult to be definitive.   
It was not possible to determine the change in piperaquine clearance in malaria infection, 
due to the absence of clearance data in single therapy for malaria infected patients. No 
difference (P = 0.24) in clearance was found, following co-administration of 
piperaquine-dihydroartemisinin when compared with piperaquine single therapy in 
healthy adult (82, 90, 91, 317, 318). Therefore piperaquine studies for healthy volunteers 
included piperaquine single and piperaquine-dihydroartemisinin combination therapy 
data and piperaquine-dihydroartemisinin combination data for malaria infected adults. 
This comparison showed no difference in piperaquine clearance in healthy and malaria 
infected adults. Nevertheless allometric exponents and coefficients of healthy species 
were used for dose determination in malaria infection for dihydroartemisinin, 
artemether, mefloquine and piperaquine. It was not possible to compare clearance data 
for clindamycin in malaria infected and healthy status. Clindamycin clearance data were 
not available in infected adults. Clindamycin apparent clearance following oral 
administration of fosmidomycin and clindamycin was available; however it was unable 
to establish whether fosmidomycin would change the clearance profile of clindamycin. 
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Table 2-7: Mean clearance of antimalarial drugs in healthy adults compared to malaria infected patients 
Drug Route of 
administration 
CL   (L/h/kg) mean ± SD                     
[Number of groups a] 
Healthy Vs Malaria References  
  Healthy Malaria infected  P value Power   
Artesunate IV 1.9 ± 0.6 [n = 3] 2.9 ± 0.8 [n = 8] 0.09 0.4 (36, 40, 41, 46, 62, 274, 319-321) 
Dihydroartemisinin 
(from IV artesunate) 
IV 1.1 ± 0.16 [n = 3] 0.81 ± 0.2 [n =9 ] 0.04 0.56 (36, 40, 41, 46, 62, 274, 319-321) 
Artemether  IM 0.88 ± 0.35 [n = 2] 1.8 ± 0.9 [n = 2] 0.32 0.13 (48, 54, 275, 322) 
Clindamycin  IV  0.32 ± 0.12 [n = 3] n/a b n/a b n/a b (142, 288, 289) 
Piperaquine c Oral 0.86 ± 0.65[n = 6] 1.55 ± 0.73 [n = 4] 0.15 0.28 (82, 86, 87, 90, 91, 317, 318, 323, 324) 
Mefloquine Oral 0.030 ± 0.014 [n =17] 0.039 ± 0.014 [n = 5] 0.24 0.21 (95, 99, 106, 109, 110, 293-303) 
Quinine  IV 0.17 ± 0.05 [n = 6] 0.07 ± 0.03 [n = 9] 0.0002 0.99 (18, 116, 132, 133, 311-314, 325-329) 
Quinine (children) IV 0.24 [n = 1] 0.064 ± 0.014 [n = 5] n/a b n/a b (125, 311, 330) 
a Some studies comprised several groups, b Not available,  c Piperaquine studies included piperaquine alone and piperaquine-dihydroartemisinin data for 
healthy volunteers, but only piperaquine-dihydroartemisinin data for patients with malaria. Our data and a previous report (89) indicate that there is no 
significant difference in piperaquine clearance when administered alone or in combination with dihydroartemisinin
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2.5.4 Application of correction factor, maximum life span potential  
As described in the methods sections, in order to correct the clearance value using the 
maximum life span potential (MLP) correction factor, the clearance values were 
multiplied by the MLP values. The calculated MLP values were 2.7, 4.8, 8.7, 20, 16, 93, 
109 and 106 years for mice, rats, rabbits, dogs, pigs, human adults, 15 kg children and 
25 kg children, respectively (268). Multiplication of clearance by these MLP values 
result in an increase of the product (MLP corrected clearance) by many fold; 3-5 fold 
for rodents, 16-20 fold for dogs and pigs, 93 fold for adult humans and >100 fold in 
human children. Thus MLP corrected clearance in the Y-axis (Figure 2.27) was 
extended by about two orders of magnitude compared to simple allometry (Figure 2.26). 
This lead to improvement of r2 values for dihydroartemisinin, mefloquine and quinine 
using MLP compared to the simple allometry. However, r2 values were slightly lower 
for artemether, clindamycin and piperaquine (Table 2.8). The exponent values obtained 
for MLP correction were higher than the simple allometric exponent and were above 0.9 
for all drugs.  
 
2.5.5 Application of liver weight  and liver blood flow correction 
factors.  
In order to correct the clearance values using liver weight and blood flow method, liver 
blood flow and liver weight of the mammalian species were multiplied by the total 
clearance values. The liver weight ranged from 0.0014 kg for mice to 1.58 kg for human 
adults. This resulted in decreasing the clearance value for mice by 800 fold and 
increasing the clearance value for humans by about 1.5 fold. Therefore, similar to the 
MLP correction, the Y-axis was extended by two orders of magnitude (Figure 2.29). 
The liver blood flow correction followed similar trends and the Y-axis was extended 
(Figure 2.30). The r2 value for the liver weight correction method improved for all the 
drugs (r2 = 0.98), whereas the r2 value for the liver blood flow method was improved for 
dihydroartemisinin, clindamycin, piperaquine, mefloquine and quinine and slightly 
decreased for artemether and artesunate. The exponent values for both liver blood flow 
(≥1.3) and weight corrections (≥1.3) were higher compared to the simple allometry. The 
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r2, exponent and coefficient for MLP, liver weight and liver blood flow corrections are 
given in Table 2.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-26: The regression line and 95% CI for allometric scaling relationship for 
dihydroartemisinin using simple allometry  
Figure 2-27: The regression line and 95% CI for allometric scaling relationship for 
dihydroartemisinin using MLP correction  
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Figure 2-29: The regression line and 95% CI for allometric scaling relationship for 
dihydroartemisinin using liver blood flow correction 
 
 
Figure 2-28: The regression line and 95% CI for allometric scaling relationship for 
dihydroartemisinin using liver weight correction  
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Table 2-8: The exponent, coefficient and coefficient of determination (r2) values for simple allometry and MLP, liver body weight and liver 
blood flow corrections 
 
a, b: Allometric coefficient and exponent for simple allometry, a*, b*: Allometric coefficient and exponent for MLP correction, a**, b**: Allometric coefficient 
and exponent for liver weight correction, a***, b***: coefficient and exponent for liver blood flow correction 
 
 
 
 
 
Drug  Simple allometry MLP correction 
 
Liver weight correction  Liver blood flow 
correction 
References  
 r2 b a  r2 b* a* r2 b** a** r2 b*** a***  
Artesunate  (IV) 0.92 0.71 7 0.95 1.19 47.9 0.99 1.61 0.25 0.71 1.31 0.73 (46, 55, 62, 167, 273, 274) 
Dihydroartemisinin 
(from IV artesunate) 
0.94 0.85 3.3 0.99 1.31 25 0.99 1.76 0.12 0.95  1.70 0.23 (46, 55, 61, 62, 167, 273, 
274) 
Artemether (IM) 0.98 0.66 3.3 0.98 1.17 28.2 0.996 1.57 0.12 0.97 1.50 0.19 (54, 55, 275, 276) 
Clindamycin (IV) 0.98 0.62 1.7 0.94 1.13 11.5 0.996 1.53 0.05 0.99 1.46 0.079 (142, 286-290) 
Piperaquine (oral)  0.99 0.96 1.6 0.91 1.46 16.2 0.997 1.86 0.06 0.99 1.8 0.078 (82, 83, 86, 90, 91, 291) 
Mefloquine (oral) 0.90 0.52 0.2 0.96 1.0 2.6 0.98 1.44 007 0.97 1.35 0.013 (95, 99, 106, 109, 110, 292-
304) 
Quinine (IV) 0.89 0.40 1.9 0.98 0.93 18.2 0.99 1.31 0.07 0.98 1.27 0.11 (116, 132, 133, 305-314) 
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2.5.6 Interpolation of drug clearance for children  
Table 2.9 compares the antimalarial drug clearance in malaria infected children (except 
quinine) from published clinical studies with the interpolated drug clearance  based on 
the simple allometric technique and correction methods; MLP, liver weight and liver 
blood flow correction. The observed drug clearance in quinine in healthy children was 
listed for comparison as quinine drug clearance in malarial infection was significantly 
different to healthy status.  
Predicted clearance values obtained by simple allometry (based on preclinical and 
human adult clearance data) for all the drugs were within the threshold of 0.5 to 2 fold 
of the observed clearance in pharmacokinetic clinical studies of children. 
Dihydroartemisinin and artemether predicted clearance values were similar to the 
observed clearance with fold difference of 1. The piperaquine clearance was available 
from two clinical studies; however the values were different from one study to the other. 
The average body weight of piperaquine study participants were 16 and 19, therefore 
predicted clearance values were similar. Therefore observed clearance was an under 
prediction for one study and over prediction for the other study. Mefloquine and quinine 
clearance values were slightly over predicted by the simple allometric techniques.  
MLP correction under predicted the drug clearance for all the drugs. The predicted 
clearance values for artemether and dihydroartemisinin were more than 4 fold lower.  
Mefloquine and quinine clearance interpolations were within 2 fold of the observed 
clearance.  
Clearance interpolated using liver weight correction was within 0.5 to 2 fold for all 
drugs. 
Liver blood flow corrections under-predicted the drug clearance for all the drugs. 
Predicted clearance for quinine was within the accepted value of 0.5 to2.  
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Table 2-9: Observed drug clearance of children in clinical studies compared to interpolated drug clearance using simple allometry and MLP, 
liver weight and liver blood flow corrections.  
a Drug clearance was interpolated using healthy control data, b Drug clearance of clinical studies were from malaria infected children and CL /F was reported 
for artemether, piperaquine and mefloquine c Piperaquine observed CL /F was reported from studies of dihydroartemisinin and piperaquine, d Mefloquine CL 
/F was determined from studies of mefloquine-sulfadoxine and pyrimethamine, e   Malaria infected children were < 2 years and mean age was 1.6 years,   f CL   
interpolated and observed for quinine were using healthy control data
Drug Predicted drug CL   (L/h/kg) a 
(Observed CL/Predicted  CL  ) 
Observed CL in  
Clinical studies b 
References 
 Simple allometry 
 
MLP correction 
 
Liver weight 
correction 
Liver blood flow 
correction  
CL   (L/h/kg) Weight (kg)  
Dihydroartemisinin 
( from IV artesunate) 
2.25 (1) 0.48 (4.5) 1.17 (1.8) 0.78 (2.8) 2.16 13 (63) 
Artemether (IM) 1.52 (1) 0.35 (4.3) 1.79 (0.8) 0.33 (4.5) 1.5 9.5 (331) 
Piperaquine (oral) 1.39 (0.6) 0.50 (1.7) 1.15 (1.7) 0.46 (1.8) 0.85 c 19.1 (87) 
Piperaquine (oral) 1.40 (1.3) 0.57 (3.2) 1.06 (1.8) 0.40 (4.6) 1.85 c 16 (332) 
Mefloquine (oral) 0.068 (0.7) 0.023 (2) 0.04 (1.0) 0.02 (2.3) 0.046 d   9.5 e (333) 
Mefloquine (oral) 0.068 (0.7) 0.023 (2.1) 0.04 (1.1) 0.02 (2.4) 0.048 d 9.5 e (334) 
Mefloquine (oral) 0.045 (0.6) 0.024 (1.1) 0.03 (0.8) 0.02 (1.3) 0.026 d 23 (335) 
Quinine (IV) f   0.37 (0.6) 0.13 (1.8) 0.31 (0.8) 0.13 (1.8) 0.24 15.4 (311) 
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2.5.7 Paediatric dose determination  
Doses were predicted for children weighing 15 and 25 kg using simple allometric 
exponent values and adult doses. Table 2.10 compares the predicted doses with the 
reference doses according to the current dosing recommendation for children. 
Allometrically predicted doses were within 10-70% higher compared to the current dose 
recommendation for children weighing 15 and 25 kg except for artemether.  
The predicted artemether dose was lower compared to the reference dosing 
recommendation. The current artemether dosing recommendations are for body weight 
ranges, 1, 2, 3 and 4 × 20 mg tablets for 5-14 kg, 15-24 kg, 25-34 kg and >34 kg, 
respectively. Therefore a dose of 40 mg is applicable for 15 to 24 kg and 60mg is 
applicable to 25-34 kg.  The adult dose of 80 mg is applicable for 35 to 70 kg and above. 
The normalized reference doses for 5, 14, 15, 24, 25, 34, 35 and 70 kg are 4, 1.42, 2.67, 
1.67, 2.40, 1.67, 2.28 and 1.14 mg/kg, therefore currently recommend children 
normalised doses are always higher than the adult doses. Allometrically predicted doses 
for 15 and 25 kg are 11/2(2 mg/kg) and 2 tablets (1.6 mg/kg).  Hence, current practical 
dose recommendations are mostly higher than adults and close or higher than the 
allometric predictions. 
Given the lower exponent values, a large increase in doses was predicted for mefloquine 
and were 1.6 to 2.5 fold higher compared to the reference doses. However the observed 
clearance for mefloquine (in combination with sulfadoxine and pyrimethamine) was 
slower compared to the predicted clearance (2.11).  
Allometric interpolation estimated doubling the dose of quinine for healthy individuals. 
However quinine clearance was lower in malaria infection (Table 2.7) and the observed 
clearance in healthy children was lower compared to the simple allometry predictions 
(Table 2.9). Therefor dose increments for malaria infected children need to be done 
cautiously. 
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Table 2-10:  Allometric interpolation of antimalarial doses in comparison to current dosage recommendations 
Drug                     Standard regimen a Dose (mg) for 15 kg child  Dose (mg) for 25 kg child 
                                                                                                       Reference b Allometry c 
(Total)  
 
(mg/kg) 
Reference b Allometry c 
(Total) 
 
(mg/kg) 
Dihydroartemisinin  
(as IV artesunate) 
IV Dose at 0, 12, 24 h, then once/day        
(2.4 mg/kg/dose) 
36 45  3 60 70 2.8 
Artemether IM Twice/day for 3 days 
(40 and 60 mg for 15 and 25 kg weights) 
40 30 2 60 40 1.6 
Clindamycin  IV Twice/day for 7 days  
(10 mg/kg/dose) 
150 260 17.3 250 360 24 
Piperaquine  Oral Once/day for 3 days  
(18 mg/kg/day) 
270 290 19.3 450 470 18.8 
Mefloquine Oral 15 mg day 1, 10mg  day 2 
(25 mg/kg total dose) 
375 790 52.6 625 1025 41 
Quinine  IV Three times per day for 5-7 days 
(10 mg/kg/dose) 
150 370 24.6 250 460 18.4 
a World Health Organization (3)  and confirmed by reference to British National Formulary (251),  b Based on mg/kg doses and practical recommendations 
c Based on reference doses  and equation (DoseCHILD = DoseADULT × (WeightCHILD/WeightADULT)
b, where adult dose was according to 70 kg body weight and 
exponent (b) from Table 2.4. Doses mostly rounded to 10 mg increment, rather than nearest practical dose.
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2.5.8 Extrapolation of clearance for human adults using preclinical 
species 
Finally, the exponents and coefficient for clearance of anti-malarial drugs were 
determined using only preclinical data. This enables determination of whether 
preclinical clearance data of antimalarials can be used to predict clearance for humans.  
Table 2.11 provides allometric coefficient and exponent obtained from scaling clearance 
of preclinical species. The table also compares the observed healthy adult clearance (in 
healthy and malaria infected adults) and predicted clearance from scaling preclinical 
data and both preclinical and human data together. Figure 2.30 and 2.31 shows the 
regression analysis for allometric scaling of clearance of dihydroartemisinin (following 
IV artesunate) and artemether (IV and IM data) using preclinical species data.   
A minimum number of three species were required for allometric scaling, however 
clindamycin, piperaquine, mefloquine and quinine had clearance data from only two 
pre-clinical species. Despite this, predicted clearance for mefloquine based on 
preclinical species was similar to the observed clearance in clinical studies and predicted 
clearance using both preclinical and human data.  
The addition of human data did not alter the exponent values for artemether and the drug 
clearance predicted is very much similar to the observed clearance in clinical studies, 
therefore allometric scaling using preclinical data is plausible for some drugs.  
The predicted values were within 0.5 to 2 fold of observed clearance for other drugs 
except dihydroartemisinin and piperaquine.   
The predicted clearance for dihydroartemisinin and piperaquine using preclinical data 
was much higher compared to the observed clearance in clinical studies was 4 and 6 
fold higher than the observed clearance in healthy adults. Despite the large difference in 
predicted clearance, a very strong r2 value (0.999) was observed for dihydroartemisinin 
(Figure 2.30). The addition of human data substantially improved the predicted 
clearance for both drugs and was within the defined threshold of 0.5 to 2 fold of the 
observed clearance.    
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Figure 2-31: Regression line and 95% CI for Interspecies scaling relationship for 
artemether (IM and IV data) clearance using preclinical species
Figure 2-30: Regression line and 95% CI for interspecies scaling relationship for 
dihydroartemisinin (following IV artesunate) clearance using preclinical species  
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Table 2-11:  Allometric prediction of drug clearance for 70 kg adult using preclinical species compared to observed clearance in human studies 
and clearance predicted using preclinical and humans data.  
Drugs  Allometric exponent 
/coefficient 
Predicted CL for 70 kg 
human adults (L/hr/kg) b 
Observed CL (Mean ± SD)  
(L/hr/kg) c 
References 
 Preclinical 
species a 
Preclinical 
species and 
human    
Preclinical 
species d 
Preclinical 
species and 
human d    
Healthy  Adults 
[No of groups] 
 
Artesunate (IV) 0.78/6.8 (r,d,p) 0.71/7.0 2.65 (0.7) 2.04 (0.9) 1.9±0.6 [n = 3] (36, 40, 41, 46, 62, 274, 319-321) 
Dihydroartemisinin 
(from IV artesunate) 
1.05/3.6 (r,d,p) 0.85/3.3 4.40 (0.2) 1.74 (0.6) 1.1±0.16 [n = 3] (36, 40, 41, 46, 62, 274, 319-321) 
Artemether (IM) 0.65/3.3 (r,d) 0.65/3.3 0.75 (1.2) 0.75 (1.2) 0.88±0.35 [n = 2] (54, 55, 275, 276) 
Artemether (IM&IV) 0.65/3.3 (r,rb,d) 0.66/3.3 0.75 (1.2) 0.79 (1.1) 0.88±0.35 [n = 2] (54, 55, 275, 276) 
Clindamycin (IV)  0.53/1.4 (r,d) 0.62/1.4 0.19 (1.7) 0.33 (1.0) 0.32±0.05 [n=3] (142, 288, 289) 
Piperaquine (oral) 1.17/2.6 (m,r) 0.96/1.6 5.35 (0.2) 1.35(0.6) 0.86±0.65 [n = 6] (82, 86, 87, 90, 91, 317, 318, 323, 324) 
Mefloquine (oral) 0.53/0.2 (m,r) 0.52/0.2 0.03 (1) 0.03 (1) 0.03±0.014[n =17] (95, 99, 106, 109, 110, 293-303) 
Quinine (IV) 0.51/2.2 (r,d) 0.42/1.9 0.27 (0.6) 0.16 (1.1) 0.17±0.05 [n = 6] (18, 116, 132, 133, 311-314, 325-329) 
a Species: m : mouse, r : rat, d : dog, p : pig, rb : rabbit, h :  human, b The exponent/coefficient in column 2 for preclinical species and column 3 for preclinical 
and human species were applied to equation ( predicted CL = aWb) to determine predicted CL for 70 kg adult. c The observed CL for healthy were obtained 
from Table 2.7, d The ratio of observed CL /Predicted  CL in heathy adults are given within the bracket
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2.6 Discussion 
Allometric scaling is based on well-established theoretical principles of a power law 
relationship between the biological parameters and the body size of the mammals. The 
present study utilized all valid published preclinical and human pharmacokinetic data to 
establish the allometric relationship in order to predict paediatric dosing. Thus 
interpolations were based on best available preclinical and human pharmacokinetic data 
compared to those made using conventional allometry where only preclinical species 
are used to extrapolate pharmacokinetic parameters for humans. 
There was a paucity of pharmacokinetic literature of antimalarials in preclinical species, 
which limited the number of drugs studied. This was evident from the reduction in the 
target list of antimalarials (amodiaquine, lumefantrine, methylene blue and artemisone) 
due to the unavailability of pharmacokinetic studies in a minimum of three preclinical 
species. Combination drug therapy is recommended in the management of malaria in 
order to delay development of drug resistance. Therefore there is a lack of published 
pharmacokinetic studies following monotherapy for some antimalarials which further 
limited the list of antimalarials studied. The true pharmacokinetic parameters following 
IV administration would have provided optimum interspecies scaling results; however 
it was considered appropriate to scale CL/F and Vz/F following an oral route of 
administration for mefloquine and piperaquine.  
The study describes the allometric relationship of the pharmacokinetic parameters 
clearance, volume of distribution and half-life for seven antimalarials. Drug clearance 
interpolations enable determination of maintenance dosing of a drug. A strong 
allometric relationship (r2 ≥ 0.9) was found for clearance of all drugs and the power 
relationship for each drug was found to be different from one another. 
The allometric power relationship for basic metabolic rate was initially described with 
a fixed exponent value of 2/3 (0.67) and later a value of 3/4 (0.75) was adopted (191, 
201, 232, 336). Over the many years, these fixed exponent values have been translated 
to be used in pharmacokinetics, where the exponents 3/4 (0.75), 1 and 1/4 (0.25) were 
established for scaling drug clearance, volume of distribution and half-life, respectively 
(123, 188, 207, 256). However, the use of fixed exponent allometry in dose 
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determination has been extensively debated and may not be universally applicable for 
all drugs (191, 201, 207, 208, 232, 256, 337). 
 In the present study, the clearance exponent and 95% CI for the antimalarial drugs 
studied did not encompass the fixed exponent 0.75 for clindamycin, piperaquine, 
mefloquine and quinine. Therefore current study data does not support the use of fixed 
exponent allometry for all drugs. Artesunate and artemether exponents and their 95 % 
CI included both 0.67 and 0.75 fixed exponent values; therefore there is no clear 
distinction or advantage between the two fixed exponent values. Linear or mg/kg 
maintenance dosing was not supported for all drugs although the 95 % CI for 
dihydroartemisinin and piperaquine encompassed 1 (Table 2.4).  
Interpolation of volume of distribution enables determination of loading dose of a 
dosage regimen. A strong allometric relationship was observed for volume of 
distribution of drugs scaled (r2 ≥0.91) with the exception of artesunate. In contrast to the 
clearance, volume of distribution exponent and its 95 % CI encompassed 1 for 
artemether, piperaquine and quinine and exponent values were ≥ 0.8 for other drugs 
(except artesunate). Hence linear scaling of loading dose is applicable for most of the 
antimalarials studied (Table 2.5).    
Riviere (177) found half-life to be the most robust pharmacokinetic parameter for 
allometric prediction. In contrast to this finding, a poor allometric relationship was 
found for half-life of study drugs with the exception of artemether (Table 2.6). This is 
comparable with Ritschel’s (269) finding that the half-life of coumarin was poorly 
related to physiological parameters, and therefore lacked interspecies scaling 
relationships. The half-life exponent values for antimalarials ranged widely (-0.16 to 
0.35); however artemether, clindamycin, piperaquine and mefloquine exponents were 
close to the half-life fixed exponent value of 0.25, but 95% CI ranged widely.  
The impact of the exponent on dose determination varies depending on the body weight. 
When the recommended dosing for a 70 kg adult is 10 mg/kg, the hypothetical 
exponents of 0.6 and 1 would lead to a predicted dose of 19.4 mg/kg and 10 mg/kg for 
a 10 kg child and 16.5mg/kg and 20mg/kg for a 20 kg child. The difference in dose due 
to change in exponent for a 10 kg child is higher and decreases with an increase in body 
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weight. Therefore it is important to have good quality, accurate allometric data as a 
small change in exponent can lead to a bigger change in doses for smaller children.  
At commencement, this study aimed to predict dosing for malaria infected children, 
which requires scaling of pharmacokinetic parameters of malaria infected species. In the 
absence of sufficient pharmacokinetic data in malaria infected preclinical species, 
exponents derived using healthy species were adopted to predict dose for malaria 
infected children provided there is no alteration in pharmacokinetics due to the infection. 
In keeping with the published literature, a clear decrease in quinine clearance was found 
in malaria infected adults compared to healthy individuals (Table 2.7), therefore 
requiring cautious use of exponents derived from data collected in healthy species.  
There is literature to show a higher area under the curve for dihydroartemisinin (hence 
lower clearance) in malaria infected patients compared to healthy individuals (62). In 
the present study, similar trends were observed when mean clearance reported from 
three heathy volunteer studies and  nine patients studies were compared; however the 
power of the test was poor, hence robust conclusions were unable to be drawn as a Type 
1 error cannot be excluded. Hence the dihydroartemisinin exponent derived using 
healthy species was used for dose predictions of children.  
Similarly, there is pharmacokinetic literature which indicates significantly lower 
apparent drug clearance of mefloquine in severe malaria infection compared to that in 
healthy individuals (296, 302). However in the present study, no change in clearance 
was found when mean clearance reported in 17 pharmacokinetic studies of healthy adult 
were compared to mean clearance of 5 malaria infected patient studies. 
In the absence of an exponent derived using malaria infected species, healthy species 
exponent was used for dose predictions of antimalarials even though power of the two 
tailed t test was below the required power of 0.8 except for quinine.   
Improvement in clearance prediction for children was explored using different 
correction factors. Most techniques required more data than was available, limiting their 
usefulness. For example, techniques such as Dedrick plots required raw concentration 
time data and in-vitro correction methods required in-vitro metabolism data, neither of 
which were available (184, 221). As described in Chapter 1, scaled antimalarials are 
mostly cleared through hepatic metabolism therefore it was assumed that correction for 
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change in liver weight (for low extraction ratio drug) and liver blood flow (for high 
extraction ratio drugs) between  mammalian species would improve clearance 
prediction by simple allometry. MLP correction is a widely adopted correction method 
for low extraction ratio drugs and the required data were available (184).  
Simple allometry had the best predictive success compared to MLP, liver blood flow 
and liver weight corrections according to the observed/predicted ratio, with predicted 
drug clearance values within 0.5-2 fold of observed clearance for all seven drugs. 
Nevertheless a general trend of over prediction of clearance was observed.  
While the r2 values were improved for three out of seven drugs when interpolated drug 
clearance was based on MLP correction, the predicted clearance was not improved for 
all. For example, predicted clearance for dihydroartemisinin was 4.5 fold lower based 
on MLP correction whereas predicted clearance by simple allometry was similar to the 
observed clearance even though r2 for dihydroartemisinin was improved by MLP 
correction. The MLP correction underestimated drug clearance at all times and 
mefloquine and quinine predicted clearance was slightly improved with improvement 
in r2 value.  
The Rule of Exponents includes MLP correction. Its use is recommended where the 
simple allometric exponent value is within the range of 0.71-0.99, while simple 
allometry is recommended for drugs with exponent in the range of 0.50 to 0.77. Thus 
the Rule of Exponents recommends MLP correction for dihydroartemisinin (exponent, 
0.85); however as stated above the interpolated clearance by MLP correction was 4.5 
fold lower than the observed clearance. Therefore the Rule of Exponents is not 
supported by the current study data.   
Similar to MLP correction, liver blood flow correction under predicted the drug 
clearance for all the drugs. By contrast for liver weight correction, while the r2 was 
improved for all drugs, the predicted clearance values were within the 0.5-2 fold of the 
observed clearance. The predictions using liver weight were comparable to simple 
allometry prediction, however a clear improvement in predictions was not observed.  
Dihydroartemisinin was found to have a high hepatic extraction ratio in an isolated 
perfused rat liver model (60) and 93% was bound to plasma protein bound (58). 
Similarly artemether has shown a high hepatic extraction ratio (37) and was 95% plasma 
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protein bound (50). Given that both artemisinin derivatives have a high hepatic 
extraction ratio, simple allometric prediction should be accurate for both drugs and the 
study results proved the same. However, the hypothesis of incorporation of differences 
in liver blood flow of mammalian species, to improve clearance prediction for high 
extraction ratio drug was not supported. The dihydroartemisinin and artemether liver 
blood flow correction under predicted clearance by 2.8 and 4.5 folds, respectively. 
Simple allometric predictions were most accurate out of the four methods.  
In rats, piperaquine has shown an absolute bioavailability of 50%, and fatty meals 
increased bioavailability in humans (83, 91). Piperaquine has also shown a very poor 
drug permeability in in-vitro Caco-2 cell models (338). Therefore lower bioavailability 
could be due to both poor absorption and high hepatic extraction ratio. Hai, Hietala (317) 
proposed that the low bioavailability of piperaquine is mostly due to poor drug solubility 
in the gastrointestinal tract rather than high hepatic extraction. The study further 
assumed that piperaquine is a low extraction ratio drug with less than 30 % hepatic 
extraction. This drug is highly protein bound (99%) in mice, rats, dogs, monkeys and 
human (84). Based on the literature, simple allometric prediction can be less accurate 
for drugs that are highly protein bound with a low extraction ratio, such as piperaquine.  
The observed apparent clearance values of piperaquine in clinical studies of children 
were inconsistent (0.85 vs 1.85 L/h/kg). This difference could be due to clinical 
differences between the two populations (Table 2.9). Two recent clinical studies have 
reported lower apparent clearance values for piperaquine. One study reported apparent 
clearance of  0.57 L/h/kg, using pooled data resulting from administering piperaquine 
with different partner drugs; dihydroartemisinin plus piperaquine (332) and artemisinin 
plus piperaquine combination (44). The other study used capillary blood for the analysis 
and reported an apparent clearance of 0.42 L/h/kg. Authors discouraged the direct 
comparison of this finding with the other available data resulting from venous blood 
(88). Data from these two studies, therefore, cannot be directly included in the present 
study for comparison.  
However given that piperaquine has lower observed apparent clearance in children, the 
predicted apparent clearance values by simple allometry and by correction methods 
were within 0.5-2 fold of the observed apparent clearance. However simple allometric 
prediction using preclinical data of piperaquine under predicted the drug clearance by 6 
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fold and prediction improved (1.6 fold difference) by incorporation of human data.  
Therefore based on piperaquine data (low extraction ratio drug) allometric dose 
interpolations are possible, when the exponents are derived using both preclinical and 
human drug clearance.  
Clindamycin had shown an absolute bioavailability of 53% (289) and is 94% bound to 
alpha 1-acid glycoprotein (138). It is reported that clindamycin is a drug with a low 
hepatic extraction ratio (142, 339). Clindamycin clearance in children was not found in 
clinical studies. However the predicted clearance using preclinical species was 1.7 fold 
lower compared to the observed healthy adult clearance, therefore simple allometry 
could be used for dose prediction of clindamycin, even though it is identified as a low 
extraction ratio drug.  
Mefloquine is extensively bound to plasma protein in humans (99%) and in rat (95%) 
and has a low intrinsic clearance (100, 101). This drug has shown enterohepatic 
recycling in humans and in rats and is mostly excreted in bile and faecal materials (101, 
302). In a study of allometric scaling of susalimod, a highly biliary excreted drug, found 
predicted human clearance to be 24 times higher than the observed clearance (340). The 
authors concluded that biliary excreted drugs result in non-predictable human clearance 
by allometric scaling of preclinical data. However predicted clearance for mefloquine 
had predictive success and was within the 0.5 - 2 fold from the observed clearance values 
for simple allometry and by two correction methods; MLP and liver weights. This was 
also correct for simple allometric prediction using preclinical species alone. Mefloquine 
(low extraction ratio) clearance predictions were expected to be improved by liver 
weight correction and the predicted clearance by liver weight correction was closest to 
the observed values. It should be noted that observed clearance in the mefloquine 
clinical studies listed in Table 2.9 were from studies of mefloquine-sulfadoxine and 
pyrimethamine. Karbwang and co-workers (298) observed a slight prolongation (16.3 
to 20.7 days) of t1/2 following combination therapy compared to mefloquine alone. 
Therefore it is possible that mefloquine drug clearance is decreased when combined 
with sulfadoxine and pyrimethamine, in that case, over prediction (0.7 fold difference) 
of drug clearance by simple allometry can be more accurate. 
Quinine is a drug with a low intrinsic clearance and is about 90% bound to alpha 1-acid 
glycoprotein (protein binding is not significantly altered in acute malaria infection) (18). 
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Both published pharmacokinetic literature and analysis from the present study have 
shown that clearance of quinine is further reduced in malaria infection (18). Despite this 
being a low extraction ratio drug, simple allometric predictions were within the 
threshold values and so were the predictions by the correction methods.  
The dose increments recommended based on this study finding (using healthy species) 
ranged from no increase in dose up to doubling the currently recommended mg/kg 
dosing (Table 2.10). Dihydroartemisinin (available as 60 mg/ mL artesunate injectable) 
and clindamycin (available as 75, 150 and 300 mg clindamycin hydrochloride capsules) 
required modest increase in doses, which can be achieved in a clinical setting. Recent 
clinical studies have also recommended higher doses of IM artesunate and proposed the 
following doses for weight bands of children; 40 mg for 14 to 16 kg and 60 mg for 21-
25 kg (171). This closely matches the allometric interpolations of this study; 3 mg/kg 
for 15 kg and 2.8 mg/kg for 25 kg children. 
The allometric exponent for piperaquine indicates only a small increase in dose. This 
increase in dose is unlikely to be practical in a clinical setting and might not result in 
blood concentration that can cause a clinically significant difference in outcome. 
However, recent clinical studies have recommended higher piperaquine doses for 
children (81, 88, 173). Therefore allometric dose predictions are not comparable with 
the clinical study recommendations. The reported observed drug clearance in clinical 
studies ranged from 0.85 to1.85 L/h/kg for children (Table 2.9) and mean drug clearance 
for healthy adults and malaria infected patients were 0.86±0.65 and 1.55±0.73 L/h/kg 
(Table 2.7). Looking at mean piperaquine clearance values, a clear difference in drug 
clearance between adults and children was unable to be seen. Therefore more 
pharmacokinetic studies in children are needed to make clear recommendations on dose 
changes.  
A large increase in mefloquine dose was recommended for 15 and 25 kg children; 2.1 
to 1.6 fold higher doses than the reference doses. This appears large and has not been 
recommended in clinical studies so far. A recent study on chloroquine (another 
quinolone group drug) has proposed a 1.6 fold increase in dose based on the concept of 
allometric scaling (264). Two clinical studies have adopted 2 fold higher doses of 
chloroquine for children (170, 341). These increments are similar to mefloquine dose 
increments suggested in the present study. However the observed drug clearance for 
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mefloquine (children on mefloquine-sulfadoxine and pyrimethamine) was lower 
compared to predicted clearance using simple allometry. The observed drug clearance 
in children is higher compared to mean adult drugs in two of the three studies. Therefore 
a dose increment can be suggested, however a lower increment compared to what is 
suggested by allometry might be more appropriate to trial.   
Based on healthy species exponents, 18-24 mg/kg quinine dosing is more appropriate 
than 10 mg/kg.  A recent study recommended a 20 mg/kg loading dose to be used in 
children with malaria (171). Table 2.7 depicts the quinine clearance in healthy children 
is higher than the mean healthy adult clearance, however mean clearance in children 
with malaria was found to be lower compared to infected adults. Therefore the general 
observation of increased drug clearance in children is not observed for quinine clearance 
in malaria infected children. Allometric scaling results for quinine need to be cautiously 
interpreted due to complex and multifactorial effects of malaria infection on 
pharmacokinetics of the drug.  
The allometric scaling data of the current study indicate the need for differing allometric 
exponent values for scaling antimalarial drugs. This could cause practical difficulties in 
the use of fixed-dose combination therapy. For example, the adult dose for 
dihydroartemisinin-piperaquine (120-960 mg) is in the ratio of 2:60 mg/kg for a 60 kg 
patient. In the case of linear dosing, a child weighing 15 kg can be given 30:240 mg. If 
allometric exponents are used, piperaquine dose would be appropriate for the child, but 
dihydroartemisinin dose needs to be increased by 20%. However, fixed dose 
combinations do not permit a disproportionate increase in doses. Hence, this would not 
be practically possible. Allometric finding in this study shows that artemisinin 
combination therapy requires a disproportionate increase in doses. 
Increased availability of pediatric dosage forms such as solutions and suspensions is 
required and would enable accurate dispensing of doses based on drug specific 
allometric exponents and the child’s body weight.  
Nevertheless dosing recommendation based on allometric scaling cannot be used in 
neonates, very young children due to clear difference in physiological function and 
immature or altered clearance mechanisms (246).  
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The use of preclinical clearance data in extrapolating human clearance was explored 
(Table 2.11). Both piperaquine and dihydroartemisinin preclinical data scaling was not 
able to predict human drug clearance to an acceptable level. It should be noted that less 
than 3 preclinical species (below the recommended number) were included for the 
analysis of some drug. Incorporation human clearance data for scaling clearly improved 
the clearance predictions of all the drugs.  
Pharmacokinetic data from young animals would have provided like for like data when 
allometry is used to extrapolate pharmacokinetic for children. However the evidence on 
the use of juvenile animals is limited and there is inadequate knowledge and no clear 
consensus on the species of animals to use, their appropriate age groups and organ 
differences at different age points (342). The European Medicines Agency and US FDA 
support conducting juvenile animal clinical trials only in instances where previous 
animal and human safety data are insufficient to support paediatric clinical trials (342).  
The physiological differences in mature and immature animals could result in altered 
metabolic profile, therefore, change in pharmacokinetic and toxicological data. 
Differences in maturation timing, functional differences in kidney, cardiovascular, 
respiratory and gastrointestinal systems and lack of robust knowledge on the different 
organ systems of different animal species at different time points in their maturation 
process pose difficulties in selection of species and their suitable ages (342, 343). 
Therefore, it is not easy to select appropriate animal species in their correct age group 
to extrapolate pharmacokinetic information to immature humans. Hence, the commonly 
adopted and accepted technique of allometry scaling based on adult animal species was 
adopted in this study.   
 
2.7 Limitations  
The main limitations in the study were the low number of mammalian species included 
for the scaling and the paucity of pharmacokinetic information in malaria infected 
species. The study included only two to three non-human species for the scaling, 
however this was consistent with previous studies (219, 264, 267). A large number of 
non-human species would have improved the quality of the allometric scaling findings.  
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It is also claimed that inclusion of large animals could improve the allometric scaling 
predictions (175); however pharmacokinetic studies on antimalarials in large animals 
were not available to be included in the analysis. 
The clearance, volume of distribution and half-life of drugs for different species for 
allometric scaling were obtained from published studies. Therefore, pharmacokinetic 
parameter data points were average values for the study subjects and it was not possible 
to obtain pharmacokinetic parameters and weights for individual subjects. Conducting 
pharmacokinetic studies for drugs of interest would enable individual pharmacokinetic 
parameters for each study subject rather than published average values. However, these 
were outside the scope of the present study investigation.  
The antimalarials scaled are mainly cleared by the hepatic metabolism. Therefore in-
vitro metabolic data as a correction factor is suitable. Lack of required information 
precluded this from the analysis. 
With the advancement in pharmacokinetic research, it has been found that there are 
differences in protein binding in animals and humans for certain drugs (344). The 
distribution and excretion of a low extraction ratio drug may be affected by drug protein 
binding in plasma and tissue. The difference in protein binding among species could 
result from differences in affinity or number of binding sites of protein (345). There 
could also be differences in expression of drug efflux transporters such as MDR1, 
MRP1, MRP2 and BCRP between different animal species and human, these variations 
could lead to change in drug absorption, distribution and elimination of antimalarials 
given that these drugs are subjected to ABC transporter mediated efflux process (346). 
However possible variation in protein binding and efflux transporter protein expression 
were not incorporated into the current analysis due to lack of required information. It 
was not able to test all the published correction factors mostly due to limitation of 
information and time.  Similarly, methods like Dedrick plots were unable to be 
performed as raw drug concentration time data required for these plots was not readily 
available in the pharmacokinetic literature. 
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2.8 Conclusion  
Clearance and volume of distribution are suitable pharmacokinetic parameters for 
interspecies scaling of antimalarials. Half-life performed poorly for most drugs based on 
r2 value. Drug clearance predicted for children based on simple allometry met the 
predictive success for all seven antimalarials irrespective of the hepatic extraction ratio. 
Predicted clearance based on liver weight correction was within the accepted range of 
the observed clearance and performed better compared to MLP and liver blood flow 
correction methods. No correction factor showed clear improvement in prediction 
compared to simple allometry. It was not possible to determine the suitability of a 
correction factor based on metabolism. The r2 value did not indicate predictive success 
at all times.  
Preclinical clearance data can be used for prediction of clearance for some of the study 
antimalarials. Incorporation of human clearance clearly improved clearance prediction 
for adults and children. 
The linear scaling of adult to paediatric doses has been recognised as flawed (208) and 
interspecies simple allometric scaling (based on preclinical and humans) technique is a 
plausible/better method for estimation of paediatric antimalarial drug doses in children. 
The allometric exponents and coefficients obtained can be adopted in designing 
pharmacokinetic and efficacy studies and population pharmacokinetic modelling of new 
and current antimalarial drugs. 
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3 In-vitro drug permeability and P-gp mediated efflux 
transport studies   
 
3.1 Introduction 
 
3.1.1 Drug permeability  
Drug transport across the gastrointestinal epithelium can be a passive or an active 
process. Gastrointestinal absorption of the majority of orally administered drugs in 
current therapeutic use is through passive permeability (passive transcellular and 
passive paracellular routes) (347). The physiochemical characteristics of these drugs 
play a large part in the permeability of drug across the lipid bilayer of gut cells from the 
mucosal side to the blood or serosal side.   
Drugs that are smaller in molecule size and lipophilicity permeate following a passive 
transcellular pathway based on Fick’s law in which the rate of absorption depends on 
the area of the absorptive surface and concentration gradient across the membrane (348).  
Small, hydrophilic, ionized drugs and peptides cross through the paracellular pathway 
(water filled intercellular pores of the epithelium) (349). The drug absorption via this 
pathway is limited due to tight intercellular junctions and relatively small surface area. 
Small hydrophilic drugs could also be transported through passive permeability to some 
extent, as transcellular space in the luminal cell membrane is very large (surface area is 
more than 1000 times) compared to the paracellular space (348, 350).  
Large (above 500 Da), hydrophilic, charged drugs often require carrier molecules for 
the transport process (351). This can be an active or a passive process.  Active carrier 
mediated transport requires metabolic energy and can be transported against a 
concentration gradient. Some hydrophilic drugs with chemical structure similar to body 
chemicals or nutrients are transported partly using active transport proteins. Whereas 
when there is higher concentration in the gut lumen, passive carrier mediated transport 
(facilitated transport) can occur where a drug permeates through membranes using a 
carrier molecule without the use of metabolic energy. Saturation of carrier molecules 
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can greatly affect the extent of drug absorption, especially for drugs that have low 
passive permeability. For these drugs, saturation of carrier molecules results in drastic 
decrease in the extent of drug absorbed and systemic exposure of drugs (352). Highly 
permeable drugs that are absorbed following both carrier mediated transport and passive 
diffusion and when carrier molecules are saturated, passive transport contribute to more 
of drug absorption (By increase in drug dose/endogenous substrate molecules) (350). 
 
Transcytosis/endocytosis is mostly used by highly potent hydrophilic macromolecules 
that cannot be transported by other transport mechanisms and is less commonly used. 
The transport generally occurs through membrane vehicles that contain large amount of 
proteolytic enzymes and these mostly get degraded in in-vitro cell monolayers. The 
reticuloendothelial system commonly uses these types of transport. Vitamin B12 and 
large peptides in the intestinal epithelium are also transported by endocytosis (348, 350, 
353).  
 
The ABCB1 P-gp efflux transporter protein functions differently as these carrier 
molecules bind to drugs/chemicals and facilitate serosal to mucosal directional 
transport, which is referred to as efflux transport. Drugs passing through the apical 
membrane of intestinal epithelium could be substrates for apical efflux transporters such 
as P-glycoprotein and MRP2, which push the drug back into the lumen (354-356). The 
efflux mechanism is an ATP-dependent process and can occur against a concentration 
gradient. 
 
3.1.2 Physicochemical properties of drugs  
The passive permeability of a drug across the gastrointestinal epithelium depends on the 
physicochemical properties such as molecular size, lipophilicity (octanol-water 
partitioning coefficient), pKa and ionization of the drug (123, 348, 350, 357).    
 
Molecular size is a key determinant on the movement of drugs across membranes with 
smaller sized drug molecules capable of crossing membranes through the paracellular 
pathway. Atenolol (MW: 246 g) can transverse the gastrointestinal epithelium 
paracellularly, whereas oxytocin (MW: 1007 g) cannot cross the gastrointestinal 
epithelium even though it can easily pass through the loosely knit nasal membrane (123, 
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358). Diffusion for smaller lipophilic drugs drops sharply as molecular size increases 
(359).  
 
The typical method of determining the lipophilicity of a substance is by establishing the 
octanol water partitioning coefficient (Poct). The Poct value can be used as a predictor of 
drug absorption and it gives a reasonable prediction on the ability of the drug to partition 
into the lipid bilayer. The partitioning coefficient at pH 7.4 (the apparent distribution 
coefficient, Doct) is often preferred in determining drug permeability. The permeability 
increases with increase in Poct values up to a value of 2 and drops after Poct value is > 4, 
as highly lipophilic drugs do not partition back out to the aqueous compartment and 
prefers to stay in the plasma membrane (360, 361). The optimum log P values for best 
systemic action is in the moderate log p value of 1.5 to 3 (362), with a positive 
correlation between drug absorption and log D up to log D of 3 (360).  
The pKa of the drug and pH of the body fluid determine the ionization of drugs. 
Unionized drugs can readily cross membranes and vice versa. However unionized drugs 
don’t have good solubility in aqueous solvents, thus resulting in solubility limitations 
for the drug.  
 
3.1.3 Drug transporting ABC efflux transporters  
The mammalian ABC (ATP-binding cassette) superfamily is highly diverse with about 
fifty different protein subfamilies and is comprised of membrane transporters, ion 
channels and receptors (363). Of these, the principal efflux transporter proteins are 
MDR1 (multidrug resistance), MRPs (multidrug resistance associated proteins) and 
BCRPs (breast cancer resistance proteins) as they are involved in the transport of many 
clinically relevant drugs. In this thesis, only MDR1 P-gp proteins will be discussed. 
 
3.1.4  P-glycoprotein (MDR) 
P-glycoprotein (P-gp/ABCB1/MDR1) was the first multidrug protein described and was 
discovered by Juliano and Liang in 1976 (364). This most commonly studied ATP- 
dependent efflux carrier molecule is involved in the transport of a diverse range of drugs 
used for different therapeutic indications. The P-gps are known as multidrug resistant 
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(MDR) transporters as many of the cytotoxic anticancer drugs developed cross 
resistance due to P-gp mediated drug efflux transport (365).  
P-glycoprotein is a 170 to 180 kDa membrane glycoprotein, a polypeptide containing 2 
halves, each with 6 transmembrane domains that are separated by both an extracellular 
loop which is highly N-glycosylated and contain two nucleotide binding domains 
(NDB) are located intracellularly ( Figure 3.1) (366).  
 
Figure 3-1: Molecular structure of MDR1 (P-glycoprotein) (363, 365) 
 
In humans there are two MDR gene families; MDR1 (ABCB1) and MDR3 (ABCB4).  
Human MDR1 is expressed highly in the kidney and adrenal glands, with intermediate 
levels on the apical surface of the epithelial cells (Villus tip enterocytes) of the intestine, 
liver, colon and lungs and low levels in the prostate, skin, spleen, heart, ovary, stomach 
and skeletal muscles (367-369). P-gp transporter proteins are also found on the luminal 
surface of capillary endothelial cells in the brain and are highly expressed in carcinoma 
cells (369, 370).  
Human MDR3 is expressed in liver and low levels are expressed in the normal human 
jejunum (371, 372). MDR3 is involved in transport of phospholipids in the liver and 
absence of MDR 3 protein in humans can cause type 3 progressive familial intrahepatic 
cholestasis (373). Digoxin, paclitaxel and vinblastine are some of the drugs with affinity 
for both MDR1 and MDR3 transporters in the liver (371). 
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3.1.4.1 Mechanism of action 
Radio ligand binding studies have shown that there are at least four drug-
binding/transport sites that can modify P-gp function (374). The drug binding sites are 
located in the transmembrane region, which might also function as a single binding site 
that can bind with more than one compound (363, 375). A model is proposed to describe 
P-gp substrate interaction where P-gp substrate need to interact with the lipid bilayer 
and partition into the lipid phase before interacting with P-gp binding sites (366, 376, 
377).  
P-glycoproteins’ have an ability to interact with a diverse range of compounds with a 
higher probability of binding with lipophilic cationic compounds. It is suggested that P-
gp substrates could be basic or uncharged compounds with a molecular size of 300 to 
2000 Da. Some weakly acidic drugs can also get transported at a lower rate. The most 
common structural feature of P-gp substrates is inclusion of both hydrophilic and 
lipophilic segments in its structure or its amphipathic nature (363, 366, 378).  
Seelig (379) proposed that recognition of whether a compound is a P-gp substrate or a 
modulator depends on the hydrogen bond acceptor groups and its spatial separation that 
interacts with the hydrogen bond donor side chains located in the transmembrane region 
of the P-gp. Induced fit mechanism is a hypothesis of P-gp and substrate interaction, 
where the shape and the size of the transmembrane segments packing of the P-gp could 
be altered based on the substrate (380, 381). 
 
3.1.4.2 P-gp mediated drug transport studies  
P-glycoprotein mediated drug efflux transport was first demonstrated using in-vitro 
Caco-2 cell lines (50). In-vivo efflux transport was demonstrated using MDR1 knockout 
mouse models. In humans, drug interactions due to P-gp mediated drug efflux can be 
determined by calculating the net change in area under the curve profile of a P-gp 
substrate when administered alone and in combination with a P-gp inhibitor.  The 
combination therapy would result in increased systemic availability of the P-gp substrate 
compared to when it was given alone. However, this can be confounded by other 
mechanisms such as CYP 450 induction and gastrointestinal anomalies, resulting in 
reduced drug absorption. For this reason, inhibition studies in humans can only give a 
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qualitative assessment of the involvement of P-gp in drug absorption (50). Compelling 
evidence of P-gp mediated efflux transport in humans was demonstrated by Hoffmeyer 
and co-workers (382), where a good correlation between duodenal P-gp expression and 
plasma levels of the P-gp substrate, digoxin, was observed. 
 
3.1.4.3 Role of P-gp efflux transport in the body 
P-glycoprotein efflux transporters are primarily located in the plasma membrane, where 
drugs, metabolites, nutrients, toxins and other compounds are effluxed out of the cell. 
Efflux transport is a protective mechanism that limits absorption and cell accumulation 
of potentially toxic compounds. In humans P-gps may play an important role in drug 
absorption, distribution, metabolism and excretion.  
The oral route is most commonly used for drug administration due to its convenience, 
safety, low cost and ease. However for a drug to be orally administered a reasonable 
gastro intestinal tract absorption ability is required. The apical membrane of the small 
and large intestinal epithelium contains a large number of P-gps, which pushes its 
substrates back into the lumen, reducing overall drug permeability. The P-gp apoprotein 
expression is similar in the stomach, jejunum and ileum of the human gastrointestinal 
tract (383). P-gp substrate with lower inherent drug permeability will have larger effect 
on in-vivo drug absorption compared to P-gp substrate with higher permeability. Other 
than the human physiological factors, drug absorption can be largely affected by 
pharmaceutical factors and the physicochemical factors of the drug itself.  
Drugs need to be distributed into the site of action to deliver the desired therapeutic 
response. In doing so it needs to cross several bio membranes and the ability to cross 
the membranes depends on the physical and biochemical properties of the membrane 
and physiochemical properties of the drug such as lipophilicity, ionization profile and 
molecule size (123, 358, 384). Penetration of drug into the brain is distinct compared to 
other body organelles. Vascular capillaries of the brain are anatomically specialized and 
function as a shield separating the brain from the general blood circulation. This is 
referred to as the blood brain barrier and is composed of very tight cell junctions 
enabling penetration of only small, lipid soluble drugs into the brain. But it has been 
found that even some of the smaller molecular lipid soluble drugs exhibit poor 
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permeability into the brain. This can be explained by high P-gp expression in the apical 
surface of the brain capillary cells pushing drugs out of the vasculature before gaining 
access to the brain proper (365, 385, 386). The brain is more sensitive to toxic chemicals 
compared to other organs in the body; therefore P-gp has a protective function of 
blocking harmful chemicals reaching it.  
The role of P-gp in the placenta is similar to its function in the brain and gastrointestinal 
tract and protects the foetus from xenobiotic (50, 365).  
In the liver drugs and endogenous toxins are released from hepatocytes into the bile, 
which ultimately are excreted out of the body as faecal waste (365). 
Other than the liver, the small intestine also contributes to the drug metabolism through 
CYP 450 enzymes. Metabolism in the gastrointestinal tract of a P-gp substrate could be 
altered by repetitive expulsion and reabsorption of drug, thus increasing the resident or 
exposure time to the intestinal drug metabolising enzymes (50). 
The apical membrane of the proximal tubules of the kidney is another place where there 
are abundant amounts of P-gp (369). In-vitro MDCK and porcine kidney (LLC-PK1) 
cell line studies have shown efflux transport of P-gp substrates, digoxin and vinblastine 
which indicate increased drug excretion in the kidney (387, 388). However this in-vitro 
study finding was not supported in-vivo in P-gp knock out mice and increased drug 
excretion in the absence of P-gp was found, rather than the expected decrease in drug 
clearance (50, 365, 389) This could be explained by an increased intestinal absorption 
or less efflux from the gut allowing more drug exposure to the kidney.  
 
3.1.4.4 P-gp substrates  
Drugs transported or effluxed out of the cells by the P-gp transporters are known as P-
gp substrates. They have some structural similarities even though P-gp extrudes a wide 
variety of chemically and structurally diverse drugs.  
P-gp substrates have relatively low Km values. For example, vinblastine, digoxin, 
cyclosporine, verapamil and indinavir have Km values of 26, 51-81, 3.8-8.4, 4.4- 31 and 
140 µM, respectively (390-392). When drugs are administered at high doses, the 
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gastrointestinal concentration of the drug is elevated above the Km value, which results 
in saturation of the P-gp transporter proteins. Indinavir was given orally at a dose of 800 
mg in one study, resulting in an intestinal lumen concentration in the mM range, far 
higher than the Km values for P-gp (50). Hence at this dose, a reduction in indinavir 
bioavailability will not be observed irrespective of person’s P-gp expression level in the 
gut.  
Nevertheless for P-gp substrates that have a large molecule size, lower solubility and 
poor dissolution will still be effluxed when given in high doses. For example 
cyclosporine at 100-700 mg and paclitaxel at 100-200 mg have resulted in lower 
bioavailability (50).  
The P-gp mediated drug efflux does not always lead to poor bioavailability of all suspect 
drugs. There are drugs with P-gp substrate activity that have reasonable oral 
bioavailability. Digoxin is a good P-gp substrate but has a bioavailability between 50 to 
85%. P-gp substrates can also have good passive permeability, therefore the amount of 
drug absorbed is equal to the net difference between the influxed amount (passive 
diffusion and active intake transport mechanisms) and the effluxed amount ( P-gp efflux 
plus the amount of drug metabolised).   
Both P-gp and CYP3A4 interact with a wide range of substrates and there is much 
overlap between P-gp and CYP3A4/5 substrates (393). This becomes more of an issue 
in-vivo as both P-gp and CYP3A4/5 are expressed in the same organs, resulting in a 
greater reduction in the systemic drug concentration of common substrates (50).    
Many anticancer drugs (vinblastine, paclitaxel, daunorubicin, mitoxantrone, teniposide, 
actinomycin D, methotrexate), anti-hypertensive (digoxin, diltiazem, verapamil), most 
HIV protease inhibitors, antibiotics (erythromycin, tetracycline, valinomycin, 
gramicidin D, sparfloxocin,), immunosuppressive agents (cyclosporine A, tacrolimus), 
corticosteroids, H2 receptor antagonistic (cimetidine, ranitidine), azole antifungals, 
some antiemetics (domperidone and ondansetron), antidiarrheal agents (loperamide), 
pesticides (ivermectin, abamectin), diagnostic dyes (rhodamine123, Hoechst 33342), 
antiarrhythmic  (quinidine), anti-gout agents (colchicine), hormones (estradiol-17B-D-
glucuronide, aldosterone) and analgesics (morphine) are found to have P-gp substrate  
activities (365, 394). 
   Page 122 of 294 
3.1.4.5 P-gp inhibitors  
A limited number of drugs are able to inhibit P-gp mediated drug efflux transport at 
physiologically relevant concentrations. These agents are found to be useful in reversing 
multidrug resistances of cytotoxic agents. However first generation P-gp inhibitors such 
as verapamil and cyclosporine could not be used to reverse multidrug resistance due to 
their own therapeutic activities and adverse effects given at the concentrations needed 
to have P-gp blocking activity. Hence specific P-gp inhibitors without other systemic 
actions were developed. The second generation P-gp inhibitor, SDZ PSC 833 
(Valspodar), a cyclosporin an analogue with no immuno suppression activity, has a high 
affinity to P-gp. This slowly transported substrate of P-gp acts as a very effective 
inhibitor because it is released from P-gp at a very slow rate (395). PSC 833 also has 
limited action on MRP1 an MRP2 (396). GF120918 is another such inhibitor and 
inhibits P-gp mediated drug transport as well has some inhibitory action on BCRP (397). 
It is important to know that P-gp substrates can also function as competitive P-gp 
inhibitors if their concentration is high enough. In addition, the substances that were 
initially identified as P-gp inhibitors such as verapamil, cyclosporin A were later found 
to be P-gp substrates. P-gp inhibitors which do not demonstrate P-gp substrate activity 
such as progesterone are likely to inhibit P-gp mediated efflux by other mechanisms 
(365). 
In order to confirm P-gp mediated drug transport, drugs can be combined with PSC 833 
and GF120918 separately to determine inhibition of efflux transport. Gastrointestinal 
epithelium and Caco-2 cell lines have efflux transporters other than P-gp, such as MRP1, 
MRP2 and BCRP. Probenecid and MK571 inhibit both MRP1 and MRP2 transporters 
and have some action on P-gp (365). There are no compounds currently known that act 
as MRP2 specific inhibitor. Ko143 is a BCRP inhibitor and this can be used to determine 
the efflux transport of a drug through BCRP.  
Atorvastatin, bromocriptine, carvedilol, cyclosporine, erythromycin, GF120918, 
itraconazole, ketoconazole, LY335979, meperidine, methadone, nelfinavir, 
pentazocine, progesterone, quinidine, ritonavir, saquinavir, tamoxifen, tariquidar, PSC 
833 and verapamil have all been shown to have P-gp inhibitory properties (394).  
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3.1.4.6 P-gp mediated drug interactions  
3.1.4.6.1 P-gp substrate interactions 
P-gp related drug-drug interactions do not follow simple kinetics but rather, follow 
multiple patterns and are substrate specific. It is likely that concurrent administration of 
P-gp substrates and inhibitors will result in drug interactions. There are three main 
categories of P-gp mediated drug interactions; competitive, non-competitive and 
cooperative stimulation.  
P-gp has multiple substrate binding sites and two ATP binding domains. In competitive 
inhibition, two P-gp substrates would act on the same binding sites of the P-gp molecule, 
competing to bind to one site. Alternatively, in non-competitive inhibition, two 
substrates would bind to two different binding sites simultaneously and function 
independently (50, 398). In-vitro studies in multidrug resistant P388 cells have shown 
that P-gp mediated daunomycin uptake is competitively inhibited by verapamil, whereas 
vinblastine noncompetitively inhibited uptake of the drug (399). 
The competition of two P-gp substrates would generally result in inhibition of P-gp 
mediated transport of one substrate, but in some cases activation of P-gp transport has 
been reported. In studies done in Chinese Hamster Ovary CH’B30 P-gp enriched cells, 
it was found that rhodamine123 and Hoechst 33342 simulated the P-gp mediated efflux 
transport of each other. Whereas daunorubicin and doxorubicin stimulated the Hoechst 
33342 transport and inhibited the rhodamine123 transport (400). This indicated that P-
gp can interact with two substrates allosterically.  
The two ATP binding domains can also be involved in drug interactions with the 
blockage of ATP hydrolysis in addition to competition for drug binding sites (401, 402). 
For example, the common P-gp substrate verapamil, competitively binds to substrate 
binding sites, while sodium ortho-vanadate, interacts with the ATP binding domain and 
cyclosporine A interferes with the substrate binding sites and ATP hydrolysis (50).  
 
3.1.4.7 P-gp inhibitor interactions 
In-vivo mice studies have shown that co-administration of a P-gp inhibitor increased P-
gp substrate concentrations in the brain more than in P-gp non-inhibited mice, and that 
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relation to plasma level were even higher in the plasma (403, 404). P-glycoprotein 
inhibition related drug interactions have also been reported in humans. Ketoconazole, a 
potent P-gp inhibitor, increased the CSF concentration of ritonavir and saquinavir in 
HIV patients, while causing minimum change in plasma concentration (405). Brain and 
placenta have high P-gp expression and are sensitive to P-gp inhibitors (50). Therefore 
P-gp inhibitors need to be used carefully to avoid risk of neurotoxicity and possible CNS 
related adverse effects (50).   
Potent P-gp inhibitors such as PSC 833 and GF120918 can restore the anticancer drug 
activity increasing drug sensitivity for anticancer drugs, this also increase tissue 
distribution of cytotoxic drug and cytotoxicity (406, 407).  
 
3.1.4.8 P-gp regulation and induction 
The expression of the ABC efflux transporter proteins is not static and is regulated at 
both transcriptional and non-transcriptional levels to maintain homeostasis (363).  
Evidence of induction of P-gp has been demonstrated both in-vitro and in-vivo (50). P-
gp induction by dexamethasone is reported in in-vitro mouse and rat cell lines (408, 
409). Pharmacokinetic drug interactions can result from up-regulation of P-gp 
transporter proteins. A pharmacokinetic study of digoxin in healthy volunteers before 
and during administration of rifampicin found a lower area under the curve of digoxin 
after treatment with rifampicin. Duodenal biopsies after treatment of rifampicin had 
shown a 3.5 fold increase in P-gp compared to before treatment (410). These studies 
suggest that induction of P-gp expression can be dose, time, tissue and species 
dependent (50).  
Co-regulation/ co-induction of P-gp and CYP3A expression has been reported in 
humans, rats and in-vitro cell lines (50). This has led to the assumption that regulation 
of CYP3A4 and P-gp gene expression is co-ordinated through similar mechanisms. P-
gp can be induced in a similar fashion to CYP3A4 with pregnane X receptor (PXR) 
having a role in regulating CYP3A4 and P-gp expression (411-413). A species 
difference in induction of CYP3A4 was observed due to sequence differences in the 
(PXR) (414), however P-gp induction may be mediated by several mechanisms in 
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addition to PXR. The P-gp regulation process is very complex and every inducer has its 
own pattern of P-gp induction. Therefore it is necessary to understand the inductive 
process of each inducer to understand its implications and consequences.(50).  
Amprenavir, clotrimazole, dexamethasone, indinavir, morphine, nelfinavir, 
phenothiazine, retinoic acid, rifampicin, ritonavir, saquinavir and St John’s Wort have 
all been shown to have P-gp inducing properties (394). 
 
3.1.5 In-vitro cell models for drug transport studies  
In-vitro cell models are used widely to determine the drug permeability across intestinal 
epithelial membranes. In-vitro drug permeability data can be used for drug absorption 
screening in the early stage of drug development, which avoids further expenditure on 
conducting costly in-vivo studies on compounds with a poor absorption profile (350). 
In-vitro techniques are also used in drug industry specifically for P-gp affinity studies. 
Drug permeability data along with aqueous solubility and physicochemical parameters 
of drugs can be utilized to determine whether in-vitro dissolution tests can replace/waive 
the need for in-vivo bioavailability studies in establishing bioequivalence for generic 
drugs. The cost of establishing in-vitro permeability, solubility and physicochemical 
characterization are 1/10th to 1/15th of a bioequivalence study (415). In-vitro cell models 
for drug transport studies ideally should mimic transcellular and paracellular 
permeability of the small intestine. Similarly it should resembles the expression of 
carriers and enzymes within the intestine (416).  
Colorectal adenocarcinoma-2 (Caco-2) cell models are the most widely used in-vitro 
cell line in establishing drug permeability of a drug.  
Madin-Darby canine kidney (MDCK) cells have gained in popularity due to rapid cell 
growth and differentiation. These cell lines are used to determine passive permeability, 
active transport, and efflux transport of drugs after 3-4 days post seeding. A transfected 
version MDCK-MDR1 is being used to determine P-gp mediated efflux transport of 
drugs in many labs, although this is not commercially available at present, with no stock 
at the ATCC nor in the European Collection of Cell Culture (ECACC). A recent study 
has used MDCK-MDR1 transfected cells and Caco-2 cells to determine the drug 
permeability of new antimalarial compounds. The study finds MDCK-MDR1 cells to 
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be advantageous over Caco-2 cells in identifying P-gp mediated drug efflux and 
interactions (417). The main limitation of this cell line is its canine origin even though 
MDCK cells are transfected with human MDR, other drugs are required in the medium 
to maintain stable levels of human MDRI, which can impact on other cell systems.  
The HT29 cell line has a useful sub clone (HT29-18-C1) which differentiates in cell 
culture conditions to polarized absorptive cells and can also be used for drug transport 
studies similar to Caco-2 cells. HT29-H cells form monolayers of mucin secreting 
human intestinal goblet cells with 50 fold higher paracellular permeability than that of 
Caco-2 (418). 
Shirasaka and colleges (419) developed a culture method for Caco-2 cells in vinblastine 
containing media as a means to increase P-gp levels of the cells to be comparable to that 
found in MDCK-MDR1 cell model extending the usefulness of the human Caco-2 
model in active efflux research.  
 
3.1.6 Caco-2 monolayers in drug transport studies  
The Caco-2 cell line is a human intestinal epithelial cell line, derived from human a 
colorectal carcinoma (420). The cell line is preferred in transport studies due to its 
human origin and close correlation to in-vivo intestinal conditions (372, 421). Many of 
the efflux transporters present in the gastrointestinal tract are similar to those expressed 
in Caco-2 cells. A strong correlation (Figure 3.2) of gene expression of these ABC efflux 
transporter proteins in the human jejunum and Caco-2 cells has been established (372). 
Thus it is clear from Figure 3.2 that the two most important multidrug efflux proteins, 
P-gp and BCRP reflects normal gut proportion of activity, but BCRP is not present as 
widely in Caco-2 cells. This makes Caco-2 a good model for P-gp related transport 
studies. MRP 1 and 2 are also well represented on Caco-2 compared to the in-vivo gut, 
although their involvement in drug transport is much less reported than P-gp.   
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Figure 3-2: Correlation of gene expression of drug efflux proteins of the ATP binding 
cassette transporter Family in human jejunum and human epithelial Caco-2 cell 
monolayers (372)   
 
Caco-2 cells have closely comparable permeability with that of in-vivo human jejunum, 
especially for drugs with high passive diffusion.  
Under normal cell culture conditions Caco-2 cells spontaneously differentiate into 
monolayers of polarized enterocytes, expressing high levels of several brush boarder 
hydrolases when allowed to develop for 2-3 weeks (422). In addition, they contain 
intestinal transport proteins which transport large substances such as  amino acids, 
vitamin B12 and dipeptides (353, 423, 424) and form a tight monolayer with trans 
epithelial electrical resistance above 300 Ωcm2, which although higher than that of the 
colon (421). The tight junctions result in little or no paracellular transport which allows 
study of trancellular transport of a drug as drugs would inevitably pass through the cells.  
Caco-2 cell lines grown on permeable filter inserts for 21 to 28 days are routinely used 
for in-vitro studies on the transepithelial transport of drugs. Bidirectional drug transport 
studies done on Caco-2 cell monolayers can be used for determination of passive 
permeability of the drugs and/or active transport using carrier molecules (350). These 
studies help identify potential drug absorption related problems and predict likely in-
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vivo drug absorption (421, 425, 426). Active transport processes involving P-gp and 
dipeptide carrier molecules are usually studied using a Caco-2 cell model. 
The noted limitations of the Caco-2 model are its the heterogenic nature and slow 
growth, which can result in some differences in transport expression from lab to lab 
requiring analysis of transport level in batches. Caco-2 cells are also deprived of 
intestinal barriers such as mucus layers, which could impair drug absorption (416).  
 
3.1.7 Correlation of in-vitro drug permeability and in-vivo drug 
absorption 
Bidirectional apparent permeability (Papp) values across Caco-2 monolayers could be 
used to identify potential absorption related problems of drugs. The in-vitro Caco-2 
monolayers are found to be comparable to more complex absorption models such as in-
situ perfusion model. A study was done to establish the predictability of in-vivo drug 
absorption from in-vitro Caco-2 monolayers and in-vivo human jejunum in-situ using 
double balloon and single pass techniques. The study looked at three categories of drugs; 
ones that are completely and rapidly absorbed by a passive transcelluar route, those 
slowly and incompletely absorbed through a passive paracellular route and drugs 
transported by an active carrier mediated route. The study found Caco-2 monolayers to 
be an excellent model for predicting passive transcellular permeability with only 2-4 
fold variation in in-vitro model prediction compared to the in-vivo values whereas in-
vitro predictions for incompletely absorbed drugs were 30 to 80 fold lower compared to 
the in-vivo jejunum (350, 427, 428). Thus Caco-2 cell permeability values for low 
permeable drugs (peptides and peptidomimetics) do not correlate with the in-vivo 
permeability as accurately as highly permeable drugs.  This difference is likely due to 
lower paracellular permeability resulting from greater tight junctions in Caco-2 
monolayer and low permeable drugs having a long duration in the gut to slowly be 
absorbed. This can be factored into a mathematical model through producing a sigmoid 
curve to represent low, medium and high permeable drugs when estimating human drug 
absorption from these cells (350). Several other studies using low permeable 
peptidomimetics have shown that it is possible to obtain reasonable in-vivo prediction 
using in-vitro Caco-2 monolayer studies using this method (429, 430).  
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Based on Papp values drugs are classified into low, medium and highly permeable drugs. 
Yee (431) used Papp values of 1, 1-10 and greater than 10 × 10
-6 cm/sec, respectively, 
having studied the correlation between in-vivo drug absorption and in-vitro permeability 
of 36 compounds. However this study failed to consider the solubility of the drug before 
establishing the relationship. HT29-18-C1 cell line study established a threshold value 
of greater than 2×10-6 cm/sec to have more than 80 % absorption and less than 2 ×10-6 
cm/sec to be poorly absorbed (426). A recent study has classified drugs into low, 
medium and high categories based on Papp values of 2, 2-20 and greater than 20 × 10
-6 
cm/sec (417).  
The limitation of Caco-2 cell lines that they are a heterogeneous cell population of 
adenocarcinoma cells. It has been shown that the active transport of thyrotropin 
releasing hormone was present only in one Caco-2 monolayer from two populations 
originated from different laboratories (432). There could be also be differences in Caco-
2 cells generated within the same laboratory (350, 433). It is indicated that monolayer 
characteristics could change within increasing passage number, duration of cell growth, 
media conditions and filter conditions. Nevertheless, the change in cell characteristics 
can be monitored by determining bidirectional transport of reference P-gp substrates 
such as rhodamine123. Therefore inter lab variability in drug permeability (Papp) values 
can be expected. But controlled bidirectional transport studies using Caco-2 monolayers 
still provides similar qualitative correlations of fraction absorbed irrespective of the 
research group or laboratory, and once controlled quantitation is possible.  
 
3.1.8 Bio-pharmaceutical classification system 
Aqueous solubility and permeability of a drug are the main parameters that control the 
rate and the extent of drug absorption across gastrointestinal epithelium (434). The pH 
of the gastrointestinal tract varies from pH 1.5 to 7.4 and drugs are considered highly 
soluble when the highest dose strength is soluble in 250 ml of aqueous media over a pH 
range of 1-7.5. Drug permeability values obtained using in-vitro Caco-2 cell line studies 
are considered as valid data to categorize drugs into the FDA’s Biopharmaceutical 
classification system (415). 
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Amidon and co-workers (434) developed the theoretical biopharmaceutical 
classification system below considering the drug solubility and permeability and 
categorizing drugs into 4 classes. Class I and II drugs, can waive any requirement 
bioavailability (bio wavier) studies for establishment of bioequivalence for generic 
product in place of in-vitro dissolution test.  
 
Class  Solubility Permeability  In-vivo in-vitro (IVIV) correlation expectation 
(434, 435)  
I High  High  Drug is dissolved rapidly and is well absorbed. 
Bioavailability problems are not expected. 
Dissolution test can waive in- vivo bioavailability & 
bioequivalence 
II Low  High Dissolution of the drug is limited but well absorbed. 
Bioavailability is controlled by the dosage form and 
rate of release of the drug substance. Dissolution test 
can waive in- vivo bioavailability & bioequivalence  
III High  Low Drug permeability is rate limited. Dissolution test 
cannot waive the in-vivo bioavailability.  
IV Low  Low  Drug permeability and dissolution is limited. No 
IVIV correlation. It is difficult to formulate a drug 
product that will deliver consistent drug 
bioavailability. An alternate route of administration 
may be needed. 
 
The solubility of a drug depends on formulation of the product factor (dissolution), 
gastrointestinal pH, gastrointestinal transit time, drug interaction) food and other drugs) 
in the intestinal tract and metabolism of drugs in the gastrointestinal tract. This 
classification also allows identification of class IV drugs, which has low solubility and 
permeability. This would allow opportunities for investigator to further improve 
chemical structures of drugs in order to have better solubility and permeability.   
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3.1.9 Current evidence on drug permeability, P-gp mediated efflux 
transport and P-gp expression regulation on antimalarials  
The P-gp inhibitory properties of antimalarials have been studied more widely compared 
to their potential P-gp substrate activities. There are only a few studies on P-gp substrate 
activity of antimalarials and there is little or no information on the P-gp induction 
properties of antimalarials.  
While there is no information on drug permeability of mefloquine and little information 
on its activity as a substrate for P-gp (436), there is convincing evidence for P-gp 
inhibitory activity (104, 436-438). However the drug transport of mefloquine in the 
combination therapy is lacking. The P-gp inhibitory properties and bidirectional 
transport of amodiaquine is reported in the current literature (439, 440). Bidirectional 
transport of artesunate has not been reported while the P-gp inhibitory properties for 
artesunate and dihydroartemisinin are available (439, 440). 
Piperaquine is highly lipid soluble and drug permeability studies in a Caco-2 cell line 
have shown very low apical to basolateral (AP-Bas) and basolateral to apical (Bas-Ap) 
permeability. Ap-Bas values were below detectable and Bas-Ap was 0.1 × 10-6 cm/sec). 
This drug was shown not to exhibit P-gp mediated transport (338).  
In-vitro Caco-2 cell line studies has suggested that quinine is a potent P-glycoprotein 
inhibitor and it might also be a P-glycoprotein substrate (441). Quinine reversed the 
resistance of doxorubicin in a multidrug resistance human myeloma cell line model. In 
this study a synergistic inhibition of P-gp was also found when quinine was combined 
with verapamil (442). 
Regulation of P-gp expression by artemisinin has been reported. It is reported that 
artemisinin induces expression of CYP2B6, CYP3A4 and P-gp in human hepatocytes 
and in LS174T (Dukes' type B,colorectal adenocarcinoma) cell lines through the 
activation of human PXR and human Constitutive Androstane receptor (CAR) (443). At 
25 µM dihydroartemisinin did not activate PXR, however authors speculated that 
dihydroartemisinin may activate PXR when present greater than 25 µM.     
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3.2 Specific Objectives  
The study of in-vitro drug permeability of antimalarials requires development of an 
robust in-vitro cell model. As discussed in the introduction Caco-2 cell monolayers are 
the most widely used human cell line for in-vitro drug permeability studies. However 
the limitation of this cell line is its possible heterogenetic nature based on cell origin and 
culturing condition. Therefore it was aimed to develop an in-vitro Caco-2 cell model for 
determination of drug permeability and P-gp mediated drug transport of anti- 
malarial drugs. 
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3.3 Methods 
3.3.1 Materials  
3.3.1.1 Drugs  
Artemisinin, mefloquine hydrochloride, amodiaquine dihydrochloride dihydrate, 
artesunate, rhodamine123 and rifampicin were purchased from Sigma Aldrich (St Louis, 
MO, USA). Dihydroartemisinin was supplied from DAFRA Pharma Manufacturers 
(Belgium). Methylene blue zinc chloride double salt was purchased from Fluka Sigma 
Aldrich (Steinem, Switzerland). Artemisone was kindly donated by Professor Richard 
Haynes, The Hong Kong University of Science and Technology, Hong Kong. 
Vinblastine hydrochloride was purchased from ICN biochemical (Seven hills, NSW, 
Australia). PSC 833, the P-gp blocking cyclosporine derivative, was donated from 
Novartis BioPharma (Basel, Switzerland). Mini Protease inhibitor tablets were supplied 
by Thermo Scientific (Rockford, USA). 
 
3.3.1.2 Chemicals 
Acetonitrile, methanol and ethanol were supplied from Fisher Scientific (Fair Lawn NJ, 
USA). Dimethyl Sulfoxide (DMSO) was purchased from Ajax Finechem (NSW, 
Australia). TRIS Hydrochloride was purchased from Ultrapure bio-reagents (NJ, USA). 
Sodium Chloride, sodium potassium tartrate and Copper (II) sulphate were purchased 
Chem-Supply (Gillman, SA). Sodium Dodecyl Sulphate, Sodium Carbonate, Casein, 
Potassium Dihydrogen Ortho Phosphate (KH2PO4), Trifluroacetic acid, Phosphoric acid 
(H3PO4), Formic acid and Nonidet P40 substitute were supplied by Sigma Aldrich (MO, 
USA). Sodium hydroxide and Folin were supplied by BDH Merck Pvt Ltd (Victoria, 
Australia).All other chemicals were of analytical grade. 
 
3.3.1.3 Cells and cell culture reagents  
The human colon carcinoma cell lines (Caco-2), passage 18 were obtained from 
American Type Culture Collection (ATCC), University Boulevard (Manassas, VA, 
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USA). LS174 T and Hela cells were gifted from Professor Michael Gottesman, NIH, 
Bethesda, USA.   
High glucose Dulbecco’s modified eagle medium (DMEM), Dulbecco’s phosphate 
buffered saline (PBS), L-Glutamine, Hanks buffered salt solution (HBSS), N-2-
hydroxyethylpiperazine-N'-2-ethane sulphonic acid (HEPES), Trypan blue stain (0.4%) 
and TrypLE Express were supplied by Gibco [Life technologies (NY, USA)]. Glucose 
was purchased from APS Finechemicals (NSW, Australia). Non-essential amino acid, 
penicillin G (10,000 u/mL) and streptomycin (10,000 µg/mL) were purchased from 
Trace Biosciences (Castle Hill, NSW, Australia). Foetal calf serum (FCS) was obtained 
from the SerANA (Bunbury, Western Australia).  
NuPAGE MOPS running buffer (20X), SeeBlue Plus2 Pre-stained Standard, Bolt 
Sample reducing agent (10X), Bolt 4-12% Bis-Tris Plus 15 well gels, NuPage Transfer 
buffer (20 X), Nupage LDS Sample buffer (4X) and NuPage Antioxidant were 
purchased from Novex by life technologies (CA, USA). 
MDR1 mouse monoclonal antibody was purchased from Santa Cruz biotechnology Inc. 
(Europe). Monoclonal Anti-beta-Actin antibody produced in mouse was supplied by 
Sigma Aldrich (MO, USA). Goat anti-mouse secondary antibodies were purchased from 
Jackson ImmunoResearch Laboratories Inc (West Grove, PA, USA) 
Clarity Western ECL substrate was supplied by BIORAD Laboratories Inc. (USA) 
 
3.3.2 Buffers, reagents and solvents  
 
The composition of the buffers, reagents and solvents are given in Appendix 1. 
 
3.3.2.1 Buffers for HPLC   
Mobile phase for all assays were prepared using KH2PO4. This was prepared by 
dissolving 2.72 g of salt in 1 L of deionized water. The pH of 20 mM buffer was adjusted 
using H3PO4. The buffer was filtered through 0.45 µm filter using a vacuum pump.   
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3.3.2.2 Solvents for LC-MS-MS sample preparation  
Preconditioning solution - 1% v/v trifluroacetic acid was prepared by pipetting in 100 
µL trifluroacetic acid and making up the volume to 10 mL with deionized water. 
Washing solution - 0.1% v/v trifloroacetic acid was prepared by pipetting in 100 µL 
trifluroacetic acid and making up the volume to 100 mL. 
Conditioning solution - 50 % v/v acetonitrile was prepared in deionized water.  
Elution solvent - 0.1% v/v formic acid in 95% v/v of acetonitrile was prepared by mixing 
11µL of 90 % formic acid, 9.5 mL of acetonitrile and 489 µL of deionized water.  
 
3.3.3 Preparation of stock and working solutions  
Mefloquine (MW: 378.3) 20 mM stock solution was prepared by dissolving 8.30 mg 
mefloquine hydrochloride (MW: 414.77) in one mL of ethanol. Concentration of 
mefloquine above 100 µM was not used for test conditions due to toxicity to the Caco-
2 cells.   
Amodiaquine (MW: 355.9) is soluble in water and sparingly soluble in ethanol and 
DMSO. Amodiaquine was found to be poorly soluble in pH 7.4 HBSS transport media 
as the solubility of amodiaquine reduces with increase in pH (72). The stock 20 mM 
amodiaquine was prepared in one mL of ethanol dissolving 9.30 mg of amodiaquine 
dihydrochloride dihydrate (MW: 464.81) and was unable to further increase the stock 
concentration. Maximum test concentration of amodiaquine was 300 µM (Higher 
concentration increases the percentage of ethanol in the working solution) 
Artesunate (MW: 384.4) 20 mM and 40 mM stock solutions were prepared by dissolving 
7.68 mg and 15.37 mg per 1 mL of ethanol respectively. Similar to artesunate 20 and 40 
mM stock solutions for artemisone (MW: 401.52) were prepared by dissolving 8.03 mg 
or 16.06 mg in 1 mL of ethanol. Methylene blue (MW: 319.85) 20 mM stock solution 
was prepared by dissolving dissolving 7.61 mg of methylene blue zinc chloride double 
salt (MW: 775.98) per mL of deionized water.  
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Dihydroartemisinin (MW: 284.4) was sparingly soluble in ethanol and highest 
concentration achieved was 20 mM by dissolving 5.68 mg per 1 mL of ethanol and 0.14 
mg of artemisinin was dissolved per mL of ethanol to prepare 0.5 mM artemisinin (MW: 
282.33) stock solution.   
Rhodamine123 (MW: 380.82) 5 mM stock solution was prepared by dissolving 1.90 mg 
of rhodamine123 per one mL of ethanol. The stock solutions for PSC 833 (MW: 1214.62 
g), rifampicin (MW: 822.94), vinblastine (MW: 909.05) and Ko143 (MW: 469.57) were 
4, 1, 0.5 and 1 mM and prepared by dissolving 4.86, 0.82, 0.45 and 0.47 mg of drugs 
respectively per 1mL of DMSO.  
MK 571 (MW: 537.07) 10 mM stock solution in deionized water was diluted in HBSS 
to prepare 40 µM test solutions. Probenecid 500 µM (MW 285.36) working solution 
was prepared by dissolving 2.14 mg in 15 mL of HBSS. 
Drug aliquots were stored at -80 ºC and standard series and test concentrations were 
prepared by using aliquots on the day of the experiment. Working/test drug solutions 
were prepared in HBSS and the percentage of solvent; namely ethanol and DMSO was 
maintained at 1% ethanol and 0.2 % DMSO. However for high concentration of 
amodiaquine and dihydroartemisinin (300 mM), the percentage of ethanol increased up 
to 1.5%. 
 
3.3.4 Assay of rhodamine123 
Rhodamine123 levels were quantified using Perkin Elmer Enspire multi-mode plate 
reader (Waltham, MA, USA) and measurement were done using fluorescence detection 
at excitation and emission wave length of 498 and 528 nm respectively. Enspire 
workstation version 4.10.3005.1440 was used for data interpretation. Figure 4.3 gives 
the standard curves for 70 ml (for assay of Bas-Ap sample) and 120 mL (for assay of 
Ap-Bas samples) of rhodamine123. Standard series (0.02 to 5 µM) were prepared in 
HBSS. Two standard curves were required, as samples were collected in 96 well plates 
in 70 (Bas-Ap sample) and 120 µL (Ap-Bas samples) volumes. The 96 well plates were 
directly placed in the detector to quantify the relative fluorescence (RFU) in these two 
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volumes. Interpretation of total fluorescence in two different volumes required the 
construction of two standard curves of 70 and 120 µL volumes.    
 
 
 
 
 
Figure 3-3 - Calibration curve for rhodamine 123 for concentration range A1) 0- 160  nM, A2) 
160- 3000 nM for 70 µL and B1) 0- 160  nM,  B2) 160- 3000 nM  for 120 µL 
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3.3.5 Development of cell model for transport studies  
3.3.5.1 Caco-2 monolayers and maintenance  
The human colon carcinoma cell line (Caco-2) passage 18 obtained from ATCC were 
frozen in 70 % medium, 10% DMSO and 20 % FCS in liquid nitrogen. The thawed cells 
were added into a falcon tube containing 11 mL of medium, centrifuged at 500 g for 7 
minutes and resuspended in 3 mL of medium. Cells were seeded (10000 cells/cm2) in 
25 cm2 flask and maintained in high glucose DMEM supplemented with 10 % FCS, 
glutamine, non-essential amino acid, penicillin and streptomycin incubated at 37 ºC, 
95% humidity and 5% CO2. Medium was replaced twice a week and cell splitting was 
done using 50:50 TrypLE Express: PBS (1.5 mL each) upon 90% confluency, in about 
10 days of post seeding. The cell suspension was centrifuged at 450 g for 7 minutes in 
a falcon tube containing 7 mL of medium. Upon centrifugation, cell pellet was re-
suspended in 3 mL of medium. Cell counting was manually carried out using 
haemocytometer and cell staining was done mixing 25 µL each of 0.4 % Trypan blue 
stain 0.4%, cell suspension and PBS. Cells were reseeded for maintenance and also to 
obtain late passage Caco-2 cells.  
 
3.3.5.2 Development of Caco-2 cell monolayer for transport experiments  
This study was done with the aim of developing a robust Caco-2 cell monolayer with 
adequate level of P-gp transporter protein expression to facilitate identification of P-gp 
inhibitory and substrate activities for lower affinity antimalarial drugs. Three 
approaches were adopted to increase the P-gp transporter protein; 
a). Exposure of Caco-2 monolayer to a known P-gp inducer;  rifampicin  
b). Exposure of Caco-2 cells to nanomolar concentrations of potent P-gp substrate, 
vinblastine for an extended period.  
c). Regular passaging of Caco-2 cells in order to determine change in P-gp transporter 
protein levels.  
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3.3.5.3 Development of Caco-2 cell model using P-gp inducer rifampicin 
(Caco-2 RIF) 
Passage 44 Caco-2 cell lines were grown on 0.6 cm2 diameter 0.45 µM pore size 
Millipore PCFTM filter inserts at the cell density of 65,000 cells/cm2. Cells were 
maintained using normal cell growth conditions as explained at 3.3.5.1. On day 24, cells 
were exposed to medium supplemented with 10 µM rifampicin. On day 28, cells were 
washed with PBS 3 times and incubated in normal medium for 4 hours. These cells were 
then used for transport experiments and bi-directional transport of rhodamine123 was 
determined. These studies were based on the protocol described in 3.3.6.1.1. 
 
3.3.5.4 Development of Caco-2 cell model using increasing concentration of 
vinblastine (Caco-2 VIN) 
Passage 41 Caco-2 cells frozen in liquid nitrogen were used for induction. Cells were 
seeded on to a 75 cm2 flask in high glucose DMEM and incubated at 37 ºC with 5% CO2. 
Normal cell growth medium was supplemented with either 10 nM vinblastine or 50 nM 
vinblastine to be used for cell growth.  The second medium change was done with high 
glucose DMEM supplemented with 10 nM vinblastine. Cells were trypsinized on day 
10 or upon 90% confluency using TrypLE Express. These cells were reseeded (20000 
cells/ cm2) back on a 75 cm2 flask and maintained on medium supplemented with 10 
nM vinblastine. This procedure was repeated for passage 42 and 43 cells and passage 
44 Caco-2 cells were seeded onto 0.6 cm2 Millipore PCF filter inserts at the cell density 
of 100,000 cells/cm2. The remaining cells in aliquots were frozen in liquid nitrogen to 
be used for other studies. Cells on filter inserts were grown on high glucose DMEM 
supplemented with 10 nM vinblastine for 17 days and vinblastine concentration was 
increased on the day 17 to medium supplemented with 50 nM vinblastine. Cells were 
maintained on 50 nM vinblastine medium for 7 days and were ready for transport 
experiment on day 24. Similar to 3.3.5.3, Caco-2 VIN cells were washed with PBS 3 
times and incubated in normal medium for 4 hours at 37 ºC with 5% CO2 prior to adding 
drugs for transport experiment. The transport experiments for rhodamine123 were 
conducted following the protocol described in 3.3.6.1.1  
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3.3.5.5 Development of late passage Caco-2 cell monolayers 
Passage 18 Caco-2 cell lines were obtained from ATCC. These cells were grown on 25 
cm2 flask in high glucose DMEM and continuous culturing was done as described in 
3.4.5.1. As described cell passaging was done every 10th day upon reaching 90% 
confluency after post seeding until the cells above passage 80 were reached. This was 
achieved in a period about one and half years and the bidirectional transport for 
rhodamine123 was determined using late passage Caco-2 monolayers (P-80 and above) 
following the protocol described in 3.3.6.1.1.  
 
3.3.6 Determinations of relative abundance of P-gp transporter 
protein in different Caco-2 models 
3.3.6.1 Study of bidirectional transport of a P-gp substrate  
Bidirectional transport of the known P-gp substrate 5 µM rhodamine123 was done for 
all three cell models based on the transport study protocol described in 3.3.6.1.1. In 
order to confirm P-gp mediated efflux, rhodamine123 was combined with a known P-
gp inhibitor, PSC 833, and change in bidirectional transport of rhodamine123 was 
studied. Significantly higher Bas-Ap directional transport compared to Ap-Bas transport 
was considered as the P-gp mediated efflux transport of rhodamine123. Inhibition of 
Bas-Ap directional transport of rohdamine123 in the presence of PSC 833 (known P-gp 
transport inhibitor) further confirmed the presence of active P-gp. The extent of the 
efflux or Bas-Ap direction transport was directly related to relative abundance of P-gp. 
Significantly higher Ap-Bas transport compared to Bas-Ap directional transport was 
considered as the cell uptake of the study drug.  
 
3.3.6.1.1 Transport experiments  
The Caco-2 cells were seeded on 0.6 cm2 0.4 µM Millipore PCFTM filter inserts at the 
cell density of 65,000 cells/cm2. The medium was replaced with high glucose DMEM 
medium twice a week and 300 and 600 µL were added to the apical and basolateral 
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chambers respectively. Cells were grown for 21-24 days for full maturation, formation 
of tight monolayers and P-gp (444-446).   
Prior to the experiment, the medium in both apical and basolateral chambers was 
replaced with pre-warmed transport medium, HBSS or HBSS plus modulators and 
incubated for 30 minutes. 
The Trans epithelial electrical resistance (TEER) was measured immediately before and 
after the experiment using an epithelial voltage/ohm meter (EVOM) and the ENDOHM 
12 chamber (World precision instruments, Sarasota, FL). TEER values above 300 
Ω.cm2 before and after the study were considered as appropriate for test condition for 
the study (446).   
The filter inserts were placed in new 24 well plates to conduct the transport experiment 
(Figure 3.4). In the determination of apical to basolateral (AP-Bas) directional transport, 
the medium in the apical chamber (donor compartment) is replaced with 300 µL drug 
or drug + inhibitor dispersed in HBSS and basolateral chamber (receiver compartment) 
was replaced with 600 µL of fresh HBSS as shown in Figure 3.4a. At 30, 60, 90, 120 
and 180 minutes transport medium (120 and 200µL for rhodamine123 and drug assays 
respectively) was collected from the receiver compartment (basolateral chamber) and 
was replaced with the same volume of fresh HBSS or HBSS+ inhibitors. At the end of 
the experiment, 100 µL of sample was removed from the donor, apical chamber.  
a).        b). 
   Apical chamber 
   Drug  
   Basolateral chamber   
 
 
 
 
In the determination of basolateral to apical (Bas-AP) transport, apical chamber medium 
was replaced with pre-warmed 300 µL HBSS and basolateral chambers were  replaced 
Figure 3-4: The diagram above shows the filter inserts placed in a 24 well plate and the 
arrows show the a) apical to basolateral and  b) basolateral to apical directional 
transport of the drugs  
   Page 142 of 294 
with 600 µL relevant concentration of drug or drug + inhibitor in HBSS (Figure 3.4b.). 
At 30, 60, 90, 120 and 180 minutes transport medium (70 and 100µL for rhodamine123 
and drug assays respectively) was withdrawn from the receiver compartment (apical 
chamber) and replaced with blank HBSS or HBSS + inhibitor. At the end of the 
experiment, 100 µL of sample was removed from the donor, basolateral chamber.   
The cells were kept in the incubator during the experiments and were removed from the 
incubator only for sample withdrawal. The plate was gently shaken soon before 
withdrawing the sample. The collected samples were refrigerated during the experiment. 
The TEER values were read at the end of the experiments to ensure monolayer tightness 
during the experiments. The cells were then washed with PBS three times and cell 
membranes were cut and placed in a microcentrifuge containing 350 µL of deionized 
water. Microcentrifuge tubes were sonicated for 10 minutes in a floating rack and 
centrifuged at 13000 RPM for 10 minutes. A sample from each supernatant was 
withdrawn for assay and all samples were frozen at -80 ºC until assayed.  
The apparent permeability (Papp) value of 3 well plates were determined for each 
direction and mean the standard error of mean values are presented as the bidirectional 
transport values of the study drug. 
 
3.3.6.1.2 Determination of apparent permeability  
The apparent permeability were calculated based on the below equation (421, 447, 
448). 
Papp = 
dQ
dt
× 
1
∆t60AC0
  
Permeability rate =  
dQ(µg)
dt(min)
  
C0    =  Initial concentration (µg/mL) 
A   = Surface area (cm2) 
A modified version of the above equation developed by Crowe and Lemaire (447) was 
used to determine the permeability. This equation accounts for the amount of drug 
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associated with the cells (cell accumulations) at the end of the experiment. The corrected 
clearance volume was determined using the equation below. 
CL.vol = Aa/{[Cd0 × Vd-[Aa+(Ca×Vs)]-(Ac)× n nfin⁄ ]/Vd 
 
CL.vol  = Clearance volume (mL)  
n  = Time (min) 
Aa  = Amount in acceptor compartment at time n (pmols) 
𝐶𝑑0   = Conc. in donor compartment at time zero (nM) 
Vd  = Volume of the donor compartment (mL) 
Ca = Conc. in acceptor compartment at the previous time point (nM) 
Vs = Sample volume of previous time point (mL) 
Ac = Amount of compound associated with the cells (nM) 
Nfin = Final time point (min) 
 
The rate of clearance was obtained by dividing the cleared volume from the time and 
this value was divided by the surface area of the monolayer (0.6 cm2) to obtain the 
apparent permeability.  
Rate of clearance = 
CL.vol (mL)
n (min)
 
 Apparent permeability (cm/sec ) = 
Rate of clearance(mL/min)
Surface area(cm2)
  
The cleared volume for different time points were plotted against time for both Ap-Bas 
and Bas-Ap transport and the slope of the regression line was divided by the surface 
area of the monolayer to obtain the apparent permeability in cm/sec.  
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3.3.6.2 Visual confirmation of P-gp by Western blotting  
Passage 44 (early) and 80s (late) Caco-2 cell lines were seeded on 9.6 cm2 diameter 6 
well plates at cell density of 10,000 cells/cm2. Passage 44 Caco-2 cells lines exposed to 
10 nM vinblastine for 3 passages (41-43) were seeded onto a 6 well plate at the cell 
density of 20,000 cells/cm2. Similar to 3.3.5.4, cells were grown on medium 
supplemented with 10 and 50 nM vinblastine for 17 and 7 days respectively. Cells from 
early, late and Caco-2 VIN were lysed on day 21, 24 and 28 and cell lysates were 
prepared as described in 3.3.6.2.2. Passage 44 Caco-2 cells seeded at 10, 000 cells/cm2 
on 6 well plates were exposed to 10 µM rifampicin from day 24 to 28 and cells were 
lysed on day 28 and cell lysate was prepared. The protein content was determined based 
on modified micro plate Lowry protein assay as described in 3.3.6.2.1. A constant 
amount of protein; 60 µg of was loaded and Western blotting was done following the 
protocol described in 3.3.6.2.2. 
 
3.3.6.2.1 Modified micro plate Lowry protein assay  
Bovine serum albumin stock solution, 2000 µg/mL was prepared in deionized water.  
The stock was diluted to prepare 10, 20, 50, 100, 150, 250, 500, 1000, 1500 µg/mL  All 
samples were assayed in duplicates using the microLowry protein assay. Samples and 
lysis buffers were diluted at 1:6 in 96 well plates and 120 µL of Lowry reagent was 
added and incubated in room temperature. After 15 minutes of incubation 60 µL of 0.5 
N Folin reagent was added and incubated for 30 minute in the plate shaker. The 
absorbance was read at 750 nm using a TECAN SUNRISE microplate absorbance 
reader (Austria, Europe) and protein content was determined using the standard curve.   
 
3.3.6.2.2 Western blotting  
Preparation of cell lysate  
The cells grown on 6 well plates were washed with PBS 3 times. Lysis buffer (300 µL) 
was added and incubated for 30 minutes. Upon lysis, cell suspension was collected into 
   Page 145 of 294 
a microcentrifuge tube and passed through a 21 gauge needle about 10 times to 
maximize cell lysis. Microcentrifuge tubes were centrifuged at 13000 RPM for 10 
minutes and the supernatant was collected. Protein solution was frozen at -20 ºC.  
 
Western blotting 
The total protein content of the supernatant was determined using the Lowry protein 
assay. Protein samples/ supernantant were processed by adding 25% Nupage sample 
buffer, 10% reducing agent and 65% of the protein sample to a total volume of 35 µL. 
This was reduced by heating for 5 minutes at 95 ºC. Uniform amount (70 µg Caco-2 and 
30 µg for  LS174 indcution studies) of proteins was loaded on to 4 -12 % Bis Tris Plus 
15 well plates. SeeBlue precolured molecular weight marker 10 µL was used as visual 
guide to electrophorosis. Gels were run at 165 V for 60 minutes using Novex Bolt Mini 
Gel Tank (Life Technologies, CA, USA). Immuno blot PVDF membrane were activated 
by soaking with methanol for 2 minutes, water for 2 minutes and finally with transfer 
buffer. The transfer cassette was prepared per manufacturers specification and transfer 
was done at  34 V for 95 minutes in a Xcell II Bolt Module  (Novex, CA, USA). PVDF 
membrane was washed for 5 minutes using TBST. The membrane was blocked over-
night at 4 ºC using 2% casein in TBS and washed 2 times using TBST (each was of 5 
minutes duration). The primary antibody; Mdr (G-1) mouse monoclonal IgG2b 200 
µg/mL in 1/225 ratio and mouse anti-beta actin (beta actin was used as the reference 
protein) in 1/7500 ratio was diluted in filtered blocking solution (1% casein in TBS). 
The membrane was incubated in the prepared primary antibody solution at room 
temperature in on a rocker platform  for 2 hours. Upon incubation, the membrane was 
washed 4 times using TBST (each was of 5 minutes duration). The antibody; HRP linked 
1 goat anti mouse secondary antibody was diluted in blocking solution at 1/6000 ratio 
and membrane was incubated in secondary antibody for 1.5 hours at room temperature. 
The membrane was washed 4 times in TBST and incubated in a BioRad clarity 
chemiluminescent substrate for 2-5 minutes. The chemiluminescent substrate was 
prepared by mixing 1 mL each of substrate and enhancer. The membrane sandwich was 
prepared for luminograph, using 2 plastic transparent sheets. The blot was read and semi 
quantified using the BIORAD Chemidoc mpt imager with Image LabTM software.  
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3.3.7 Data analysis  
The apparent permeability values were calculated based on the equation described above 
and Microsoft EXCEL template was used for calculations and graphing. Standard errors 
and two tailed t test were done using SigmaPlot version 12.5 Systat Software, Inc. 
(Chicago, IL). 
Efflux ratios were calculated by dividing Papp of Bas-Ap from Ap-Bas values. A higher 
Bas-Ap transport (P < 0.05) compared to Ap-Bas transport was considered as possible 
efflux and a higher Ap-Bas transport (P < 0.05) was considered as possible uptake of 
drug. The results are presented as the mean ± standard error of mean.  
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3.4 Results 
3.4.1 Development of a robust Caco-2 model for bidirectional 
transport studies 
The early and late passage Caco-2 cell monolayer showed TEER values above > 300 
Ω.cm2 within 21 to 24 days and hence transport studies were carried out during this 
period. The Caco-2 VIN model studies were done on day 24 as it took up to day 24 to 
achieve the TEER value above 300 Ω.cm2. The Ap-Bas and Bas-Ap directional transport 
of rhodamine123 through passage 44 Caco-2 cells are shown in Figure 3.5.  
 
 
 
 
  
 
 
Figure 3-5: Ap-Bas ( ) and Bas-Ap ( ) directional permeability of rhodamine123 
across P-44 Caco-2 cell monolayer (N=3, Mean ± SEM) 
 
Apparent permeability values for 5 µM rhodamine123 through 3 cell monolayer models; 
cells exposed to rifampicin (Caco-2 RIF), Caco-2 exposed to increasing concentrations 
of vinblastine (Caco-2 VIN) and late passage Caco-2 (P-80s and above) are given in the 
Table 3.1. 
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Table 3-1: Apparent permeability (Papp ± SEM, N=3) for Rhodamine123 (5 µM) alone 
and when combined with PSC 833 (4 µM) for different Caco-2 cell monolayer models  
* Significant at the level of P < 0.05, ** Significant at the level of P < 0.005, a The Papp of Bas-
Ap direction was divided by the Ap-Bas direction to obtain net transport, b The mean TEER 
value for 3 well plates before the test.  
 
As shown in Table 3.1, Bas-Ap directional transport of rhodamine123 was significantly 
higher compared to AP-Bas directional transport in all four versions of Caco-2 cells 
tested. Therefore higher serosal to luminal directional transport (efflux) of 
rhodamine123 rather than luminal to serosal directional transport (uptake) of 
rhodamine123 is evident. The addition of PSC 833 inhibited the efflux transport of 
rhodamine123 and efflux ratio dropped to one indicating no net transport. Therefore it 
is evident that P-gp transporter proteins are expressed in early, Caco-2 RIF, Caco-2 VIN 
and late passage Caco-2 cell monolayers.  
The Ap-Bas directional transport of rhodamine123 in Caco-2 VIN and late passage 
Caco-2 cell models was around 0.5 × 10-6 cm/sec and the cell intake was about 4 fold 
lower than the early passage and Caco-2 RIF models where Papp was in the range of 2.1-
2.2 × 10-6 cm/sec. The serosal to mucosal directional efflux transport of rhodamine123 
in the late passage Caco-2 was not higher compared to early passage Caco-2 cells. 
However the drop in cell uptake or Ap-Bas directional transport clearly increased the 
efflux ratio (1.4 to 4.74) in late passage Caco-2 cells compared to the earlier passage. 
Therefore later stage Caco-2 monolayers are more likely to identify moderately effluxed 
Caco-2 
monolayer 
models 
Drug 
 
Ap-Bas 
(10-6 
cm2/min) 
Ap-Bas 
TEERb 
 
Bas-Ap 
(10-6 
cm2/min) 
Bas-Ap 
TEERb 
 
Efflux 
ratio 
Net transporta   
(P value) 
P- 44 Rh123 2.2 ± 0.1 357 3.2 ± 0.2 387 1.4 Efflux (0.02)* 
 Rh123 + PSC 2.3 ± 0.2 410 2.3 ± 0.1 390 1.0 No flux (0.98) 
Caco-2 RIF Rh123 2.1 ± 0.0 403 3.1 ± 0.3 420 1.5 Efflux (0.01)* 
Rh123 + PSC 2.8 ± 0.2 452 2.6 ± 0.1 432 0.9 No flux (0.57) 
Caco-2 VIN Rh123 0.5 ± 0.0 603 6.6 ± 0.4 614 13.2 Efflux (0.0001)*** 
Rh123 + PSC 0.7 ± 0.1 628 0.6 ± 0.0 599 0.9 No flux (0.31) 
P- 80 Rh123 0.5 ± 0.1 665 2.4 ± 0.3 760 4.7 Efflux (0.003)** 
Rh123 + PSC 0.5 ± 0.1 680 0.5 ± 0.0 674 1.0 No flux (0.96) 
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P-gp substrate and thus a better model than early passage Caco-2 cells. Both early and 
late passage cells had cell differentiation, monolayer tightness and reached TEER > 300 
Ω.cm2 by day 21-24 therefore form a good cell barrier for drug transport. But P-gp 
expression appeared to be higher in late passage cells and this is also illustrated in 
Western blotting image section (Figure 3.10).  
The attempt to force a P-gp overexpression by using a continuous low level of 
vinblastine exposure to stress the Caco-2 cells was productive and resulted in much 
greater rhodamine123 efflux than that developing naturally during late passage culture. 
Caco-2 VIN showed the highest increase in P-gp with an efflux ratio of 13 for 
rhodamince123. The highest serosal to mucosal directional transport (efflux) was also 
observed for Caco-2 VIN model and was 6.6× 10-6 cm/sec. However, this was rather a 
time consuming approach to increase P-gp expression with 3 passages of previous 
ongoing exposure and further exposure of vinblastine at two different concentrations. 
Given that late passage Caco-2 cells started to exhibit sufficient spontaneous P-gp 
expression, it was decided to use late passage Caco-2 cells in preference to vinblastine 
loading of Caco-2 cells for many studies during this thesis.  
P-glycoprotein induction using rifampicin exposure did not result in notable increase of 
rhodamine123 Bas-Ap transport.  
The presence of P-gp was further proven by complete blockage of rhodamine123 efflux 
transport when combined with of P-gp inhibitor, PSC 833 as shown in figures 3.6 to 3.8 
for interventions (Caco-2 RIF Caco-2 VIN and late passage Caco-2 cells).  
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Figure 3-6: Ap-Bas ( ) and Bas-Ap ( ) transport rhodamine123 alone (A) and combined 
with P-gp inhibitor PSC 833 (B) across Caco-2 RIF (N=3, Mean ± SEM) 
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Western blotting  
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Figure 3-7 : Ap-Bas ( ) and Bas-Ap ( ) transport rhodamine123 alone (A) and combined 
with P-gp inhibitor PSC 833 (B) across Caco-2 VIN (N=3, Mean ± SEM) 
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Figure 3-8 : Ap-Bas ( ) and Bas-Ap ( ) transport rhodamine123 alone (A) and combined 
with P-gp inhibitor PSC 833 (B) across P-80 Caco-2 cell monolayer (N=3, Mean ± SEM) 
A 
B 
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Relative abundance of P-gp transporters in different Caco-2 monolayers were 
determined using Western blot analysis.  
Western blot images for the expression of P-gp protein are shown in Figure 3.9; Lanes 
1 to 2: P-44 days 24 and 28, lane 3: P-44 Caco-2 RIF, lanes 4-6: Passage 83 day 21, 24 
and 28, lane 7-9: Caco-2 VIN days 21, 24 and 28 and lanes 11 and 12 are molecular 
weight marker and Hela cell Positive control.  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
  1       .2       3       .4       5        6       7        8        9       10      11 
   
P-gp  
(170 kDa) 
 
β-Actin  
(42 kDa) 
Figure 3-9: Western blot analysis for MDR1 P-glycoprotein (170kDa) and beta-actin (42 kDa) 
for 3 Caco-2 cell models. Lanes 1 to 2: P-44 days 24 and 28, lane 3: P-44 Caco-2 RIF, lanes 4-
6: Passage 83 day 21, 24 and 28, lane 7-9: Caco-2 VIN days 21, 24 and 28 and lanes 10 and 11 
are molecular weight marker and Hela cell Positive control respectively 
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The highest P-gp expression was observed for day 24 Caco-2 VIN model (Lane 9) and 
highest P-gp expression for P-83 Caco-2 cells were observed for day 28 (Lane 7). The 
day 24 P-gp levels for Caco-2 VIN cells were 3 fold higher compared day 21 P-83 Caco-
2 cells (Figure 3.10). This was consistent with rhodamine123 efflux ratios observed (4.7 
for P-80 and 13 for Caco-2 VIN model) for 2 cell models. P-44 cells and Caco-2 RIF 
gave faint bands for P-gp and were unable to quantify.   
Western blotting images further confirmed that the late passage Caco-2 cell lines and 
cells exposed to increasing concentration of vinblastine were better models to determine 
P-gp mediated drugs transport compared to the early passage Caco-2 cell lines.  
Early passage Caco-2 cells were used for initial drug transport studies and the study was 
repeated using late passage Caco-2 cells.  
Drug transport of antimalarials was studied using Caco-2 VIN and Caco-2 RIF models 
for further confirmation of results as necessary.  
Figure 3-10 : Expression of P-gp over day 21 to 28 for P-44 cells and 3 cell models [1-2 
(P-44), 3 (Caco-2 RIF), 4-6 (P-83 caco-2), 7-9 (Caco-2 VIN)] 
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3.5 Discussion 
In-vitro Caco-2 cell monolayers are the most widely used epithelial cell model for drug 
transport studies. Caco-2 cells have some advantages over other cell lines that form tight 
junctions such as the canine cell line, MDCK, which is transfected with human MDR1. 
Unlike the Caco-2 cells, the MDCK cell line is not of human origin and requires 
maintenance of high P-gp levels and tight junctions using selection pressures. Further, 
these transfected MDCK cell lines require a usage agreement with the laboratories that 
created them as they are modified cells and can also be time consuming to create de 
novo.  Whereas Caco-2 cells are commercially available from ATCC and a good 
correlation is established between ABC transporter protein expression of in-vitro Caco-
2 cells and in-vivo jejunum (372). Most importantly, the column shape and microvilli 
architecture of the Caco-2 cells allow good in-vivo and in-vitro correlation, which 
enables good predictions of in-vivo drug absorption from in-vitro apparent permeability 
values (372, 420, 421, 449).  
The main limitation noted for use of Caco-2 cells is its heterogenic nature between labs 
and within each lab (416). These changes could be cell characteristics in relation to the 
passage number and the culturing condition within and between laboratories. Hence to 
minimise variability, consistent cell culture conditions were adopted in our laboratory 
and maintained throughout the current study. Cells were passaged upon 90% confluency 
to obtain maximum P-gp expression.   
The passage 18 cells obtained from the ATCC for the study had little functional P-gp 
expression and had poorer tightness between cells. Therefore labs considering Caco-2 
bidirectional efflux studies to examine P-gp substrates activity of drugs are likely to get 
leaky monolayers (low TEER) and low expression of P-gp at the time of test if they use 
low passage number Caco-2 cells.  
There is some evidence in the literature supporting this. For instance, a bidirectional 
transport study examining peptidomimetics using passage 35-50 cells concluded that 
the drugs themselves were not P-gp substrates as their transport was equivalent in both 
directions (450). Similarly, high cell uptake for cephalosporin antibiotics were reported 
in passage 37 Caco-2 cells (451). While our data suggests that P-gp in early passage 
Caco-2s may not have been as active compared to late passages, potentially masking 
any real P-gp mediated efflux. Other groups that have used low passage number Caco-
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2 monolayers have focused on permeability characteristics that have little to do with 
active efflux proteins. (452, 453), and such data would be expected to be relatively 
consistent irrespective of the passage used.  
In this study, three interventions; Caco-2 RIF, Caco-2 VIN and continuous passaging 
were adopted to improve P-gp expression of early passage Caco-2 cells. Upon 
development of the models, cell characteristic were studied visually by Western blotting 
technique and functionality of the P-gp was monitored by a bidirectional transport study 
of a known P-gp substrate, rhodamine123. Passage 41 cells were used as the baseline 
cells. 
The very low passage Caco-2 cells obtained from ATCC were continuously passaged. 
The Caco-2 cells grown for three weeks on filter inserts reached TEER values between 
250 to 350 ohm.cm2 for passage 20-25 and 300 to 500 ohm.cm2 for passage 44s. This 
was one of the primary reasons for continuous passaging of Caco-2 after acquisition 
from ATCC. The continuous passaging enabled tighter monolayers with higher TEER 
(600-800 ohm.cm2) on millicell inserts for late passage Caco-2 cells (passage 80). A 
change in P-gp expression was also observed over 40 passages of Caco-2 cells, Ap-Bas 
transport of rhodamine123 was altered in late passage cells (P80+) compared to earlier 
passages ( < P 40s). The early passage cells had high cell uptake of rhodamine123 
(2.2×10-6 cm/sec), and this dropped to 0.5×10-6 cm/sec for late passage cells. The 
change in rhodamine123 uptake could be attributed to increased expression of P-gp in 
late passage Caco-2 cell monolayer and formation of tighter monolayers. Passage 
number caused no significant differences in Bas-Ap transport of rhodamine123. 
However, the Ap-Bas changes were enough to increase the efflux ratio to 4.7 for P-80 
compared to 1.4 for passage 44 cells. Western blotting imaging and quantification 
showed a clear increase in P-gp expression in late passage Caco-2 cells (Figure 3.9). 
Thus in keeping with the current literature (416), an increase in the P-gp expression over 
40 passages was observed (not merely an increase in monolayer tightness) which would 
mostly affect the cell uptake of the potent P-gp substrate rhodamine123. Hence, it was 
important to study the bidirectional transport of a standard P-gp substrate (such as 
rhodamine123) at regular intervals with the increase in passages number (especially 
when the Caco-2 cells ordered from ATCC were at passage 18) (454).   
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A small increase in P-gp expression was also observed for P-80 cells over day 21, 24 
and 28 with the highest P-gp expression on day 28. This observation is consistent with 
the current literature where Hosoya and co-workers (445) observed a significantly 
higher P-gp expression on day 27 compared to day 17.  
P-gp induction properties by rifampicin have been shown before (455). However 
induction of P-gp expression using the P-gp inducer rifampicin did not alter the P-gp 
expression of P-44 cells to a notable level compared to those treated with normal media 
(The efflux ratio increased from 1.4 to 1.5) in the present study. The low passage Caco-
2 cells with inherently low P-gp expression might not have the capacity to upregulate 
P-gp expression following short term co-incubation (48 hours) with an inducer such as 
rifampicin. It is also likely that Pregnane X receptor, the target of rifampicin is expressed 
in low amounts in the nuclei of these cells. In a study of P-gp induction using grapefruit 
juice, a much lower upregulation of P-gp expression was observed in passage 30 to 40 
Caco-2 cells compared to MDCK-MDR1 cell lines. Similar to the present study, the P-
gp expression of Caco-2 could be due to the inherently low P-gp in early passage Caco-
2s. Hence, a short term induction model using P-gp inducer was of limited use. 
However, long term exposure of P-gp inducers were successful in the current study. In 
the third intervention, cells were exposed to a potent P-gp substrate, vinblastine (Caco-
2 VIN) at low levels for an extended period in increasing concentrations (10-50 nM) 
(419). The short-term culture method using differentiation medium suggested in 
Shirasaka and colleagues (419) was not adopted in the current study due to concerns 
regarding the cell monolayer tightness. This approach does not depend on Pregnane-X 
receptor but instead is a more chronic cell stress approach to force the cells to create 
more functional P-gp for their own survival. Out of the three models, Caco-2 VIN model 
showed the highest P-gp expression with an efflux ratio of 13. Low nanomolar 
concentrations of vinblastine used in the study were not found to be toxic to the cell 
monolayer despite the cytotoxic nature of the drug. However, use of higher cell numbers 
(100,000 cells/cm2 compared to 65,000 cells/cm2 for other intervention) was required 
when cells frozen in liquid nitrogen were seeded. The Caco-2 VIN cells reached required 
TEER levels which were maintained throughout the experiment. The Bas- Ap 
directional transport of rhodamine123 increased by about three fold. This was also 
visually apparent in Western blots where day 24 P-gp expression for Caco-2 VIN was 
three fold higher than the day 21 late passage Caco-2. Hence, the increase in efflux was 
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directly related to the increased P-gp expression. The Papp values for Ap-Bas directional 
transport of rhodamine123 was similar for both late passage Caco-2 cells and the Caco-
2 VIN model, hence having similar drug absorption values, while Caco-2 VIN increased 
the saturation threshold for the P-gp substrate of interest. This allowed identification of 
low affinity P-gp substrates.   
The early passage cells had comparatively lower P-gp expression; therefore this cell 
model is unlikely to be useful for identification of low affinity P-gp substrates. Further, 
extensive cell uptake could be observed for potent P-gp substrates.  However, the Ap-
Bas directional transport of passively permeable drugs will be minimally affected by the 
changes in P-gp expression in most instances. Thus, when P-gp was not likely to be 
involved and instead the cell monolayer only represented a physiologically relevant 
barrier that reflects physicochemical properties of the drugs, irrespective of early or late 
passages, the Caco-2 model exhibited similar results. Hence, the early and late passage 
Caco-2 cell models compared well to determine the passive permeability of 
antimalarials not shown to be P-gp substrates. 
 
3.6 Limitations  
The up-regulation of P-gp expression was determined by Rh123 transport and Western 
blotting. Molecular level confirmation based on PCR would have added increased 
validity and provided the molecular basis.  
Further passaging of late passage (> P- 80) Caco-2 cells and Rh123 transport studies on 
these cells would have been helpful to further confirm the results. 
The comparison of Caco-2 cell models with other in-vitro cell models such as MDCK 
MDR1 cells lines would have increased the validity, but this cell line was not 
commercially available. 
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3.7 Conclusion  
A clear change in P-gp expression was observed over 40 passages of Caco-2 cells. A 
significantly higher P-gp expression was observed in the late passage Caco-2 cells and 
was suitable to use as a cell model for identification of the P-gp mediated drug transport 
of antimalarials. Exposure of Caco-2 cells to the P-gp inducer, rifampicin did not result 
in a notable increase in the P-gp efflux of rhodamine123. The Caco-2 VIN model had 
the highest P-gp expression and can function as an in-vitro model to identify P-gp 
substrates with low affinity for P-gp. Both early and late passage Caco-2 cells are 
suitable to determine the passive permeability of a drug. 
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4 Antimalarial transport studies  
 
4.1 Rationale 
The antimalarials drugs are administered orally in single and combination therapy for 
the management of uncomplicated Plasmodium falciparum malaria.  
Development of drug resistance is a major problem in the management of malaria and 
there are reports of increased resistance for current artemisinin combination therapies. 
Antagonistic pharmacokinetic interactions are possible in antimalarial combination 
therapy and this could be drug absorption related. Hence it is important to look at the 
drug permeability and P-glycoprotein mediated transport of available antimalarial 
drugs. Clear evidence of the pharmacokinetics of antimalarials helps in the design of 
optimum dosage regimens which indirectly helps in combating the development of drug 
resistance in antimalarial therapy.   
P-gp drug interactions result from concurrent administration of P-gp substrates and 
inhibitors. Pre-exposure to P-gp inducers could lead to decrease in absorption of a P-gp 
substrate. This could be a potential issue especially in antimalarial therapy as 
antimalarials are recommended to be administered in combinations. In Africa and South 
East Asia where malaria is endemic the probability of patients receiving antimalarial 
therapy, while being on other medications, is high. For example, many antivirals used 
in HIV antiretroviral therapy are identified as P-gp substrates and concurrent 
administration of antiviral and antimalarial drugs (77, 78, 173) with P-gp inhibitory 
properties can result in an unexpected increase in systemic availability of the P-gp 
substrate.  
The literature on P-gp substrate and inhibitory actions of antimalarials is limited and no 
or little information of this relates to combination therapy. Artesunate and 
dihydroartemisinin are artemisinin derivatives used in the combination therapy of 
malaria. However artesunate is costly to manufacture (64) and its active metabolite 
dihydroartemisinin can cause neurotoxicity (68, 69). There are also reports of drug 
resistance developing for these derivatives (456). In order to address these issues of the 
currently available artemisinin derivatives, a new artemisinin derivative, artemisone, 
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has been introduced. The drug permeability and P-gp mediated drug transport of 
artemisone is not available for either single or combination therapy. It is proposed that 
artemisone can be given in combination with long acting quinolone derivatives such as 
amodiaquine and mefloquine (70). Thus it is important to determine the permeability of 
artemisone in single therapy in order to establish whether the permeability of artemisone 
would be altered in combination therapy.  
Methylene blue in the treatment of malaria has been revisited and clinical trials have 
found superior efficacy of methylene blue plus amodiaquine therapy compared to 
artesunate plus amodiaquine therapy (145). Methylene blue can be administered both 
orally and intravenously. Similar to artemisone, permeability data and the P-gp substrate 
or inhibitory action of methylene blue has not been reported. It is important to determine 
the drug permeability and possible P-gp mediated drug interactions of methylene blue 
to optimize dosing in patients.  
The literature on P-gp inhibitory properties of artesunate is conflicting. In two in-vitro 
studies, artesunate at 100 µM, 200 µM and 1 mM has shown P-gp inhibitory properties 
(440, 457). In contrast to this another study claimed lack of P-gp inhibitory properties 
of artesunate (439). Thus additional literature on P-gp inhibitory properties would be 
valuable. 
Drug permeability data for mefloquine and artesunate has not been reported.  
Literature on the permeability and P-gp substrate and inhibitory properties of 
antimalarial drugs is incomplete. There is some information on one or more of these 
properties for the four drugs; mefloquine, amodiaquine, artesunate and 
dihydroartemisinin. However, available studies discuss only the inhibitory properties of 
antimalarials in single therapy. There are no reports on these properties in antimalarial 
combination therapy to date, and this would be a valuable addition to the current 
literature. 
Regulation of P-gp expression of antimalarials has been published for artemisinin; 
however this information is not available for artesunate, artemisone, amodiaquine and 
mefloquine. Similarly P-gp regulation in artemisinin combination therapy has not been 
reported in the literature to date. Up regulation of P-gp transporter protein can result in 
decreased systemic exposure of P-gp substrates subsequently administered, which can 
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lead to loss of pharmacological activity of a drug, treatment failure and eventually drug 
resistance.  
In this context it was aimed to determine permeability and P-gp mediated drug transport 
of antimalarials in single and combination therapy using in-vitro Caco-2 based cell 
model.  
 
4.2 Specific Objectives  
To establish analytical techniques for quantification of anti- malarial drugs (artesunate, 
artemisone, mefloquine, amodiaquine and methylene blue) in the laboratory.  
To determine the inhibitory properties of anti-malarial drugs against P-gp mediated drug 
efflux.  
To determine drug permeability and the potential involvement of MDR1 P-gp mediated 
drug efflux of antimalarials. 
To determine the role of antimalarial drugs in the regulation of MDR1 P-gp transporter 
expression. 
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4.3 Methods 
4.3.1 P-gp inhibitory properties of antimalarials  
The P-gp inhibitory properties of single and combination therapy antimalarials were 
studied at 100 and 300 µM concentration. Antimalarials were combined with the known 
P-gp substrate, 5 µM rhodamine123, and change in efflux transport of rhodamine123 
was studied. As mentioned above, the maximum concentration tested was 300 µM due 
to solubility limitations and possible toxicity of the drugs on the cell monolayer at higher 
concentrations.  
The early and late passage Caco-2 cell lines were used to test the inhibitory properties 
of the antimalarials.   
Rhodamine123 levels were quantified using fluorescence detection and method 
described in 3.4. See Figure 3.3 for normal calibration curve for rhodamine123. 
However when rhodamine123 was co-incubated with methylene blue a reduction in 
rhodamine123 absorbance was observed at high concentrations. Therefore 
rhodamine123 standard curve for determination of rhodamine123 for efflux for 
methylene blue and rhodamine123 co-incubation study was done by serial dilution of 
rhodamine123 and methylene blue stock sample (10 µM each) (Figure 4.1). 
 
4.3.1.1 Assay of rhodamine123 in the presence of methylene blue  
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4.3.2 Drug permeability and P-gp substrate of antimalarial drugs  
The permeability and P-gp substrate activity of antimalarials in single and combination 
therapy were studied at 10, 20 or 100 µM. Methylene blue transport was studied at 100 
µM as 10 µM resulted in low recovery due to high percentage cell accumulation of 
methylene blue. Artesunate test dilutions were prepared at 100 µL due to drug 
degradation to its metabolite dihydroartemisinin. The study was initially designed to 
study the permeability activity of antimalarials 10 µM (low concentration) and 100 µM 
(high concentration). However the lower concentration of 10 µM was increased to 20 
µM for later studies to increase the recovery of drugs in the system, and thus, improve 
reliability of the results. 
The permeability and P-gp substrate activity was determined by studying the bi-
directional (Ap-Bas and Bas-Ap) transport of antimalarial drugs. P-gp substrate activity 
or P-gp mediated efflux transport of antimalarial was confirmed by combining the drug 
with known P-gp inhibitor, PSC 833. Full or partial inhibition of efflux transport by PSC 
833 suggested the presence of P-gp mediated drug efflux.  
Figure 4-1 : Calibration curve for rhodamine 123 in the presence of methylene blue for 
concentration range A1) 0- 160  nM, A2) 160- 3000 nM for 70 µL and B1) 0- 160  nM,  B2) 
160- 3000 nM  for 120 µL 
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4.3.3 Drug transport studies  
Bidirectional transport studies of antimalarials were conducted based on the method 
described in 3.3.6.1.1. The transport experiments were repeated in at least two 
concentrations.  The permeability tests of methylene blue were performed in 10 and 100 
µM (however due to lower recovery at 10 µM, the results are not shown in the thesis).  
Samples were collected at 30, 60, 90 and 120 minutes (triplicates, N=3 for each sample 
point) for both Ap-Bas and Bas-Ap directional transport. The TEER values were 
measured just before and at the completion of the experiment. The experimental results 
were considered valid only if the TEER was maintained > 300 Ω.cm2 throughout the 
experiment. Passive permeability and absence of paracellular permeability was based 
on > 300 Ω.cm2 TEER values before and throughout the experiments. The apparent 
permeability (Papp) value of 3 well plates (N=3) were determined for each direction and 
mean ± standard error of mean values are presented as the bidirectional transport values 
of study drugs. 
Amodiaquine, mefloquine and methylene blue drug samples were assayed using HPLC 
techniques and artesunate, artemisone and dihydroartemisinin were assayed using 
LCMS-MS techniques.  
 
4.3.4 Assays of mefloquine, amodiaquine and methylene blue  
4.3.4.1 HPLC instrumentation and chromatographic conditions  
All three drugs were assayed using High Performance Liquid Chromatography (HPLC) 
techniques. The analysis was performed using Agilent 1200 series HPLC consisting of 
binary gradient pump with a degasser, auto sampler, a thermostated   column oven and 
a duel wave length UV detector (Agilent Technology, Waldbronn, Germany). 
Chemstation software version, Rev. B. 03.01.SRI was used to process data (Agilent 
Technology, Waldbronn, Germany).  
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4.3.4.2 Development of calibration curves for mefloquine, amodiaquine 
and methylene blue 
All authentic standard curves were prepared at the concentration of 20 mM in ethanol, 
aliquots and stored at -80 ºC. Working standard solutions were prepared by serial 
dilution in HBSS from the primary stock regularly. Standard curves were prepared in 
HBSS as the analytical samples were dispersed in HBSS. Two separate calibration 
curves were constructed for lower and higher concentration ranges of each drug. 
 
4.3.4.2.1 Assay of mefloquine  
Assay of mefloquine was adopted from Davis and colleague (458) with slight 
modifications. Drug transport study samples obtained at different time points were 
collected in HPLC vials and stored at – 80 ºC. Samples were in HBSS solution and did 
not require further extraction; therefore analysis was carried out without including an 
internal standard. Separations were performed using an Apollo C18 (5 µm, 4.6x150mm) 
column attached to an Apollo C18 (5 µm, 4.6x5.5 mm) guard column. The mobile phase 
consisted of KH2PO4 (w/v 20 mM) in deionized water (42% v/v) adjusted to pH 3.0 
using H3PO4 and acetonitrile (58:42). The injection volume was 40 µL.  The mobile 
phase was pumped at 1 mL/min and the analytes were detected at UV absorbance 222 
nm. The column oven was maintained at 35 ºC. Retention time for mefloquine was 5.6 
minutes. Peak area was used for quantification. The limit of detection and 
quantifications were 10 and 20 nM respectively. Inter and intra batch coefficient of 
variation for mefloquine was 1.0, 2.9 and 3.6% and 12.5, 8.0 and 10.8 % for 10, 1 and 
0.1 µM respectively. The calibration curves for lower (a) and higher (b) concentration 
range are given in Figure 4.2. 
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4.3.4.2.2 Assay of amodiaquine  
Assay of amodiaquine was done based on a method by Pussard and co-workers (459) 
and slight modifications were done to adjust laboratory conditions. Separation was done 
using a Prevail C18 (3 µm, 4.6x150mm) column attached to a Direct-connect
TM universal 
column prefilter. The mobile phase consisted of 20 mM (w/v) KH2PO4 in deionized 
water with pH adjusted 3.0 and acetonitrile (82:18) v/v. The injection volume was 40 
µL and the mobile phase was pumped at 1 mL/min. The analytes were detected at UV 
absorbance 343 nm and column oven was maintained at 30 ºC. The retention time was 
2.4 minutes. The limit of detection and quantifications were 2.2 and 5 nM respectively. 
The intra batch coefficient of variation for amodiaquine was 4.3, 3.6 and 10.9 % for 10, 
1 and 0.1 µM respectively. 
 
 
 
 
 
 
Figure 4-2 - Calibration curve for mefloquine A) Lower concentration range (0.02- 1 µM) 
and B) Higher concentration range (1 -100 µM)   
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4.3.4.2.3 Assay of methylene blue  
Methylene blue assay was based on a method by Peter and colleagues (151) and similar 
to mefloquine and amodiaquine some modifications were done to suit the laboratory 
conditions. Drug samples in HBSS collected at different time points stored in -80 ºC 
were thawed and centrifuged before the assay. 
Separations were performed using Apollo C18 (5 µm, 4.6x150mm) column attached to 
an Apollo C18 (5 µm, 4.6x5.5mm) guard column. The mobile phase consisted of 60% 
20 mM (w/v) KH2PO4 adjusted to pH 3 using H3PO4, 35% acetonitrile and 5% methanol 
and was pumped at 1 mL/min. The injection volume was 40 µL and the analytes were 
detected at 660 nm in the visual spectrum. The column oven was maintained at 30 ºC. 
The retention time for methylene blue was 3.8 minutes and peak area was used for 
quantification. The limits of detection and quantification were 1.2 and 3 nM 
respectively. The inter and intra batch coefficient of variation was 2.1% and 4.0% for 
10 µM, 0.4% and 6.9% for 1 µM and 3.3% and 12.3 % for 0.1 µM. 
 
 
Figure 4-3 - Calibration curve for amodaiquine A) lower concentration range  0.025 - 1 
µM and B) higher concentration range (1-100 µM) 
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Figure 4-4 - Calibration curve for methylene blue A) lower concentration range  0.025 - 1 
µM and B). higher concentration range (1-100 µM) 
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4.3.4.2.4 Simultaneous assay of methylene blue and mefloquine  
Similar assay techniques based on Peter and colleagues (151) for methylene blue was 
used for simultaneous determination of mefloquine and methylene blue.   
Separations were performed using an Apollo C18 (5 µm, 4.6x150mm) column attached 
to an Apollo C18 (5 µm, 4.6x5.5mm) guard column. The mobile phase consisted of 60 
% 20 mM (w/v) KH2PO4, 35% acetonitrile and 5% methanol adjusted to pH 3 using 
H3PO4  and was pumped at 1 mL/min.. The injection volume was 40 µL and the 
mefloquine and methylene blue peaks were detected at 222 nM UV and 660 nm visual 
spectrums respectively. The column oven was maintained at 30 ºC. The retention time 
for methylene blue and mefloquine were 3.8 and 12 minutes respectively. The peak area 
was used for quantification. The limit of detection and quantifications were 2.2 and 4.7 
nM for methylene blue and 2.0 and 6.3 nM for mefloquine respectively.  
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Figure 4-5 : Calibration curve for mefloquine a) lower concentration range  A). 0.02 - 1 
µM and B). higher concentration range (1-100 µM) 
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Figures 4.5 and 4.6 are the calibration curves for mefloquine and methylene blue when 
both drugs were detected simultaneously. The intra batch coefficient of variation was 
5.9 %, 3.5% and 1.7% for methylene blue and 9%, 5% and 1.8% for mefloquine for 0.1, 
1 and 10 µM respectively.  
 
 
 
Figure 4-6 – Calibration curve for methylene blue for A) lower concentration range  0.02 - 1 
µM and B) higher concentration range (1-100 µM) 
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4.3.4.3 Assay of artesunate, dihydroartemisinin and artemisone using 
liquid chromatography and mass spectrometry (LC-MS-MS) drug 
Assay 
 
4.3.4.3.1 Sample preparation for LC-MS-MS 
Artesunate, artemisone and dihydroartemisinin sample from Caco-2 studies were 
collected in HBSS which contained salts; sodium chloride, potassium chloride, calcium 
chloride, potassium phosphate monobasic, disodium phosphate, magnesium sulphate, 
and sodium bicarbonate. Salt removal was necessary for assay of drugs using LC-MS-
MS. Agilent Bond Elute OMIX 96 C4 pipette tips contained a small bed of reversed 
phase or ion-exchange monolithic sorbent inserted into the pipette tip. This reversed 
phase resin is effective in salt removal and recommended to use prior assay using LC-
MS-MS.  
Therefore Agilent Bond Elute OMIX 96 C4 100 µL pipette tips were used for salt 
removal. A constant volume of 40 µL of sample was spiked with 5 µL internal standard 
from stock 0.5 mM artemisinin. The sample was pre-treated with 4 µL of 1 % 
trifluoroacetic solution by pipetting in and out numerous times. 
The pipettor was adjusted to the maximum volume (100 µL).  The tips were conditioned 
by aspirating and discarding a conditioning solution made up of 50 % acetonitrile and 
water. This step was repeated twice. Following this, an equilibration process was 
performed, in which washing solution (0.1% trifluoroacetic acid) was aspirated and 
discarded two times. These tips were used for removing salts from the pre-treated 
samples using the protocol as described.  
Pre-treated samples were loaded into the above processed tips by gently aspirating and 
discarding into the same vial. The process was repeated 10 times in order to increase 
binding efficiency of drugs to the OMIX 96 C4 matrix. The tips were washed with 
washing solution (0.1% TFA) by aspiration and discarding four times. The samples were 
then eluted in 100 µL of the elution solution (0.1% formic acid in 95% acetonitrile). 3 
µL of the sample was injected into the LC-MS.   
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4.3.4.3.2 Mass spectrometry 
The UPLC-MS-MS system consisted of Nexera UPLC (LC-30A), degasser (DGU-
20A5), autosampler (SIL-30A) and column oven (CTO-30A) coupled with a Shimadzu 
triple Quadrupole Mass Spectrometer (model 8030 Shimadzu, Kyoto, Japan). Electro 
Spray Ionisation (ESI) and Atmospheric Pressure Chemical Ionisation (APCI) interfaces 
were included in the system. 
 
4.3.4.3.3 Assay of artesunate and dihydroartemisinin  
Artesunate and dihydroartemisinin were measured by previously described LC-MS 
method by Salman and co-workers (44) but modified to suit LC-MS-MS conditions. 
Chromatographic separation was performed on a Waters Acquity BEH C18 column (1.7 
µm, 2.1 x 50mm) connected with VanGuard Acquity UPLC BEH C18 pre-column (1.7 
µm, 2.1 x 5mm) (Waters Corp, Wexford, Co. Wexford, Ireland) at 40 ºC.  Mobile phase 
A consisted of 0.1 % v/v formic acid and mobile phase B consisted of acetonitrile + 
0.1% v/v formic acid. The analytes were eluted using the following gradient given 
below.  
Time (min)       Solvent A (%)   Solvent B (%) 
0.5 70 30 
3 5 95 
4 5 95 
4.1 70 30 
6 Stopped   
 
The retention times for α and β DHA were 2.2 and 2.4 min, respectively. The retention 
time for Artesunate was 2.48 min and the retention time for Artemisinin was 2.65 
minute. Quantitation was performed in multiple reactions monitoring (MRM) mode, 
using DUIS (ESI+ and APCI+) ion sources. The Precursor-product ion pairs were as 
follows: DHA α and β m/z 267→249.3; Artesunate m/z 401.8→267.3 and Artemisinin 
m/z 283→265. The optimized mass spectra were acquired with an interface voltage of 
4.5kV, a detector voltage of 1.0 kV, a heat block temperature of 500 ºC and a desolvation 
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temperature of 160 ºC. Nitrogen was used as the nebulizer gas at a flow rate of 3 L/min 
and drying gas flow was maintained at 8 L/min. Argon was used as collision gas at 230 
Kpa. Dwell time for all the compound were 100 msec. Collision energy for α and β DHA 
was -7.2 and the collision energy for artesunate and artemisinin were -11.3 and -9.2, 
respectively. Limit of quantification and limit of detection for artesunate were 0.14 and 
0.05 µM respectively. The intra batch variation for 0.5, 5 and 20 µM of artesunate was 
3.7%, 6.7 % and 5.4 %. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 - Calibration curve for artesunate A) lower concentration range  0.04 - 1 
µM and B) higher concentration range (1-50 µM) 
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Transport of dihydroartemisinin across the Caco-2 monolayer   
Transport of dihydroartemisinin across the Caco-2 cell monolayer was calculated by the 
percentage of the peak area of the receiver compartment divided by the peak area of the 
donor compartment at the last time point.  
Percentage transfer =
Peak area ratio receiver compartment 
Peak area ratio donor compartment 
× 100 
The percentage transport of the dihydroartemisinin was compared to the percentage 
transfer of the prodrug, artesunate.  
 
4.3.4.3.4 Assay of artemisone  
Artemisone assay was based on the LC-MS method described by Manning’s group 
(460) and modified to suit the LC-MS-MS conditions in our laboratory. 
Chromatographic separation was same as described above with minor modification of 
gradient steps:  
Time(min) Solvent A (%)   Solvent B (%) 
0.3 50 50 
3 5 95 
3.5 5 95 
3.6 50 50 
5 stopped  
 
The retention time for artemisone was 1.96 min and the retention time for the internal 
standard artemisinin was 1.71 min. Quantitation was performed in multiple reactions 
monitoring (MRM) mode, using ESI+ interface. The Precursor-product ion pairs were 
as follows: artemisone m/z 402.17→163.4 and artemisinin m/z 283→265. The 
optimized mass spectra were acquired with an interface voltage of 4.5 kV, a detector 
voltage of 1.0 kV, a heat block temperature of 300 ºC and a desolvation temperature of 
180°C. Nitrogen was used as the nebulizer gas at a flow rate of 3 L/min and drying gas 
flow was maintained at 12 L/min. Argon was used as collision gas at 230 Kpa. Dwell 
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time for all the compound were 100 msec. Collision energy for artemisone was -21 and 
the collision energy for artemisinin was -9.1. Limit of quantification and limit of 
detection for artemisone were 0.01 µM and 0.004 µM respectively. Intra batch 
coefficient of variation was 1.2%, 4 % and 2.2% for 0.1, 1 and 20 µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4-8: Calibration curve for artemisone A) lower concentration range  0.04 – 1 µM 
and B) higher concentration range (1-100 µM) 
A. 
B. 
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4.3.5 Determination of P-gp regulation in the presence of 
antimalarials  
Late passage Caco-2 cells (Passage 80-83) and LS174T cells at 10,000 cells/cm2 (P-66) 
were seeded on to 6 well plates. Cell suspension (1.5 mL) prepared (at 62,000 cells/ mL) 
in cell growth medium was added on to the 9.3 cm2 6 well plates and medium was 
replaced twice weekly. 
Caco-2 cells were grown for 21 days for full maturation and formation of tight cell 
monolayer and LS174 T cells were grown for 6 days. Drugs and drug combinations 
prepared in cell growth medium were added to the cells at these times and exposed for 
48 (LS174 T) or 96 (Caco-2) hours.  
Caco-2 monolayers were unable to withstand 100 µM drug concentrations for 96 hours 
and lifted from the plate (mefloquine and amodiaquine are found to be more toxic to 
Caco-2 cells), therefore induction studies were done at 20 µM for 96 hours. Drugs used 
were artesunate, dihydroartemisinin, artemisone, mefloquine, amodiaquine and 
methylene blue as a single drug and drug combinations were artesunate plus 
amodiaquine, artesunate plus mefloquine, dihydroartemisinin plus amodiaquine, 
dihydroartemisinin plus mefloquine, dihydroartemisinin plus amodiaquine, 
dihydroartemisinin plus mefloquine, artemisone plus amodiaquine and artemisone plus 
mefloquine.   
Artemisinin derivatives, artesunate and artemisone were found to be toxic to LS174T 
cells (unlike Caco-2 cells) and could not be exposed up to 96 hours. Therefore exposure 
was limited up to 48 hours at 20 µM.  
After drug exposure, cells were washed three times using PBS and cell lysate was 
prepared as described in 3.3.6.2.2. The protein content was quantified using Lowry 
protein assay and regulation of P-gp was determined using Western blotting. Up 
regulation of P-gp was determined comparing Western blot images for treated and 
control samples.  
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4.4 Results  
4.4.1 Inhibitory properties of anti-malarial drugs against P-gp 
mediated drug efflux 
Bidirectional transport of rhodamine123 alone and in combination with antimalarials 
were studied to determine the ability of antimalarials to inhibit the P-gp activity. 
Relative inhibition of P-gp mediated drug efflux of rhodamine123 was determined to 
find the inhibitory properties of antimalarial drugs. The antimalarial drugs at 100 µM 
were combined with 5 µM rhodamine123 and bidirectional transport studies were done 
across passage 44 Caco-2 cell monolayers. Table 4.1 gives the apparent permeability 
values and efflux ratio for rhodamine123. 
 
Table 4-1: Apparent permeability (Papp ± SEM) for rhodamine123 (5 µM) alone and 
when combined with of antimalarial drugs (100 µM) across P-44 Caco-2 cell 
monolayers  
Drug  Ap-Bas 
(10-6 
cm/sec) 
Ap-Bas 
TEERc 
 
Bas-Ap 
(10-6 
cm/sec) 
Bas-Ap 
TEERc 
 
Efflux 
ratio 
Ap-Bas  
(P value)a 
Bas-Ap 
(P value)b 
Rh123  2.2 ± 0.1 333 3.2 ± 0.2 329 1.4   
Rh123+ PSC 2.3 ± 0.2 340 2.3 ± 0.1 399 1.0 0.83 0.05* 
Rh123 + MQ 2.1 ± 0.2 330 2.7 ± 0.1 358 1.3 0.55 0.12 
Rh123 + AQ 2.5 ± 0.1 304 3.6 ± 0.1 310 1.4 0.14 0.87 
Rh123 + MB 2.2 ± 0.2 356 3.8 ± 0.3 346 1.7 0.97 0.09 
Rh123 + AM 2.0 ± 0.0 325 3.5 ± 0.1 338 1.7 0.06 0.29 
aPapp Ap-Bas of rhodamine123 alone was compared with Ap-Bas of rhodamine123 in 
combination, bPapp Bas-Ap of rhodamine123 alone was compared with Bas-Ap of rhodamine123 
in combination * Significant at the level of P < 0.05, rh123: rhodamine123, PSC: PSC833, MQ: 
mefloquine, AQ: amodiaquine, MB: methylene blue, AM: artemisone, c The mean TEER value 
for 3 well plates before the test.  
 
The apparent permeability for Ap-Bas directional transport (cell uptake) was 2.24 × 10-
6 cm/sec whereas efflux transport (Bas-Ap) transport was 3.17 × 10-6 cm/sec. Therefore 
only a modest P-gp substrate activity was shown for known P-gp substrate, 
rhodamine123 with efflux ratio of 1.4. None of the antimalarials were able to exert 
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inhibitory properties similar to potent PSC 833 and was not able to inhibit rhodamine123 
efflux significantly when early passage Caco-2 cells were utilized for the study. As the 
efflux ratio was very small, it was likely that only strong inhibitors would be observable 
in such a weakly P-gp expressing system. This the study was repeated months later using 
late passage (P-80 to 83) Caco-2 cell monolayers with better native P-gp expression to 
observe inhibitory properties of less potent P-gp inhibitors (Table 4.2). 
 
Table 4-2:  Apparent permeability (Papp ± SEM) for rhodamine123 (5 µM) alone and 
when combined with of antimalarial drugs (100 µM) across P-80 Caco-2 cell 
monolayers  
aPapp Ap-Bas of rhodamine123 alone was compared with Ap-Bas of rhodamine123 in 
combination, bPapp Bas-Ap of rhodamine123 alone was compared with Bas-Ap of rhodamine123 
in combination * Significant at the level of P < 0.05, ** Significant at the level of P < 0.005, 
rh123: rhodamine123, PSC: PSC833, MQ: mefloquine, AQ: Amodiaquine, MB: methylene 
blue, AM: artemisone, cThe mean TEER value for 3 well plates before the test. 
 
The efflux ratios for rhodamine123 found to be 4-5 when transported through late 
passage Caco-2 cell. Mefloquine at 100 µM, inhibited the Bas-Ap transport of 
rhodamine123 significantly and efflux ratio was reduced by half (Figure 4.9). The Papp 
for Bas-Ap transport was reduced from 2.42 to 1.34 × 10-6 cm/sec with a significance 
Drug  Ap-Bas 
 (10-6 cm/sec) 
Ap-Bas 
TEERc 
 
Bas-Ap 
(10-6 cm/sec) 
Bas-Ap 
TEERc 
 
Efflux 
ratio  
Ap-Basa  
(P value) 
Bas-Apb 
(P value) 
Rh123  (P-80)  0.5 ± 0.1 624 2.4 ± 0.3 604 4.7   
Rh123+PSC 0.5  ± 0.1 711 0.5 ± 0.0 716 1.0 0.74 0.003** 
Rh123+MQ 0.5 ± 0.0 643 1.3 ± 0.1 755 2.3 0.64 0.02* 
Rh123+AQ 0.4 ± 0.0 531 2.4 ± 0.3 557 5.9 0.14 0.63 
Rh123+MB 0.4 ± 0.0 623    3.0 ± 0.3 617 6.7 0.24 0.21 
Rh123+ ART 0.5 ± 0.0 523 2.3 ± 0.3 613 5.2 0.32 0.88 
Rh123+ AM 0.5 ± 0.1 608 2.0 ± 0.1 610 4.3 0.54 0.28 
Rh123 + ART + MQ  0.5 ± 0.1 505 1.3 ± 0.1 614 2.4 0.81 0.02* 
Rh123 + AM + MQ  0.5 ± 0.0 519 1.5 ± 0.2 573 3.3 0.43 0.05* 
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level of P = 0.02. Amodiaquine, artesunate, mefloquine and artemisone did not exhibit 
P-gp inhibitory properties at 100 µM (Table 4.2).  
In addition, when mefloquine was combined with short acting artemisinin derivatives, 
artesunate and artemisone, the percentage of P.gp inhibition observed remained the 
same as when using mefloquine alone. This reaffirms the lack of inhibition by the 
artemisinin derivatives (Table 4.2 and Figure 4.10).  
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Figure 4-9: Ap-Bas ( ) and Bas-Ap (   ) transport of rhodamine123 alone and Ap-Bas ( ) 
and Bas-Ap (  ) transport of rhodamine123 when combined with mefloquine (N=3, Mean 
±SEM) 
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Figure 4-10:  Ap-Bas ( ) and Bas-Ap (  ) transport of rhodamine123 when combined with 
mefloquine and Ap-Bas ( ) and Bas-Ap (  ) transport of rhodamine123 when combined with 
mefloquine and artesunate (N=3, Mean ±SEM) 
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P-gp inhibitory properties of antimalarials other than mefloquine were further tested 
increasing the drug concentration up to 300 µM (Table 4.3). However no change in 
bidirectional transport of rhodamine123 was observed, indicating no involvement of P-
gp in these drug’s transport.   
 
 Table 4-3: Apparent permeability (Papp ± SEM) for rhodamine123 (5 µM) alone and 
when combined with 300 µM of antimalarials across P-82 Caco-2 cell monolayers 
aPapp Ap-Bas of rhodamine123 alone was compared with Ap-Bas of rhodamine123 in 
combination, bPapp Bas-Ap of rhodamine123 alone was compared with Bas-Ap of rhodamine123 
in combination, rh123: rhodamine123, PSC: PSC833, AQ: amodiaquine, MB: methylene blue, 
AM: artemisone, cThe mean TEER value for 3 well plates before the test. 
 
4.4.2 Determination of drug permeability and P-gp substrate activity 
of antimalarial drugs  
If the bidirectional transport study gives equivalent Papp in both Bas-Ap and Ap-Bas 
directions, this indicates equivalent transport of drug in both directions. Therefore 
transport ratio of efflux direction over uptake direction would give a value close to 1 
indicating no net flux in either direction. Then only diffusion has taken place and it 
would be unlikely for P-gp to be involved in transporting the drug out of the cell.  
When the Papp value for Ap-Bas direction is higher than the Bas-Ap direction, there is 
influx or cell uptake of the drug. Whereas when Papp for Bas-Ap directional transport of 
a drug is higher than the Ap-Bas directional transport, the serosal to mucosal directional 
transport is higher and there is less cell intake of drug indicating efflux transport of the 
drug. Incubation with a P-gp inhibitor such as PSC 833 would inhibit the efflux transport 
of the drug which confirms P-gp mediated drug transport.  
Drug  Ap-Bas 
 (10-6 cm/sec) 
Ap-Bas 
TEERc 
Bas-Ap  
(10-6 cm/sec) 
Bas-Ap 
TEERc 
Efflux 
ratio  
Ap-Bas a   
(P value) 
Bas-Ap b 
(P value) 
Rh123  (P-82) 0.5 ± 0.1 713 2.8 ± 0.6 798 5.7   
Rh123+ AQ 0.5 ± 0.1 614 2.6 ± 0.1 755 5.0 0.95 0.09 
Rh123+ ART 0.4 ± 0.0 608 2.9 ± 0.2 610 7.5 0.07 0.22 
Rh123+AM  0.5 ± 0.1 778 3.0 ± 0.1 795 5.6 0.70 0.24 
Rh123+MB  0.5 ± 0.0 665 2.9 ± 0.1 660 5.3 0.56 0.71 
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Previous research on drug permeability studies within the our laboratory has shown that 
drugs with a Papp value above 25 ×10
-6 cm/sec to have a high permeability and  would 
have complete drug absorption across much of the gut. Compounds with Papp less than 
1×10-6 cm/sec were considered to have a low permeability and will not achieve complete 
drug absorption (447, 449). The threshold values 1 and 25×10-6 cm/sec were used in 
determining the high, medium and low permeability of the drugs.  
 
4.4.2.1 Bidirectional transport of mefloquine  
Bidirectional transport of mefloquine was tested at the concentration of 10, 20 and 100 
µM using Caco-2 cell monolayers. Ap-Bas Papp values of mefloquine were found to be 
in the range of 6 to10 × 10-6 cm/sec and Bas-Ap directional transport ranged from 5 to 
11× 10-6 cm/sec (Table 4.4). At 10 µM an efflux ratio of 0.7 was observed, therefore 
instead of efflux a potential uptake pathway was noted. At tenfold higher concentration 
(100 µM) of mefloquine also showed little change in efflux value, further confirming 
that inherent physiological chemical properties of the drug defines the bidirectional 
transport of mefloquine. Certainly in later passages using 20 µM mefloquine indicated 
similar pattern in transport, showing absence of efflux transport for mefloquine (Figure 
4.11).  
 
 
 
 
 
 
 
Figure 4-11: Ap-Bas ( ) and Bas-Ap ( ) transport of mefloquine across late passage 
Caco-2 cells (N=3, Mean ±SEM)  
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When co-incubated with PSC 833, mefloquine bidirectional transport at 10 and 20 µM 
appeared to show very little difference from the values without co-treatment, suggesting 
that it was unlikely that multiple opposing mechanisms were at play when mefloquine 
was used alone. No net transport of mefloquine was found. Hence mefloquine is not 
subjected to P-gp mediated drug efflux at concentrations above10 µM.   
The current WHO recommended antimalarial combinations consist of a short acting 
artemisinin derivative and long acting quinolone. The two quinolones studied were 
mefloquine and amodiaquine and combination drug studies were mostly confined to 
mefloquine combinations. Bidirectional transport of mefloquine in combination with 
short acting artemisinin derivatives and intermediate acting methylene blue were 
studied. A first study was done for mefloquine and artesunate combinations at 10 and 
100 uM and the results are shown in Table 4.4. The transport velocity for Ap-Bas and 
Bas-Ap directional transport of mefloquine was not altered when combined with 
artesunate at low and high concentrations. Two combinations were also combined with 
PSC at 4 µM and this also did not alter the Papp values of mefloquine widely. 
Mefloquine was also combined with methylene blue and artemisone and two drugs in 
combination with mefloquine did not alter the bidirectional transport of mefloquine 
(Table 4.4).  
No change in apparent permeability of mefloquine with the co-treatment of PSC 833, 
artesunate, artemisone and methylene blue shows that mefloquine passive diffusion is 
unlikely to be altered by the co-treatment; therefore illustrate to the absence of 
permeability related drug interactions.     
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Table 4-4: Apparent permeability (Papp ± SEM) and efflux ratio for mefloquine through 
Caco-2 cell monolayer.   
a Studies were done using passage 44 Caco-2 cell lines, b Studies were done using passage 80 
Caco-2 cell lines c, d, power of the test was 0.5,  e ,f power of the test was  0.8,   g power of the test  
was 0.6, h Mean Papp for Bas-Ap direction was divided by the Ap-Bas direction, 
i Mean Papp of 
Ap-Bas direction and Bas-Ap direction transport  was compared in a two tailed t test to 
determine p values (N=3), MQ: mefloquine, PSC: PSC833, ART: artesunate, MB: methylene 
blue, AM: artemisone, j The mean TEER value for 3 well plates before the test. 
  
4.4.2.2 Bidirectional transport of amodiaquine  
Permeability and P-gp substrate activity of amodiaquine, derivative was determined at 
the concentration of 10 and 100 uM. The Papp values for both concentrations was found 
to be higher than mefloquine and ranged from 16 to 22 × 10-6 cm/sec in the Ap-Bas 
directions (Table 4.5).   
At 10 µM, amodiaquine showed an efflux ratio of 1.2 with a higher Bas-Ap transport, 
yet the efflux ratio was low and this is unlikely to represent even a moderate affinity for 
P-gp. At a higher concentration (100 µM) efflux become exactly 1 showing no net efflux 
transport.   
Drug  Con: 
(µM) 
Ap-Bas 
 (10-6 cm/sec) 
Ap-
Bas 
TEERj 
Bas-Ap 
(10-6 
cm/sec) 
Ap-
Bas 
TEERj 
Efflux 
ratioh  
Net flow 
direction          
(P valuei) 
MQa 10  9.9 ± 0.7 328 6.6 ± 0.4 350 0.7 In flux (0.02)c 
MQ + PSCa 10+4  11.0 ± 0.5 417 12.0 ± 1.0 429 1.0 No flux(0.4) 
MQa 100   8.9 ± 0.8 346 11.4 ± 0.8 409 1.2 No flux (0.08) 
MQ + PSCa 100+4 11.1 ± 0.1 442 12.4 ± 0.4 410 1.1 Efflux (0.04)d 
MQ + ARTa 10 +10 14.4 ± 1.2 360 8.6 ± 0.7 385 0.6 Influx(0.01)e 
MQ + ART+ PSCa 10+10 + 4 11.3 ± 0.1 390 9.3 ± 0.5 405 0.8 In flux(0.02)f 
MQ + ARTa 100 +100 8.4 ± 0.5 687 11.5 ± 2.1 706 1.4 No flux(0.23) 
MQ + ART+ PSCa 100 +100 + 4 10.2 ± 0.4 674 14.0 ± 1.1 643 1.4 Efflux(0.03)g 
MQ b 20b 5.8 ± 0.7 728 5.3 ± 0.9 660 0.9 No flux (0.66) 
MQ + PSC b 20+4 6.5 ± 0.4 671 7.6 ± 0.2 703 1.2 No flux (0.44) 
MQ+ MBb  50+100 8.1 ± 0.3 617 9.0 ± 1.1 629 1.1 No flux (0.79) 
MQ + AMb 50+20 6.7 ± 1.2 680 6.3 ± 0.6 720 0.9 No flux (0.49) 
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The high Papp values indicates high intestinal permeability of amodiaquine, therefore 
any slight efflux transport at lower concentration is unlikely to affect the extent of drug 
absorption of amodiaquine. 
 
Table 4-5: Apparent permeability (Papp ± SEM) and efflux ratio for amodiaquine 
through Caco-2 cell monolayer   
Drug  Con: 
(µM) 
Ap-Bas 
(10-6 cm/sec) 
Ap-Bas 
TEERc 
Bas-Ap 
(10-6 cm/sec) 
Bas-Ap 
TEERc 
Efflux 
ratioa  
Net flow 
direction  
(P valueb) 
AQ a 10  16.0 ± 1.1 423 21.5 ± 0.9 389 1.3 Efflux (0.02)* 
AQ a 100  22.5 ± 2.0 416 23.3 ± 0.8 390 1.0 No flux (0.74) 
AQ + PSC a  100  24.5 ± 2.0 418 26.7 ± 0.7 400 1.1 No flux (0.36) 
AQ + AM a 10+10 16.7 ± 0.7 431 18.3 ± 2.6 434 1.1 No flux  (0.52) 
a Studies were done using Passage 44 Caco-2 cells * Significant at the level of P < 0.05 a Mean 
Papp for Bas-Ap direction was divided by the Ap-Bas direction, 
b Mean Papp of Ap-Bas direction 
and Bas-Ap direction transport was compared in a two tailed t test to determine p values (N=3), 
AQ: amodiaquine, PSC: PSC833, AM: artemisone, c The mean TEER value for 3 well plates 
before the test.  
 
Amodiaquine permeability in combination with short acting artemisone was studied and 
the Papp values for amodiaquine in the presence of artemisone were 17 and 18 × 10
-6 
cm/sec for Ap-Bas and Bas- Ap directions respectively. Therefore amodiaquine 
bidirectional transport was not significantly affected, when combined with artemisone 
and thus it is unlikely to cause a clinically significant alteration in absorption of 
amodiaquine.   
Further testing of amodiaquine was not deemed necessary as high Papp values show that 
major proportion of the drug is clearly absorbed following passive diffusion ensuring 
almost 100 % drug absorption.  
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4.4.2.3 Bidirectional transport of methylene blue  
Methylene blue is an intermediate acting anti-malarial drug and clinical trials in the last 
few years have re-explored the use of methylene blue in anti-malarial therapy, reigniting 
earlier trials before the drugs of selective drug therapy in 1960s.   
Methylene blue (100 µM) transport across Caco-2 cell lines were first tested using 
passage 44 cells and the drug exhibited increased Bas-Ap transport with the efflux ratio 
of 2.6. The Papp values for Ap-Bas and Bas-Ap were 2.8 and 7.4 ×10
-6 cm/sec as shown 
in Table 4.6. The low Ap-Bas transport indicate low permeability of methylene blue.  
The study was repeated in Caco-2 RIF, Caco-2 VIN and on late passage Caco-2 cell 
monolayers in order to confirm possible P-gp mediated drug transport of methylene 
blue. All three studies had similar patterns with significantly higher transport in Bas-
Ap direction, showing possible efflux transport of methylene blue.  
 
Table 4-6:  Apparent permeability (Papp ± SEM) and efflux ratios for methylene blue 
transport through different Caco-2 cell models 
 
a Mean Papp for Bas-Ap direction was divided by the Ap-Bas direction, 
b Mean Papp of Ap-Bas 
direction and Bas-Ap direction transport  was compared in a two tailed t test to determine p 
values (N=3), c N=2, MB: methylene blue, PSC: PSC833, cThe mean TEER value for 3 well 
plates before the test.  
 
Drug  Cell line Ap-Bas 
 (10-6 cm/sec) 
Ap-
Bas 
TEERc 
Bas-Ap 
(10-6 cm/sec) 
Bas-
Ap 
TEERc 
Efflux 
ratioa 
Net Transport  
(P valueb) 
MB P-44 Caco-2 2.8 ± 0.1 438 7.4 ± 0.2 472 2.6  Efflux (<0.001) 
MB P-80 Caco-2 1.8 ± 0.1 620 7.3 ± 0.5 634 4.1 Efflux (<0.001) 
MB+PSC P-80 Caco-2 2.5 ± 0.1 612 5.5 ± 0.3 684 2.2 Efflux (<0.001) 
MB Caco-2 VIN 1.6 ± 0.1 720 8.3 ± 0.2 690 5.1 Efflux (<0.001) 
MB+PSC Caco-2 VIN 2.9 ± 0.4 690 5.3 ± 0.1 742 1.9 Efflux (<0.01) 
MB  Caco-2 RIF 2.6 ± 0.1 534 6.1 ± 0.2a 474 2.4 Efflux (<0.001) 
MB+PSC  Caco-2 RIF 3.0 ± 0.1 556 4.8 ± 0.3 488 1.6 Efflux (<0.01) 
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Caco-2 VIN model showed maximum efflux with an efflux ratio of 5.1 and Papp values 
for Ap-Bas and Bas-Ap directions were 1.6 and 8.3 ×10-6 cm/sec respectively. All tests 
had strong statistical strength having power of 1 for all tests.   
The drug was combined with a known P-gp inhibitor, PSC 833 and this resulted in 
increased Ap- Bas and decreased Bas-Ap transport of methylene blue for all three cell 
models. However PSC-833 was not able to block efflux transport of methylene blue 
completely suggesting involvement of gastrointestinal efflux mechanisms other the P-
gp mediated efflux transport. Figures 4.12, 4.13 and 4.14 show the change in 
bidirectional transport of methylene blue in the presence of PSC 833 for Caco-2 cell 
models.  
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Figure 4-12: Ap-Bas ( ) and Bas-Ap (  ) transport of methylene alone and Ap-Bas ( ) and 
Bas-Ap ( ) of methylene blue when combined with PSC 833 across late passage Caco-2 cell 
monolayer (N=3, Mean ±SEM) 
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Figure 4-13: Ap-Bas ( ) and Bas-Ap (  ) transport of methylene alone and Ap-Bas ( ) 
and Bas-Ap (  ) of methylene blue when combined with PSC 833 across Caco-2 VIN 
cell monolayer (N=3, Mean ±SEM)  
 
 
 
 
 
 
 
 
 
In all these figures the efflux was significantly greater than cell uptake direction. The 
inclusion of PSC-833 inhibited this efflux in all cases.  
Figure 4-14: Ap-Bas ( ) and Bas-Ap (  ) transport of methylene blue alone and Ap-Bas ( ) 
and Bas-Ap (  ) of methylene blue when combined with PSC 833 across Caco-2 RIF cell 
monolayer (N=3, Mean ±SEM) 
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4.4.2.4 Bidirectional transport of artesunate and dihydroartemisinin  
Bidirectional transport of artesunate at 100 uM was studied using test solution prepared 
from 20 mM stock samples frozen at -80 ºC. The zero time test sample indicated that 
part of the artesunate has converted to its metabolite dihydroartemisinin and both α and 
β anomers were detected.  
As shown in Table 4.8, the Bas-Ap transport of artesunate was higher compared to the 
Ap- Bas directional transport and the difference was significant. Efflux transport was 
observed again when the study was repeated. Efflux transport of artesunate was 
inhibited when combined with PSC 833 and mefloquine. However as indicated for 
amodiaquine such small increases in Bas-Ap transport or efflux will have negligible 
effect on systemic absorption. The Papp values for Ap- Bas and Bas-Ap directional 
transport for artesunate ranged from 8-11 × 10-6 cm/sec. This permeability range of 
artesunate places it in a medium category suggesting passive diffusion contributes to 
drug absorption of artesunate, although absorption is likely to be incomplete through the 
gastrointestinal tract.  
 
Table 4-7: Apparent permeability (Papp ± SEM) and efflux ratios for of artesunate 
through Caco-2 cell lines  
Drug  Ap-Bas 
 (10-6 
cm/sec) 
Ap-Bas 
TEERe 
Bas-Ap 
(10-6 cm/sec) 
Bas-Ap 
TEERe 
Efflux 
ratioc  
Net transport 
(P valued) 
ARTa  (50 µM) 7.2 ± 0.2 496 10.5 ± 0.5 477 1.5 Efflux (0.003) 
ARTa +MQ   (45 µM) 8.5 ± 0.2 497 9.4 ± 1.5 513 1.1 No flux (0.60)  
ART +MQ  + PSCa (45µM) 9.6 ± 0.5 514 10.2 ± 0.8 480 1.1 No flux (0.57) 
ART b (55 µM) 10.2 ± 0.3 705 12.3 ± 0.1 601 1.2 Efflux (0.002) 
ART + PSCb (60 µM) 5.9 ± 0.1 697 9.1 ± 1.1 668 1.5 No flux(0.05) 
a Stock solution was diluted to prepare 100 µM, however due to product conversion to 
dihydroartemisinin, the zero test concentration was in the range of 45- 50 µM and the study was 
done using P-44 monolayers. b Stock solution was diluted to prepare 100 µM, however due to 
product conversion to dihydroartemisinin, the test concentration was in the range of 55- 60 µM) 
and the study was done using P-80 monolayers, cMean Papp for Bas-Ap direction was divided by 
the Ap-Bas direction, d Mean Papp of Ap-Bas direction and Bas-Ap direction transport  was 
compared in a two tailed t test to determine p values (N=3), ART: artesunate, MQ: mefloquine, 
PSC: PSC833, e The mean TEER value for 3 well plates before the test 
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Apparent permeability of dihydroartemisinin was unable to be calculated due to absence 
of a separate standard curve. Therefore percentage of dihydroartemisinin and artesunate 
transferred across Caco-2 monolayer at the last time point were calculated and 
compared. The percentage of dihydroartemisinin (α and β anomers peaks were added 
together and peak area ratio of dihydroartemisinin to artemisinin were considered) 
passed across the Caco-2 monolayer at the last time point in the Ap-Bas direction ranged 
from 40 to 43 % and the percentage transfer in Bas-Ap directional ranged from 68 to 
76%. Whereas the percentage transferred for artesunate was lower in both the directions; 
Ap-Bas direction 11-14 % and Bas-Ap 18-22%. Therefore dihydroartemisinin has a 
better permeability across the Caco-2 monolayer compared to artesunate.  
 
4.4.2.5 Bidirectional transport of artemisone 
Artemisone is a newly investigated artemisinin derivative and drug permeability studies 
for artemisone were done at 10 and 20 µM. The net transport of artemisone was much 
higher than the other artemisinin derivatives tested. The Ap-Bas transport ranged from 
37 to 59 × 10-6 cm/sec and Bas-Ap transport ranged from 35 to 47 × 10-6 cm/sec (Table 
4.9). Therefore the new artemisinin derivative has a much higher passive diffusion than 
the currently used artesunate and dihydroartemisinin which ensured complete drug 
absorption. Addition of PSC-833 did not alter the bidirectional transport significantly; 
therefore artemisone is not subjected to P-gp mediated drug efflux transport. 
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Table 4-8: Apparent permeability (Papp ± SEM) and efflux ratios for artemisone 
through Caco-2 cell lines  
Drug  Con: 
(µM) 
Ap-Bas 
 (10-6 cm/sec) 
Ap-Bas 
TEERe 
Bas-Ap 
(10-6 cm/sec) 
Bas-Ap 
TEERe 
Efflux 
ratioc  
Net transport 
(P valued) 
AM a  10 59.64 ± 4.19 453 46.90 ± 8.52 380 0.79 No flux (0.25) 
AM b  20 36.96 ±4.70 664 34.66 ±2.67 659 0.94 No flux (0.69)  
AM+ PSC b  20 42.92±1.46 662 52.91±6.89 684 1.23 No flux (0.23) 
AM + MQ b 20+ 50  57.64± 7.89 695 57.95± 8.28 645 1.00 No flux  (0.98) 
a Passage 44 cell were sued to determine the bidirectional transport, b Passage 80 cell were used 
to determine the bidirectional transport, cMean Papp for Bas-Ap direction was divided by the Ap-
Bas direction, d Mean Papp of Ap-Bas direction and Bas-Ap direction transport was compared in 
a two tailed t test to determine p values (N=3), AM: artemisone, PSC: PSC833, MQ: mefloquine, 
e The mean TEER value for 3 well plates before the test.  
 
 
4.4.3 Antimalarial regulation of P-gp expression 
The regulation of P-gp in the presence of antimalarials in single and combination 
therapies was studied. The initial exposure was planned for 100 µM for 4 days, however 
it was not possible as Caco-2 cell monolayers became detached from the 6 well plates 
after about days exposure. The similar trend was observed for 50 µM exposure. 
Mefloquine and amodiaquine were found to be more toxic to Caco-2 cells than 
artemisinin derivatives.  Hence Caco-2 cell were exposed to 20 µM drug concentrations 
for 96 hours and protein showing Western blot images for Caco-2 cells are given in 
Figure 4.15. P-gp levels more than 1.5 fold of the control well was considered as the 
threshold level for up-regulation of the transporter protein. 
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Figure 4-16: Regulation of P-gp transporter protein compared to control following 96 
hours of antimalarials exposure  on confluent Caco-2 cell monolayer. 
 
Figure 4-15: Western blot for 96 hours exposure of antimalarials on Caco-2 cell monolayer. Beta 
actin was used as the reference protein. Lanes 1-15 were loaded with cell lysates of exposure 
1)methylene blue, 2)mefloquine, 3)amodiaquine, 4)artesunate, 5)dihydroartemisinin, 6)artemisone, 
7)0.5% ethanol, 8)artesunate plus mefloquine, 9)artesunate plus amodiaquine, 10)artemisone plus 
mefloquine, 11)artemisone plus amodiaquine, 12)dihydroartemisinin plus mefloquine, and 
13)dihydroartemisinin plus amodiaquine 14) molecular weight marker 15) transfected Hela MDR1 
positive control respectively 
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As shown in Figure 4.16, an up regulation of transporter protein for single drugs; 
methylene blue, amodiaquine, artesunate and dihydroartemisinin were observed. 
Artemisone and dihydroartemisinin in combinations with amodiaquine and mefloquine 
also resulted in up regulation of P-gp. However similar trends were not observed for 
artesunate combinations and no up regulation was observed for artesunate in 
combination with mefloquine or with amodiaquine.  
A similar study was done using LS174T cells and Figure 4.17 shows Western blot for 
cells. These cells were more sensitive to antimalarial drugs and especially artemisinin 
derivatives were found to be more toxic to LS174T cells compared to amodiaquine and 
mefloquine. The cells were exposed to drugs for 48 hours at 20 µM as longer exposure 
than that resulted in toxicity and cells death.   
 
 
 
 
 
Figure 4-17:  Western blot for 48 hours exposure of 10 µM antimalarials as single drug or 
combination on LS174T cells. Beta actin was used as the reference protein. Lanes   1-15 were 
loaded with cell lysates of exposure 1)methylene blue, 2)mefloquine, 3)amodiaquine, 
4)artesunate, 5)dihydroartemisinin, 6)artemisone, 7)0.5% ethanol, 8)artesunate plus 
mefloquine, 9)artesunate plus amodiaquine, 10)artemisone plus mefloquine, 11)artemisone plus 
amodiaquine, 12)dihydroartemisinin plus mefloquine, and 13)dihydroartemisinin plus 
amodiaquine, 14) Molecular weight marker 15) transfected Hela MDR1 positive control 
respectively. 
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Similar trends as of Caco-2 cells were observed for drug combinations and there was 
clear up regulation of P-gp for artemisone and dihydroartemisinin combinations. This 
trend was not observed for artesunate combination. Unlike what was observed in Caco-
2 cells, no up regulation of P-gp was observed for antimalarials in single therapy (Figure 
4.18).  
It is clear that artemisone and dihydroartemisinin in combination therapies created 
greater P.gp expression than using each drug alone.  
 
 
 
 
 
Figure 4-18:  Regulation of P-gp transporter protein compared to control following 20 µM  
antimalarials exposure  for 48 hours on LS174T cells.  
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4.5 Discussion 
4.5.1 Transport studies using the Caco-2 cell model 
In the present study the bidirectional transport of antimalarials was studied using both 
early and late passage Caco-2 cells with the exception of amodiaquine where only early 
passage cells were used for the study. To minimise the change in P-gp expression the 
transport studies were confined to Passage 44 of early passage cells and 80-83 of late 
passage cells. Caco-2 RIF models and Caco-2 VIN were also used to study the P-gp 
substrate activity of methylene blue in order to confirm the P-gp substrate activity.   
The threshold values 1 and 25×10-6 cm/sec established within our laboratory were used 
in determining the low and high permeability of the drugs with values around 10×10-6 
cm/sec defining medium permeability (447, 449). 
 
4.5.2 P-gp inhibitory action of antimalarial drugs  
Low P-gp expression in early passage Caco-2 cells would enable detection of only the 
potent P-gp blockers. No antimalarials exhibited such potent P-gp inhibitory properties 
and P-gp inhibition by antimalarials was not observed in early passage Caco-2 cells 
utilized in the study. Thus no antimalarials tested have affinity and potency similar to 
the second generation P-gp inhibitor, PSC 833 in exerting P-gp inhibitory properties. 
Late passage Caco-2 with higher P-gp expression allowed weaker P-gp inhibitors to 
become evident. Hence mefloquine became detectable.  Mefloquine inhibited the P-gp 
efflux at 100 µM and 50 % inhibition of Bas-Ap directional transport was observed and 
the Ap-Bas transport of rhodamine123 was not altered.  
Intravenous administration of mefloquine caused local irritation at the drug 
administration site and hence possible toxicity of the drugs (20, 96-98). This was also 
exhibited in in-vitro cell lines where at high concentration of mefloquine cells became 
detached and lifted from the bottom of the flask. Therefore inhibitory properties of 
mefloquine were tested only at 100 µM and the general toxicity prevented the 
determination of the concentration at which mefloquine would bring about 100 % 
inhibition of P-gp efflux transport. The therapeutic dose for mefloquine at which it 
exerts antimalarial activity is high and would attain a high drug concentration (mM 
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range) in the gastrointestinal tract. The volume of the human intestinal lumen is 
considered to be 2.5 L (426) and at this volume, the therapeutic doses of 10 and 15 
mg/kg/day would attain mefloquine concentration of between 0.75 and 1.1 mM for a 70 
kg adult (homogenous distribution is unlikely but concentration in the early millimolar 
range is likely). This is 7 to10 fold higher than the concentration exerting 50% inhibition 
of the P-gp mediated efflux transport. Therefore at therapeutic dose level of mefloquine, 
the complete blockage of P-gp mediated efflux transport of P-gp substrate can be 
expected.  
This finding is consistent with the published literature and P-gp inhibitory properties of 
mefloquine were demonstrated in four different in-vitro cell lines. Riffkin and co-
workers (104) carried out an in-vitro study using the human tumour cells CEM, which 
had been primed with vinblastine to overexpress P-gp (CEM/VBL) and used a photo 
affinity labelling technique to determine the interaction of mefloquine with P-gp 
substrate binding sites. At a concentration of 50 µM mefloquine, verapamil and 
chloroquine reduced the binding of a photo-reactive analog by 89%, 75% and 20 % 
respectively. Therefore mefloquine has better affinity, and is thus a more potent P-gp 
inhibitor than verapamil. The investigators further observed that mefloquine was able to 
block rhodamine123 efflux efficiently. The study concluded that mefloquine at 1-10 µM 
serum concentration can modulate P-gp substrate function and thus should be 
considered for reversing multidrug resistance in cancer chemotherapy. The P-gp 
inhibitory properties of mefloquine were also shown in P388 leukaemia cells 
(P388/ADR) (437). A synergistic inhibition of P-gp was observed between the P-gp 
modulators mefloquine, vinblastine and tamoxifen, the interaction being non-
competitive in nature. The synergistic actions allowed these drugs to be given at lower 
doses to inhibit P-gp (438). Stereoselectivity of mefloquine for P-gp interaction was 
studied using immortalised rat brain capillary endothelial cells GPNT and Caco-2 cells. 
P-glycoprotein inhibitory action was observed in both the cell lines for the racemic 
mixture and enantiomers. However, stereoselectivity was observed only in the GPNT 
cells. In Caco-2 cells, both stereoisomers equally inhibited the P-gp efflux (436).  
Based on the present study and the previously published literature, it is evident that 
mefloquine clearly has P-gp inhibitory properties. The affinity of mefloquine is lower 
compared to PSC 833, higher compared to verapamil and has a synergistic effect in 
combination with vinblastine and tamoxifen. P-gp mediated drug interactions are likely 
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between P-gp substrates and mefloquine and could result in an unexpected increase in 
systemic exposure and related adverse effects of the P-gp substrate. For example, in 
patients with comorbidities of malaria and AIDS increased adverse effects can be 
expected due to increased plasma levels of antiretrovirals (P-gp substrate) if 
administered with mefloquine. This would also be important in antimalarial therapy 
itself when combination therapies are considered.    
However contrary to this, in a pharmacokinetic study of ritonavir and mefloquine in 
humans, no change in the pharmacokinetic behaviour of ritonavir (less than 8% of AUC 
and Cmax) was observed. The authors speculated that possible up-regulation of P-gp by 
mefloquine and ritonavir could have masked the P-gp inhibitory properties of 
mefloquine. Further these study finding was weakened by high variability of ritonavir 
pharmacokinetics of study participants (301). Therefore further in-vivo pharmacokinetic 
studies are needed to confirm P-gp mediated pharmacokinetic interactions of 
mefloquine. 
Based on the current study, mefloquine exerted P-gp inhibitory properties at a 10 fold 
lower dose compared to the therapeutic dose for antimalarial activity whereas in a study 
by Riffkin and colleagues (104) inhibitory properties were observed at a 20 fold lower 
dose. Thus this is indicative that mefloquine has a practical role in reversing multidrug 
resistance in cancer chemotherapy at a much lower dose other than its role in 
antimalarial therapy. Further decrease in doses might be possible when combined with 
anticancer drugs due to P-gp synergistic effects (438). This lower dosing compared to 
the antimalarial dose would minimise the side effects exerted and other noted side 
effects such as nausea, vomiting and occasional neurotoxicity. Mefloquine has lower 
affinity compared to first generation P-gp inhibitors such as PSC 833 and would 
minimise CNS related effects resulting from penetration of the BBB.    
The currently recommended artemisinin combination therapies for malaria include 
mefloquine and artesunate combination (3). The new artemisinin derivative artemisone 
has been proposed to be combined with mefloquine in the management of malaria (70). 
Co-incubation of mefloquine with artesunate or artemisone did not demonstrate additive 
P-gp inhibitory properties in Caco-2 cell lines.  
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Amodiaquine did not exhibit P-gp inhibitory properties at tested concentrations. In 
contrast to finding in the present study, P-gp inhibitory properties of amodiaquine were 
observed at 100 and 1000 µM concentrations in in-vitro Caco-2 cell lines (440). Yet 
other studies claimed to show P-gp mediated taxol efflux inhibited by 50% with as little 
as 16 µM amodiaquine (439). Amodiaquine inhibitory properties at high concentration 
were precluded from testing in the current study mainly due to its solubility limitations. 
Amodiaquine was readily soluble in water, however in pH 7.4 HBSS transport buffer it 
had limited solubility. Therefore amodiaquine was dissolved in a co-solvent ethanol, 
enabling maximum stock concentration of 20 mM. Test concentration such as 1000 µM 
amodiaquine would result in toxic ethanol (> 1.5%) and amodiaquine concentration to 
Caco-2 cells.  
P-gp inhibitory properties for methylene blue are not available in the current literature 
and no P-gp inhibitory properties were observed for methylene blue in the present study.  
The artemisinin derivatives; artesunate and artemisone did not exhibit p-gp inhibitory 
properties in the present study. The published literature on inhibitory properties of 
artesunate is inconsistent. Similar to current study findings, an in-vitro study of Caco-2 
cell lines found no P-gp inhibitory properties of artesunate at 36 and 107 µM (439). In 
contrast, a study of multidrug resistance reversal by artesunate in erythromyelogenous 
leukemic P-gp over expressing K562/ADR cells and human small cell lung cancer 
observed poor inhibitory properties for artesunate (110 µM) compared to verapamil and 
cyclosporin (457). Similarly (440) observed P-gp inhibitory properties of artesunate at 
100 and 1000 µM in in-vitro Caco-2 cell lines.  
It is clear that mefloquine has a higher affinity and potency as a P-gp inhibitor compared 
to the other antimalarials tested and some of the first generation P-gp inhibitors such as 
verapamil. The inconsistent findings of P-gp inhibitory properties of amodiaquine, 
artesunate, dihydroartemisinin and artemisone of the present study and available 
literature show the need for further in-vitro and in-vivo studies in the area. Some studies 
used high concentration of the inhibitor; such concentrations however can be toxic to 
cell lines, in addition to P-gp inhibition complicating any interpretation regarding 
transporter specific functionality. However the apparent discrepancy of inhibitory 
properties at low concentration between studies is likely to be an anomaly P-gp related 
expression/activity.  
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4.5.3 Permeability and  P-gp mediated drug transport 
of  antimalarials  
 
4.5.3.1 Mefloquine drug transport  
Mefloquine is a small molecule and is available as its hydrochloride salt. The n-
octanol/water partition coefficient is 2.197 and is in the optimum range for maximum 
absorption. Mefloquine is a diprotic weak base and at physiological pH the positively 
charged molecular structure is more prominent, where its pyridine moiety is protonated 
(23, 98).  
While the small molecular size and optimum log p value (within 2 to 4) facilitate passive 
diffusion, the ionized mefloquine at intestinal pH might slow down the process. As 
predicted from the physicochemical properties, the bidirectional permeability of 
mefloquine was found to be in the medium range and the Ap-Bas directional transport 
was in the range of 6 to10 ×10-6 cm/sec in early and late passage Caco-2 cells. Hence 
mefloquine is mostly likely to have medium permeability based on the threshold values 
set by previous studies on drug permeability within the same laboratory.   
The net efflux transport of mefloquine was close to 1 and a higher Bas-Ap directional 
transport was not observed. Incubation with the P-gp inhibitor, PSC 833 did not alter 
the Bas-Ap and Ap-Bas directional transport. The equivalent transport rates in both 
directions, a transport ratio of efflux direction over uptake direction of 1 indicates that 
only diffusion has taken place. Thus mefloquine is not subjected to P-gp mediated drug 
efflux at concentrations above 10 µM. 
Another study has shown some P-gp substrate activity of mefloquine at nanomolar 
concentrations, where 14C mefloquine (160 nM) cell accumulation was decreased when 
incubated with 10 µM verapamil (436). However efflux transport observed at such low 
concentrations is unlikely to be significant when it comes to gastrointestinal drug 
absorption. Such low concentrations may be relevant at the blood brain barrier, which 
could be a significant factor in CNS toxicity of the drug. In this current study the focus 
was on the P-gp at the gastrointestinal tract for systemic absorption changes and the data 
presented in this thesis shows no significant effect. The oral dosing results in 0.74 to 
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1.11 mM of mefloquine concentration in the intestinal lumen. At such high 
concentrations of mefloquine, P-gp transporters become saturated and efflux transport 
observed at nanomolar concentrations becomes irrelevant to the Papp values for passive 
diffusion and the extent of drug absorption.  
Information on the oral bioavailability or systemic availability for mefloquine is not 
available in the literature and bidirectional transport of mefloquine in in-vitro cell lines 
has not been reported previously. This study suggests a medium permeability and 
therefore less than 100 % drug absorption of mefloquine 
A pharmacokinetic study of artesunate and mefloquine in humans found changes in 
pharmacokinetics (increase in clearance and volume of distribution and decrease in 
Cmax) of mefloquine when administered concurrently (112). However no change in 
permeability of mefloquine was found when co-incubated with artesunate in the current 
study, hence change in Cmax were unlikely to be permeability related. Similarly 
mefloquine permeability was not altered when incubated with methylene blue or 
artemisone. The absence of P-gp mediated efflux at test concentrations and minimum 
change in apparent permeability of mefloquine in the co-treatment with other drugs in 
the current study shows that lack of permeability related drug interactions of 
mefloquine.  
 
4.5.3.2 Amodiaquine drug transport  
Amodiaquine is a smaller sized drug, its log D being 2.6. Similar to mefloquine, 
amodiaquine is a diprotic weak base and at physiological pH amodiaquine equilibrium 
favours the uncharged/neutral compound (23, 73), which is likely to improve passive 
diffusion. The Ap-Bas directional transport of amodiaquine is higher compared to 
mefloquine and ranged from 17 to 22 ×10-6 cm/sec. Hence amodiaquine appears to have 
high drug permeability and almost complete drug absorption. There was a small efflux 
transport rate (1.3) observed at 10 µM. However at higher concentration no such trend 
was observed and the slight efflux transport observed at 10 µM is deemed to be clinically 
insignificant.  
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Permeability data for amodiaquine is available in the literature. Hayeshi and co-workers 
(439) confirmed the absence of P-gp mediated drug transport of amodiaquine and 
bidirectional transport ranged from 44 to111 × 10-6 cm/sec between 10 and 50 µM, 
respectively. Cell uptake of amodiaquine was observed at all test concentrations.  
The drug permeability of amodiaquine was tested while incubating the drug with 
artemisone and no change in permeability was found. Significant changes in 
amodiaquine permeability are unlikely to be seen by co-administration with other drugs 
due to the high passive permeability of the drug. 
Suggested oral drug doses for amodiaquine ranged from 7.5 to 15 mg/kg/day resulting 
in gastrointestinal concentration of 0.6 to 1.2 mM (>10 µM), which would saturate P-
gp carrier molecules. Based on the present study and current literature, amodiaquine has 
a high passive permeability, ensuring almost 100% drug absorption. Rapid absorption 
of amodiaquine is shown in pharmacokinetic studies where amodiaquine reaches its 
peak concentration within 1 hour. Amodiaquine bioavailability has not be reported in 
the current literature, however it is claimed that amodiaquine has a pharmacokinetic 
profile similar to that of chloroquine (74) and chloroquine bioavailability is found to be 
78-89% (461).  
 
4.5.3.3 Methylene blue drug transport 
In the drug industry, two forms of methylene blue are used: reddish brown crystal 
methylene blue and green golden crystal methylene blue. The reddish brown crystal 
methylene blue supplied by Fluka Sigma was used for drug transport studies. The blue 
coloured oxidized form of methylene blue which is administered as the therapeutic agent 
has a pKa of 0-1 and would remain oxidized in the pH range of the gut (143, 462). 
Cationic methylene blue has a log P value of -0.9 at pH 7 and its log D value is 0.06, 
hence it has poor partitioning into the lipid bilayer (462). Other than the small molecular 
size of methylene blue, inherent physicochemical parameters of methylene blue are not 
in favour of passive diffusion of this molecule. 
As anticipated from the inherent physicochemical properties of cationic methylene blue, 
a low permeability was observed for methylene blue. The Ap-Bas directional transport 
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of methylene blue ranged from 1.6 to 2.8 ×10-6 cm/sec, therefore at the test 
concentration, low cell uptake of methylene blue can be expected.  
The Bas-Ap transport of methylene blue was higher than the AP-Bas transport which 
proposes efflux transport of methylene blue in the gastrointestinal tract. The efflux 
transport of methylene blue was consistently observed in all four Caco-2 cell models. 
The highest efflux transport was observed for the Caco-2 VIN model (efflux ratio 5.1), 
the model with highest P-gp expression. The efflux ratio for methylene was reduced by 
about 50% when co-incubated with PSC 833, which still left a significant efflux ratio 
associated with this drug, implying other efflux transporters were functioning when P-
gp was blocked. Hence efflux transport is not fully mediated by P-gp and there is 
possible involvement of other gastrointestinal ABC efflux transporters.  
The most common structural feature of P-gp substrates is their amphipathic nature and 
conforming to this methylene blue has hydrophilic and hydrophobic moieties in its 
molecular structure.  
The poor in-vitro cell uptake of methylene blue suggests possible low bioavailability in-
vivo. Strikingly different bioavailability values (7% vs 72%) for methylene blue in 
humans are reported in two pharmacokinetics studies of humans (152, 463). The high 
bioavailability found in the second study was accounted for by increased sensitivity of 
the analytical techniques adopted in that study. Peters and Robinson (463) proposed that 
the earlier and low bioavailability could be due to high first pass elimination. 
Nevertheless, P-gp mediated drug efflux could also contribute to this large discrepancy 
in bioavailability.  In the first pharmacokinetic study, volunteers were given 100 mg of 
methylene blue, which would result in gastrointestinal concentration around 125 µM, a 
concentration similar to the test concentration used in the present study (463).  
Therefore, it is likely that low in-vivo methylene blue bioavailability observed in the 
first study is related to the ABC transporters mediated efflux in the gut.  
In the second study, on the other hand, a higher oral drug dose was administered 
resulting in a higher gastrointestinal concentration (625 µM). At this fivefold higher 
concentration, it is possible that saturation of efflux transporters and cell accumulation 
were attained. In the absence of efflux transport, a higher proportion of drug can be 
permeated resulting in higher bioavailability of methylene blue (152).  
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A high accumulation of methylene blue in the brain following IV administration was 
observed in rats (463). Blood brain capillaries contain a large amount of P-gp and it is 
unlikely for cationic methylene blue to pass through this shield unless a very high 
plasma concentration of methylene blue was attained. Therefore this could be due to 
possible exofacial conversion of cationic methylene blue into leuco-methylene blue (by 
NADPH) and leuco-methylene blue can easy cross through membranes (463). A high 
accumulation of methylene blue was found in intestinal walls of rats (463) and high 
accumulation of methylene blue in Caco-2 cell lines was also observed in the present 
study, especially at low concentrations such as 10 µM. Therefore a methylene blue dose 
which can saturate efflux transporters and cell accumulation is required to result in 
sufficient bioavailability of the drug. The currently used dose of methylene blue for 
children is 12 mg/kg which is 8 and 1.7 fold higher than the Peter and co-workers (463) 
and Walter-Sack and co-workers (152) studies, respectively.  At the currently used dose 
efflux transporters and cell accumulation would be saturated resulting in high 
bioavailability of the drug. Thus 12 mg/kg methylene blue can be recommended to be 
used in the management of malaria to achieve adequate therapeutic concentration.  
 
4.5.3.4 Artesunate drug transport  
Similar to amodiaquine and mefloquine, physiochemical parameters of artesunate are in 
favour of passive diffusion. However ionization of artesunate at physiological pH (pKa 
of 4.28) is plausible. A medium permeability was observed for artesunate with Papp 
values of 7 to 10 ×10-6 cm/sec. A medium permeability of artesunate has been reported 
in previous study of Caco-2 monolayers, where Papp value for sodium artesunate was 
found to be 4 ×10-6 cm/sec (17) Artesunate showed a higher Bas-Ap transport (efflux 
ratio of 1.5) therefore minimum affinity to P-gp. This is unlikely to result in difference 
in permeability and therefore systemic absorption. 
As described in methods, the transport experiment was of 2 hours duration and during 
the experiment, the 24 well plated were kept in the incubator at 37 ºC and removed for 
sample collection. According to the literature, some degradation of artesunate to 
dihydroartemisinin is possible at incubation temperature (464). This need to be 
considered when in-vitro Papp values of artesunate is used to predict in-vivo drug 
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absorption. However the qualitative information of artesunate is still valid which is 
indicative of medium permeability and less than 100% drug absorption.  
The “zero” time artesunate samples also contained the active metabolite of artesunate, 
dihydroartemisinin. The active metabolite, dihydroartemisinin has favourable 
physicochemical parameters for passive diffusion with a pKa of 12.6 (unionized at the 
physiological pH) and log p of 2.19. The percentage of dihydroartemisinin passed across 
the cell monolayer was about 4 times higher than artesunate percentage passed through; 
therefore dihydroartemisinin is likely to have better passive diffusion compared to 
artesunate. 
Previous work done within our own lab using an in-vitro Caco-2 monolayers study using 
radiolabelled dihydroartemisinin found Ap-Bas and Bas-Ap transport of 21 to 30 and 
32 to 39×10-6 cm/sec transport of dihydroartemisinin (338). This Papp values are 
indicating almost complete drug absorption of dihydroartemisinin, which is higher than 
artesunate permeability observed in the current study. Similar trends were observed in-
vivo where in healthy volunteers, the absolute oral bioavailability of dihydroartemisinin 
found to be 80% following oral artesunate administration (62) whereas absolute oral 
bioavailability of artesunate found to be 23% (40, 41).  
 
4.5.3.5 Artemisone drug transport 
Artemisone has the very favourable physicochemical parameters to facilitate passive 
diffusion. Artemisone has a basic centre and is more likely remain unionized at the 
physiological pH; this has an optimum log P value and has a relatively small molecule 
weight for maximum drug absorption. Artemisone showed the highest Papp value out of 
the drug tested for bidirectional transport confirming passive permeability and 100 % 
drug absorption. P-gp mediated efflux transport was not observed for artemisone, hence 
unlikely to observe P-gp mediated pharmacokinetic drug interactions. As anticipated, 
no change in Papp of artemisone was observed when co-incubated with mefloquine. 
Artemisone has also shown higher bioavailability compared to artesunate in monkeys 
(70). P-gp mediated efflux transport was not observed for artemisone, hence unlikely to 
observe P-gp mediated pharmacokinetic drug interactions. As anticipated, no change in 
Papp of artemisone was observed when co-incubated with mefloquine. 
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4.5.4 Biopharmaceutical classification (BCS) of antimalarials  
The biopharmaceutical classification system enables establishment of in-vivo and in-
vitro correlation of immediate release drugs on the basis of drug solubility and 
permeability. This classification can be used to determine the feasibility of using in-
vitro dissolution data as a surrogate to establish bioequivalence of multisource generic 
drugs (in other words biowaiver for multisource products). This information can be 
useful, especially in a resource poor setting for drug regulatory bodies for registration 
of multisource generic products (465).  
The BCS requires the solubility of the maximum dose strength of drug in 250 mL of 
aqueous media over the pH range of 1 to 7.5 (465). The solubility of drug in water and 
at pH 7.4 was obtained from the literature. Drug was considered to have a low solubility 
if the estimated drug concentration at the highest dose strength was higher than the 
reported drug solubility at physiological pH. The drug solubility, estimated 
gastrointestinal concentration and drug permeability obtained from the present study are 
listed in Table 4.10. 
 
Table 4-9: Estimated gastrointestinal concentration for highest strenght dose of the 
drug, drug solubility and Ap-Bas directional Papp values for antimalarials found in the 
present study are listed.   
a Not available, b The in-vitro Ap-Bas Permeability observed in the current study for each drug 
is listed,  MQ: mefloquine, AQ: amodiaquine, MB: methylene blue, ART: artesunate, AM: 
artemisone  
 
Based on the previous work done within the our laboratory drugs with Papp value of more 
than 25×10-6 cm/s were considered to have complete drug absorption and drugs with 
Drug Aqueous 
Solubility  
(mg/mL) 
Solubility  
at pH 7.4 
(mg/mL) 
Tablet 
strength 
(mg) 
GUT Con. 
(mg/mL) 
250 mL 
Ap-Bas 
permeability b  
 (×10-6 cm/s) 
Reference 
MQ 1.8  0.303 250 1 6-10 (3, 93, 94, 98) 
AQ 8  0.08  600 2.4 16-22 (3, 73) 
MB  40 n/a a 200 0.8 2-3  (143, 146, 462) 
ART 2  <15 200 0.8 7-10 (3, 466) 
AM n/a a  89  20 0.1 37-60 (66, 67) 
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Papp value less than 1×10
-6 cm/s were considered to have low permeability (447, 449). 
The BCS classification place drugs into highly permeable category when the extent of 
absorption is 90 %. Considering both solubility and the permeability, the antimalarials 
studied were categorized into different BCS class as given in Table 4.11.  
 
Table 4-10 : Biopharmaceuctical classitifiaction for antimalarials  
Drugs  Solubility  Permeability  BCS class  
MQ Low  Medium  II/IV 
AQ Low  High  II 
MB  n/aa Low  III/IV 
ART High  Medium  I/III 
DHA Low Medium  II/IV 
AM High  High  I 
a Not available 
 
Mefloquine hydrochloride showed medium permeability and less than 100 % drug 
absorption. The slow rate of drug absorption is evident from the clinical research where 
tmax of mefloquine reported was about 20 hours (297, 298). Mefloquine has poor drug 
solubility at physiological pH and hence can be classified into either class II or IV of 
the BCS class. However given the variability in the use of excipients, formulation and 
manufacturing process, it would be safer to place mefloquine in class IV. Hence 
immediate release multisource products of mefloquine cannot be granted a biowaiver in 
place of in-vitro dissolution test. Similarly a previous study on biowaiver monograph of 
mefloquine hydrochloride, did not recommend a biowaiver for mefloquine (98).  
In contrast, amodiaquine permeability was found to be higher than mefloquine. The Ap-
Bas transport was close to the threshold value set by our laboratory and can be 
considered to have high permeability giving more than 90 % drug absorption. 
Amodiaquine has a good aqueous solubility and the solubility decreases with increase 
in pH. The estimated expected gastrointestinal concentration is about 30 fold higher than 
the solubility limitation at pH 7.4. Previously published biowaiver monograph has 
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placed amodiaquine in class IV due to the absence of permeability information. 
However considering the present study findings, other in-vitro literature (439) and 
similarity of amodiaquine pharmacokinetic data to chloroquine (461), this drug can be 
placed in class II of the BCS classification. Hence immediate release multisource 
products of amodiaquine can be granted a biowaiver in place of in-vitro dissolution test.  
Methylene blue has a good aqueous solubility; however solubility at physiological pH 
has not been reported. As depicted in Table 4.11, methylene blue can be classified into 
class III or IV. Therefore IVIV correlation for methylene blue cannot be established for 
low doses (dose less than 100 mg). However based on the bioavailability data in healthy 
human studies, good bioavailability of methylene blue was observed in a 5 fold higher 
dose of methylene blue. Hence it is likely for IVIV correlation could be seen at a high 
dose (more than 500 g) of methylene blue. However this concentration was not tested 
in this present study. Further studies on drug permeability are needed to determine if 
methylene blue can be granted a biowaiver.   
Artesunate has good drug solubility at gut pH and the estimated gut concentration is 
much lower than the solubility limitation of the artesunate, whereas dihydroartemisinin 
aqueous solubility (0.314 mg/mL) is much lower than its prodrugs and has a lower 
solubility threshold compared to the expected gastrointestinal concentration. This places 
artesunate in class I or III. Similar to mefloquine, caution is needed to place artesunate 
in class III of the BCS. This is also justifiable considering the limited validity of Papp 
values of artesunate due to its degradation during the experiment.  
The newly developed artemisinin derivative artemisone showed the highest 
permeability and can be placed in class I of the BCS. At the dose used for 
pharmacokinetic study in humans (66), the estimated gastrointestinal concentration is 
much lower than the solubility limitation of artemisone. Class I drugs have high 
permeability and when the dissolution is rapid in relation to gastric emptying, drug 
absorption is unlikely to be dependent on drug dissolution and gastric emptying time. 
IVIV correlation of artemisone can be established; hence a biowaiver for multisource 
products of artemisone is feasible. 
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4.5.5 Antimalarial regulation of P-gp expression 
In Caco-2 cell lines, an up regulation of P-gp expression was observed for antimalarials 
in the single therapy yet this trend was not evident for LS174T cells. This could be due 
to the comparatively shorter exposure of the drugs (48 hours compared to 96 hours 
exposure of Caco-2). Methylene blue in Caco-2 cells up regulated the P-gp by 2 fold 
and this was higher than up regulation observed for other antimalarials.  In the current 
study methylene blue was identified as a P-gp substrate; hence up regulation of P-gp 
expression is plausible. P-gp substrates such as vinblastine and some antiretrovirals have 
shown P-gp induction properties previously (365, 394).  
Regulation of P-gp expression by artemisinin has been reported. It is reported that 
artemisinin induces expression of CYP2B6, CYP3A4 and P-gp in human hepatocytes 
and in LS174T cell lines through the activation of human PXR and human Constitutive 
Androstane receptor (CAR) (443). At 25 µM dihydroartemisinin did not activate PXR, 
however authors speculated that dihydroartemisinin may activate PXR at higher 
concentration. Up regulation of P-gp was observed in the present study when artesunate 
and dihydroartemisinin were exposed to Caco-2 cells for 4 days. The molecular structure 
of mefloquine suggests that it has the ability to induce P-glycoproteins (467). However, 
this was not observed in the present study. Hence further studies are required to confirm 
on this.   
Interestingly dihydroartemisinin and artemisone in combination therapies (both in 
combination with mefloquine and amodiaquine) showed a clear up regulation of P-gp 
expression. This up regulation was seen in LS174 cells. This increases the possible drug 
interactions for dihydroartemisinin and artemisone combination therapies, resulting in 
sub-therapeutic levels of drugs with P-gp substrate activity.   
Unlike the two artemisinin derivatives, incubation of artesunate with mefloquine or 
amodiaquine in combinations did not show up regulation of P-gp. This was evident in 
both the cell lines and however the possible mechanism for this is not clear.  
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4.6 Limitations  
In-vitro study results and their implications can be of limited validity when it comes to 
the in-vivo situation. Yet in-vitro study data can be used to plan in-vivo studies for 
further confirmation of results.  
Testing drug permeability and P-gp substrate activity of antimalarials in other in-vitro 
cells models such as MDCK MDR1 cells lines would enable further comparison. 
However that was not carried out due to lack of time, resources and cost involved.  
During the transport study, 24 well plates were stored in the incubator at 37 ºC and 
withdrawn for sample removal. Some degradation of artesunate is possible at the 
incubation temperature. Hence small differences in Papp values were possible. However 
the recovery of artesunate was measured at more than 90%. 
Caco-2 cells do not have all the gut metabolising enzymes, thick mucus layer and the 
complex dynamic flow environment found in the human gastrointestinal epithelium. 
Therefore, study findings need to be interpreted considering these limitations and in-
vitro findings need to be further tested under in-vivo conditions to draw final 
conclusions. 
The very low drug concentrations expected at body organ sites (other than the gut 
boundary) was unable to be tested due to limitations of the sensitivity of analytical 
techniques for drug assays (HPLC). 
.  
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4.7 Future studies 
An in-vitro drug permeability study of methylene blue at a concentration of 500 µM 
needs to be done to determine the change in Ap-Bas directional transport. Co- incubation 
with other ABC transporter blockers such as MK571, probenecid, ko143 and with 
methylene blue might help in understanding other efflux transporters involved in 
methylene blue efflux transport.  In-vivo bioavailability studies of methylene blue in 
human would be able to answer the question of dose dependent bioavailability of 
methylene blue. 
Molecular mechanisms of up regulation of P-gp expression need to be explored. 
Pregnane X receptor (PXR) has shown to mediate expression of P-gp and this need to 
be explored in future studies. Involvement of PXR in up-regulation of P-gp expression 
in the artemisinin combination therapy would help understanding the molecular 
mechanism of up regulation of P-gp.  
P-gp mediated drug interactions are multifactorial, therefore in-order to understand the 
in-vivo situation it is important to conduct in-vivo studies. In-vivo P-gp mediated 
pharmacokinetic drug interactions studies of P-gp inhibitors mefloquine and P-gp 
substrates are worth exploring. 
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4.8 Conclusion 
Mefloquine exhibited P-gp inhibitory properties at 100 µM and had less affinity 
compared to PSC 833. Amodiaquine, methylene blue, artesunate and artemisone did not 
show P-gp inhibitory properties at test concentrations.  
Mefloquine, amodiaquine, artesunate and artemisone did not exhibit P-gp substrate 
properties that can be clinically significant and permeated through passive diffusion. 
Amodiaquine and artemisone were found to have high permeability predicting almost 
100 % drug absorption. These two drugs can be placed in class II and I of the BCS, 
therefore biowaiver can be granted. Mefloquine and artesunate showed medium 
permeability, therefore less than 100% in-vivo drug absorption can be expected. 
Methylene blue showed very low permeability, therefore drug absorption. Methylene 
blue found to have P-gp mediated efflux transport and however there are other efflux 
mechanisms involved in the process. A clear up regulation of P-gp expression was 
observed for dihydroartemisinin and artemisone in combination with amodiaquine and 
mefloquine. This trend was not observed for artesunate combination. Up regulation 
trends were also observed for methylene blue artesunate amodiaquine and 
dihydroartemisinin in Caco-2 cells.  
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5 Summary  
 
My PhD project consists of two main areas concerning the pharmacokinetics of 
antimalarial drugs. The first part of the study includes allometric scaling of antimalarials 
for interpolation of pharmacokinetic parameters and drug doses for children.  
The second part of the study includes bidirectional transport studies of antimalarial 
drugs in both single and combination therapy to determine drug permeability and P-gp 
mediated drug efflux transport of antimalarials. Finally, regulation of P-gp expression 
in the presence of antimalarials in single and combination therapy was determined.   
Allometric scaling is a well-established pharmacokinetic technique which relates 
pharmacokinetic parameters of mammalian species with their body size/weight.  Study 
antimalarials were selected using WHO guidelines for the treatment of malaria. A 
comprehensive literature search of pharmacokinetic parameters was conducted in main 
databases and by cross referencing. Pharmacokinetic parameters: clearance, volume of 
distribution and half-life were collected in healthy and malaria infected preclinical and 
human species. After data screening based on specific selection criteria, the list of drugs 
were limited to artesunate (IV), its active metabolite, dihydroartemisinin (IV), 
artemether (IV and IM), artemisinin (IV, intraperitoneal and oral), clindamycin (IV), 
piperaquine (oral), mefloquine (oral) and quinine (IV). Due to paucity of data it was not 
possible to scale pharmacokinetic parameters for malaria infected species. Instead 
scaling was done using healthy species. In conventional allometry pharmacokinetic 
parameters of pre-clinical species are used to extrapolate human pharmacokinetics 
whereas in the current study both preclinical species and human pharmacokinetic 
parameters were used for interpolation of pharmacokinetic parameters for children.  The 
pharmacokinetic parameters were plotted in a log-log scale against the body weight of 
the species to obtain the allometric plot. The slope of the allometric plot was calculated 
to determine the allometric exponent and the antilog of the coefficient was obtained as 
the allometric coefficient. Allometric power relationships were established for the three 
pharmacokinetic parameters; clearance, volume of distribution and half-life of selected 
drugs,  
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Selected allometric correction factors were also tested to determine superiority of 
correction factor techniques compared to simple allometry. The correction factors 
maximum life span potential and Rule of Exponents were tested. In addition, two new 
correction factors, liver weight and liver blood flow, were also tested. It was 
hypothesised that liver weight correction would improve clearance prediction of low 
hepatic extraction ratio drugs and liver blood flow correction would improve clearance 
prediction of high hepatic extraction ratio drugs. The interpolated drug clearance by 
simple allometry and correction factors; maximum life span potential, liver weight 
correction and liver blood flow corrections were compared to the observed drug 
clearance in clinical studies in children. The predictive success was determined and the 
ratio of observed to predicted drug clearance in the range of 0.5 to 2 were considered 
acceptable.  
Drug clearance in healthy and malaria infected adults was compared. Given that there 
is no difference in pharmacokinetics in malaria infection, the exponent derived using 
healthy species were used for dose determination in malaria infected children.  
Paediatric drug doses were determined for arbitrary body weights of 15 and 25 kg. Doses 
for children less than 2 years were excluded due to known physiological and 
pharmacokinetic differences.  
Finally drug clearance values of preclinical species were used to extrapolate clearance 
of adults to determine the predictive success of the conventional allometry for 
antimalarials.   
Strong allometric scaling relationships were observed for drug clearance of drugs 
scaled. The regression analysis for clearance had r2 value above 0.9 for all drugs scaled. 
The allometric exponent values were 0.71, 0.85, 0.66, 0.83, 0.62, 0.96, 0.52 and 0.40 
for artesunate, dihydroartemisinin (following IV artesunate), artemether, artemisinin, 
clindamycin, piperaquine, mefloquine and quinine, respectively. The 95% confidence 
interval (CI) for piperaquine, mefloquine and quinine did not encompass both universal 
exponent values of 0.67 and 0.75. Therefore data included in the present study does not 
support the use of universal exponent values for extrapolation of doses. Small exponent 
values indicated the need for a large increase in doses for mefloquine and quinine. The 
95% CI of the exponent did not encompass one except for dihydroartemisinin and 
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piperaquine, therefore linear scaling or mg/kg adult dosing is not applicable for all 
antimalarials. 
Similar to clearance, volume of distribution also showed a strong allometric relationship 
for all drugs (r2 > 0.91) except for artesunate with an r2 of 0.69. This could be due to its 
prodrug nature. The exponents for volume of distribution for other drugs ranged from 
0.81 for clindamycin to 1.16 for piperaquine (the exponent for artesunate was 0.54). The 
95% CI of the exponent for artemether, piperaquine and quinine did encompass 1, 
therefore linear scaling is possible. The exponent for volume of distribution is used for 
loading dose determination. Further analysis of volume of distribution was not done as 
loading doses are not recommended for adults with malaria infection except for quinine.  
The regression analysis showed poor allometric relationship for half-life of antimalarials 
except for artemether, therefore no further analysis of half-life was carried out.  
Quinine clearance in malaria infected adults was found to be lower compared to that of 
healthy adults. Therefore it was not suitable to use exponent data from healthy subjects 
for dose determination of quinine in children with malaria infection. Dihydroartemisinin 
showed a similar pattern, however the power of the two-tailed t test was lower. The drug 
clearance of artesunate, artemether, clindamycin, mefloquine and piperaquine showed 
no difference in malaria infection, with low power (< 0.8). The large standard deviation 
and low power of the test made it difficult to make definitive conclusions. Nevertheless, 
in the current study exponents of healthy species were used for dose interpolations of 
dihydroartemisinin, artemether, clindamycin, piperaquine and mefloquine for children 
with malaria. 
In general the correction factors extended the Y axis by two orders of magnitude, which 
improved the r2 value. The liver weight correction improved the r2 value for all drugs, 
whereas maximum life span potential correction leads to r2 improvement of 
dihydroartemisinin, mefloquine and quinine. The liver blood flow correction also 
selectively improved r2 values of dihydroartemisinin, clindamycin, piperaquine, 
mefloquine and quinine. The exponent values for all drugs by all methods were ≥ 1.  The 
drug clearance predicted using simple allometry and liver body weight correction had 
the best predictive success. The predicted clearance based on simple allometry was 
within 0.5 to 2 for all the drugs scaled and mostly over-predicted the drug clearance. 
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The predictions using liver weight correction were also within the accepted threshold 
values, however no clear improvement in clearance prediction compared to simple 
allometry was observed. The maximum life span potential and liver blood flow 
corrections did not meet the predictive success in some cases and these two correction 
factors under-predicted the drug clearance at all times.  
Of the drugs scaled, dihydroartemisinin and artemether are high extraction ratio drugs. 
However liver blood flow correction did not improve clearance prediction for 
dihydroartemisinin and artemether but simple allometry predictions were accurate. 
Piperaquine and mefloquine were low extraction ratio drugs. The simple allometric 
predictions for these drugs were found to be accurate despite literature to indicate that 
low extraction ratio drugs are poor predictors by simple allometry. The predicted drug 
clear clearance by liver weight and MLP corrections (recommended correction methods 
for low extraction ratio drugs) also met the predictive success for mefloquine. No 
correction factor performed better than simple allometric predictions. 
The current recommendation for antimalarial drug dosing in children is to use mg/kg 
adult doses except for artemether. Artemether doses are recommended for body weight 
ranges. The predicted drug doses based on simple allometric exponents were 10 to 70% 
higher compared to the currently recommended doses with the exception of artemether. 
Currently recommended artemether mg/kg dosing for children is higher than the adult 
doses and higher than the allometric predictions in most instances. Therefore in general 
allometric scaling recommends an increase in doses for children compared to the mg/kg 
adult dosing.  
The conventional allometry where preclinical clearance data are used to extrapolate 
pharmacokinetics for humans did not work for all antimalarials. Scaling using 
preclinical species alone was difficult due to insufficient data. Artemether, clindamycin, 
piperaquine, mefloquine and quinine scaling was done using two preclinical species. 
Despite this artemether and mefloquine exponents were similar to the exponent derived 
using both preclinical and human species. The predicted clearance for 
dihydroartemisinin and piperaquine were 4 and 6 fold higher than the observed 
clearance. Addition of human pharmacokinetic data improved clearance prediction and 
was within threshold values at all times.  
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The second part of the study required development of a robust in-vitro Caco-2 cell 
monolayer with sufficient expression of P-gp. Three interventions were adopted to 
improve P-gp transporter expression in early passage (P-44) Caco-2 cells; exposure of 
Caco-2 cells to a known P-gp inducer, rifampicin (Caco-2 RIF), exposure to Caco-2 
cells to a potent P-gp substrate, vinblastine at nanomolar concentrations for an extended 
period (Caco-2 VIN) and lastly regular passaging of Caco-2 cells to obtain late passage 
Caco-2 cells.  
P-gp expression was determined using the Western blotting technique and functionality 
of P-gp was determined by conducting bidirectional transport studies of a known P-gp 
substrate, rhodamine123. Rhodamine123 was quantified using fluorescence 
spectroscopy. Bidirectional transport studies required growth of Caco-2 cells on 0.4 
micrometre filter inserts at 65,000 cells/cm2 and the transport experiments were 
conducted on day 21 to 24 upon reaching suitable cell differentiation, monolayer 
tightness and transepithelial electrical resistance above 300 Ω/cm2.  
Bidirectional transport studies showed efflux transport of rhodamine123 in early 
passage (passage 44), Caco-2 RIF, Caco-2 VIN and in late passage (passage 80s) Caco-
2 cells. The efflux transport of rhodamine123 was inhibited when co-incubated with the 
P-gp transporter inhibitor, PSC 833. Therefore it was evident that P-gp transporter 
proteins are expressed in all four Caco-2 cell lines. This was also visually observed in a 
Western blot. Faint blots for early passage Caco-2 and Caco-2 RIF models were not 
quantified. The blots for late passage Caco-2 and Caco-2 VIN models showed that there 
was a small change in P-gp expression over days 21, 24 and 28. The highest P-gp 
expression for late passage Caco-2 cells and Caco-2 VIN were on day was on day 28 
and 24 respectively.  
There was insufficient increase in P-gp expression in the Caco-2 RIF model and the 
efflux ratio was 1.5 compared to 1.4 of the passage 44 Caco-2 cells. Caco-2 VIN had 
the highest P-gp expression with an efflux ratio of 13. However development of Caco-
2 VIN model was a rather time consuming process. A clear improvement in P-gp 
expression was observed with the increase in passage number; the efflux ratio for 
passage 80 was 4.7 compared to 1.4 for passage 44 Caco-2 cells.  Therefore late and 
early passage Caco-2 monolayers were selected for routine bidirectional transport 
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studies. Caco-2 VIN and Caco-2 RIF models were used only for further confirmation of 
P-gp substrate activity of a drug.  
P-gp inhibitory properties of antimalarials were determined by assessing the change in 
bidirectional transport of rhodamine123, when co-incubated with antimalarials. 
Rhodamine123 transport alone and in combination with antimalarials was studied. The 
inhibition of efflux transport of rhodamine123 was used to determine the P-gp inhibitory 
properties of antimalarials.   
P-gp inhibitory properties of antimalarials were not observed in early passage Caco-2 
cells. Therefore no antimalarial in the current study had potent P-gp inhibitory properties 
to compare with the second generation P-gp inhibitor, PSC833. Mefloquine at 100 µM 
showed P-gp inhibitory properties in late passage Caco-2 cells where 50% inhibition of 
rhodamine123 efflux was observed. The concentration at which mefloquine exerted 100 
% inhibition of efflux transport of rhodamine123 could not be determined as mefloquine 
was found to be toxic to cells at higher concentrations.  Amodiaquine, artesunate, 
methylene blue and artemisone did not exhibit P-gp inhibitory properties at both 100 
and 300 µM. Mefloquine in combination with artesunate or with artemisone did not 
attain any additive inhibition of rhodamine123 efflux compared to mefloquine 
incubation alone.  
Bidirectional transport studies to determine the P-gp substrate activity and permeability 
of antimalarials require drug assays to quantify drugs at different time points in apical 
and basolateral compartments. Assays of mefloquine, amodiaquine and methylene blue 
were done using different HPLC techniques. Assay of artesunate and artemisone 
required an LC-MS-MS technique.  
Bidirectional transport of mefloquine in early and late passage Caco-2 cells showed a 
Papp value in the range of 6 to 10 × 10
-6 cm/sec in the apical to basolateral direction (cell 
uptake) and 5 to 11× 10-6 cm/sec in the basolateral to apical direction (efflux to 
transport). The efflux ratio ranged from 0.7 to 1, therefore absence of efflux transport. 
Bidirectional transport was not altered in the presence of PSC 833. This further 
confirmed that mefloquine was not subjected to efflux transport at concentrations ≥ 10 
µM. No change in permeability of mefloquine was observed when co-incubated with 
artesunate, artemisone and methylene blue. Apical to basolateral Papp values show a 
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medium permeability for mefloquine and this has a low solubility in the gut at 
physiological pH. Therefore mefloquine can be classified into Class IV of the 
biopharmaceutical classification system. Therefore an in-vitro dissolution test can’t 
replace the requirement for in-vivo bioequivalence studies for bioequivalence of 
immediate release multisource generic products of mefloquine. 
The apical to basolateral directional transport of amodiaquine ranged from 16 to 23 × 
10-6 cm/sec which indicates near complete drug absorption of amodiaquine. At 10 µM, 
higher basolateral to apical directional transport of amodiaquine was observed with an 
efflux ratio of 1.3. However such small increase in serosal to mucosal directional 
transport will not change drug absorption and systemic availability of amodiaquine to 
cause a clinically significant change in outcome. At 100 µM, the efflux ratio was found 
to be one, indicating no net transport of amodiaquine. The Papp value of amodiaquine 
indicates that amodiaquine has high permeability and drug solubility at pH 7.4 is much 
lower compared to the estimated drug concentration achieved from highest tablet 
strength. Therefore amodiaquine can be placed in class II of the bio pharmaceutical 
classification, which allows a biowaiver for multisource generic products of 
amodiaquine in place of the in-vitro dissolution test.   
Out of the drugs studied methylene blue had the lowest bidirectional permeability and 
the basolateral to apical directional transport was higher than the apical to basolateral 
directional transport. This was consistently observed in all 4 models of the Caco-2 cell 
monolayers with the Caco-2 VIN model giving the highest efflux ratio of 5.1. However 
co-incubation with PSC833 was not able to fully block (about 50% inhibition was 
observed) the efflux transport of methylene blue. Therefore it is likely methylene blue 
efflux transport is mediated through other efflux transporters in addition to P-gp. The 
Papp value apical to basolateral directional transport of methylene blue ranged from 1.6 
to 2.8 × 10-6 cm/sec at 100 µM, therefore low cell uptake of methylene blue can be 
expected. The physicochemical parameters other than the small molecule size of 
methylene blue are also not in favour of passive permeability. Methylene blue has good 
aqueous solubility but solubility at pH 7.4 was not available in the literature. At 100 µM 
methylene blue has a low permeability which places methylene blue in class III or IV 
of the biopharmaceutical classification system, therefore in-vivo and in-vitro correlation 
of methylene blue cannot be established at 100µM.     
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Artesunate showed a medium permeability with apical to basolateral transport of 7 to 
10 × 10-6 cm/sec. Similar to amodiaquine, artesunate also showed efflux transport with 
an efflux ratio of 1.5 which is not large enough to cause a clinically significant difference 
in therapeutic outcome. Artesunate can be placed in class III of the biopharmaceutical 
classification system with its medium permeability and good solubility at physiological 
pH.  
Out of the drugs studied, artemisone had the highest bidirectional permeability and this 
was also evident from its physicochemical parameters. The apical to basolateral and 
basolateral to apical transport of artemisone ranged from 37-60 to 35-47 × 10-6 cm/sec, 
respectively, indicating complete drug absorption of artemisone.  Efflux transport of 
artemisone was not observed. Artemisone solubility at physiological pH is higher than 
the estimated gastrointestinal concentration from the highest dosage strength. Therefore 
artemisone can be placed in class I of the biopharmaceutical classification system, which 
allows a biowaiver for multisource generics of artemisone in place of in-vitro dissolution 
testing.  
The final part of the study was to determine the regulation of P-gp expression in the 
presence of antimalarials in single and combination therapy. This was tested in Caco-2 
and LS174 T cells. Antimalarials, especially artemisinin derivatives, were found to be 
toxic on LS174 T cells. Therefore exposure was limited to 48 hours at 20 µM for LS174 
T cell and 96 hours for Caco-2 cells. A clear up-regulation of P-gp was observed in both 
cell lines for dihydroartemisinin and artemisone in combination with mefloquine or 
amodiaquine. This was not observed for artesunate combinations. Methylene blue 
upregulated the P-gp expression in Caco-2 cells when exposed for 96 hours. This could 
be due to P-gp substrate activity of methylene blue.  However this was not observed in 
LS174 T cells and could be due to shorter exposure time. Some up-regulation was also 
observed for dihydroartemisinin, artesunate and amodiaquine in Caco-2 cells.  
Overall, simple allometric scaling is a plausible technique for dose determination in 
children. The correction factors were unable to show clear improvement in clearance 
prediction compared to simple allometry.  Mefloquine exhibited P-gp inhibitory 
properties. Mefloquine, amodiaquine, artesunate and artemisone did not exhibit P-gp 
substrate activity. Methylene blue was found to have P-gp mediated efflux transport as 
one of the multiple mechanisms available to transport methylene blue. It also showed 
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low permeability, while mefloquine and artesunate showed medium and amodiaquine 
and artemisone high permeability across Caco-2 monolayers.  A clear up-regulation of 
P-gp expression was observed for dihydroartemisinin and artemisone in combination 
with amodiaquine and mefloquine in Caco-2 and LS174 T cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Page 220 of 294 
6 References  
1. Diseases NCfZV-BaE. The history of malaria, an ancient disease: Centres for 
Disease Control and Prevention; 2010 [cited 2015 31 August 2015 ]. Available 
from: http://www.cdc.gov/malaria/about/history/index.html. 
2. Phillips R. Current status of malaria and potential for control. Clin Microbiol 
Rev  2001;14(1):208-26. 
3. Organization WH. Guidelines for the treatment of malaria. Geneva: WHO Press, 
World Health Organization; 2010. 
4. Organization WH. Severe and complicated malaria. Trans R Soc Trop Med Hyg. 
1990;84:1-65. 
5. Organization WH. World malaria report 2014: World Health Organization; 
2014. 
6. Moore BR. Pharmacodynamic studies of antimalarial drugs in a Murine Malaria 
Model [PhD]: Curtin University 2011. 
7. Bray R, Garnham P. The life-cycle of primate malaria parasites. Br Med Bull. 
1982;38(2):117-22. 
8. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med.2005;352 (15) 
:1565-77. 
9. Miller LH, Ackerman HC, Su X-z, Wellems TE. Malaria biology and disease 
pathogenesis: insights for new treatments. Nat Med. 2013;19(2):156-67. 
10. Organization WH. Malaria diagnosis: memorandum from a WHO meeting. Bull 
World Health Organ. 1988;66(5):575-94. 
11. Laishram DD, Sutton PL, Nanda N, Sharma VL, Sobti RC, Carlton JM, et al. 
The complexities of malaria disease manifestations with a focus on 
asymptomatic malaria. Malar J. 2012;11(1):29. 
12. Organization WH. World malaria report 2012. 2012. 
13. Enayati A HJ. Malaria management: past, present, and future. Annu Rev 
Entomol. 2010;55:569-91. 
   Page 221 of 294 
14. White N, Pongtavornpinyo W. The de novo selection of drug–resistant malaria 
parasites. Philos Trans R Soc London [Biol]. 2003;270(1514):545-54. 
15. Craft JC. Challenges facing drug development for malaria. Curr Opin Microbiol. 
2008;11(5):428-33. 
16. Stepniewska K, White N. Pharmacokinetic determinants of the window of 
selection for antimalarial drug resistance. Antimicrob Agents Chemother. 
2008;52(5):1589-96. 
17. Senarathna SG, Batty KT. Interspecies allometric scaling of antimalarial drugs 
and potential application to pediatric dosing. Antimicrob Agents Chemother. 
2014;58(10):6068-78. 
18. Pukrittayakamee S, Looareesuwan S, Keeratithakul D, Davis TME, Teja-
Isavadharm P, Nagachinta B, et al. A study of the factors affecting the metabolic 
clearance of quinine in malaria. Eur J Clin Pharmacol. 1997;52:487-93. 
19. Warhurst D. Antimalarial drugs. Drugs. 1987;33(1):50-65. 
20. Rosenthal P, Goldsmith R. Antiprotozoal drugs Basic and Clinical 
Pharmacology. 11 ed. New York, NY: Lange Medical Publications; 2009. p. 
899-912. 
21. Martindale W, Parfitt K, Britain RPSoG. Martindale: the complete drug 
reference: Pharmaceutical press London; 1999. 
22. Wagner H, Hikino H, Farnsworth N. Economic and medicinal plant research: 
Academic Press; 2012. 
23. Debrus B, Lebrun P, Kindenge JM, Lecomte F, Ceccato A, Caliaro G, et al. 
Innovative high-performance liquid chromatography method development for 
the screening of 19 antimalarial drugs based on a generic approach, using design 
of experiments, independent component analysis and design space. J 
Chromatogr A. 2011;1218(31):5205-15. 
24. Luo XD, Shen CC. The chemistry, pharmacology, and clinical applications of 
qinghaosu (Artemisinin) and its derivatives. Med Res Rev. 1987;7(1):29-52. 
   Page 222 of 294 
25. Meshnick S, Taylor T, Kamchonwongpaisan S. Artemisinin and the antimalarial 
endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev. 
1996;60(2):301-15. 
26. Koopmans R, Duc DD, Kager PA, Khanh NX, Dien TK, de Vries PJ, et al. The 
pharmacokinetics of artemisinin suppositories in Vietnamese patients with 
malaria. Trans R Soc Trop Med Hyg. 1998;92(4):434-6. 
27. Ashton M, Sy N, Van Huong N, Gordi T, Hai T, Huong D, et al. Artemisinin 
kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. 
Clin Pharmacol Ther 1998;63(4):482-93. 
28. Titulaer HAC, Zuidema J, Kager PA, Wetsteyn JCFM, Lugt CB, Merkus 
FWHM. The pharmacokinetics of artemisinin after oral, intramuscular and rectal 
administration to volunteers. J Pharm Pharmacol. 1990;42(11):810-3. 
29. Augustijns P, D'Hulst A, Van Daele J, Kinget R. Transport of artemisinin and 
sodium artesunate in Caco-2 intestinal epithelial cells. J Pharm Sci 
1996;85(6):577-9. 
30. Ashton M, Gordi T, Hai TN, Van Huong N, Sy ND, Nieu NT, et al. Artemisinin 
pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. 
Biopharm Drug Dispos. 1998;19(4):245-50. 
31. Hassan Alin M, Ashton M, Kihamia C, Mtey G, Björkman A. Multiple dose 
pharmacokinetics of oral artemisinin and comparison of its efficacy with that of 
oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg. 
1996;90(1):61-5. 
32. Ashton M, Hai T, Sy N. Artemisinin pharmacokinetics is time-dependent during 
repeated oral administration in healthy male adults. Drug Metab Dispos. 
1998;26:25 - 7. 
33. Hassan Alin M, Ashton M, Kihamia CM, Mtey G, Björkman A. Clinical efficacy 
and pharmacokinetics of artemisinin monotherapy and in combination with 
mefloquine in patients with falciparum malaria. Br J Clin Pharmacol. 
1996;41(6):587-92. 
34. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. Artemisinin 
pharmacokinetics and efficacy in uncomplicated-malaria patients treated with 
   Page 223 of 294 
two different dosage regimens. Antimicrob Agents Chemother. 
2002;46(4):1026-31. 
35. Navaratnam V, Mansor S, Sit N, Grace J, Li Q, Olliaro P. Pharmacokinetics of 
artemisinin-type compounds. Clin Pharmacokinet. 2000;39:255 - 70. 
36. Ilett KF, Batty KT, Powell SM, Binh TQ, Thu LTA, Phuong HL, et al. The 
pharmacokinetic properties of intramuscular artesunate and rectal 
dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol. 
2002;53(1):23-30. 
37. Hien TT, Davis TME, Chuong LV, Ilett KF, Sinh DXT, Phu NH, et al. 
Comparative Pharmacokinetics of Intramuscular Artesunate and Artemether in 
Patients with Severe Falciparum Malaria. Antimicrob Agents Chemother. 
2004;48(11):4234-9. 
38. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy 
against falciparum malaria on the Cambodia–Thailand border. Emerg Infect Dis. 
2008;14(5):716. 
39. Qigui Li LHX, Yuanzheng Si, ElaineWong,Ravi Upadhyay, DanielleYanez, 
Peter J.Weina. Toxicokinetics and hydrolysis of artelinate and artesunate in 
malaria infected rats. Int J Toxicol. 2005;24:241-50. 
40. Batty KT, Anh Thu LT, Davis TME, Ilett KF, Xuan Mai T, Canh Hung N, et al. 
A pharmacokinetic and pharmacodynamic study of intravenous vs oral 
artesunate in uncomplicated falciparum malaria. Br J Clin Pharmacol. 
1998;45(2):123-9. 
41. Batty KT, AnhThu LTA, Ilett KF, Phuctien N, Powel SM, Hung NC, et al. A 
pharmacokinetic and pharmacodynamic study of artesunate for Vivax malaria. 
Am J Trop Med Hyg. 1998;59(5):823-7. 
42. Olliaro P. Pharmacokinetics of artesunate after single oral administration to rats. 
BMC Pharmacol. 2001;1(1):12. 
43. Khanh N, de Vries P, Ha L, van Boxtel C, Koopmans R, Kager P. Declining 
concentrations of dihydroartemisinin in plasma during 5-day oral treatment with 
artesunate for falciparum malaria. Antimicrob Agent Chemother. 1999;43:690 - 
2. 
   Page 224 of 294 
44. Salman S, Page-Sharp M, Batty KT, Kose K, Griffin S, Siba PM, et al. 
Pharmacokinetic comparison of two piperaquine-containing artemisinin 
combination therapies in Papua New Guinean children with uncomplicated 
malaria. Antimicrob Agents Chemother. 2012;56(6):3288-97. 
45. Thuy LD, Hung LN, Danh P, Na-Bangchang K. Absence of time-dependent 
artesunate pharmacokinetics in healthy subjects during 5-day oral 
administration. Eur J Clin Pharmacol. 2008;64(10):993-8. 
46. Miller R, Li Q, Cantilena L, Leary K, Saviolakis G, Melendez V, et al. 
Pharmacokinetic profiles of artesunate following multiple intravenous doses of 
2, 4, and 8mg/kg in healthy volunteers: Phase 1b study. Malar J. 2012;11(1):255. 
47. Davis TM, England M, Dunlop AM, Page-Sharp M, Cambon N, Keller TG, et 
al. Assessment of the effect of mefloquine on artesunate pharmacokinetics in 
healthy male volunteers. Antimicrob Agents Chemother. 2007;51(3):1099-101. 
48. Silamut K, Newton PN, Teja-Isavadharm P, Suputtamongkol Y, Siriyanonda D, 
Rasameesoraj M, et al. Artemether Bioavailability after Oral or Intramuscular 
Administration in Uncomplicated Falciparum Malaria. Antimicrob Agents 
Chemother. 2003;47(12):3795-8  
49. Teja-Isavadharm P, Nosten F, Kyle DE, Luxemburger C, Ter Kuile F, Peggins 
JO, et al. Comparative bioavailability of oral, rectal, and intramuscular 
artemether in healthy subjects: use of simultaneous measurement by high 
performance liquid chromatography and bioassay. Br J Clin Pharmacol. 
1996;42(5):599-604. 
50. Lin JH. Drug–drug interaction mediated by inhibition and induction of P-
glycoprotein. Adv Drug Deliv Rev. 2003;55(1):53-81. 
51. Xing J, Bai KH, Liu T, Wang RL, Zhang LF, Zhang SQ. The multiple-dosing 
pharmacokinetics of artemether, artesunate, and their metabolite 
dihydroartemisinin in rats. Xenobiotica. 2011;41(3):252-8. 
52. van Agtmael M, Shan C, Jiao X, Mull R, van Boxtel C. Multiple dose 
pharmacokinetics of artemether in Chinese patients treated for falciparum 
malaria. Int J Antimicrob Agents. 1999;12:151 - 8. 
   Page 225 of 294 
53. Suputtamongkol Y, Newton PN, Angus B, Teja-Isavadharm P, Keeratithakul D, 
Rasameesoraj M, et al. A comparison of oral artesunate and artemether 
antimalarial bioactivities in acute falciparum malaria. Br J Clin Pharmacol. 
2002;52(6). 
54. Karbwang J, Na-Bangchang K, Congpuong K, Molunto P, Thanavibul A. 
Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur 
J Clin Pharmacol. 1997;52(4):307-10. 
55. Li QG, Peggins JO, Fleckenstein LL, Masonic K, Heiffer MH, Brewer TG. The 
pharmacokinetics and bioavailability of dihydroartemisinin arteether, 
artemether, artesunic and arteline acid in rats. J Pharm Pharmacol. 1998;50:173 
- 82. 
56. Van Agtmael M, Gupta V, Van Der Wösten T, Rutten J-P, Van Boxtel C. 
Grapefruit juice increases the bioavailability of artemether. Eur J Clin 
Pharmacol. 1999;55(5):405-10. 
57. McLean W, Ward S. In vitro neurotoxicity of artemisinin derivatives. Med Trop 
(Mars). 1998;58(3 Suppl):28 - 31. 
58. Batty KT, Ilett KF, Davis TM. Protein binding and α: β anomer ratio of 
dihydroartemisinin in vivo. Br J Clin Pharmacol. 2004;57(4):529-33. 
59. Batty KT, Ilett KF, Powell SM, Martin J, Davis TME. Relative bioavailability 
of artesunate and dihydroartemisinin: Investigations in the isolated perfused rat 
liver and in healthy Caucasian volunteers. Am J Trop Med Hyg. 2002;66(2): 
130- 6. 
60. Batty KT, Ilett KF, Edwards G, Powell SM, Maggs JL, Park BK, et al. 
Assessment of the effect of malaria infection on hepatic clearance of 
dihydroartemisinin using rat liver perfusions and microsomes. Br J Pharmacol. 
1998;125(1):159-67. 
61. Xie LH. Pharmacokinetics, tissue distribution and mass balance of radiolabeled 
dihydroartemisinin in male rats. Malar J. 2009;8(1):112. 
62. Binh TQ, Ilett KF, Batty KT, Davis TME, Hung NC, Powell SM, et al. Oral 
bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients 
with falciparum malaria. Br J Clin Pharmacol 2001;51(6):541-6. 
   Page 226 of 294 
63. Nealon C, Dzeing A, Müller-Römer U, Planche T, Sinou V, Kombila M, et al. 
Intramuscular bioavailability and clinical efficacy of artesunate in Gabonese 
children with severe malaria. Antimicrob Agents Chemother. 
2002;46(12):3933-9. 
64. Newton PN, van Vugt M, Teja-Isavadharm P, Siriyanonda D, Rasameesoroj M, 
Teerapong P, et al. Comparison of oral artesunate and dihydroartemisinin 
antimalarial bioavailabilities in acute falciparum malaria. Antimicrob Agents 
Chemother. 2002;46(4):1125-7. 
65. Krishna S, Planche T, Agbenyega T, Woodrow C, Agranoff D, Bedu-addo G, et 
al. Bioavailability and Preliminary Clinical Efficacy of Intrarectal Artesunate in 
Ghanaian Children with Moderate Malaria. Antimicrob Agents Chemother. 
2001;45(2):509-16. 
66. Nagelschmitz J, Voith B, Wensing G, Roemer A, Fugmann B, Haynes RK, et al. 
First assessment in humans of the safety, tolerability, pharmacokinetics, and ex 
vivo pharmacodynamic antimalarial activity of the new artemisinin derivative 
artemisone. Antimicrob Agents Chemother. 2008;52(9):3085-91. 
67. Haynes RK. Artemisone—a highly active antimalarial drug of the artemisinin 
class. Angew Chem Int Ed 2006;118(13):2136. 
68. Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, Vanijanonta S, Angus 
BJ, White NJ. Assessment of the neurotoxicity of parenteral artemisinin 
derivatives in mice. Am J Trop Med Hyg. 1998;59(4):519-22. 
69. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J 
Parasitol. 2002;32(13):1655-60. 
70. Vivas L, Rattray L, Stewart L, Robinson B, Fugmann B, Haynes R, et al. 
Antimalarial efficacy and drug interactions of the novel semi-synthetic 
endoperoxide artemisone in vitro and in vivo. Antimicrob Agents Chemother. 
2007;59(4):658-65. 
71. Base BbRd. Amodiaquine BARD bioassay Research data Base Available from: 
https://bard.nih.gov/BARD/bardWebInterface/showCompound?cid=2165. 
   Page 227 of 294 
72. Scholtz JC. Preparation, stability and in vitro evaluation of liposomes containing 
amodiaquine/Jacques C. Scholtz [M.Sc. Thesis ]. Potchefstroom: North-West 
University; 2010. 
73. Nair A, Abrahamsson B, Barends DM, Groot D, Kopp S, Polli JE, et al. 
Biowaiver monographs for immediate release solid oral dosage forms: 
Amodiaquine hydrochloride. J Pharm Sci 2012;101(12):4390-401. 
74. Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of 
amodiaquine in man after oral administration. Br J Clin Pharmacol. 
1987;23(1):1-7. 
75. Pussard E, Verdier F. Antimalarial 4‐aminoquinolines: mode of action and 
pharmacokinetics. Fundam Clin Pharmacol. 1994;8(1):1-17. 
76. Orrell C. Pharmacokinetics and tolerability of artesunate and amodiaquine alone 
and in combination in healthy volunteers. Eur J Clin Pharmacol. 2008;64(7):683. 
77. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, et 
al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate 
and efavirenz. Clin Infect Dis. 2007;44(6):889-91. 
78. Gasasira AF. Interactions between HIV infection and malaria in children living 
in sub-Saharan Africa in the era of widening access to improved interventions 
[Ph.D. Thesis ]: UC Berkeley; 2010. 
79. Davis TM, Hung T-Y, Sim K, Karunajeewa HA, Ilett KF. Piperaquine. Drugs. 
2005;65(1):75-87. 
80. Hien TT, Dolecek C, Mai PP, Dung NT, Truong NT, An DTH, et al. 
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium 
falciparum malaria in Vietnam: randomised clinical trial. Lancet. 2004;363 
(9402):18-22. 
81. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HLE, Kenangalem E, 
et al. Clinical and Pharmacological Determinants of the Therapeutic Response 
to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria. Antimicrob 
Agents Chemother. 2007;51(11):4090-7. 
82. Ahmed T, Sharma P, Gautam A, Varshney B, Kothari M, Ganguly S, et al. 
Safety, Tolerability, and Single- and Multiple-Dose Pharmacokinetics of 
   Page 228 of 294 
Piperaquine Phosphate in Healthy Subjects. J Clin Pharmacol. 2008;48(2):166-
75. 
83. Tarning J, Lindegardh N, Sandberg S, Day N, White N, Ashton M. 
Pharmacokinetics and metabolism of the antimalarial piperaquine after 
intravenous and oral single doses to the rat. J Pharm Sci. 2008;97(8):3400-10. 
84. Gigras R, Gautam A, Paliwal JK. preclinical in vitro and in vivo diposition of an 
anitmalarial compound piperaquine Indian. J Pharmacol. 2008;40(2). 
85. Hung T-Y, Davis TM, Ilett KF. Measurement of piperaquine in plasma by liquid 
chromatography with ultraviolet absorbance detection. J Chromatogr B 
2003;791(1):93-101. 
86. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, et 
al. Population Pharmacokinetics of Piperaquine after Two Different Treatment 
Regimens with Dihydroartemisinin-Piperaquine in Patients with Plasmodium 
falciparum Malaria in Thailand. Antimicrob Agents Chemother. 2008;52(3) 
:1052-61. 
87. Hung T-Y, Davis TME, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, et al. 
Population pharmacokinetics of piperaquine in adults and children with 
uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol. 2004;57 
(3):253-62. 
88. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, et al. 
Population Pharmacokinetics and Pharmacodynamics of Piperaquine in 
Children With Uncomplicated Falciparum Malaria. Clin Pharmacol Ther. 
2012;91(3):497-505. 
89. Liu C, Zhang R, Hong X, Huang T, Mi S, Wang N. Pharmacokinetics of 
piperaquine after single and multiple oral administrations in healthy volunteers. 
Yakugaku Zasshi. 2007;127(10):1709-14. 
90. Chinh NT, Quang NN, Thanh NX, Dai B, Travers T, Edstein MD. Short Report: 
Pharmacokinetics of the Antimalarial Drug Piperaquine in Healthy Vietnamese 
Subjects. Am J Trop Med Hyg. 2008;79(4):620-3. 
   Page 229 of 294 
91. Sim I-K, Davis TME, Ilett1 KF. Effects of a High-Fat Meal on the Relative Oral 
Bioavailability of Piperaquine. Antimicrob Agents Chemother. 2005;49 
(6):2407-11. 
92. Cook G. Malaria prophylaxis. Mefloquine toxicity should limit its use to 
treatment alone. Br Med J. 1995;311(6998):190. 
93. European Pharmacopoeia 5.0. 2005. p. 1241. 
94. U.S. Pharmacopeia. 2005; USP 29. 
95. Gimenez F, Pennie RA, Koren G, Crevoisier C, Wainer IW, Farinotti R. 
Stereoselective pharmacokinetics of mefloquine in healthy caucasians after 
multiple doses. J Pharm Sci. 1994;83(6):824-7. 
96. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin 
Pharmacokinet. 1990;19(4):264-79. 
97. Desjardins RE, Pamplin CL, 3rd, von Bredow J, Barry KG, Canfield CJ. 
Kinetics of a new antimalarial, mefloquine. Clin Pharmacol Ther. 1979;26 
(3):372-9. 
98. Strauch S, Jantratid E, Dressman J, Junginger H, Kopp S, Midha K, et al. 
Biowaiver monographs for immediate release solid oral dosage forms: 
mefloquine hydrochloride. J Pharm Sci. 2011;100(1):11-21. 
99. Kolawole JA, Mustapha A, Abudu-Aguye I, Ochekpe N. Mefloquine 
pharmacokinetics in healthy subjects and in peptic ulcer patients after cimetidine 
administration. Eur J Drug Metab Pharmacokinet. 2000;25(3-4):165-70. 
100. Schwartz DE, Eckert G, Hartmann D, Weber B, Richard-Lenoble D, Ekue JM, 
et al. Single dose kinetics of mefloquine in man. Plasma levels of the unchanged 
drug and of one of its metabolites. Chemotherapy. 1982;28(1):70-84. 
101. Mu J, Israili Z, Dayton P. Studies of disposition and metabolism of mefloquine 
HCl (WR 142,490), a quinolinemethanol antimalarial, in the rat  Limited Studies 
with an Analog, WR 30,090. Drug Metab Dispos. 1975;3(3):198-210. 
102. Tajerzadeh H, Cutler D. Blood to plasma ratio of mefloquine: interpretation and 
pharmacokinetic implications. Biopharm Drug Dispos. 1993;14(1):87-91. 
   Page 230 of 294 
103. Chung H, Jimmerson V, Rozman R, Sanders J. Disposition of the 
diastereoisomer of mefloquine in mice. Pharmacology. 1982;24(5):267-74. 
104. Riffkin CD, Chung R, Wall DM, Zalcberg JR, Cowman AF, Foley M, et al. 
Modulation of the function of human MDR1 P-glycoprotein by the antimalarial 
drug mefloquine. Biochem Pharmacol. 1996;52(10):1545-52. 
105. Håkanson A, Landberg-Lindgren A, Björkman A. Comparison of the activity in 
in vitro and two metabolites against Plasmodium falciparum. Trans R Soc Trop 
Med Hyg. 1990;84(4):503-4. 
106. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaipol P, Sunbhanich M. 
Effect of Rifampin on Plasma Concentrations of Mefloquine in Healthy 
Volunteers. J Pharm Pharmacol. 2000;52(10):1265-9. 
107. Karbwang J, Na Bangchang K, Back DJ, Bunnag D. Effect of ampicillin on 
mefloquine pharmacokinetics in Thai males. Eur J Clin Pharmacol. 1991;40 
(6):631-3. 
108. Karbwang J, Na Bangchang K, Back DJ, Bunnag D, Rooney W. Effect of 
tetracycline on mefloquine pharmacokinetics in Thai males. Eur J Clin 
Pharmacol. 1992;43(5):567-9. 
109. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M. 
Ketoconazole increases plasma concentrations of antimalarial mefloquine in 
healthy human volunteers. J Clin Pharm Ther. 2005;30(3):285-90. 
110. Crevoisier C, Handschin J, Barre J, Roumenov D, Kleinbloesem C. Food 
increases the bioavailability of mefloquine. Eur J Clin Pharmacol. 1997;53 
(2):135-9. 
111. Na‐Bangchang K, Karbwang J, Molunto P, Banmairuroi V, Thanavibul A. 
Pharmacokinetics of mefloquine, when given alone and in combination with 
artemether, in patients with uncomplicated falciparum malaria. Fundam Clin 
Pharmacol 1995;9(6):576-82. 
112. Karbwang J, Na Bangchang K, Thanavibul A, Back DJ, Bunnag D, Harinasuta 
T. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull 
World Health Organ. 1994;72(1):83-7. 
   Page 231 of 294 
113. Ged C, Rouillon J, Pichard L, Combalbert J, Bressot N, Bories P, et al. The 
increase in urinary excretion of 6 beta‐hydroxycortisol as a marker of human 
hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol. 1989;28(4):373-
87. 
114. Zhao X-J, Ishizaki T. The in vitro hepatic metabolism of quinine in mice, rats 
and dogs: comparison with human liver microsomes. J Pharmacol Exp Ther. 
1997;283(3):1168-76. 
115. Brodie BB, Baer JE, Craig LC. Metabolic products of the cinchona alkaloids in 
human urine. J Biol Chem. 1951;188(2):567-81. 
116. White NJ, Chanthavanich P, Krishna S, Bunch C, Silamut K. Quinine 
disposition kinetics. Br J Clin Pharmacol. 1983;16(4):399-403. 
117. Wanwimolruk S, Denton JR. Plasma Protein Binding of Quinine: Binding to 
Human Serum Albumin, α1‐Acid Glycoprotein and Plasma from Patients with 
Malaria. J Pharm Pharmacol. 1992;44(10):806-11. 
118. Roy L, Bannon P, Villeneuve JP. Quinine pharmacokinetics in chronic 
haemodialysis patients. Br J Clin Pharmacol. 2002;54(6):604-9. 
119. Edstein MD, Prasitthipayong A, Sabchareon A, Chongsuphajaisiddhi T, 
Webster HK. Simultaneous measurement of quinine and quinidine in human 
plasma, whole blood, and erythrocytes by high-performance liquid 
chromatography with fluorescence detection. Ther Drug Monit,. 1990;12(5) 
:493-500. 
120. Supanaranond W, Davis T, Pukrittayakamee S, Silamut K, Karbwang J, Molunto 
P, et al. Disposition of oral quinine in acute falciparum malaria. Eur J Clin 
Pharmacol. 1991;40(1):49-52. 
121. Silamut K, Molunto P, Ho M, Davis T, White N. Alpha 1‐acid glycoprotein 
(orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br 
J Clin Pharmacol. 1991;32(3):311-5. 
122. Silamut K, White NJ, Looareesuwan S, Warrell DA. Binding of quinine to 
plasma proteins in falciparum malaria. Am J Trop Med Hyg. 1985;34(4):681-6. 
123. Rowland M, Tozer T. Clinical Pharmacokinetics and Pharmacodynamics: 
concepts and applications. 2011. Lippincott Williams & Wilkins. 
   Page 232 of 294 
124. Molyneux ME, Looareesuwan S, Menzies IS, Grainger SL, Phillips RE, 
Wattanagoon Y, et al. Reduced hepatic blood flow and intestinal malabsorption 
in severe falciparum malaria. Am J Trop Med Hyg. 1989;40(5):470-6. 
125. Sabchareon A, Chongsuphajaisiddhi T, Attanath P. Serum quinine 
concentrations following the initial dose in children with falciparum malaria. 
Southeast Asian J Trop Med Public Health. 1982;13(4):556-62. 
126. Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P. Effects of 
cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin 
Pharmacol. 1986;22(3):346-50. 
127. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. 
Pharmacokinetic interactions between ritonavir and quinine in healthy 
volunteers following concurrent administration. Br J Clin Pharmacol. 
2010;69(3):262-70. 
128. Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S. 
Marked enhancement by rifampicin and lack of effect of isoniazid on the 
elimination of quinine in man. Br J Clin Pharmacol. 1995;40(1):87-91. 
129. Wanwimolruk S, Wong SM, Coville PF, Viriyayudhakorn S, Thitiarchakul S. 
Cigarette smoking enhances the elimination of quinine. Br J Clin Pharmacol. 
1993;36(6):610-4. 
130. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Effects 
of concurrent administration of nevirapine on the disposition of quinine in 
healthy volunteers. J Pharm Pharmacol. 2009;61(4):439-43. 
131. Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S. Grapefruit juice has no effect 
on quinine pharmacokinetics. Eur J Clin Pharmacol. 1999;55(5):393-8. 
132. Salako LA, Sowunmi A. Disposition of quinine in plasma, red blood cells and 
saliva after oral and intravenous administration to healthy adult Africans. Eur J 
Clin Pharmacol. 1992;42(2):171-4. 
133. Paintaud G, Alvan G, Ericsson O. The reproducibility of quinine bioavailability. 
Br J Clin Pharmacol. 1993;35(3):305-7. 
   Page 233 of 294 
134. Babalola CP, Adebayo A, Omotoso A, Ayrinde O. Comparative bioavailability 
study of a new quinine suppository and oral quinine in healthy volunteers. Trop 
J Pharm Res 2004;3(1):291-7. 
135. Steen B, Rane A. Clindamycin passage into human milk. Br J Clin Pharmacol. 
1982;13(5):661-4. 
136. HART L, Avery G. Drug Treatment. Principles and Practice of Clinical 
Pharmacology and Therapeutics. Ann Intern Med. 1980;93:384-5. 
137. DeHaan R, Metzler C, Schellenberg D, VandenBosch W, Masson E. 
Pharmacokinetic studies of clindamycin hydrochloride in humans. Int J Clin 
Pharmacol Ther Toxicol. 1972;6(2):105-19. 
138. Gordon R, Regamey C, Kirby W. Serum protein binding of erythromycin, 
lincomycin, and clindamycin. J Pharm Sci. 1973;62(7):1074-7. 
139. Yang SH, Lee MG. Dose-independent pharmacokinetics of clindamycin after 
intravenous and oral administration to rats: Contribution of gastric first-pass 
effect to low bioavailability. Int J Pharm. 2007;332(1–2):17-23. 
140. Gatti G, Malena M, Casazza R, Borin M, Bassetti M, Cruciani M. Penetration 
of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal 
fluid following intravenous infusion of clindamycin phosphate in patients with 
AIDS. Antimicrob Agents Chemother. 1998;42(11):3014-7. 
141. Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC. In vitro 
metabolism of clindamycin in human liver and intestinal microsomes. Drug 
Metab Dispos. 2003;31(7):878-87. 
142. Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC. 
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. 
Antimicrob Agents Chemother. 1989;33(5):618-20. 
143. Impert O, Katafias A, Kita P, Mills A, Pietkiewicz-Graczyk A, Wrzeszcz G. 
Kinetics and mechanism of a fast leuco-Methylene Blue oxidation by copper 
(II)–halide species in acidic aqueous media. Dalton Trans. 2003(3):348-53. 
144. Müller T. Methylene blue supravital staining: an evaluation of its applicability 
to the mammalian brain and pineal gland. Histol Histopathol. 1998;13(4):1019-
26. 
   Page 234 of 294 
145. Coulibaly B, Zoungrana A, Mockenhaupt FP, Schirmer RH, Klose C, 
Mansmann U, et al. Strong gametocytocidal effect of methylene blue-based 
combination therapy against falciparum malaria: a randomised controlled trial. 
PLoS ONE. 2009;4(5). 
146. Schirmer RH, Adler H, Pickhardt M, Mandelkow E. Lest we forget you—
methylene blue. Neurobiol Aging. 2011;32(12):2325. e7-. e16. 
147. Zoungrana A, Coulibaly B, Sié A, Walter-Sack I, Mockenhaupt FP, Kouyaté B, 
et al. Safety and Efficacy of Methylene Blue Combined with Artesunate or 
Amodiaquine for Uncomplicated Falciparum Malaria: A Randomized 
Controlled Trial from Burkina Faso. PLoS ONE. 2008;3(2):e1630. 
148. Meissner PE, Mandi G, Witte S, Coulibaly B, Mansmann U, Rengelshausen J, 
et al. Safety of the methylene blue plus chloroquine combination in the treatment 
of uncomplicated falciparum malaria in young children of Burkina Faso 
[ISRCTN27290841]. Malar J. 2005;4(1):45. 
149. Rengelshausen J, Burhenne J, Fröhlich M, Tayrouz Y, Singh SK, Riedel K-D, 
et al. Pharmacokinetic interaction of chloroquine and methylene blue 
combination against malaria. Eur J Clin Pharmacol. 2004;60(10):709-15. 
150. Amaral L, Viveiros M, Kristiansen JE. Phenothiazines: potential alternatives for 
the management of antibiotic resistant infections of tuberculosis and malaria in 
developing countries. Trop Med Int Health. 2001;6(12):1016-22. 
151. Peter C, Hongwan D, Küpfer A, Lauterburg B. Pharmacokinetics and organ 
distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 
2000;56(3):247-50. 
152. Walter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O, 
Meissner P, et al. High absolute bioavailability of methylene blue given as an 
aqueous oral formulation. Eur J Clin Pharmacol. 2009;65(2):179-89. 
153. Disanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs II: 
Methylene blue—absorption, metabolism, and excretion in man and dog after 
oral administration. J Pharm Sci. 1972;61(7):1086-90. 
   Page 235 of 294 
154. May JM, Qu Z-c, Whitesell RR. Generation of oxidant stress in cultured 
endothelial cells by methylene blue: protective effects of glucose and ascorbic 
acid. Mol Pharmacol. 2003;66(5):777-84. 
155. Merker M, Bongard R, Kettenhofen N, Okamoto Y, Dawson C. Intracellular 
redox status affects transplasma membrane electron transport in pulmonary 
arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2002;282 
(1):L36-L43. 
156. Mutabingwa TK. Artemisinin-based combination therapies (ACTs): Best hope 
for malaria treatment but inaccessible to the needy! Acta Trop. 2005;95 (3): 305-
15. 
157. Winstanley P. Modern chemotherapeutic options for malaria. Lancet Infect Dis 
2001;1(4):242-50. 
158. Basco LK, Ringwald P. In vitro activities of piperaquine and other 4-
aminoquinolines against clinical isolates of Plasmodium falciparum in 
Cameroon. Antimicrob Agents Chemother. 2003;47(4):1391-4. 
159. Nosten F, Brasseur P. Combination therapy for malaria. Drugs. 
2002;62(9):1315-29. 
160. Organization WH. Antimalarial drug combination therapy: Report of a WHO 
Technical Consultation: World Health Organization.; 2001. 
161. Wellems T, Plowe C. Chloroquine-resistant malaria. J Infect Dis. 2001;184 
(6):770-6. 
162. Payne D. Spread of chloroquine resistance in Plasmodium falciparum. 
Parasitology today. 1987;3(8):241-6. 
163. Watkins WM, Spencer HC, Kariuki DM, Sixsmith DG, Boriga DA, Kipingor T, 
et al. Effectiveness of amodiaquine as treatment for chloroquine resistant 
plasmodium falciparum infections in Kenya. Lancet. 1984;323(8373):357-9. 
164. Boudreau E, Webster HK, Pavanand K, Thosingha L. Type II mefloquine 
resistance in Thailand. Lancet. 1982;320(8311):1335. 
   Page 236 of 294 
165. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin 
resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455-
67. 
166. Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, et al. 
World Antimalarial Resistance Network (WARN) III: molecular markers for 
drug resistant malaria. Malar J 2007;6(1):121. 
167. Sinou V, Taudon N, Mosnier J, Aglioni C, Bressolle FM, Parzy D. 
Pharmacokinetics of artesunate in the domestic pig. J Antimicrob Chemother. 
2008;62(3):566-74. 
168. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-
pyrimethamine pharmacokinetics in malaria: Pediatric dosing implications. Clin 
Pharmacol Ther. 2006;80(6):582-96. 
169. Obua C, Hellgren U, Ntale M, Gustafsson LL, Ogwal‐Okeng JW, Gordi T, et al. 
Population pharmacokinetics of chloroquine and sulfadoxine and treatment 
response in children with malaria: suggestions for an improved dose regimen. 
Br J Clin Pharmacol. 2008;65(4):493-501. 
170. Ursing J, Kofoed P-E, Rodrigues A, Bergqvist Y, Rombo L. Chloroquine is 
grossly overdosed and overused but well tolerated in Guinea-bissau. Antimicrob 
Agents Chemother. 2009;53(1):180-5. 
171. Hendriksen ICE, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, et al. 
Population Pharmacokinetics of Intramuscular Artesunate in African Children 
With Severe Malaria: Implications for a Practical Dosing Regimen. Clin 
Pharmacol Ther. 2013;93(5):443-50. 
172. Krishna S, Nagaraja NV, Planche T, Agbenyega T, Bedo-Addo G, Ansong D, et 
al. Population pharmacokinetics of intramuscular quinine in children with severe 
malaria. Antimicrob Agents Chemother. 2001;45(6):1803-9. 
173. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, et al. 
Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-
piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis. 
2013;207 (11):1646-54. 
   Page 237 of 294 
174. Mahmood I. Application of allometric principles for the prediction of 
pharmacokinetics in human and veterinary drug development. Adv Drug Deliv 
Rev. 2007;59(11):1177-92. 
175. Mahmood I, Martinez M, Hunter RP. Interspecies allometric scaling. Part I: 
prediction of clearance in large animals. J Vet Pharmacol Ther. 2006;29(5):415-
23. 
176. Mordenti J. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm 
Sci. 1986;75(11):1028-40. 
177. Riviere JE, Martin-Jimenez T, Sundlof SF, Craigmill AL. Interspecies allometric 
analysis of the comparative pharmacokinetics of 44 drugs across veterinary and 
laboratory animal species. J Vet Pharmacol Ther 1997;20(6):453-63. 
178. Knibbe CAJ, Zuideveld KP, Aarts LPHJ, Kuks PFM, Danhof M. Allometric 
relationships between the pharmacokinetics of propofol in rats, children and 
adults. Br J Clin Pharmacol 2005;59(6):705-11. 
179. Mahmood I. Interspecies Scaling for the Prediction of Drug Clearance in 
Children. Clin Pharmacokinet. 2010;49(7):479-92. 
180. Peeters MY, Allegaert K, van Oud-Alblas HJB, Cella M, Tibboel D, Danhof M, 
et al. Prediction of propofol clearance in children from an allometric model 
developed in rats, children and adults versus a 0.75 fixed-exponent allometric 
model. Clin Pharmacokinet. 2010;49(4):269-75. 
181. Adolph EF. Quantitative relations in the physiological constitutions of 
mammals. Science. 1949;109(2841):579. 
182. Ings RMJ. Interspecies scaling and comparisons in drug development and 
toxicokinetics. Xenobiotica 1990;20(11):1201-31. 
183. Boxenbaum H, D'Souza R. Interspecies pharmacokinetic scaling: Reductionist 
and allometric paradigms. Topics in Pharmaceutical Sciences. 1987:49-62. 
184. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the 
ground plan of pharmacokinetics. J Pharmacokinet Biopharm. 1982;10(2):201. 
185. Gould SJ. Allometry and size in ontogeny and phylogeny. Biol Rev. 
1966;41(4):587-638. 
   Page 238 of 294 
186. Günther B, León dlBB. On the space-time continuum in biology. Acta physiol 
lat am 1965;16(3):221-31. 
187. Stahl WR. The analysis of biological similarity. Adv Biol Med Phys. 1962;9: 
355-464. 
188. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. The allometric 
approach for interspecies scaling of pharmacokinetic parameters. Comp 
Biochem Physiol C Toxicol Pharmacol 1992;103(2):249-53. 
189. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations 
of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood 
flow, plasma and blood cell binding, and the hepatocellular enzymatic activity 
on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5(6):625-53. 
190. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-
comparative paradigm. Drug Metab Rev. 1984;15(5-6):1071-121. 
191. White CR, Seymour RS. Allometric scaling of mammalian metabolism. J Exp 
Biol 2005;208(9):1611-9. 
192. Kleiber M. Body size and metabolism. ENE. 1932;1:E9. 
193. Lester D, Keokosky WZ. Alcohol metabolism in the horse. Life Sci.1967;6(21) 
:2313-9. 
194. Mellett LB. Comparative drug metabolism.  Progress in Drug Research/ 
Fortschritte der Arzneimittelforschung/Progrès des recherches 
pharmaceutiques: Springer; 1969. p. 136-69. 
195. Dedrick R, Bischoff K, Zaharko D. Interspecies correlation of plasma 
concentration history of methotrexate (NSC-740). Cancer Chemother Rep 
1970;54(2):95-101. 
196. Weiss M, Sziegoleit W, Förster W. Dependence of pharmacokinetic parameters 
on the body weight. Int J Clin Pharmacol Biopharm 1977;15(12):572-5. 
197. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and 
antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and 
phenytoin. J Pharmacokinet Biopharm. 1980;8(2):165-76. 
   Page 239 of 294 
198. Mordenti J. Forecasting cephalosporin and monobactam antibiotic half-lives in 
humans from data collected in laboratory animals. Antimicrob Agents 
Chemother. 1985;27(6):887-91. 
199. Ibrahim SS, Boudinot FD. Pharmacokinetics of 2′, 3′‐Dideoxycytidine in Rats: 
Application to Interspecies Scale‐up. J Pharm Pharmacol. 1989;41(12):829-34. 
200. Paxton J. The allometric approach for interspecies scaling of pharmacokinetics 
and toxicity of anti-cancer drugs. Clin Exp Pharmacol Physiol 1995;22(11) :851-
4. 
201. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric 
scaling laws in biology. Science. 1997;276(5309):122-6. 
202. Hunter RP. Interspecies allometric scaling. Handb Exp Pharmacol. 2010(199) 
:139-57. 
203. McNamara P. Interspecies scaling in pharmacokinetics. Drugs Pharm Sci 
1991;48:267-300. 
204. Brody S. Bioenergetics and Growth. New York: Reinhold; 1945. 
205. Hoppeler H, Weibel ER. Scaling functions to body size: theories and facts. J Exp 
Biol. 2005;208(9):1573-4. 
206. Kleiber M. The fire of life. An introduction to animal energetics1961. 
207. Anderson BJ, Holford NHG. Mechanism-Based Concepts of Size and Maturity 
in Pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48(1):303-32. 
208. Holford N, Heo Y-A, Anderson B. A pharmacokinetic standard for babies and 
adults. J Pharm Sci. 2013:n/a-n/a. 
209. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry 
and allometric scaling of organisms. science. 1999;284(5420):1677-9. 
210. Mahmood I. Interspecies scaling of renally secreted drugs. Life Sci. 
1998;63(26):2365-71. 
211. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in 
humans. Three different approaches. Xenobiotica. 1996;26(9):887-95. 
   Page 240 of 294 
212. Mahmood I, Balian JD. Interspecies scaling: predicting pharmacokinetic 
parameters of antiepileptic drugs in humans from animals with special emphasis 
on clearance. J Pharm Sci. 1996;85(4):411-4. 
213. The Lifespan of Animals (Colloquia on Ageing), Volume 5. In: - CFS, editor.: J 
& A Churchill Ltd 1959. 
214. Jerison H. Evolution of the Brain and Intelligence New York: Academic Press; 
1973. 
215. Sacher GA. On longevity regarded as an organized behavior: The role of brain 
structure.  Contributions to the Psychobiology of Aging: Springer; 1965. p. 99-
110. 
216. Boxenbaum H. Evolutionary Biology, Animal Behavior, Fourth-Dimensional 
Space, and the Raison ďEtre of Drug Metabolism and Pharmacokinetics. Drug 
Metab Rev. 1983;14(5):1057-97. 
217. Boxenbaum H, Fertig JB. Scaling of antipyrine intrinsic clearance of unbound 
drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet. 1984;9(2): 
177-83. 
218. Mahmood I. Interspecies pharmacokinetic scaling: Principles and Application of 
Allometric scaling. Rockville: Pine House Publishers; 2005. 
219. Brocks DR, Freed MI, Martin DE, Sellers TS, Mehdi N, Citerone DR, et al. 
Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 
107647) in rats, dogs, and oncologic patients. Pharm Res. 1996;13(5):794-7. 
220. Boxenbaum H, D'souza R. Interspecies pharmacokinetic scaling, biological 
esign and neoteny. J adv drug res. 1990;19:139-96. 
221. Lave T, Dupin S, Schmitt C, Chou R, Jaeck D, Coassolo P. Integration of in vitro 
data into allometric scaling to predict hepatic metabolic clearance in man: 
application to 10 extensively metabolized drugs. J Pharm Sci. 1997;86(5):584-
90. 
222. Lave T, Schmitt-Hoffmann A, Coassolo P, Valles B, Ubeaud G, Ba B, et al. A 
new extrapolation method from animals to man: application to a metabolized 
compound, mofarotene. Life Sci. 1995;56(26):473-8. 
   Page 241 of 294 
223. Lave T, Coassolo P, Ubeaud G, Brandt R, Schmitt C, Dupin S, et al. Interspecies 
scaling of bosentan, a new endothelin receptor antagonist and integration of in 
vitro data into allometric scaling. Pharm Res. 1996;13(1):97-101. 
224. Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, et al. 
Interspecies scaling of tolcapone, a new inhibitor of catechol-O-
methyltransferase (COMT). Use of in vitro data from hepatocytes to predict 
metabolic clearance in animals and humans. Xenobiotica. 1996;26(8):839-51. 
225. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Macintyre F, et al. The 
prediction of human pharmacokinetic parameters from preclinical and in vitro 
metabolism data. J Pharmacol Exp Ther. 1997;283(1):46-58. 
226. Mahmood I, Sahajwalla C. Interspecies scaling of biliary excreted drugs. J 
Pharma Sci. 2002;91(8):1908-14. 
227. Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR, 
et al. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin 
receptor antagonist. Drug Metab Dispos. 1999;27(11):1232-41. 
228. Tang H, Mayersohn M. A novel model for prediction of human drug clearance 
by allometric scaling. . Drug Metab Dispos. 2005;33(9):1297-303. 
229. Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation 
of extrapolation of intravenous pharmacokinetic parameters from rat, dog and 
monkey to humans. I. clearance. Drug Metab Dispos. 2004;32(6):603-11. 
230. Bonate PL, Howard D. Critique of prospective allometric scaling: Does the 
emperor have clothes? J Clin Pharmacol. 2000;40(4):335-40. 
231. Boxenbaum H, DiLea C. First‐Time‐in‐Human Dose Selection: Allometric 
Thoughts and Perspectives. J Clin Pharmacol. 1995;35(10):957-66. 
232. Tang H, Mayersohn M. Controversies in Allometric Scaling for Predicting 
Human Drug Clearance: An Historical Problem and Reflections on What Works 
and What Does Not. Curr Top Med Chem. 2011;11(4):340-50. 
233. Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors 
in the allometric predictivity of clearance from rat, dog, and monkey to humans. 
J Pharma Sci. 2004;93(10):2522-34. 
   Page 242 of 294 
234. Shargel S, Wu-Pong S, Yu ABC. Applied Biopharmaceutics & 
Pharmacokinetics. 5 ed. United States of America McGrowe-Hill; 2005. 
235. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick 
plots. Am J Physiol. 1983;245(6):R768-75. 
236. Kim SH, Kim WB, Lee MG. Interspecies pharmacokinetic scaling of a new 
carbapenem, DA‐1131, in mice, rats, rabbits and dogs, and prediction of human 
pharmacokinetics. Biopharm Drug Dispos 1998;19(4):231-5. 
237. Efthymiopoulos C, Battaglia R, Benedetti MS. Animal phannacokinetics and 
interspecies scaling of FCE 22101, a penem antibiotic. J Antimicrob Chemother. 
1991;27(4):517-26. 
238. Gogerty J. Preclinical research evaluation. New Drug Approval Processes New 
York: Marcel Dekker. 1987:25-54. 
239. Mahmood I, Balian JD. The pharmacokinetic principles behind scaling from 
preclinical results to phase I protocols. Clin Pharmacokinet. 1999;36(1):1-11. 
240. Mahmood I, Green MD, Fisher JE. Selection of the First-Time Dose in 
Humans:Comparison of Different Approaches Based on Interspecies Scaling of 
Clearance. J Clin Pharmacol. 2003;43:692-7. 
241. Staschen C-M, Mahmood I. A population pharmacokinetic model of 
remifentanil in pediatric patients using body-weight-dependent allometric 
exponents. Drug Metabol Drug Interact. 2013;28(4):231-7. 
242. Habtemariam B, Sallas W, Sunkara G, Kern S, Jarugula V, Pillai G. Population 
pharmacokinetics of valsartan in pediatrics. Drug Metab Pharmacokinet 
2009;24(2):145-52. 
243. Trenque T, Simon N, Villena I, Chemla C, Quereux C, Leroux B, et al. 
Population pharmacokinetics of pyrimethamine and sulfadoxine in children with 
congenital toxoplasmosis. Br J Clin Pharmacol. 2004;57(6):735-41. 
244. Läer S, Elshoff J-P, Meibohm B, Weil J, Mir TS, Zhang W, et al. Development 
of a safe and effective pediatric dosing regimen for sotalol based on population 
pharmacokinetics and pharmacodynamics in children with supraventricular 
tachycardia. J Am Coll Cardiol. 2005;46(7):1322-30. 
   Page 243 of 294 
245. Halpern SA. American pediatrics: the social dynamic of professionalism, 1880 
-1980. Berkeley University of California Press; 1988. 
246. Cella M, Knibbe C, Danhof M, Della Pasqua O. What is the right dose for 
children? Br J Clin Pharmacol 2010;70(4):597-603. 
247. Lack JA, Stuart-Taylor ME. Calculation of drug dosage and body surface area 
of children. Br J Anaesth. 1997;78:601-5. 
248. Augsberger A. Old and new rules for dosage determination in paediatrics. 
Triangle (Sandoz). 1962;5:200-7. 
249. Johnson TN. The problems in scaling adult drug doses to children. Arch Dis 
Child 2008;93(3):207-11. 
250. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet. 
1996;30(5):329-32. 
251. Committee PF. BNF for Children: Pharmaceutical Press; 2013. 
252. Moore B. The relationship of dosage of a drug to the size of the animal treated, 
especially in regard to the cause of the failures to cure trypanosomiasis, and other 
protozoan diseases in man and in large animals. Biochem J. 1909;4(5-7):323. 
253. Du Bois D, Du Bois EF. Clinical calorimetry: tenth paper a formula to estimate 
the approximate surface area if height and weight be known. Arch Intern Med. 
1916;17(6_2):863-71. 
254. Gehan EA, George SL. Estimation of human body surface area from height and 
weight. Cancer Chemoth Rep 1. 1970;54(4):225-35. 
255. Mahmood I. Prediction of drug clearance in children from adults: a comparison 
of several allometric methods. Br J Clin Pharmacol. 2006;61(5):545-57. 
256. Mahmood I. Theoretical versus empirical allometry: Facts behind theories and 
application to pharmacokinetics. J Pharm Sci. 2010;99(7):2927-33. 
257. Tod M, Jullien V, Pons G. Facilitation of Drug Evaluation in Children by 
Population Methods and Modelling. Clin Pharmacokinet 2008;47(4):231-43. 
258. Mahmood I. Prediction of drug clearance in children: impact of allometric 
exponents, body weight, and age. Ther Drug Monit. 2007;29(3):271-8. 
   Page 244 of 294 
259. Abernethy DR, Burckart G.J. Pediatric dose selection. Clin Pharmacol Ther. 
2010;87(3):270-1. 
260. British Medical Association RCopach, Royal Pharmaceutical Society of Great 
Britain BNF for children London: BMJ publishing group, RPS Publishing, 
RCPCH publications, 2006. ; 2006. 
261. Meakin G. Role of propofol in paediatric anaesthetic practice. Paediatr Anaesth. 
1995;5(3):147-9. 
262. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical 
pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 
1997;33(5):313-27. 
263. FDA U. Guidance for Industry. E11 Clinical Investigation of Medicinal Products 
in the Pediatric Population. 2000. 
264. Moore BR. Pharmacokinetics, Pharmacodynamics and Allometric Scaling of 
Chloroquine in a Murine Malaria Model. Antimicrob Agents Chemother. 
2011;55(8):3899. 
265. Davies B, Morris T. Physiological parameters in laboratory animals and humans. 
Pharm Res. 1993;10(7):1093-5. 
266. Cox S. Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and 
difloxacin pharmacokinetics: a retrospective analysis. J Vet Pharmacol Ther. 
2007;30(5):381-6. 
267. Hu T-M, Hayton WL. Allometric scaling of xenobiotic clearance: uncertainty 
versus universality. Aaps Pharmsci. 2001;3(4):30-43. 
268. Haddad S, Restieri C, Krishnan K. Characterization of age-related changes in 
body weight and organ weights from birth to adolescence in humans. J Toxicol 
Env Heal  B. 2001;64(6):453-64. 
269. Ritschel W, Vachharajani N, Johnson R, Hussain A. Interspecies scaling of the 
pharmacokinetic parameters of coumarin among six different mammalian 
species. Methods Find Exp Clin Pharmacol. 1991;13(10):697-702. 
270. Wilkinson G. Clearance approaches in pharmacology. Pharmacol Rev. 
1987;39(1):1. 
   Page 245 of 294 
271. Feng MR, Lou X, Brown RR, Hutchaleelaha A. Allometric pharmacokinetic 
scaling: towards the prediction of human oral pharmacokinetics. Pharm Res. 
2000;17(4):410-8. 
272. Yamazaki S, Toth LN, Black ML, Duncan JN. Comparison of prediction 
methods for in vivo clearance of (S, S)-3-[3-(methylsulfonyl) phenyl]-1-
propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. 
Drug Metab Dispos. 2004;32(4):398-404. 
273. Bennett K, Si Y, Steinbach T, Zhang J, Li Q. Pharmacokinetic and 
pharmacodynamic evaluation of intramuscular artesunate in healthy beagle 
dogs. Am J Trop Med Hyg. 2008;79(1):36-41. 
274. Li Q, Cantilena L, Leary K, Saviolakis G, Miller R, Melendez V, et al. 
Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 
2, 4, and 8 mg/kg in healthy volunteers: a phase I study. Am J Trop Med Hyg. 
2009;81:615 - 21. 
275. Zhao K-C, Chen Z-X, Lin B-L, Guo X-B, LI G-Q, Zong Z-Y. Studies on the 
phase 1 clinical pharmacokinetics of Artesunate and Artemether Chin J Clin 
Pharmacol. 1988;4(2):76-81. 
276. Zhao Kai-Cun, CHEN Q-M, Zong Z-Y. Studies on the pharmacokinetics of 
qinghaosu and two of its active derivatives in dogs Acta Pharm Sin 1986;21:736-
9. 
277. Zeng Y-l, Zhang Y-d, Xu G-y, Wang C-g, Jiang J-r. The pharmacokinetics and 
bioavailability of omethyldihydroartemesinine in the rabbit Acta Pharmaceutica 
Sinica. 1984;19(2):82-3. 
278. Ashton M, Johansson L, Thornqvist AS, Svensson USH. Quantitative in vivo 
and in vitro sex differences in artemisinin metabolism in rat. Xenobiotica. 
1999;29(2):195-204. 
279. Benakis A, Paris M, Loutan L, Plessas CT, Plessas ST. Pharmacokinetics of 
Artemisinin and Artesunate after Oral Administration in Healthy Volunteers Am 
J Trop Med Hyg 1997 56:17-23. 
   Page 246 of 294 
280. Duc DD, De Vries PJ, Nguyen XK, Le Nguyen B, Kager PA, Van Boxtel CJ. 
The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese 
subjects. Am J Trop Med Hyg. 1994;51(6):785-90. 
281. Hien TT, Hanpithakpong W, Truong NT, Dung NT, Toi PV, Farrar J, et al. 
Orally Formulated Artemisinin in Healthy Fasting Vietnamese Male Subjects: 
A Randomized, Four-Sequence, Open-Label, Pharmacokinetic Crossover Study. 
Clin Ther. 2011;33(5):644-54. 
282. Isacchi B, Arrigucci S, Marca G, Bergonzi1 MC, Vannucchi MG, Novelli A, et 
al. Conventional and long-circulating liposomes of artemisinin: preparation, 
characterization, and pharmacokinetic profile in mice. J Liposome ResJ 
Liposome Res. 2011;21(3):237-44. 
283. Rath K, Taxis K, Walz G, Gleiteer CH, Li SM, Heide L. Pharmacokinetic study 
of artemisinin after oral intake of a traditional preparation of Artemisia annua. 
L( annual wormwood). Am J Trop Med Hyg. 2004;70:128-32. 
284. Li L, Pabbisetty D, Carvalho P, Avery MA, Williamson JS, Avery BA. Ultra-
performance liquid chromatography–tandem mass spectrometric method for the 
determination of Artemisinin in rat serum and its application in 
pharmacokinetics. J Chromatogr B. 2008;867(1):131-7. 
285. Zhang S-Q, Hai TN, Ilett KF, Huong DX, Davis TME, Ashton M. Multiple dose 
study of interactions between artesunate and artemisinin in healthy volunteers. 
Br J of ClinPharmacol. 2001;52(4):377-85. 
286. Batzias GC, Delis GA, Athanasiou LV. Clindamycin bioavailability and 
pharmacokinetics following oral administration of clindamycin hydrochloride 
capsules in dogs. Vet J. 2005;170(3):339-45. 
287. Budsberg SC, Kemp DT, Wolski N. Pharmacokinetics of clindamycin phosphate 
in dogs after single intravenous and intramuscular administrations. Am J Vet 
Res. 1992;53(12):2333-6. 
288. Flaherty JF, Rodondi LC, Guglielmo BJ, Fleishaker JC, Townsend RJ, 
Gambertoglio JG. Comparative pharmacokinetics and serum inhibitory activity 
of clindamycin in different dosing regimens. Antimicrob Agents Chemother. 
1988;32(12):1825-9. 
   Page 247 of 294 
289. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J. Comparative 
study of bioavailabilities and pharmacokinetics of clindamycin in healthy 
volunteers and patients with AIDS. Antimicrob Agents Chemother. 
1993;37(5):1137-43. 
290. Lavy, Ziv, Shem T, Glickman, Dey. Pharmacokinetics of clindamycin HCl 
administered intravenously, intramuscularly and subcutaneously to dogs. J Vet 
Pharmacol Ther 1999;22(4):261-5. 
291. Batty KT, Moore BR, Stirling V, Ilett KF, Page-Sharp M, Shilkin KB, et al. 
Toxicology and pharmacokinetics of piperaquine in mice. Toxicology. 
2008;249(1):55-61. 
292. Baudry S, Pham YT, Baune B, Vidrequin S, Crevoisier C, Gimenez F, et al. 
Stereoselective passage of mefloquine through the blood-brain barrier in the rat. 
J Pharm Pharmacol. 1997;49(11):1086-90. 
293. Boudreau EF, Fleckenstein L, Pang LW, Childs GE, Schroeder AC, Ratnaratorn 
B, et al. Mefloquine kinetics in cured and recrudescent patients with acute 
falciparum malaria and in healthy volunteers. Clin Pharm Ther. 1990;48(4):399-
409. 
294. Charles BG, Blomgren A, Nasveld PE, Kitchener SJ, Jensen A, Gregory RM, et 
al. Population pharmacokinetics of mefloquine in military personnel for 
prophylaxis against malaria infection during field deployment. Eur J Clin 
Pharmacol. 2007;63(3):271-8. 
295. Franssen G, Rouveix B, Lebras J, Bauchet J, Verdier F, Michon C, et al. 
Divided-dose kinetics of mefloquine in man. Br J Clin Pharmacol. 
1989;28(2):179-84. 
296. Juma FD, Ogeto JO. Mefloquine disposition in normals and in patients with 
severePlasmodium falciparum malaria. Eur J Drug Metab Pharmacokinet 
1989;14(1):15-7. 
297. Karbwang J, Back DJ, Bunnag D, Breckenridge AM. A comparison of the 
pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients 
with falciparum malaria. Eur J Clin Pharmacol. 1988;35(6):677-80. 
   Page 248 of 294 
298. Karbwang J, Bunnag D, Breckenridge AM, Back DJ. The pharmacokinetics of 
mefloquine when given alone or in combination with sulphadoxine and 
pyrimethamine in Thai male and female subjects. Eur J Clin Pharmacol. 
1987;32(2):173-7. 
299. Karbwang J, Looareesuwan S, Back DJ, Migasana S, Bunnag D, Breckenridge 
AM. Effect of oral contraceptive steroids on the clinical course of malaria 
infection and on the pharmacokinetics of mefloquine in Thai women. Bull 
WHO. 1988;66(6):763-7. 
300. Karbwang J, Looareesuwan S, Phillips RE, Wattanagoon Y, Molyneux ME, 
Nagachinta B, et al. Plasma and whole blood mefloquine concentrations during 
treatment of chloroquine-resistant falciparum malaria with the combination 
mefloquine-sulphadoxine-pyrimethamine. Br J of Clin Pharmacol. 
1987;23(4):477-81. 
301. Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. 
Pharmacokinetic interaction between mefloquine and ritonavir in healthy 
volunteers. Br J Clin Pharmacol. 2001;51(6):591-600. 
302. Looareesuwan S, White NJ, Warrell DA, Forgo I, Dubach UG, Ranalder UB, et 
al. Studies of mefloquine bioavailability and kinetics using a stable isotope 
technique: a comparison of Thai patients with falciparum malaria and healthy 
Caucasian volunteers. Br J Clin Pharmacol. 1987;24(1):37-42. 
303. Pennie RA, Koren G, Crevoisier C. Steady state pharmacokinetics of mefloquine 
in long-term travellers. Trans R Soc Trop Med Hyg. 1993;87(4):459-62. 
304. Rozman RS, Molek NA, Koby R. The absorption, distribution, and excretion in 
mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-
piperidyl)-4-quinolinemethanol hydrochloride. Drug Metab Dispos. 
1978;6(6):654-8. 
305. Watari N, Wakamatsu A, Kaneniwa N. Comparison of disposition parameters 
of quinidine and quinine in the rat. J Pharmacobiodyn. 1989;12(10):608-15. 
306. Wanwimolruk S, Nyika S, Kepple M, Ferry DG, Clark CR. Effects of capsaicin 
on the pharmacokinetics of antipyrine, theophylline and quinine in rats. J Pharm 
Pharmacol 1993;45(7):618-21. 
   Page 249 of 294 
307. Zhang HU, Ramsay N, Coville PF, Wanwimolruk S. Effect of Erythromycin, 
Rifampicin and Isoniazid on the Pharmacokinetics of Quinine in Rats. J Pharm 
Pharmacol. 1999;5(7):467-72. 
308. Zhang H, Wong CW, Coville PF, Wanwimolruk S. Effect of grapefruit flavonoid 
naringin on pharmacokinetics of quinine in rats Drug Metabol Drug Interact. 
2000;17:351-63. 
309. Clohisy DR, Gibson TP. Comparison of pharmacokinetic parameters of 
intravenous quinidine and quinine in dogs. J Cardiovasc Pharmacol. 
1982;4(1):107-10. 
310. Brum Jr L, Leal MG, De Toni Uchoa F, Kaiser M, Guterres SS, Dalla Costa T. 
Determination of quinine and doxycycline in rat plasma by LC-MS-MS: 
Application to a pharmacokinetic study. Chromatographia. 2011;73(11-
12):1081-8. 
311. Pussard E, Barennes H, Daouda H, Clavier F, Sani AM, Osse M, et al. Quinine 
disposition in globally malnourished children with cerebral malaria. Clin 
Pharmacol Ther. 1999;65(5):500-10. 
312. Claessen FA, van Boxtel CJ, Perenboom RM, Tange RA, Wetsteijn JC, Kager 
PA. Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy 
Caucasian subjects and in patients with falciparum malaria. Trop Med Int 
Health. 1998;3(6):482-9. 
313. Karbwang J, Davis TM, Looareesuwan S, Molunto P, Bunnag D, White NJ. A 
comparison of the pharmacokinetic and pharmacodynamic properties of quinine 
and quinidine in healthy Thai males. Br J Clin Pharmacol. 1993;35(3):265-71. 
314. Karbwang J, Thanavibul A, Molunto P, Na Bangchang K. The pharmacokinetics 
of quinine in patients with hepatitis. Br J Clin Pharmacol. 1993;35(4):444-6. 
315. Zhao K-C, Chen Q-M, Song Z-Y. Studies on the pharmacokinetics of qinghaosu 
and two of its active derivatives in dogs Acta Pharm Sin 1986;21:736-9. 
316. Hasan MM, Hassan MA, Rawashdeh NM. Effect of oral activated charcoal on 
the pharmacokinetics of quinidine and quinine administered intravenously to 
rabbits. Pharmacol Toxicol. 1990;67(1):73-6. 
   Page 250 of 294 
317. Hai TN, Hietala SF, Van Huong N, Ashton M. The influence of food on the 
pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta 
tropica. 2008;107(2):145-9. 
318. Röshammar D, Hai TN, Hietala SF, Van Huong N, Ashton M. Pharmacokinetics 
of piperaquine after repeated oral administration of the antimalarial combination 
CV8 in 12 healthy male subjects. Eur J Clin Pharmacol. 2006;62(5):335-41. 
319. Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Mayanja-Kizza H, 
Katabira E, et al. Pharmacokinetics and pharmacodynamics of intravenous 
artesunate during severe malaria treatment in Ugandan adults. Malar J. 
2012;11:132. 
320. Davis TME. Pharmacokinetics and pharmacodynamics of intravenous 
artesunate in severe falciparum malaria. Antimicrob Agents Chemother. 
2001;45(1):181. 
321. Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, 
Navaratnam V, Bates I, et al. Antimalarial Bioavailability and Disposition of 
Artesunate in Acute Falciparum Malaria. Antimicrob Agents Chemother. 
2000;44(4): 972-7. 
322. Karbwang J, Na-Bangchang K, Tin T, Sukontason K, Rimchala W, Harinasuta 
T. Pharmacokinetics of intramuscular artemether in patients with severe 
falciparum malaria with or without acute renal failure. Br J Clin Pharmacol. 
1998;45(6):597-600. 
323. Hodel EMS, Guidi M, Zanolari B, Mercier T, Duong S, Kabanywanyi AM, et 
al. Population pharmacokinetics of mefloquine, piperaquine and artemether-
lumefantrine in Cambodian and Tanzanian malaria patients. Malar J. 
2013;12(1):235. 
324. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, et al. 
Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant 
and non-pregnant women with uncomplicated malaria. Antimicrob Agents 
Chemother. 2012:AAC. 05756-11. 
325. Abdelrahim I, Adam I, Elghazali G, Gustafsson L, Elbashir M, Mirghani R. 
Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women 
   Page 251 of 294 
with uncomplicated Plasmodium falciparum malaria. J Clin Pharm Ther. 
2007;32(1):15-9. 
326. Couet W, Laroche R, Floch J-J, Istin B, Fourtillan J-B, Sauniere J-F. 
Pharmacokinetics of Quinine and Doxycycline in Patients with Acute 
Falciparum Malaria: A Study in Africa. Ther Drug Monit. 1991;13(6):496-501. 
327. Davis TME, Supanaranond W, Sasithon P, Karbwang J, Molunto P, Sopon M, 
et al. A Safe and Effective Consecutive-Infusion Regimen for Rapid Quinine 
Loading in Severe Falciparum Malaria. J Infect Dis. 1990;161(6):1305-8. 
328. Davis TME, White NJ, Looareesuwan S, Silamut K, Warrell DA. Quinine 
pharmacokinetics in cerebral malaria: predicted plasma concentrations after 
rapid intravenous loading using a two-compartment model. Trans R Soc Trop 
Med Hyg. 1988;82(4):542-7. 
329. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T. 
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated 
falciparum malaria. Am J Med 1982;73(4):564-72. 
330. Shann F, Stace J, Edstein M. Pharmacokinetics of quinine in children. J Pediatr. 
1985;106(3):506-10. 
331. Mithwani S, Aarons L, Kokwaro GO, Majid O, Muchohi S, Edwards G, et al. 
Population pharmacokinetics of artemether and dihydroartemisinin following 
single intramuscular dosing of artemether in African children with severe 
falciparum malaria. Br J Clin Pharmacol. 2004;57(2):146-52. 
332. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, et al. 
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian 
children with uncomplicated malaria. Antimicrob Agents Chemother. 
2008;52(1):237-43. 
333. Bourahla A, Martin C, Gimenez F, Singhasivanon V, Attanath P, Sabchearon A, 
et al. Stereoselective pharmacokinetics of mefloquine in young children. Eur J 
Clin Pharmacol. 1996;50(3):241-4. 
334. Singhasivanon V, Chongsuphajaisiddhi T, Sabcharoen A, Attanath P, Webster 
H, Wernsdorfer W, et al. Pharmacokinetics of mefloquine in children aged 6 to 
24 months. Eur J Drug Metab Pharmacokinet. 1992;17(4):275-9. 
   Page 252 of 294 
335. Singhasivanon V, Chongsuphajaisiddhi T, Sabchareon A, Attanath P, Webster 
H, Edstein M, et al. Pharmacokinetic study of mefloquine in Thai children aged 
5–12 years suffering from uncomplicated falciparum malaria treated with MSP 
or MSP plus primaquine. Eur J Drug Metab Pharmacokinet. 1994;19(1):27-32. 
336. West GB. The importance of quantitative systemic thinking in medicine. Lancet. 
2012;379(9825):1551-9. 
337. McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between 
drug clearance and body size. Clin Pharmacokinet. 2012;51(5):319-30. 
338. Crowe A, Ilett KF, Karunajeewa HA, Batty KT, Davis TM. Role of P 
glycoprotein in absorption of novel antimalarial drugs. Antimicrob Agents 
Chemother. 2006;50(10):3504-6. 
339. Townsend RJ, Baker RP. Pharmacokinetic comparison of three clindamycin 
phosphate dosing schedules. Drug Intell Clin Pharm. 1987;21(3):279-81. 
340. Palhlman I, Edholm M, Kankaaneanta S, Odell M. Pharmacokinetics of 
Susalimod, a Highly Biliary‐excreted Sulphasalazine Analogue, in Various 
Species. Nonpredictable Human Clearance by Allometric Scaling. Pharm 
Pharmacol Commun 1998;4(10):493-8. 
341. Ursing J, Kofoed P-E, Rodrigues A, Blessborn D, Thoft-Nielsen R, Björkman 
A, et al. Similar efficacy and tolerability of double-dose chloroquine and 
artemether-lumefantrine for treatment of Plasmodium falciparum infection in 
Guinea-Bissau: a randomized trial. J Infect Dis. 2011;203(1):109-16. 
342. Baldrick P. Juvenile animal testing in drug development–Is it useful? Regul 
Toxicol Pharmacol. 2010;57(2):291-9. 
343. Baldrick P. Developing drugs for pediatric use: a role for juvenile animal 
studies? Regul Toxicol Pharmacol. 2004;39(3):381-9. 
344. Lin JH. Applications and limitations of interspecies scaling and in vitro 
extrapolation in pharmacokinetics. Drug Metab Dispos. 1998;26(12):1202-12. 
345. Callan W, Sunderman Jr F. Species variations in binding of 63 NI (II) by serum 
albumin. Res Commun Chem Pathol Pharmacol. 1973;5(2):459. 
   Page 253 of 294 
346. Chu X, Bleasby K, Evers R. Species differences in drug transporters and 
implications for translating preclinical findings to humans. Expert Opin Drug 
Metab Toxicol 2013;9(3):237-52. 
347. Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and 
related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv 
Rev. 1997;25(2):129-57. 
348. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods 
and studies. Fundam Clin Pharmacol. 1999;13(2):154-68. 
349. Hayashi M, Tomita M, Awazu S. Transcellular and paracellular contribution to 
transport processes in the colorectal route. Adv Drug Deliv Rev. 
1997;28(2):191-204. 
350. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and 
theoretical predictions of drug transport. Adv Drug Deliv Rev. 1996;46(1):27-
43. 
351. Sinko PJ, Hu M, Amidon GL. Carrier mediated transport of amino acids, small 
peptides, and their drug analogs. J Controlled Release. 1987;6(1):115-21. 
352. Lennernas H, Nilsson D, Aquilonius S, Ahrenstedt O, Knutson L, Paalzow L. 
The effect of L‐leucine on the absorption of levodopa, studied by regional jejunal 
perfusion in man. Br J Clin Pharmacol. 1993;35(3):243-50. 
353. Dix C, Hassan I, Obray H, Shah R, Wilson G. The transport of vitamin B12 
through polarized monolayers of Caco-2 cells. Gastroenterology. 1990;98(5 Pt 
1):1272-9. 
354. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen L, et al. Drug 
export activity of the human canalicular multispecific organic anion transporter 
in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin 
Invest. 1998;101(7):1310. 
355. Hunter J, Jepson M, Tsuruo T, Simmons N, Hirst B. Functional expression of P-
glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of 
vinblastine secretion and interaction with modulators. J Biol Chem. 1993; 
268(20):14991-7. 
   Page 254 of 294 
356. Hunter J, Hirst BH, Simmons NL. Drug absorption limited by P-glycoprotein-
mediated secretory drug transport in human intestinal epithelial Caco-2 cell 
layers. Pharma Res. 1993;10(5):743-9. 
357. Potts RO, Guy RH. A predictive algorithm for skin permeability: the effects of 
molecular size and hydrogen bond activity. Pharma Res. 1995;12(11):1628-33. 
358. Levin VA. Relationship of octanol/water partition coefficient and molecular 
weight to rat brain capillary permeability. J Med Chem. 1980;23(6):682-4. 
359. Potts RO, Guy RH. Predicting skin permeability. Pharma Res. 1992;9(5):663-9. 
360. Martin YC. A practitioner's perspective of the role of quantitative structure-
activity analysis in medicinal chemistry. J Med Chem. 1981;24(3):229-37. 
361. Wils P, Warnery A, Phung-Ba V, Legrain S, Scherman D. High lipophilicity 
decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther. 
1994;269(2):654-8. 
362. Ramu K, Baker JK. Synthesis, characterization, and antimalarial activity of the 
glucuronides of the hydroxylated metabolites of arteether. J Med Chem. 
1995;38(11):1911-21. 
363. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: 
efflux proteins limiting drug absorption and bioavailability. Eur J Pharma Sci. 
2004;21(1):25-51. 
364. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in 
Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152-
62. 
365. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP 
binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 
2003;55(1):3-29. 
366. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the 
multidrug transporter. Annu Rev Biochem. 1993;62(1):385-427. 
367. Gatmaitan ZC, Arias IM. Structure and function of P-glycoprotein in normal 
liver and small intestine. Adv Pharmacol 1993;24:77-97. 
   Page 255 of 294 
368. Fojo AT, Shen D, Mickley L, Pastan I, Gottesman M. Intrinsic drug resistance 
in human kidney cancer is associated with expression of a human multidrug-
resistance gene. J Clin Oncol 1987;5(12):1922-7. 
369. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 
Cellular localization of the multidrug-resistance gene product P-glycoprotein in 
normal human tissues. Proc Natl Acad Sci. 1987;84(21):7735-8. 
370. Cordon-Cardo C, O'brien J, Boccia J, Casals D, Bertino J, Melamed M. 
Expression of the multidrug resistance gene product (P-glycoprotein) in human 
normal and tumor tissues. J Histochem Cytochem. 1990;38(9):1277-87. 
371. Smith AJ, van Helvoort A, van Meer G, Szabó K, Welker E, Szakács G, et al. 
MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several 
cytotoxic drugs and directly interacts with drugs as judged by interference with 
nucleotide trapping. J Biol Chem. 2000;275(31):23530-9. 
372. Taipalensuu J, Törnblom H, Lindberg G, Einarsson C, Sjöqvist F, Melhus H, et 
al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding 
cassette transporter family in normal human jejunum and in human intestinal 
epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther. 2001;299(1):164-70. 
373. De Vree JML, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, et al. 
Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. 
P Natl Acady Sci. 1998;95(1):282-7. 
374. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. 
Communication between multiple drug binding sites on P-glycoprotein. Mol 
Pharmacol. 2000;58(3):624-32. 
375. Sharom F, LU P, LIU R, YU X. Linear and cyclic peptides as substrates and 
modulators of P-glycoprotein: peptide binding and effects on drug transport and 
accumulation. Biochem J. 1998;333:621-30. 
376. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends 
Biochem Sci 1992;17(1):18-21. 
377. Bellamy WT. P-glycoproteins and multidrug resistance. Annu Rev Pharmacol 
Toxicol. 1996;36(1):161-83. 
   Page 256 of 294 
378. Ueda K, Taguchi Y, Morishima M, editors. How does P-glycoprotein recognize 
its substrates? Semin Cancer Biol; 1997: Elsevier. 
379. Seelig A. A general pattern for substrate recognition by P‐glycoprotein. Eur J 
Biochem. 1998;251(1‐2):252-61. 
380. Loo TW, Clarke DM. Identification of residues in the drug-binding site of human 
P-glycoprotein using a thiol-reactive substrate. J Biol Chem. 
1997;272(51):31945-8. 
381. Loo TW, Clarke DM. Identification of residues in the drug-binding domain of 
human P-glycoprotein Analysis of transmembrane segment 11 by cysteine-
scanning mutagenesis and inhibition by dibromobimane. J Biol Chem. 
1999;274(50):35388-92. 
382. Hoffmeyer S, Burk O, Von Richter O, Arnold H, Brockmöller J, Johne A, et al. 
Functional polymorphisms of the human multidrug-resistance gene: multiple 
sequence variations and correlation of one allele with P-glycoprotein expression 
and activity in vivo. P Natl Acad Sci. 2000;97(7):3473-8. 
383. Canaparo R, Finnström N, Serpe L, Nordmark A, Muntoni E, Eandi M, et al. 
Expression of CYP4A isoformes and P-glycoprotein in human stomach, 
jejunum, ilium. Clin Exp Pharmacol Physiol 2007;34(11):1138-44. 
384. Chikhale EG, Ng K-Y, Burton PS, Borchardt RT. Hydrogen bonding potential 
as a determinant of the in vitro and in situ blood–brain barrier permeability of 
peptides. Pharm Res. 1994;11(3):412-9. 
385. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed 
MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by 
endothelial cells at blood-brain barrier sites. P Natl Acad Sci. 1989;86(2):695-8. 
386. Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham M. 
Immunohistochemical localization in normal tissues of different epitopes in the 
multidrug transport protein P170: evidence for localization in brain capillaries 
and crossreactivity of one antibody with a muscle protein. J Histochem 
Cytochem 1989;37(2):159-64. 
   Page 257 of 294 
387. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, et al. 
Transport of digoxin by human P-glycoprotein expressed in a porcine kidney 
epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992;263(2):840-5. 
388. Horio M, Chin K-V, Currier S, Goldenberg S, Williams C, Pastan I, et al. 
Transepithelial transport of drugs by the multidrug transporter in cultured 
Madin-Darby canine kidney cell epithelia. J Biol Chem. 1989;264(25):14880-4. 
389. Smit JW, Schinkel AH, Weert B, Meijer DK. Hepatobiliary and intestinal 
clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b 
genes have been disrupted. Br J Pharmacol. 1998;124(2):416-24. 
390. Stephens R, O'neill C, Warhurst A, Carlson G, Rowland M, Warhurst G. Kinetic 
profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal 
epithelia. J Pharmacol Exp Ther. 2001;296(2):584-91. 
391. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of p‐
glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo 
correlation. Br J Pharmacol. 1996;118(7):1841-7. 
392. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein 
transports cyclosporin A and FK506. J Biol Chem. 1993;268(9):6077-80. 
393. Kirn RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. 
Interrelationship between substrates and inhibitors of human CYP3A and P-
glycoprotein. Pharma Res. 1999;16(3):408-14. 
394. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug 
metab Rev 2002;34(1-2):47-54. 
395. Smith AJ, Mayer U, Schinkel AH, Borst P. Availability of PSC833, a substrate 
and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl 
Cancer Inst. 1998;90(15):1611-166. 
396. Fischer V, Rodríguez-Gascón A, Heitz F, Tynes R, Hauck C, Cohen D, et al. 
The Multidrug Resistance Modulator Valspodar (PSC 833) Is Metabolized by 
Human Cytochrome P450 3A Implications for Drug-Drug Interactions and 
Pharmacological Activity of the Main Metabolite. Drug Metab Dispos. 
1998;26(8):802-11. 
   Page 258 of 294 
397. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal 
of multidrug resistance by GF120918, an acridonecarboxamide derivative. 
Cancer Res. 1993;53(19):4595-602. 
398. Ford J. Experimental reversal of P-glycoprotein-mediated multidrug resistance 
by pharmacological chemosensitisers. Eur J Cancer. 1996;32(6):991-1001. 
399. Ayesh S, Shao Y-M, Stein WD. Co-operative, competitive and non-competitive 
interactions between modulators of P-glycoprotein. BBA-Mol Basis Dis. 
1996;1316(1):8-18. 
400. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P‐
glycoprotein with distinct drug specificities. Eur J Biochem. 1997;250(1):130-
7. 
401. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, 
et al. Human P-glycoprotein exhibits reduced affinity for substrates during a 
catalytic transition state. Biochemistry. 1998;37(14):5010-9. 
402. Senior AE, Al-Shawi MK, Urbatsch IL. The catalytic cycle of P-glycoprotein. 
FEBS letters. 1995;377(3):285-9. 
403. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, et al. 
Pharmacological inhibition of P-glycoprotein transport enhances the distribution 
of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 
2000;28(6):655-60. 
404. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, 
et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), 
an HIV protease inhibitor. Pharma Res. 1999;16(8):1206-12. 
405. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron DW. Effect of 
ketoconazole on ritonavir and saquinavir concentrations in plasma and 
cerebrospinal fluid from patients infected with human immunodeficiency virus*. 
Clin Pharmacol Ther. 2000;68(6):637-46. 
406. Minami H, Ohtsu T, Fujii H, Igarashi T, Itoh K, Uchiyama‐Kokubu N, et al. 
Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug 
Resistance. Cancer Sci. 2001;92(2):220-30. 
   Page 259 of 294 
407. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, Van der Vijgh W, et al. 
A dose-finding and pharmacokinetic study of reversal of multidrug resistance 
with SDZ PSC 833 in combination with doxorubicin in patients with solid 
tumors. Clin Cancer Res. 1997;3(11):2005-15. 
408. Fardel O, Lecureur V, Guillouzo A. Regulation by dexamethasone of P-
glycoprotein expression in cultured rat hepatocytes. FEBS letters. 
1993;327(2):189-93. 
409. Zhao J, Ikeguchi M, Eckersberg T, Kuo M. Modulation of multidrug resistance 
gene expression by dexamethasone in cultured hepatoma cells. Endocrinology. 
1993;133(2):521-8. 
410. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, von Richter O, Zundler J, 
et al. The role of intestinal P-glycoprotein in the interaction of digoxin and 
rifampin. J Clin Invest 1999;104(2):147-53. 
411. Quattrochi LC, Guzelian PS. CYP3A regulation: from pharmacology to nuclear 
receptors. Drug Metab Dispos. 2001;29(5):615-22. 
412. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR 
coordinately regulates drug metabolism and efflux. Nat Med. 2001;7(5):584-90. 
413. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate 
induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581-7. 
414. LeCluyse EL. Pregnane X receptor: molecular basis for species differences in 
CYP3A induction by xenobiotics. Chem Biol Interact. 2001;134(3):283-9. 
415. Bock U, Kottke T, Gindorf C, Haltner E. Validation of the Caco-2 cell 
monolayer system for determining the permeability of drug substances 
according to the Biopharmaceutics Classification System (BCS). Saarbrucken: 
Across Barriers. 2003:1-7. 
416. Artursson P, Borchardt RT. Intestinal drug absorption and metabolism in cell 
cultures: Caco-2 and beyond. Pharm Res. 1997;14(12):1655-8. 
417. Jin X, Luong T-L, Reese N, Gaona H, Collazo-Velez V, Vuong C, et al. 
Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for 
anti-malarial drug screening and drug investigations. J Pharmacol Toxicol 
Methods. 2014;70(2):188-94. 
   Page 260 of 294 
418. Wikman A, Karlsson J, Carlstedt I, Artursson P. A drug absorption model based 
on the mucus layer producing human intestinal goblet cell line HT29-H. Pharma 
Res. 1993;10(6):843-52. 
419. Shirasaka Y, Kawasaki M, Sakane T, Omatsu H, Moriya Y, Nakamura T, et al. 
Induction of human p-glycoprotein in Caco-2 cells: development of a highly 
sensitive assay system for p-glycoprotein-mediated drug transport. Drug Metab 
Pharmacokinet 2006;21(5):414-23. 
420. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor 
cell lines producing tumors in nude mice. J Natl Cancer Inst 1977;59(1):221-6. 
421. Artursson P, Karlsson J. Correlation between oral drug absorption in humans 
and apparent drug permeability coefficients in human intestinal epithelial 
(CACO-2) cells. Biochem Biophys Res Commun. 1991;175(3):880-5. 
422. Cell B. Enterocyte-like differentiation and polarization of the human colon 
carcinoma cell line Caco-2 in culture. Biol Cell. 1983;47. 
423. Hidalgo IJ, Borchardt RT. Transport of a large neutral amino acid 
(phenylalanine) in a human intestinal epithelial cell line: Caco-2. BBA-
Biomembranes. 1990;1028(1):25-30. 
424. Dantzig AH, Bergin L. Uptake of the cephalosporin, cephalexin, by a dipeptide 
transport carrier in the human intestinal cell line, Caco-2. BBA-Biomembranes. 
1990;1027(3):211-7. 
425. Wilson G, Hassan I, Dix C, Williamson I, Shah R, Mackay M, et al. Transport 
and permeability properties of human Caco-2 cells: an in vitro model of the 
intestinal epithelial cell barrier. J Control Release. 1990;11(1):25-40. 
426. Wils P, Warnery A, Phung-Ba V, Scherman D. Differentiated intestinal 
epithelial cell lines asin vitro models for predicting the intestinal absorption of 
drugs. Cell Biol Toxicol. 1994;10(5-6):393-7. 
427. Lennernäs H, Palm K, Fagerholm U, Artursson P. Correlation between 
paracellular and transcellular drug permeability in the human jejunum and Caco-
2 monolayers. Int J Pharm. 1996;127:103-7. 
   Page 261 of 294 
428. Lennernäs H, Ahrenstedt Ö, Hällgren R, Knutson L, Ryde M, Paalzow LK. 
Regional jejunal perfusion, a new in vivo approach to study oral drug absorption 
in man. Pharma Res. 1992;9(10):1243-51. 
429. Kirn D-C, Burton PS, Borchardt RT. A correlation between the permeability 
characteristics of a series of peptides using an in vitro cell culture model (Caco-
2) and those using an in situ perfused rat ileum model of the intestinal mucosa. 
Pharma Res. 1993;10(12):1710-4. 
430. Conradi RA, Wilkinson KF, Rush BD, Hilgers AR, Ruwart MJ, Burton PS. In 
vitro/in vivo models for peptide oral absorption: Comparison of Caco-2 cell 
permeability with rat intestinal absorption of renin inhibitory peptides. Pharm 
Res. 1993;10(12):1790-2. 
431. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo 
(small intestinal) absorption in man—fact or myth. Pharm Res. 1997;14(6): 763-
6. 
432. Walter E, Kissel T. Transepithelial transport and metabolism of thyrotropin-
releasing hormone (TRH) in monolayers of a human intestinal cell line (Caco-
2): evidence for an active transport component? Pharma  Res. 1994;11(11) 
:1575-80. 
433. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn‐Langguth H, Wunderli‐
Allenspach H, et al. P‐glycoprotein (P‐gp) mediated efflux in Caco‐2 cell 
monolayers: The influence of culturing conditions and drug exposure on P‐gp 
expression levels. J Pharma Sci. 1998;87(6):757-62. 
434. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a 
biopharmaceutic drug classification: the correlation of in vitro drug product 
dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20. 
435. Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology McGraw-
Hill LANGE; 2009. 
436. Pham Y-T, Régina A, Farinotti R, Couraud P-O, Wainer IW, Roux F, et al. 
Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in 
an immortalised rat brain capillary endothelial cell line, GPNT. BBA-Gen 
Subjects 2000;1524(2):212-9. 
   Page 262 of 294 
437. Lan L-B, Ayesh S, Lyubimov E, Pashinsky I, Stein WD. Kinetic parameters for 
reversal of the multidrug pump as measured for drug accumulation and cell 
killing. Cancer Chemother Pharmacol. 1996;38(2):181-90. 
438. Shao Y-m, Ayesh S, Stein WD. Mutually co-operative interactions between 
modulators of P-glycoprotein. Biochimica et Biophysica Acta (BBA) - 
Molecular Basis of Disease. 1997;1360(1):30-8. 
439. Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL. The potential 
inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein 
mediated efflux. Eur J Pharm Sci. 2006;29(1):70-81. 
440. Oga E, Sekine S, Shitara Y, T. H. Potential P-glycoprotein-mediated drug-drug 
interactions of antimalarial agents in Caco-2 cells. Am J Trop Med Hyg  
2012;87(1):64-9. 
441. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: 
from genomics to mechanism. Oncogene. 2003;22(47):7468-85. 
442. Lehnert M, Dalton W, Roe D, Emerson S, Salmon SE. Synergistic inhibition by 
verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a 
human myeloma cell line model. Blood. 1991;77(2):348-54. 
443. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, et al. 
Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression 
by activation of xenosensors pregnane X receptor and constitutive androstane 
receptor. Mol pharmacol. 2005;67(6):1954-65. 
444. Bailey CA, Bryla P, Malick AW. The use of the intestinal epithelial cell culture 
model, Caco-2, in pharmaceutical development. Adv Drug Deliv Rev. 
1996;22(1):85-103. 
445. Hosoya K-i, Kim K-J, Lee VH. Age-dependent expression of P-glycoprotein 
gp17O in Caco-2 cell monolayers. Pharm Res. 1996;13(6):885-90. 
446. Crowe A, Wong P. pH dependent uptake of loperamide across the 
gastrointestinal tract: an in vitro study. Drug Dev Ind Pharm. 2004;30(5):449-
59. 
   Page 263 of 294 
447. Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human 
intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison 
with rapamycin. Pharma Res. 1998;15(11):1666-72. 
448. Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying 
the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm 
Sci 1990;79(6):476-82. 
449. Crowe A, Teoh YK. Limited P-glycoprotein mediated efflux for anti-epileptic 
drugs. J Drug Target. 2006;14(5):291-300. 
450. Camenisch GP, Wang W, Wang B, Borchardt RT. A comparison of the 
bioconversion rates and the Caco-2 cell permeation characteristics of Coumarin-
based cyclic prodrugs and methylester-based linear prodrugs of RGD 
peptidomimetics. Pharma Res. 1998;15(8):1174-81. 
451. Wenzel U, Gebert I, Weintraut H, Weber W-M, Clauss W, Daniel H. Transport 
characteristics of differently charged cephalosporin antibiotics in oocytes 
expressing the cloned intestinal peptide transporter PepT1 and in human 
intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996;277(2):831-9. 
452. Faust RA, Albers JJ. Regulated vectorial secretion of cholesteryl ester transfer 
protein (LTP-I) by the CaCo-2 model of human enterocyte epithelium. J Biol 
Chem. 1988;263(18):8786-9. 
453. Dulfer WJ, Groten JP, Govers H. Effect of fatty acids and the aqueous diffusion 
barrier on the uptake and transport of polychlorinated biphenyls in Caco-2 cells. 
J Lipid Res. 1996;37(5):950-61. 
454. Artursson P, Karlsson J, Ocklind G, Schipper N. Models of absorptive epithelia 
for studying transport processes. In: Shaw E, editor. Cell models of epithelial 
tissues-A practical approach: Oxford; 1996. p. 111-33. 
455. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, et 
al. Induction of P‐glycoprotein by rifampin increases intestinal secretion of 
talinolol in human beings: A new type of drug/drug interaction. J Pharmacol Exp 
Ther. 2000;68(4):345-55. 
   Page 264 of 294 
456. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, et al. Failure of artesunate-
mefloquine combination therapy for uncomplicated Plasmodium falciparum 
malaria in southern Cambodia. Malar J. 2009;8(1):10. 
457. Reungpatthanaphong P, Mankhetkorn S. Modulation of multidrug resistance by 
artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr 
resistant cell lines. Biol Pharm Bull. 2002;25(12):1555-61. 
458. Davis TM, England M, Dunlop A-M, Page-Sharp M, Cambon N, Keller TG, et 
al. Assessment of the effect of mefloquine on artesunate pharmacokinetics in 
healthy male volunteers. Antimicrob Agents Chemother. 2007;51(3):1099-101. 
459. Pussard E, Verdier F, Blayo M-C. Simultaneous determination of chloroquine, 
amodiaquine and their metabolites in human plasma, red blood cells, whole 
blood and urine by column liquid chromatography. J Chromatogr B Biomed Sci 
Appl. 1986;374:111-8. 
460. Manning L, Laman M, Page-Sharp M, Salman S, Hwaiwhanje I, Morep N, et al. 
Meningeal inflammation increases artemether concentrations in cerebrospinal 
fluid in Papua New Guinean children treated with intramuscular artemether. 
Antimicrob Agents Chemother. 2011;55(11):5027-33. 
461. Gustafsson L, Walker O, Alvan G, Beermann B, Estevez F, Gleisner L, et al. 
Disposition of chloroquine in man after single intravenous and oral doses. Br J 
Clin Pharmacol. 1983;15(4):471-9. 
462. Agency EM. Assessment report Methylthioninium chloride Proveblue  
[02.12.2014]. Available from: http://www.ema.europa.eu/docs/en_GB/ 
document_library/EPAR_-_Public_assessment_report/human/ 
002108/WC500107131.pdf. 
463. Peters W, Robinson PJ. Handbook of Animal Models of Infection. In: In: 
SANDE MA ZO, editor. Malaria. London: Academic Press; 1975. 
464. Batty KT, Ilett KF, Davis M. Chemical stability of artesunate injection and 
proposal for its administration by intravenous infusion. J Pharm Pharmacol. 
1996;48(1):22-6. 
465. Food, Administration D. Guidance for industry: waiver of in vivo bioavailability 
and bioequivalence studies for immediate-release solid oral dosage forms based 
   Page 265 of 294 
on a biopharmaceutics classification system. Food and Drug Administration, 
Rockville, MD. 2000. 
466. Agnihotri J, Singh S, Bigonia P. Formal chemical stability analysis and 
solubility analysis of artesunate and hydroxychloroquinine for development of 
parenteral dosage form. J Pharm Res. 2013;6(1):117-22. 
467. Österberg T, Norinder U. Theoretical calculation and prediction of P-
glycoprotein-interacting drugs using MolSurf parametrization and PLS 
statistics. Eur J Pharm Sci. 2000;10(4):295-303. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Page 266 of 294 
7 Appendix  
 
7.1 Buffers, reagents and solvents 
 
Transport media; Hank Balanced Salt Solution  
HBSS 25 mM transport medium ( pH 7.4) 250 mL 
HBSS 10 X 25 mL 
25 mM glucose (MW 180.16 ) 0.87 g 
10 mM HEPES (MW 283.3 ) 0.58 g 
Deionized water to  250 mL 
1M NaOH was used to adjust pH to 7. 
 
Cell growth medium  
Ingredient  Quantity  
DMEM 500 mL 
2 mM glutamine  5 mL of 200 mM 
1 mM non-essential amino acid  5 mL of 100 mM 
1,000 u/mL penicillin and streptomycin 5 mL of 100,000 units/mL 
10% foetal calf serum (FCS)  50 mL of 100% FCS 
 
Cell lysis buffer  
Ingredient  Amount for 100 mL  
20 mM Tris HCl    (MW 157.6) 0.315 g 
120 mM  NaCl   (MW 58.55) 0.701 g 
0.1% Sodium dodecyl sulphate 100 mg 
Nonidet p40 substitute  1 mL 
Mini protease inhibitor tablet was added to 10 mL aliquot of lysis buffer and sonicated 
for 10 minutes in a floating rack. 
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CTC reagent  
Ingredient  Quantity  
CuSO4.H2O 0.1 g 
Na-K-Tartrate 0.2 g 
Na2CO3 10.0 g 
Deionized water to 100 mL  
The CTC reagent was warmed to room temperature prior use and stirred to dissolve 
crystals formed during refrigeration.  
 
Lowry Reagent for protein assay    
Ingredient  Quantity in parts   
CTC reagent  1 
0.8 M NaOH  1 
Deionized water  2 
 
 
Folin reagent (0.5 N)  
Ingredient  Quantity  
Folin stock ( 2N)  Part 1 
Deionized water  Part 4 
 
Tris Buffered saline (TBS) 
Ingredient  Quantity  
Tris HCL   3.14 mg  
NaCl   9 g 
Deionized water to  1000mL 
5 M NaOH was used to  adjust pH to 7.4  
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Tris Buffered saline with 0.05% Tween 20 (TBST) 
Ingredient  Quantity  
Tris HCL   3.14 mg  
NaCl   9 g 
Tween 20  0.5 mL 
Deionized water to  1000mL 
5 M NaOH was used to adjust pH to 7.4  
 
Transfer Buffer  
Ingredient  Quantity  
Methanol  200mL 
Nupage sample anti-oxidant  1mL 
Transfer buffer (20X conc)  50mL 
Deionized water  749mL 
 
MOPs Running Buffer 1X 
Ingredient  Quantity  
20 X BoltTM MOPS SDS running buffer 20 mL 
deionized water 380 mL 
 
Blocking buffer 
Ingredient  Quantity  
Casein  4 g 
TBS 200 mL 
 
 
 
